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Abstract 
Genetic defects in AIPL1 cause a heterogeneous set of clinical conditions 
depending on the severity of the mutant alleles. Diseases can range from 
Leber Congenital Amaurosis (LCA), the severest form of early-onset retinal 
degeneration, to milder forms such as retinitis pigmentosa (RP) and cone-rod 
dystrophy. There is currently no effective treatment for LCA and inherited 
retinal dystrophies, which are the commonest cause of childhood blindness. 
AIPL1 is expressed primarily in retinal photoreceptors and is required for the 
biosynthesis of photoreceptor phosphodiesterase (PDE).  
This thesis describes a programme of work that examines the potential and 
efficacy of gene replacement therapy in the treatment of AIPL1- associated 
retinal diseases. It centres on the use of recombinant adeno-associated virus 
for the transfer of murine and human AIPL1 cDNA into photoreceptor cells. 
AAV-mediated gene replacement was assessed in two genetically 
engineered mouse models carrying null and hypomorphic alleles, Aipl1 -/- 
and Aipl1 h/h mice, which simulate retinal degenerations similar to human 
LCA and RP respectively. Three different rates of photoreceptor 
degeneration were simulated using the mouse models. To treat the different 
rates of degeneration, two pseudotypes of AAV (serotype 2 and 8) exhibiting 
different transduction kinetics were used for gene transfer. Substantial and 
long term rescue of the disease phenotype was seen as a result of Aipl1 
transgene expression mediated by AAV2/2 vector in Aipl1 h/h mice and by 
AAV2/8 in rapid degenerations in light accelerated Aipl1 h/h mice and in 
Aipl1 -/- mice. Thus, the results presented in this thesis validates the efficacy 
of AIPL1 gene replacement using AAV vectors in varying rates of 
degeneration that reflected the clinical spectrum of disease. This is the first 
study to report long-term rescue of a photoreceptor-specific defect and to 
demonstrate effective rescue of rapid photoreceptor degeneration. 
 
The development of an efficient therapy depends on the identification of 
patients and characterisation of disease phenotype. A panel of DNA samples 
from patients with LCA and early onset severe retinal dystrophy was 
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screened for mutations in the AIPL1 gene.  Patients identified with AIPL1-
associated disease demonstrated varying severity of disease from LCA to 
milder form of rod cone dystrophy. Clinical characterisation and imaging of 
the patients highlighted distinctive features which will direct future 
identification and molecular screening of patients. Residual retinal integrity 
and function in young patients and patients with milder phenotype suggests 
that AIPL1 defects may be amenable to treatment. 
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1 Introduction 
 
Gene technology has revolutionized the 21st century and soon, it will become 
an important influence on many sectors of our lives. Recently, developments 
in gene transfer technology have opened new doors, particularly in the 
medical field. These advances have lead to the potential of treating genetic 
and acquired diseases using gene therapy, thus establishing a promising tool 
for the development of new and effective treatment strategies for numerous 
diseases which are thus far incurable. Diseases which may benefit from 
gene therapy include cancer, certain infectious diseases, inherited disorders 
of the nervous system, haematological diseases and inherited retinal 
degenerations. Although the use of gene therapy to treat diseases has 
mainly been proven in animal studies, many of these treatments have now 
gone to clinical trials. It may be possible, in near future, to use gene therapy 
to treat diseases whose genetic defects have been identified.  One group of 
diseases which stand to benefit greatly from gene therapy is inherited eye 
diseases and the use of gene therapy in the treatment of ocular diseases has 
only recently been explored. 
 
The human eye is regarded as the most important sense organ since 85% of 
the information about our environment is perceived through the eyes. 
Inherited retina degenerations are one of the most common causes of 
blindness in the western world, for which currently no efficient treatment 
exists. The best characterised form of inherited retinal degenerations is 
retinitis pigmentosa (RP) with prevalence up to 1:3500 [54].  To date, many 
genes responsible for inherited retinal diseases have been identified, 
providing a basis for the development of gene-based treatment strategies.  
The unique properties of the eye that makes it particularly suitable as a 
model system for gene therapy. The eye is a small and highly 
compartmentalized organ with immune-privileged properties making it 
possible to deliver small volumes of viral vector precisely to obtain 
transduction of selected retinal cell types with minimal risk of systemic 
dissemination or invoking vector-directed immune responses. Its transparent 
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nature makes it  highly accessible and allows for non-invasive techniques to 
monitor and measure the effects of treatment such as retinal imaging, slit 
lamp biomicroscopy, electrophysiology and psychophysical tests [10,408]. As 
such, diseases of the eye are prime candidates for gene therapy 
approaches. 
 
The past decade has seen an exponential increase in advances in the field 
of molecular genetics, particularly in genotyping and diagnostic technology.  
The impact on the field of ophthalmology has been tremendous; the 
discovery of new disease genes has lead to better understanding of disease 
pathogenesis. The development and discovery of animal models has  
culminated in successful rescue of vision in some models of hereditary 
retinal dystrophies using gene replacement therapy.  This has occurred 
mainly in different studies of recessively inherited retinal dystrophies where 
the condition is caused by mutations resulting in the loss of function of an 
encoded protein. Insertion and subsequent expression of the therapeutic 
transgene was followed by observations of functional and morphological 
improvements, some of these effects were sustained over a long term. 
These studies have provided robust proof-of-principal for gene replacement 
therapy in recessively inherited retinal dystrophies which until now were 
untreatable, and justification to bring this research from the laboratory bench 
to the clinics in the form of human trials.  
 
Previously, preclinical studies of gene replacement therapy to treat retinal 
degeneration have found that photoreceptor cell defects were more difficult 
to treat. In an early study of gene replacement therapy using a mouse model 
of Retinitis Pigmentosa that carried a null mutation the Prph2 gene, 
subretinal delivery of an adenovirus carrying Prph2 transgene led to 
structural and functional improvement but the treatment did not affect the 
rate of degeneration [14]. With the improvements in vector design, functional 
improvement and a degree of photoreceptor rescue has been reported in a 
few animal models with defects in photoreceptor-specific genes such as 
RPGRIP, GUCY2D, ABCA4, and usherin [363,496] [281,518]. These defects 
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cause a spectrum of retinal disorders ranging from Lebers Congenital 
Amaurosis, Stargardt disease, and retinitis pigmentosa respectively.   
 
Gene replacement therapy have been more successful in conditions where 
the genetic defects originated in the retinal pigment epithelium such as  
RPE65, MERTK, and LRAT, all of which are causes of recessive hereditary 
retinal dystrophies [1,42,437,471]. RPE defects are generally easier to treat 
because the RPE forms a single layer of cells that are efficiently transduced 
by viral vectors, whereas many more photoreceptor cells are arranged 
multiple layers which makes gene transfer to these cells less efficient. Since 
each RPE cell is in contact with several photoreceptor cells, the transduction 
of a single RPE cell might protect or restore function to several photoreceptor 
cells, thus allowing for widespread correction of the defect. Furthermore, the 
photoreceptor cells in RPE-specific defects are primarily healthy and 
structurally intact despite the metabolic derangement. By correcting the 
metabolic derangement in the RPE, the function and survival of these 
photoreceptor cells may be restored.  
 
Clinical trials of gene replacement therapy treating patients with early onset 
severe rod cone dystrophy or Lebers Congenital Amaurosis caused by 
RPE65 mutations are currently in progress, one of these is being conducted 
by our group at the Institute of Ophthalmology.  Preliminary reports that have 
been recently published from these trials reported good safety profile of the 
treatment and limited improvement in retinal function. This will pave the way 
for more human trials in the future and as such further experimental studies 
in animal models are urgently required to evaluate the potential for benefit in 
retinal degenerations caused by other genes. It would be particularly 
desirable to be able to achieve robust long term rescue in a model with 
photoreceptor-specific gene defect since most inherited retinal dystrophies 
originate from photoreceptor defects and have been more difficult to treat. 
This would provide proof that photoreceptor-specific defects are amenable to 
treatment.  
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1.1 Aims and objectives  
 
1.The aim of this research project is to investigate the efficacy of gene 
replacement therapy for the treatment of a murine model of Type 4 Leber 
Congenital Amaurosis (LCA) due to a primary defect in a photoreceptor-
specific gene AIPL1.  
2. To evaluate whether AAV-mediated AIPL1 expression leads to structural 
and functional rescue of photoreceptors with subsequent prolongation of 
their survival in this model of severe retinal degeneration.  
3. To identify and characterise patients with mutations in AIPL1 through 
genetic screening of a panel of patients with Leber Congenital Amaurosis 
and early onset severe retinal dystrophies. This will also facilitate possible 
future translation of this gene-based treatment by identifying suitable 
candidates for clinical trials and establishing baseline clinical outcome 
measures. 
Therefore, we state that the null hypothsis is that AAV-mediated expression 
of AIPL1 does not lead to structural or functional preservation of 
photoreceptor cells and there is no increase in photoreceptor survival 
following treatment. 
 
1.2  The eye – structure and function 
 
The primary function of the eye is to respond to visual stimuli by converting a 
response to light into neuronal signals that are interpreted by the brain. To 
perform this sensory function, the eye carries out a variety of intricate cellular 
and molecular processes which are dependent on maintaining a tightly 
regulated microenvironment within the eye through the differentiated status 
of various cell types, vasculogenesis and modulation of the local immune 
system. The vast range of cell types within the eye reflects the diversity of 
function that is carried out in this small organ. Consequently, the eye is 
highly sensitive to genetic and environmental factors. Any slight changes in 
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the fine balance pattern of gene expression, subtle environmental insults and 
infections can lead to disease. The neurosensory retina in particular is the 
center of many genetic diseases, many of which lead to blindness. Despite 
increased knowledge of the aetiology and pathology of diseases, many 
ocular conditions, especially inherited eye diseases currently lack effective 
treatments. 
 
The differentiation of the retina during development involves the close 
interaction between two cell types: the photoreceptor cells and the retinal 
pigment epithelium (RPE) cells. Both cell types are dependent on each other 
during different developmental stages, by providing various survival, growth 
and differentiation factors. This close interaction is not only seen during 
development but also in the adult eye. Retinal physiology and morphology 
depends on the close interaction and communication of these two cell types 
and involves complex, cellular signaling pathways, the most important of 
which will be discussed in more details in the following chapters. 
 
The mammalian eye consists of concentric layers of tissues derived from 
three of the primitive embryonic layers: surface ectoderm and its derivative 
neural crest, neural ectoderm and mesoderm. Figure 1.1 illustrates the 
overall layered architecture of the eye, including a magnified view of the 
retina which is where the capture light photons, amplification and 
transduction of light signals to the visual cortex take place [142].  
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Figure 1.1 Structure of the eye 
A schematic diagram showing a vertical section through the human eye.   
(Adapted from McGraw-Hill) 
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1.2.1  The retina  
 
The retina is primarily divided into 2 distinct tissue compartments:  the inner 
or neurosensory retina, and the outer supporting layer of cells known as the 
retinal pigment epithelium (RPE). The neurosensory retina is a highly 
specialised laminated structure that perform the central functions in the 
phototransduction cascade and visual pathway. There are 10 histological 
layers in the retina as depicted in Figure 1.2. The outermost layer is a single 
layer of melanin-containing cuboidal cells known as the retinal pigment 
epithelium (RPE), and separates the neurosensory retina from the choroid.  
 
There are approximately 5 million RPE cells in the human retina which 
regulate the movements of nutrients and metabolites required for the 
maintenance of the photoreceptors throughout the interphotoreceptor 
matrix[449]. The basal aspect of the RPE lies on the connective tissue layer 
known as Bruch’s membrane. The apical aspect of the RPE has microvilli on 
its internal surface which invaginate the photoreceptor outer segments. 
Functionally, The RPE cells have vital roles in the maintenance of 
photoreceptor cells by ingesting and degrading the oldest outer segment 
discs of the photoreceptors [177]. They also contribute to the renewal of the 
retinoids in a series of reactions which are part of in the visual cycle. These 
RPE cells provide much of the trophic support required to maintain the 
photoreceptor cells in the form of various growth factors and components of 
the inter-photoreceptor matrix essential for the development and support of 
rods and cones [395]. The RPE is thus crucial for maintenance of the 
neurosensory retina and defects in RPE function give rise to various 
inherited and acquired retinal diseases; some of these diseases include 
important conditions such as age-related macular degeneration. 
 
The outer and inner segments of photoreceptor cells form the photoreceptor 
layer which lies internal to the RPE, and distal to outer nuclear layer. There 
are three layers of nuclei consisting of photoreceptor cell nuclei in the outer 
nuclear layer, the bipolar, horizontal and amacrine cells in the inner nuclear 
layer, and the ganglion cells layer which lies adjacent to the vitreous. 
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Photoreceptor cells, the rods and the cones share the same basic structure 
and are one of the most highly metabolic cell types in the body. All 
photoreceptor cells have light-sensitive visual pigments in their outer 
segment membranes, which after the absorption of a photon change their 
structure and thereby initialise the phototransduction cascade. Rods contain 
the pigment rhodopsin and are sensitive to conditions of dim light, thereby 
are responsible for scotopic (night) vision and peripheral vision. Cones 
contain different cone opsins depending on which sub-type of cone cell they 
belong to, and thus respond to bright light of varying wavelengths allowing 
colour vision. Rods dominate the photoreceptor cell population in the 
mammalian eye; there are approximately 18 times as many rods as cones in 
an adult human eye. In humans, cones are responsible for central visual 
acuity due to their spatial distribution (see below). The human retina contains 
3 types of cones, and, depending on the exact structure of the opsin 
molecule, are maximally sensitive to either long wavelengths of light (L-
cones, red light), medium wavelengths of light (M-cones, green light) or short 
wavelengths of light (S-cones, blue light). Rodents and most other 
mammalian species are di-chromatic, meaning they only have 2 types of 
cone cells that respond to medium-and short-wavelength light (M- and S- 
cones) [5,6]. Rods and cones in the photoreceptor layer are surrounded by 
the processes of specialized glial cells, Műller cells which are large glial cell 
types found in the inner nuclear layer and provide survival factors and 
nutrients for the inner retinal cells. The Műller cells are linked to each other 
by cellular tight junctions or zonula adherens comprised of foot processes of 
Műller cells known as the outer limiting membrane. This barrier is essential 
for the intra-neuroretina homeostasis. Between the layers of nuclei, are two 
layers of synapses, the outer and inner plexiform layers which form 
connections between the interneurons, photoreceptor cells and ganglion 
cells. The axons of the ganglion cells and astrocytes lie in the nerve fibre 
layer located internal to the ganglion cell layer and through which they join to 
the optic nerve. The inner limiting membrane, formed by Műller cells, is the 
innermost layer and separates the retina from the vitreous.  
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The average adult human eye has 5 million cone photoreceptors and 92 
million rod photoreceptors arranged in a non-uniform fashion across the 
scleral surface of the retina.[303] The distribution of photoreceptors varies 
between the central retina and the periphery. In the human retina, there is a 
central, pigmented portion of the retina called the macula which is enriched 
for cone photoreceptor cells. The macula measures approximately 5 mm in 
diameter and is located 3 mm lateral to the optic disc.  At the center of the 
macula area, the central portion of retinal tissue is referred to as the fovea 
centralis (Figure 1.3) which subserves the central vision and contributes 
most to visual acuity in humans because it contains the highest 
concentration of cone cells. There is a lack of rod photoreceptors at the 
fovea, cone cells are closely packed in the centre of the retina and the inner 
retinal cells here are displaced away from the underlying photoreceptors, 
allowing a greater proportion of incident light to be absorbed by the cells in 
this region. This also contributes to the increase in visual acuity in this central 
area. Towards the periphery, the density of cones decreases while the 
density of rods increases and is maximal in a 5 mm ring centered in the 
macula. Rodents and other mammals (other than non-human primates) lack 
a macula, with cones and rods more evenly distributed throughout the retina. 
Despite lack of an anatomically defined macula in rats and mice, the murine 
retina remains a useful model system in which human retinal disease can be 
studied. Many of the hereditary retinal disorders in humans have either a 
naturally-occuring equivalent in rodents, or have been created using 
transgenic, knock-out or selective gene ablation technologies [132].  Studies 
based on these animal models have provided valuable insights into the 
pathophysiology and mechanisms of these diseases in humans. However, 
the differences between human and animal retinal biology must always be 
borne in mind when extrapolating conclusions from animal experiments and 
applying these to the clinical scenario. 
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Mature photoreceptors are structurally and functionally polarized neurons 
with four separate domains comprising of outer and inner segments, a cell 
body that contains the nucleus and a synaptic region (Figure1.4). The light 
sensitive structures of the photoreceptors are the outer segments, that lie in 
the inter-photoreceptor matrix (IPM) between the apical microvilli of the RPE 
cells. In cones, the outer segments contain lamellae which are invaginations 
of the plasma membrane whereas rod outer segments contain dense stacks 
of membranous discs which are discrete from the plasma membrane.  
Inserted into cone lamellae and rod discs are the structural proteins 
peripherin-2 and rom-1, both of which are required for the formation and 
maintenance of outer segments. The discs and lamellae are formed 
constantly and act to enlarge the sensory surface. As the discs mature, they 
are diplaced distally and are phagocytosed by the RPE cells when they 
reach the tip of the outer segment. Incorporated into the rod photoreceptors 
membrane discs and cone lamellae are the light sensitive pigments 
rhodopsin and cone opsins respectively. These are the site of light 
absorption and phototransduction. The cilium connects the outer segment 
with the inner segment and is involved in the transport of proteins between 
the two. The inner segment is packed with a large number of mitochondria 
that provides the energy required for the process of phototransduction. The 
synapses hold vesicles, that distribute neurotransmitters after light 
excitement of the photopigment, thereby passing the signal on to bipolar 
cells in the inner nuclear layer. The flow of visual information in the retina can 
follow two paths: a direct path, from light receptors to bipolar cells to ganglion 
cells; and an indirect path, in which horizontal cells may be interposed 
between the photoreceptors and bipolars, and amacrine cells between 
bipolars and retinal ganglion cells. Horizontal cells, amacrine cells and 
interplexiform cells modulate the passage of impulses on their way from the 
photoreceptors to the ganglion cells. 
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1.2.2  Phototransduction  
 
The steady state for rod and cone cells is one of depolarization (Figure 1.5); 
unstimulated photoreceptor cells have open cation channels that allow 
sodium and calcium to enter and potassium ions to exit the cell. The steady 
influx of sodium ions maintains an electrical membrane potential of -40 mV 
on the inner cell membrane.  At this resting membrane potential, the 
neurotransmitter glutamate is released into the synaptic space where it is 
bound by receptors on post-synaptic bipolar cells. Upon stimulation, rods and 
cone cells revert to a hyperpolarised state which leads to a reduction in 
neurotransmitter release into the postsynaptic space, and subsequently 
gives rise to a neural message that is sent to the brain via other neuronal 
cells of the retina.  
 
The first step of translating light energy into a biological signal involves the 
phototransduction cascade (Figure 1.6) in photoreceptor cells.This 
commences with the absorption of a photon by the visual pigments in 
photoreceptor cells. The visual pigments are the opsins (rhodopsin in rods 
and cone opsins in cones) which are G-protein coupled receptors, seven-
pass transmembrane proteins inserted into the membranes of outer 
segments discs. The opsins contain the chromophore, 11-cis retinal, a 
vitamin A-derivative which is bound at the seventh intradiscal domain of the 
opsin molecule (Figure 1.7). On the absorption of light, 11-cis retinal 
undergoes photoisomerization to all-trans retinal and releases from the 
opsin, triggering the conformational change in the opsin GPCR [213]. This 
conformation change initiates a complex intra-photoreceptor signaling 
pathway, the phototransduction cascade, which is finally converted and 
amplified into an electrical response which is passed on to retinal neurons 
and to the brain via the optic nerve (for reviews on phototransduction, see 
[66], and [26]). 
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The conformational change in rhodopsin produces an active form of protein, 
metarhodopsin II [43]. Metarhodopsin II is the binding site for regulator 
proteins such as transducin, rhodopsin kinase and arrestin [167]. Each light-
excited photopigment binds several molecules of transducin which results in 
a 102 to 103 amplification of the visual cascade. Transducin is a member of 
the guanosine-5'-triphosphate (GTP) binding protein (G protein) family that 
connect receptors with their second messenger pathway. On interaction with 
metarhodopsin II, transducin molecules exchange bound guanosine 
diphosphate (GDP) for guanosine triphosphate (GTP), forming an active 
GTP-transducin (Gα*) complex.  
 
The newly formed Gα* molecule is an activated complex which dissociates 
from rhodopsin and the inhibitory Gβγ dimer. The GTP-transducin complex in 
turn activates phosphodiesterase (PDE) by binding to the PDE inhibitory γ-
subunit. PDE enzyme is made up of three subunits, α, β and γ. The binding 
of the PDE γ-subunit results in the dissociation of the PDE α and β-subunits 
from the γ-subunit. The αβ PDE dimer hydrolyses cyclic guanosine 
monophosphate (cGMP) to 5’-GMP. In dark conditions, the cellular cationic 
channels in photoreceptor membranes are kept in an open state by bound 
cGMP. The decrease in intracellular cGMP following light exposure causes 
the cGMP-gated Na+/Ca+ channels to close [510]. This prevents influx of 
sodium ions into the rod cells, and causes hyperpolarisation of the surface 
membrane along the entire cell. This in turn results in the voltage-gated Ca2+ 
channels closing and a subsequent decrease in the intracellular calcium ion 
(Ca2+) concentration. As a result, the neurotransmitter glutamate, which is 
continuously released in unstimulated conditions, is prevented from being 
released. The drop in glutamate release by the photoreceptor cells upon light 
exposure is sensed by bipolar cells, which respond either by depolarising or 
hyperpolarising their own synaptic membranes, depending whether they are 
ON- or OFF-bipolar cells.  
 
To complete the phototransduction cascade, the photoreceptor must be 
returned to the dark state. This involves shutting down of the enzymatic 
cascade and restoration of intracellular cGMP levels (Figure 1.7). The low 
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intracellular Ca2+ concentration activates recoverin which in turn leads to the 
activation of rhodopsin kinase, a serine/thereonine kinase belonging to the 
G-protein receptor kinase family whose phosphorylation activity is limited to 
the active form of rhodopsin [291]. Metarhodopsin II is inactivated by the 
ATP-dependent phosphorylation by rhodopsin kinase which allows a second 
photorecovery protein, arrestin to bind. The binding of arrestin causes steric 
hindrance which prevents transducin to be bound to phosphorylated 
rhodopsin, thus halting downstream signalling in the phototransduction 
cascade [495]. The inactivated photopigment (phosphorylated rhodopsin) 
exchanges all-trans retinal for 11-cis retinal and releases arrestin.  
  
In order for photoreceptor cells to return to their ‘ground state’ of 
depolarisation following light stimulation, the cGMP-dependent Na+/Ca2+ 
channels need to reopen through the resynthesis of cGMP. The decrease in 
intracellular Ca2+ after photoexcitation causes activation of guanylate cyclase 
activating proteins (GCAP I and II). The GCAP proteins are part of the 
calmodulin-like superfamily of calcium-binding proteins [147]. At low calcium 
levels, the GCAP proteins bind to the intracellular domain of retinal guanylate 
cyclase or RetGC, thereby stimulating the resynthesis of cGMP by retinal 
guanylate cyclase. The increase in cGMP levels allows them to bind to the 
cationic channels to reopen the channels and subsequently return the 
photoreceptor to its initial depolarised state in the dark. The period of time 
following light-excitation where cells return to their ground state is known as 
recovery. 
 
A key feature of phototransduction is the amplification of signal that can be 
achieved during the various steps in the cascade. The isomerisation of one 
rhodopsin molecule leads to the activation of hundreds of transducin 
molecules. Each activated transducin molecule then activates PDE which 
hydrolyses several cGMP molecules and leads to hyperpolarisation of 
around 1 mV. These tiers of amplification result in the sensitivity of 
photoreceptor cells where only a few photons are required for phtoreceptors 
to become hyperpolarised.  
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1.2.3 The visual cycle 
 
The ability of photoreceptors to function during many hours of continuous 
illumination requires that the inactivated visual pigment be continuously 
regenerated. The inactivation of metarhodopsin II by its phophorylation and 
arrestin binding and subsequently by its thermal decay produces opsin 
apoprotein and all-trans-retinal. The conversion of all-trans-retinal back to 
11-cis-retinal requires a complex sequence of biochemical reactions 
involving several enzymes and retinoid binding proteins. Collectively, these 
reactions are known as the visual cycle or retinoid cycle and take place 
primarily in the retinal pigment epithelium (RPE). This cycle generates a 
supply of new 11-cis-retinal which recombines with free opsin within the rod 
and cone outer segments to reform light-sensitive visual pigments (rhodopsin 
in rods and cone opsin in cones).The resynthesis and recovery of 11-cis 
retinal during the visual cycle is important to maintain sensitivity of the visual 
system (for reviews, see [396],[246,255].  
 
The visual cycle (Figure 1.8) begins with the release of all-trans-retinal from 
metarhodopsin II and is transported out of the outer segment disc by the rim 
protein, ATP-binding cassette protein in the retina (ABCA4). In the 
photoreceptor cytoplasm, all-trans-retinal is converted to all-trans-retinol by a 
rod-specific dehydrogenase (t-RDH). All-trans-retinol is transferred to the 
RPE, bound to interphotoreceptor retinoid binding protein (IRBP). In the 
RPE, all-trans-retinol is then bound to the intracellular transporter protein 
CRBP1.  The all-trans-retinol bound to CRBP1 is esterified to form all-trans-
retinyl ester bylecithin retinol acyl transferase (LRAT), through the transfer of 
a fatty acid from phosphatidylcholine. The next reaction is the most important 
reaction for the whole cycle, this couples hydrolysis of the retinyl ester with 
all-trans to 11-cis isomerisation of retinol. The energy released by ester 
hydrolysis is used to power the isomerization. This reaction is mediated by 
the isomerohydrolase RPE65 [332,399]. Subsequent steps in the visual cycle 
involve the oxidation of the 11-cis-retinol to the aldehyde form, 11-cis-retinal 
by by 11-cis retinol dehydrogenase (c-RDH). In RPE cells, 11-cis-retinal is 
carried by cellular retinaldehyde-binding protein (CRALBP). To get across 
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the subretinal space, 11-cis retinal is bound to IRBP and transported into the 
photoreceptors, where it is bound to the photopigment apoprotein in the 
outer segment discs and forms part of the visual pigment.  
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The established visual or retinoid cycle described above is the only source of 
rod opsin regeneration. It also provides for some cone opsin regeneration as 
well. However, the majority of cone opsin regeneration occurs through an 
alternative pathway that involves interactions between cones and Muller cells 
(Figure 1.9)[25,304]. This alternative pathway was discovered following 
observations that photoisomerization rates in sunlight greatly exceeds the 
maximal rate of all-trans to 11-cis re-isomerization by the established retinoid 
cycle in RPE, and that cultured Muller cells were able to isomerize all-trans-
retinol to 11-cis-retinol [98]. The cone-specific retinoid cycle is dependent on 
3 unique enzymes, an all-trans-retinol isomerase, an 11-cis-retinyl synthase 
and an 11-cis-retinol dehydrogenase. In this cycle, all-trans-retinol leaving 
the photoreceptor cells is absorbed by Muller cells, where it is directly 
converted to 11-cis-retinol by all-trans-retinol isomerase. The isomerization 
of 11-trans-retinol to 11-cis-retinol is thought to be driven by mass-action 
through the activity of 11-cis-retinyl synthase, which uses palmitoyl-CoA as 
an acyl donor. The palmitoyl-CoA dependent synthesis of 11-cis-retinyl ester 
results in the removal of 11-cis-retinol from the reaction space so that the 
equilibrium between all-trans-retinol and 11-cis-retinol is shifted towards 11-
cis-retinol formation.  The formed 11-cis-retinyl ester is eventually hydrolysed 
by retinyl ester hydrolase to yield 11-cis-retinol, which is taken up by the 
cones. The all-trans-retinol and 11-cis-retinol within the extracellular space in 
transit between the cones and Muller cells are bound to IRBP. Inside cones, 
11-cis-retinol is finally oxidized to 11-cis-retinal by a cone-specific 11-cis-
retinol dehydrogenase. The cone-specific retinoid cycle works at 20-fold 
faster than the RPE-based visual cycle. The pathway can only be utilized by 
cones since rods are unable to oxidize 11-cis-retinol to 11-cis-retinal; this 
prevents isomerized retinoids from being utilized by rods under daylight 
conditions when rod vision is not very important. Through this cycle, rods 
also effectively contribute towards the regeneration of cone pigments by 
supplying all-trans-retinol substrate for the Muller cell isomerase. All of these 
features work to regenerate cone visual pigments more rapidly. This allows 
cone to dark adapt more rapidly than rods and also allows them to maintain 
an appreciable fraction of regenerated pigment even at high light intensities 
so that they remain responsive at almost any level of illumination[25]. 
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The physiological processes in the phototransduction and the visual cycle 
depend on the close cooperation between the neuroretina and RPE. Defects 
in RPE-specific genes can also have deleterious effects on photoreceptor 
cells and vice versa. There is consequently much overlap in the clinical 
presentation of diseases of the photoreceptor cells and the RPE. The 
importance of this interaction is reflected in different retinal disorders. For 
example, mutations in the photoreceptor-specific gene, ABCA4 cause a type 
of juvenile macular degeneration, known as Stargardt disease and presents 
an example where defects in photoreceptor cells leads to RPE toxicity and 
death which subsequently results in photoreceptor degeneration. The protein 
encoded by ABCA4 is a transporter protein responsible for the ATP-
dependent translocation of N-retinylidene PE, an intermediate in the visual 
cycle from the lumen of the outer segment discs to the photoreceptor 
cytoplasm. The loss of functional ABCA4 results in accumulation of these 
intermediates in the outer segment discs, high levels of which lead to the 
formation of lipofuscin. The outer segment are subsequently shed and 
phagocytosed by RPE cells, leading to the accumulation of toxic lipofuscin in 
the RPE. Patients with this type of disease present with visual loss due to 
loss of RPE caused by the accumulation of toxic lipofuscin in these cells 
[234]. 
 
Many of these defects leading to retinal degeneration are inherited. The 
current study is focused on one of these inherited retinal diseases that is 
caused by defects in a gene encoding a photoreceptor specific protein 
known as AIPL1. 
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1.3  Inherited retinal degeneration 
 
1.3.1  Background 
 
Inherited retinal dystrophies are a relatively common group of human 
diseases and include conditions such as retinitis pigmentosa (RP) and Leber 
Congenital Amaurosis (LCA). Approximately 1/3000 people worldwide are 
affected by inherited retinal degeneration. It is characterized by the 
progressive death of the photoreceptor cells leading to loss of vision, and 
there is currently no effective treatment available. Retinopathies are caused 
by defects in any of a number of genes and have been an area of much 
interest as photoreceptors are increasingly used as a model system for 
studying neuronal cell biology. The identification of new retinal genes has 
grown particularly over the last decade; to date over 197 chromosomal loci 
and 154 causal genes have been identified (www.sph.uth.tmc.edu/Retnet/), 
accounting for 50% of the genetic defects in patients (Table 1.1). 
Identification of these genes and elucidation of their functions have provided 
new insights into the understanding of disease pathogenesis and provided 
the impetus to develop gene-based treatment strategies. In the past decade, 
studies in animals have reported that some forms of inherited retinal 
dystrophies are amenable to gene therapy. Recently, three clinical trials 
treating a form of LCA using gene therapy have reported preliminary results 
indicating that the treatment was safe and may be beneficial [34,181,293].   
 
The hallmark of this group of diseases is the genetic and clinical 
heterogeneity. Many of the mutations causing retinal dystrophies affect 
proteins which are specifically expressed either in photoreceptor cells or the 
retinal pigment epithelium. The functions of these proteins are diverse, 
ranging from phototransduction, visual cycle, retinal metabolism, 
photoreceptor structure to photoreceptor-specific transcription factors. 
Although the primary cell affected in retinal degeneration is often the 
photoreceptor cell, defects in other cell types such as the RPE or Muller cells 
can lead to reduced photoreceptor function and their subsequent loss (for a 
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review, see [467]). The mechanisms by which these disease mutations lead 
to death of photoreceptor cells are not completely understood. However, it is 
thought that in all forms of retinal degeneration, photoreceptors die via 
apoptosis (see [469] for a review). Mutations in the same gene can result in 
different diseases and different genes can share similar phenotypic features. 
Furthermore, allelic heterogeneity has been described where the same 
disease alleles can give rise to different phenotypes in patients even within 
the same family [432,519] (for review see[101]). The genetic and phenotypic 
heterogeneity of these conditions make the classification of these disorders a 
challenging task. Clinically, the difficulties are the overlapping signs and 
symptoms of the genetically distinct conditions and the intra-and inter-familial 
variability, in patients with the same gene defect and even in patients 
carrying the same mutation. Even though retinal disorders have been 
identified since the 19th century, the immense  genetic and clinical 
heterogeneity present great challenges for gene identification, mutation 
analysis, genetic counselling and development of therapies.(for reviews see 
[16,54,95]). 
 
Retinal dystrophies can be classified according to their clinical phenotype, 
and now increasingly according to their underlying molecular defects. 
Inherited retinal dystrophies can be further sub-classified according to the 
exact cell type affected. Rod dystrophies are caused primarily by the 
disruption of function and/or death of rod cells, while the cone population 
remains largely intact.  Patients with rod dystrophies present with primarily 
night blindness and progressive loss of visual field. Similarly, cone 
dystrophies affect only cones, resulting in impairment of colour vision and 
visual acuity, but night vision and peripheral visual fields remain unaffected. 
Most of the inherited retinal dystrophies involve a degree of loss of both rods 
and cones, and are therefore called rod-cone or cone-rod dystrophies, 
depending on which photoreceptor subtype is primarily affected. Notably, in 
advanced stages of these retinal dystrophies, both types of photoreceptor 
cells are involved resulting in loss of central vision which is the primary cause 
of loss of quality of life in these patients. These conditions can be further 
classified according to whether these disorders present as stationary or 
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progressive conditions; stationary disorders are caused by dysfunctional 
photoreceptors and have a stable disease, while progressive disorders are 
being caused by death of photoreceptors due to their underlying mutations.  
 
The inherited retinopathies can be classified as autosomal recessive, 
autosomal dominant or X-linked disorders. The main types of hereditary 
retinal dystrophies include RP, infantile onset LCA, achromatopsia, 
Stargardt’s macular dystrophy and cone-rod dystrophies, and the 
commonest mode of inheritance in majority of these disorders is autosomal 
recessive.	   	  Table 1.1 summarizes the various disease genes according to 
sub-type of retinal degeneration they are associated with.  Retinitis 
pigmentosa is the commonest form of hereditary retinal dystrophy affecting 
1.5 million people worldwide [54]. However, it is the most severe form of 
inherited retinal blindness, LCA that has been the main focus of ocular gene 
therapy in the past decade. In treating this condition, it is hoped that this will 
enable further treatments to be developed for other forms of genetic eye 
diseases.  
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Table 1.1 1 Summary of the number of genes causing inherited retinopathies according to 
disease category. The table shows the number of loci and genes that have been found 
which are associated with the various types of inherited retinal disorders. (RetNet, last up-
dated 8 Jan 2010) 
Disorder Number of Loci Number of 
genes identified 
Retinitis pigmentosa, autosomal recessive 
 
25 22 
Retinitis pigmentosa, autosomal dominant 
 
17 17 
Retinitis pigmentosa, X-linked 
 
6 2 
Cone-rod dystrophy, autosomal recessive 
 
7 6 
Cone-rod dystrophy, autosomal dominant 
 
7 5 
Cone-rod dystrophy, X-linked 
 
1 0 
Leber congenital amaurosis, autosomal recessive 
 
12 12 
Leber congenital amaurosis, autosomal dominant 
 
2 2 
Congenital stationary night blindness, autosomal recessive 
 
6 6 
Congenital stationary night blindness, autosomal dominant 
 
1 1 
Congenital stationary night blindness, X-linked 
 
2 2 
Macular degeneration, autosomal recessive 
 
2 2 
Macular degeneration, autosomal dominant 
 
13 7 
Chorioretinal atrophy, autosomal dominant 
 
1 1 
Syndromic/systemic diseases with retinopathy, autosomal 
recessive 
30 24 
Syndromic/systemic diseases with retinopathy, autosomal 
dominant 
8 7 
Syndromic/systemic diseases with retinopathy, autosomal X-
linked 
3 2 
Bardet-Biedl syndrome, autosomal recessive 
 
12 12 
Usher syndrome 
 
11 9 
Optic atrophy, autosomal recessive 2 1 
 
Optic atrophy, autosomal dominant 3 1 
 
Optic atrophy, X-linked 
 
1 0 
Other retinopathies, autosomal recessive 
 
15 12 
Other retinopathies, autosomal dominant 
 
10 5 
Other retinopathies, X-linked 
 
8 7 
Other retinopathies, mitochondrial 
 
7 7 
Ocular-retinal developmental disease, autosomal dominant 
 
1 1 
Totals 
Autosomal recessive diseases:     106  genes identified 
Autosomal dominant diseases:      47 genes identified 
X-linked diseases:                          13 genes identified 
Mitochondrial and other:                  7 genes identified 
213 173 
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1.3.1  Leber Congenital Amaurosis  
 
LCA is the most severe form of retinal dystrophy, causing loss of vision 
before the age of 1 year and accounts for 5% of all inherited retinopathies. It 
is the commonest cause of congenital blindness in children accounting for 
10-18% of cases[426]; with a population incidence of about 1/30000 [235], 
approximately 200,000 children worldwide suffer from this hereditary retinal 
dystrophy. It was originally described by Theodore Leber in 1869 as a 
congenital form of retinitis pigmentosa, presenting with blindness at birth with 
an essentially normal retina in appearance, nystagmus and sluggish pupils. 
This clinical definition was later modified to include a non-recordable or 
extinguished electroretinogram by Franceschetti and Dierterle in 1956[143]. 
Compared with other retinal dystrophies such as RP, a greater proportion of 
the causative genes have been identified and there are more studies 
demonstrating genotype-phenotype association in LCA, allowing for the 
prediction of the affected gene from the phenotypic characteristics. As it is 
well characterised, LCA has been a focus for preclinical research and the 
development of treatments. It is the first form of retinal dystrophy for which 
clinical trials of gene therapy has been developed. Success in these trials will 
form a stepping stone for other retinal diseases to be treated with gene 
therapy. 
 
 
1.3.1.1  Molecular genetics of LCA      
 
LCA is a genetically and clinically heterogenous disease. To date, more than 
400 mutations have been identified in 14 genes associated with LCA (Figure 
1.10A)(for a review, see[101]). A small number of dominant cases of LCA 
has been reported, and are associated with 2 genes, CRX and IMPDH1 
[59,365,406,443].  Apart from these, mutations in 12 genes, GUCY2D, 
AIPL1, CRB1, RPGRIP, RPE65, RD3, RDH12, LCA5, CEP290, LRAT, 
TULP1 and MERTK have been found to be associated with the more 
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common type of autosomal recessive LCA. The relative disease load varies 
for different genes [95,235] and is shown in Figure 1.10A. Together, the 
currently known LCA genes account for 60-70% of the cases while the 
remaining 30% of cases await discovery [236]. CEP290(15%) GUCY2D 
(12%) and CRB1 (10%) are the most frequently mutated genes and account 
for a large proportion of LCA cases.  
 
LCA genes encode a wide variety of retinal proteins that participate in a 
plethora of retinal cycles and pathways (Figure 1.10B).  LCA-associated 
proteins such as GUCY2D (retinal guanylate cyclase) and AIPL1 are 
involved in the phototransduction pathway; GUCY2D (retinal guanylate 
cyclase) is an enzyme that resynthesizes cGMP required for the recovery of 
the dark state after phototransduction, while AIPL1 (aryl hydrocarbon 
receptor interacting protein-like 1) is involved in biosynthesis of 
phosphodiesterase. Three LCA genes encode proteins that play important 
roles in visual retinoid recycling; RPE65 encodes a microsomal protein 
involved in the isomerization of all-trans-retinol to all-cis-retinol, RDH12 
encodes a retinol dehydrogenase that catalyzes the reduction of all-trans 
retinal to all-trans retinol and protects cells against the leakage of toxic all-
trans retinal into the inner segments [290], and LRAT encodes a protein that 
catalyzes the synthesis of retinyl esters in the visual cycle and is a part of the 
process to recycle used all-trans retinal to the active chromophore 11-cis 
retinal [40,198].  Other genes are involved in the development of the retina 
such as CRX (cone-rod homeobox) which encodes a transcription factor that 
is crucial for outer segment development as it transactivates a number of key 
retinal proteins, while CRB1 (Crumbs homolog protein) is critical for 
photoreceptor morphology and retinal architecture by ensuring correct 
functioning in cell-to-cell adhesion, intercellular signalling and directional 
transport of molecules.  IMPDH1 directs the biosynthesis of guanine, a key 
component of DNA and cGMP which plays a vital role in phototransduction. 
Several LCA proteins localize to the connecting cilia of photoreceptors and 
are involved in protein trafficking such as RPGRIP (retinitis pigmentosa 
GTPase interacting protein1), CEP290 (centrosomal protein 290) and LCA5 
(lebercilin), highlighting the emerging role of the ciliary processes in the 
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pathogenesis of LCA. CEP290 likely participates in transport of 
phototrasduction proteins through the ciliary apparatus of the photoreceptor. 
Finally RD3 encodes a photoreceptor nuclear protein whose function is not 
yet known. 
 
 Recently, it has been suggested that phenotypes caused by mutations in a 
single gene become more severe when a mutation in an additional gene is 
also present and such additional gene is known as a modifier gene. 
Examples of modifier genes have been described in Stargardt’s disease 
[521] and Usher’s syndrome [3]. A systematic analysis of all known 
mutations in LCA genes revealed that a greater number of LCA patients 
carry a third variant or disease allele than might be expected by chance 
alone [519]. Family members who carried a third disease allele in another 
gene had a more severe phenotype than family members who did not carry 
this allele, suggesting that these alleles may act as genetic modifiers 
[432,519]. Clearly, the manifestation of the disease depends much on 
interplay between different genes or loci and also influences from by external 
factors such as the environment. 
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1.3.2.2 Clinical features and genotype-phenotype 
correlation in LCA 
 
As well as having diverse genetic causes, LCA is clinically heterogenous, 
making clinical diagnosis a difficult task for the practising ophthalmologist. 
The LCA phenotype overlaps with many other similar but separate retinal 
diseases, and several syndromic disease can have an “LCA-like ocular 
phenotype” that may initially present without the systemic features, but these 
develop and dominate the phenotype later on. The most important of these 
include Alstrom syndrome, Batten disease, Joubert syndrome, peroxisomal 
diseases and Senior-Loken syndrome. All of these syndromic diseases 
present in infancy like LCA with early central visual loss and nystagmus, but 
these children later develop the full syndrome with multisystem disorders. 
The underlying pathology, molecular defects, prognosis, inheritance and 
treatment of these overlapping syndromic and non-syndromic ocular 
diseases are entirely different from those of LCA. It is crucial to separate 
these overlapping eye diseases from LCA, and rapid and accurate clinical 
diagnosis is therefore essential. 
 
The classical LCA patient presents early in life, at about 6 weeks with 
severely reduced vision, nysytagmus, poor fixation, amaroutic pupils, 
oculodigital behaviour and the fundal appearance is frequently 
unremarkable. Manifest visual function and visual acuity in LCA patients can 
range widely, usually from 6/60 to light perception or no perception of light. 
Longitudinal studies of visual function in LCA patients performed before the 
disease gene were identified, found that patients fell into three categories of 
visual prognosis. The majority (75%) of LCA patients displayed a relatively 
stable course, a smaller group (15%) showing visual deterioration, and the 
smallest group (10%) had measureable improvement in function 
[61,149,184]. Later, it has been found that the natural history of visual 
function in LCA patients could be correlated with certain genotypes (Figure 
1.11). Patients with CEP290 and GUCY2D mutations appear to have poor 
but stable visual function [235]. LCA patients with AIPL1, RDH12 and 
RPGRIP1 mutations have progressively deteriorating visual function with age 
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[104,236]. Patients with CRB1 and RPE65 mutations exhibit mild 
improvements in early ages, but then decline mainly during school years 
after a period of stability [285,517]. The reason for this transient improvement 
is not fully understood but a part of it may be due to postnatal physiological 
cone maturation. At young ages, patients with RPE65 mutations also appear 
to have better visual function than is than is typically associated with other 
genetic forms of LCA, and a number of patients maintain some useful visual 
function beyond the second decade of life [468]. 
  
Fundal appearances range from essentially normal to peripheral 
pigmentation, vessel attenuation, and varying chorioretinal and macular 
atrophy. Other retinal features include pseudopapilloedema of the optic disc, 
maculopathy, macula coloboma, bone spicule pigmentation, nummular 
pigmentation, salt and pepper pigmentation, yellow confluent spots, white 
retinal spots, preserved para-arteriolar RPE (PPRPE) and Coats reaction. 
Despite the fact that hereditary retinal dystrophies and LCA gene defects 
converge on a limited number of apoptotic death pathways and that the 
highly specialized retina only has a limited number of injury responses, it 
appears possible to identify the causal gene based on the retinal appearance 
or a phenotypic parameter in certain cases. Genotype-phenotype 
correlations have been described in the retinal appearances and longitudinal 
changes in visual function [236]. These are summarised in Table 1.2. 
Patients with CRB1 mutations often have a thickened immature, poorly 
laminated retina on optical coherence tomography (OCT) scanning and 
evidence of PPRPE in the fundus [205]. Improving visual function and a 
translucent retina suggests RPE65 involvement [285], while a rapidly 
declining visual function and maculopathy suggests RDH12 [427]. Severe 
visual loss and an essentially normal retinal appearance suggests defects in 
either CEP290 [100] or GUCY2D[103], while severe visual loss with a 
pigmentary retinopathy suggests RPGRIP [103]. Figure 1.11 shows 
examples of the retinal appearances of LCA patients with defects in various 
genes, highlighting the retinal differences associated with the genotypes.  
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Table 1.2   Summary of phenotype-genotype correlations in LCA 
  
 
Phenotype characteristic 
 
Probable gene defect 
Preserved para-arteriolar retinal pigment epithelium (PPRE) CRB1 
Nummular retinal pigment CRB1 
Thickened retina on OCT CRB1 
Coats-like vasculopathy CRB1 
Severe early visual loss with relatively normal fundus GUCY2D, CEP290 
Severe early visual loss, progressive course and retinal 
pigmentation 
RPGRIP1 
Severe early visual loss, keratoconus, variable maculopathy, 
optic disc pallor 
AIPL1 
Moderate visual loss, maculopathy CRX 
Early moderate visual loss with progressive deterioration, 
maculopathy, marked retinal pigmentation 
RDH12 
Relatively stable vision, blond fundus LRAT 
Transient visual improvement followed by decline, translucent 
RPE 
RPE65, LRAT 
Pseudopapilloedema LCA5 
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Electroretinography (ERG) is a method of recording mass retinal electrical 
impulses generated by photoreceptors in the retina on exposure to light 
stimulus and provides a measurement of the visual function in tested 
subjects. Indirectly, the ERG response gives an indication of the progress of 
photoreceptor cell loss over time (for a review, see {Holder, 2001 708 /id}) 
and can be used as an uninvasive means to monitor the effects of treatment 
over time. The electrical response generated by the retina in response to 
light is measured by the single flash electroretinogram which has 3 main 
components: The initial negative deflection is known as the a-wave and is 
generated by the depolarization of photoreceptors following the closure of 
cyclic GMP channels in the outer segments in response to photon capture. It 
reflects the level of phototransduction that occurs in the retina as a whole. 
The a-wave is followed by a large positive deflection known as the b-wave 
which is generated by Muller and bipolar cells in the inner nuclear layer. The 
b-wave amplitude depends on the degree of depolarization that has taken 
place in photoreceptors. Hence, the b-wave indirectly correlates with the 
number of functional photoreceptors in the retina. The final component of the 
ERG is the c-wave which is a positive signal that occurs near the end of the 
tracing and is largely elicited by the retinal pigment epithelium (RPE). The 
disappearance of the c-wave is an indication of the disturbed function of the 
RPE, and is often seen at an early stage a disease since RPE is integral to 
photoreceptor homeostasis. A series of little wavelets seen on the upslope 
between the a and b-waves of an ERG trace are known as oscillatory 
potentials. They represent postsynaptic neuronal activity in the inner retina, 
and reflect the health of the inner layers of the retina{Wachtmeister, 1998 
707 /id}.  In ERG analysis, the waveform amplitude and implicit time are 
normally measured. By varying the conditions of testing and adaptation, the 
ERG can measure rod and cone responses separately; the scotopic ERG 
which is performed after a period of dark adaptation measures rod responses 
and maximal combined response when elicited with a bright white flash, 
while the photopic ERG or flicker ERG isolates the cone responses.	   The 
ERG responses are classically absent or severely diminished in LCA 
patients. This is one of the basic features of the condition. ERG analysis of 
family members may also aid the identification of disease genes as cone 
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ERG dysfunction has been found in heterozygous carriers of GUCY2D 
mutations, and rod and cone ERG dysfunction has been found in 
heterozygous carriers of RPGRIP mutations. The advent of more detailed 
imaging technology has enabled further characterisation of retinal phenotype 
in LCA patients. Fundus autofluorescence measures lipofuscin accumulation 
in the RPE which is related to photoreceptor disc shedding. This allows for 
the visualization of disease-specific distribution of lipofuscin in the RPE 
which is not yet visible on ophthalmoscopy. Notably, reduced autofluoscence 
has been described in LCA patients with compound heterozygous or 
homozygous RPE65 mutations, suggesting a lack of lipofuscin manufacture 
due to the loss of normal functioning of the visual cycle.  
 
Optical coherence tomography (OCT) is a non-contact, non invasive imaging 
technique used to obtain cross-section images of the retinal architecture at 
much higher longitudinal resolution of about 10 µm  in the retina. It is a useful 
tool in determining the extent of retinal integrity in selected retinal 
dystrophies and the retinal response to the genetic lesion. Work by Jacobson 
et al.  using OCT imaging demonstrated that patients with RPE65 mutations 
had measurable outer nuclear layer (ONL) and many had normal foveal 
thickness [202]. This study showed that despite advanced age and visual 
loss, retinal dystrophy patients with RPE65 defects have viable 
photoreceptors and residual cone photoreceptor structure and function 
persisted for decades. This finding suggested that these patients may be 
amenable to gene replacement therapy and visual improvement may be 
observed if treatment was performed at an early age. The study was  
instrumental in supporting clinical trials of gene replacement therapy in LCA 
patients with RPE65 mutations. OCT studies of LCA patients with CRB1 
mutations on the other hand revealed a lack of normal retinal lamination, 
increased overall retinal thickness apart from the loss of the ONL at the 
foveal centre [205]. Similarly, LCA patients with RDH12 mutations had thick 
retinas with the same disorganised pattern which is evidently different from 
RPE65-associated disease [207]. These findings indicate that these patients 
may not be particularly suitable for gene therapy as there is early 
derangement of the retinal structure and lack of viable photoreceptor cells 
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remaining in the retina. LCA patients with RPGRIP mutations showed normal 
ONL measurements at the foveal centre, although measurements rapidly 
declined with increasing eccentricity from the fovea [206]. LCA patients with 
CEP290 mutations unexpectedly retained photoreceptors in the cone-rich 
fovea, despite severe visual loss [88], while patients with GUCY2D defects 
were found to contain intact cone photoreceptors up to 7 years of age [321]. 
LCA patients with mutations in other genes such as AIPL1, CRX, IMPDH1, 
LCA5 and RD3 have yet been analysed in the same way. These studies 
suggest that despite the presence of retinal modelling in LCA, viable 
photoreceptors appear to remain in certain forms of disease until relatively 
late in the disease process, providing a window of opportunity for therapeutic 
intervention. These types of genotype-phenotype studies must be viewed 
with caution, however, as the connection between gene defect and resulting 
phenotype is not straightforward. Environmental, genetic background, 
modifier alleles and overlap between gene defects affect this relationship, 
while different mutations in the same gene can give rise to different 
phenotype. The importance of genetic testing and being able to determine a 
molecular diagnosis in a complex and varied group of diseases such as 
retinal dystrophies is obvious. It allows for more specific characterisation of 
the disease than the clinical phenotyping can provide, facilitates information 
sharing, prognostication and helps to establish a genotype-phenotype 
correlation system. It will also aid in identifying new retinal genes and in the 
selection of candidates for gene-base treatments in the future.  
 
Histopathological studies of LCA in human tissue are scarce, understandably 
due to the difficulty in obtaining specimens. To date, only thirteen 
pathological specimens from LCA patients have been described in the 
literature and three possible disease categories have emerged from the 
analysis of these studies. Seven cases appeared to represent degenerations 
in which the photoreceptor, inner retinal layer and RPE layer showed 
extensive atrophy and gliosis [138,381,453]. Three cases appeared to 
represent aplasias, and showed complete absence of the photoreceptor 
layer or the presence of very unusual looking, primitive cuboidal cells in this 
layer [141,157,483]. Finally, a further three cases suggested biochemical 
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dysfunction or dysplasia as the disease process. In these specimens, almost 
the entire retina was retained; the inner retinal layers, the photoreceptor layer 
and the RPE appeared intact despite the fact that the globes came from 
adults who were blind from LCA since young [141,191,235,321]. Moreover, 
in six of the thirteen globes, the inner retina was essentially normal in 
appearance and architecture based on microscopic evaluations. These 
observations suggest that some forms of LCA may still respond favourable to 
treatment based on the presence of an intact retinal structure even in 
advanced stages of disease. Unfortunately, most of the cases in these 
studies were not genotyped, thus precluding any useful histopathology-
genotype correlations which may aid towards identifying the forms of LCA 
which may be amenable to treatment. 
 
1.3.2.3 AIPL1 mutations in inherited retinal dystrophies   
 
Mutations in the aryl hydrocarbon receptor-interacting protein-like 1 gene 
(AIPL1) are thought to cause approximately 7-8% of LCA worldwide 
[103,174,444]. The gene was discovered during an effort to identify and map 
genes expressed exclusively in the retina and pineal gland as candidates for 
inherited retinal degeneration. AIPL1 was mapped to chromosome 17p13.1, 
near the candidate region of several inherited retinal degenerations and was 
the fourth gene to be associated with LCA [440].  The AIPL1 gene 
encompasses six exons encoding a protein of 384 amino acids in length.  
The AIPL1 protein is found exclusively in photoreceptors [475] and recent 
studies have shown that AIPL1 is expressed in both rods and cones where it 
is essential for the survival and function of photoreceptors [65,232]. 
 
It has been suggested that AIPL1 could fulfil a molecular chaperone function 
for retinal protein folding [79]. By sequence comparison, AIPL1 is related to 
the FK-506-binding protein (FKBP) family which comprise the immunophilin 
superfamily of proteins[439], many of which function as specialised 
chaperones. The chaperone function of this protein family does not typically 
act at the step of initial polypeptide folding, but rather assist client proteins in 
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later stages of maturation, subunit assembly, transport and degradation 
[511]. Many such client proteins are components of signal transduction 
pathways. The protein sequence of AIPL1 includes three consecutive 
tetratricopeptide repeat (TPR) motifs, a 34-amino acid degenerate motif 
comprising of a pair of anti-parellel α-helices (Figure 1.13A). TPR domains 
act as molecular scaffolds mediating protein interactions and are conserved 
in structurally related proteins that participate in diverse biological functions, 
including the coordination of multiprotein complex assembly and protein 
translocation [55].  The presence TPR motifs makes AIPL1 more closely 
related to the larger members of the FKBP family (Figure 1.13B) such as 
FKBP52 , which forms a complex with the large heat shock protein Hsp90 
and functions as a specialised co-chaperone [511]. AIPL1 also shares 49% 
amino acid identity with aryl hydrocarbon receptor interacting protein (AIP), 
which is a known specialised chaperone required for bonding to aryl 
hydrocarbon receptor, a transcription factor that shuttles in and out of the 
nuclei [73,370]. These sequence similarities suggest that AIPL1 may also 
function as a specialised chaperone in photoreceptor cells, facilitating protein 
translocation and as a component of chaperone complexes. A 56-amino acid 
polyproline-rich sequence is present at the carboxyl-terminus of human 
AIPL1 protein (Figure 1.12B). This sequence forms a hinge region in the 
protein and is primate-specific. Sequence comparison between primate 
species suggest that there is a high amount of sequence conservation within 
this hinge region between primates (squirrel monkey, rhesus monkey, and 
humans). The function of this region is unknown but similar sequences are 
found in proteins acting in processes requiring rapid recruitment or 
interchange of several proteins, such as signalling cascades or initiation of 
transcription [223]. 
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Several possibilities have been proposed regarding the essential role of 
AIPL1 in the retina. Using yeast two-hybrid analysis, AIPL1 has been found 
to interact with Nedd8-ultimate buster protein-1 (NUB1), a ubiquitously 
expressed protein thought to play an important role in regulating cell cycle 
progression and cell signalling [7]. Through its association with NUB1, AIPL1 
has been predicted to be involved in the regulation of these events. While 
AIPL1 is predominantly cytoplasmic, NUB1 is predominantly nuclear. Co-
transfection of AIPL1 with GFP-tagged NUB1 demonstrated that AIPL1 is 
able to modulate the nuclear translocation of NUB1 from the nucleus to 
cytoplasm, and suppress the formation of inclusions by NUB1 fragments and 
redistribute these fragments in the cytoplasm [476]. Using site-directed 
mutagenesis, known pathogenic variants of AIPL1 were generated and co-
transfected into neuroblastoma cells to characterise the effect of these 
mutations on the ability of AIPL1 to modulate NUB1 localization and inclusion 
formation. This function of AIPL1 was shown to be severely compromised by 
the expression of some of the disease-associated mutant AIPL1 proteins 
such as the pathological mutation, W278X; other mutations such as R302L 
resulted in less efficient nuclear translocation of NUB1[476]. However, the 
impact of the AIPL1-specific NUB1 modulatory function on biological events 
downstream of NUB1 is unknown. 
 
Yeast two-hybrid analysis also demonstrated that AIPL1 is able to interact 
with and aid in the processing of farnesylated proteins in the retina [393].  
Farnesylation is a specific type of prenylation. In the retina, protein 
prenylation facilitates protein-protein and protein-membrane interactions, and 
is important for the maintenance of retinal and photoreceptor 
cytoarchitecture.  Inhibition of prenylation has been shown to cause 
photoreceptor outer segment degeneration [378]. The ability of AIPL1 to 
interact with and enhance the processing of farnesylated proteins is severely 
compromised by certain pathogenic mutations such as M79T and the non-
functional W278X.  Some AIPL1 mutants such as A197P, are partially 
defective in their ability to facilitate the processing of farnesylated proteins, 
but are functional with respect to their effect on NUB1. Other mutants such 
as R302L on the other hand, do not show any defect in protein farnesylation 
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but are compromised in NUB1 function. Retinal proteins which are known to 
be farnesylated include cGMP PDE-α subunit, transducin and rhodopsin 
kinase [23,148,200,252].  
 
Yeast two-hybrid studies however are not always reliable, and the findings 
from these in vitro studies of AIPL1 interactions do not appear to be 
supported by in vivo studies using animal models. Three mouse models of 
LCA have been generated with either complete or partial loss of AIPL1. Two 
Aipl1 -/- mouse strains carry targeted disruptions in the Aipl1 gene and 
produces no AIPL1 [119,392]. Retinal degeneration in these models is 
extremely rapid degeneration in this model (all photoreceptors are loss by 
three weeks of age). The other model, the Aipl1 h/h mouse contain an Aipl1 
hypomorphic mutation with reduced AIPL1 levels and has a slower rate of 
photoreceptor degeneration [282]. In both models, normal retinal histology 
and morphological photoreceptor development were observed at birth. 
Hence, despite evidence that seems to suggest a role for AIPL1 in cell cycle 
regulation and retinal development, the absence of gross abnormalities in 
young AIPL1-deficient mice indicate that AIPL1 is not essential for retinal 
proliferation or the commitment to photoreceptor cell fate. Moreover, retinal 
degeneration in both models did not begin until postnatal 8-10 days in the 
Aipl1 -/- mouse and 12 weeks after birth in the Aipl1 h/h model.  
 
Analysis of the null and hypomorphic mouse models showed that retinal 
degeneration in AIPL1 mutations is due to disturbance in the biosynthesis or 
stability of rod photoreceptor cGMP PDE (PDE6). Almost no PDE6 is found 
to accumulate in the Aipl1 -/- mouse [392]. In the Aipl1 h/h mouse, there is a 
decline in PDE level which is proportional to the reduction in the level of 
AIPL1, and all three subunits α, β and γ of PDE6 are similarly affected. This 
observation is highly specific for PDE, as analysis of a large number of other 
photoreceptor proteins found no change in their expression levels in the 
Aipl1 h/h mouse [282]. Analysis by semiquantitative RT-PCR found no 
substantial decrease in the mRNA levels of any of the PDE6 subunits, 
indicating that AIPL1 acted to modulate PDE6 levels at a post-translational 
stage. Given the homology of AIPL1 to other members of the FKBP family, it 
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would seem reasonable to presume that AIPL1 functions as a specialised 
chaperone to assist in PDE6 biosynthesis. As a specialised chaperone, it is 
likely that AIPL1 plays a role in the final maturation or trafficking step of 
PDE6 synthesis rather than as a folding accessory protein. In all the mouse 
models, it was shown that apart from PDE6, levels of expression and 
subcellular distributions of all other retinal proteins, including rhodopsin 
kinase and transducin which are normally farnesylated, were unaffected 
[282,392]. These observations thus rule out a generalized defect in protein 
farnesylation in mutant photoreceptors.  The link between AIPL1 and PDE6 
has since been further elucidated, despite the destabilization of PDE6 in the 
absence of AIPL1, AIPL1 is not involved in the synthesis individual PDE6 
subunits. AIPL1 has been found to interact with the α-catalytic subunit of rod 
PDE and is required for the proper assembly of functional PDE6 
subunits[240]. In the absence of AIPL1, rod PDE6 subunits are rapidly 
degraded by proteosomes. 
 
Recently, through the development of a novel transgenic mouse that 
expresses human AIPL1 solely in rod photoreceptor cells (tg hAIPL;Aipl1-/-), 
it was shown that AIPL1 was also crucial to the survival and function of cone 
photoreceptors[232].   Although the cones lacking AIPL1 in this transgenic 
model developed normally, they were not functional and eventually 
degenerate in the absence of AIPL1. The degeneration of cones in this novel 
model was however significantly slower in the presence of viable rods, in 
contrast to the Aipl1-/- mouse where rods also degenerate. Further analysis 
by demonstrated that cone PDE6 levels was severely reduced in the retinal 
extracts although cone PDE mRNA was not altered despite the lack of 
AIPL1. This indicated that the reduction of cone PDE6 levels occurred at a 
post-translational level, in a similar way seen in rods lacking AIPL1[282]. 
Since AIPL1-deficiency did not cause developmental defects in cones, the 
lack of cone function this model was thought to be due to disruption in 
phototransduction consequent to the severe reduction of cone PDE6. It has 
been suggested that the slow degeneration of cones in this model may be 
analogous to the cones in the fovea of patients with AIPL1 defects surviving 
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for a longer period of time[232]. This may offer an extended window for 
treatment that allows the preservation of cone vision. 
 
1.3.2.4 Molecular genetics of AIPL1 mutations  
 
Genetic defects in AIPL1 cause a heterogenous set of clinical conditions 
depending on the nature of the alleles.  AIPL1 mutations have been 
estimated to cause approximately 7% of recessive LCA cases [442] and 
have also been associated with cone-rod dystrophy and retinitis pigmentosa 
[103,441]. To date, at least 20 different disease-causing AIPL1 mutations 
have been identified (HGMD; www.hgmd.org). Often the variability in 
phenotype can be explained by the type of mutation. Some mutations lead to 
truncation of the reading frame and hence are expected to result in complete 
absence of a functional protein, such as nonsense mutations and splice site 
mutations. In these cases where there is no AIPL1 function, a severe 
phenotype results. On the other hand, missense mutations may not abolish 
protein function completely and may therefore be associated with a milder 
phenotype [8,393,476].  
 
Most of the gene defects in AIPL1 identified to date are homozygous or 
compound heterozygous mutations in an autosomal recessive pedigree.  A 
homozygous mutation is present when identical sequence variants are found 
in both alleles, while a compound heterozygous mutation comprises of two 
different sequence variants found in the maternal and paternal alleles of a 
particular gene. The difference between a compound heterozygote and 
digenic disease is that in digenic inheritance, mutation in a gene causes 
disease only in patients who also carry mutation in a diferent gene. Two 
large mutation analysis studies in patients with disease-associated AIPL1 
mutations have found that the W278X mutation comprised approximately half 
of the total disease alleles found [103,174].  If expressed, this allele would 
produce a severely truncated protein that is shorter than the wild-type AIPL1 
by 107 amino acids. The truncated protein includes only 20 of the 34 amino 
acids of the third TPR motif, a highly conserved region on the AIPL1 protein.  
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This mutation was originally identified in homozygous form in two 
consanguinous Pakistani families, a non-consanguinous family of European 
descent, and in compound heterozygous form in another European family 
[440] together with a 2-bp deletion in codon 336 (A336∆2 bp). This deletion 
resulted in a frameshift and a termination codon 47 amino acids later. A 
further study that screened AIPL1 in a large cohort of patients with a wide 
range of clinical diagnosis of inherited retinal dystrophies reported 
homozygous and compound heterozygous W278X mutation in non-
consanguinous European families; the W278X mutation was found in 
combination with a splice-site mutation (c.277-2A>G) and an amino acid 
substitution G262S [442]. Interestingly, the results from this study suggested 
that AIPL1 mutations may also cause autosomal dominant cone-rod 
dystrophy and retinitis pigmentosa [442].  The probands of two families were 
heterozygous for a 12 bp deletion (P351∆12 bp) within the sequence 
encoding the hinge region of AIPL1. The mutant protein hinge was predicted 
to lack four amino acids, this included two proline residues located at 
positions that were conserved across the primate species. This deletion 
occured adjacent to a predicted casein kinase II phosphorylation site, that 
might be involved in protein complex regulation [327]. This deletion was not 
found in control individuals and in the DNA from two unaffected individuals of 
the family. However, the pedigrees from these families were small and DNA 
samples from additional family members were unavailable. It would be 
important for additional studies to be performed on more autosomal 
dominant pedigrees with these clinical diagnoses to confirm the segregation 
of the mutation with retinal degeneration, and further expression studies 
would be helpful in determining the effect of the mutation on protein structure 
and function.  The function of the proline-rich region of AIPL1 is currently not 
known and the effects of mutations such as P351∆12, A336∆2 and P376S 
that are located within the hinge region are uncertain. Preliminary data 
suggests that a high amount of sequence conservation exists within the 
hinge region between the primate species. More importantly, this proline-rich 
region is only found in primates and therefore may have an important role in 
primate vision or in cone-rich retina. 
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1.3.2.5   The phenotype of LCA in patients with AIPL1                               
              mutations 
 
The phenotype of LCA in patients with LCA due to mutations in AIPL1 is 
relatively severe compared with that of most other forms of LCA [103]. 
Studies comprising of mutational analyses of AIPL1 mutations in patients 
with retinal dystrophies are relatively few in number and most of them include 
only small cohorts of patients. The largest study thus far was by Dharmaraj 
et.al., which described the phenotypic features of 26 probands with AIPL1-
related LCA [103]. Of these subjects, 17 probands were homozygotes and 9 
were compound heterozygotes, and the ages of the patients at examination 
ranged from 4 months to 57 years.  Visual acuities were severely reduced in 
these patients, ranging from 6/60 to light perception. The majority of the 
patients achieved only light perception (LP) by the time they reached the 
second decade, although there was one patient in the study who maintained 
vision of 6/360 at the age of 27 years. The youngest patient aged 4 months, 
was able to fixate and follow objects. Cycloplegic refraction showed that 
most of these patients had moderate hypermetropia, ranging from +3.00 to 
+7.00 dioptres [103].  A different study by Galvin et al. performed a mutation 
screen in a cohort of LCA patients across six genes and found that LCA 
patients with disease-causing sequence variations in AIPL1 had severely 
decreased vision at a younger age compared to other genotypes, although 
the number of patients identified with AIPL1 variation in this study was small 
(n=7) [151].  These findings were in keeping with findings of other reports 
[435,440]. Longitudinal evaluations of visual acuity in AIPL1 patients are very 
limited. It has been suggested that there is a progressive decline in visual 
acuity in many patients, usually over a 10-20 year follow up period [151]. A 
few patients, however,  mostly those with heterozygous mutations have been 
noted to have relatively stable vision. One of these patients was reported to 
maintain visual acuity of 20/200 after 16 years [151]. 
Features of night blindness and photosensitivity are variable in patients with 
AIPL1-related disease.  The study by Dharmaraj et al. reported night 
blindness or nyctalopia in approximately half of the patients with AIPL1 
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mutations, and photoaversion or photophobia was reported in only 15% of 
their patients. The study by Galvin et al. reported nyctalopia in almost all of 
the patients with AIPL1 mutations (6 out of 7), while less than half had 
photophobia. These findings were in contrast to a study by Hanein et al.  
which was a comprehensive mutation analysis of 6 LCA genes (GUCY2D, 
RPGRIP, AIPL1, RPE65, CRB1 and CRX) in a cohort of 179 unrelated LCA 
patients. Six patients (3.4% of cases) were found to have mutations in AIPL1 
in this study. Based on clinical observations, the authors divided LCA 
patients into 2 groups displaying either photophobia or night blindess.  
Features of photophobia but not night blindess at an early age were thought 
to be a feature of AIPL1 mutations.  Photophobia in early stages is also seen 
in other LCA mutations such as GUCY2D and RPGRIP. Although the precise 
underlying mechanism of photophobia in retinal dystrophies is not well 
understood, it has been suggested that the feature is related to cone 
dysfunction and is a hallmark in conditions with primary derangement of cone 
function such as cone dystrophies and achromatopsia.  
 
There is more consensus across various studies in terms of the fundal 
appearances associated with AIPL1 mutations.  At early ages, from birth to 
pre-school age, essentially normal retinas and maculae have been observed 
[103,151].  By school age, patients tend to develop diffuse hypopigmentation 
and RPE mottling primarily in the mid-peripheral retina (Figure 1.14A). In 
advanced disease, usually around the sixth and seventh decades of life, 
there is extensive bone-spicule pigmentary clumping, atrophy of the RPE 
and chorioretina, atrophic maculopathy, optic nerve pallor and attenuation of 
the retinal vasculature (Figure 1.14C and D) [103,151,435].  Some patients 
have also been described to have drusen-like deposits in the retina in the 
first and second decades of life (Figure 1.14B) [151]. Variable levels of 
maculopathy was observed in majority of patients. Early stages of 
maculopathy in the form of an indistinct foveal reflex may be seen in young 
children of school ages. Later, the maculopathy in patients can range from 
mild foveal atrophy to bull’s eye-appearing atrophic macular lesion to gross 
aplasia [103,151,435]. In the study by Dhamaraj et al, the youngest patient 
with macular atrophy was 8 years old [103]. Optic nerve pallor was noted in 
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all patients at later ages. Compared with other genotypes, a higher 
proportion of AIPL1 patients were found to have keratoconus and cataracts 
The types of lens opacities ranged from cortical to posterior subcapsular 
opacities[103,440].  The incidence of cataracts and keratoconus is increased 
with age; the youngest patient described with keratoconus and cataracts was 
10 years patient [103].  Visual fields and electroretinogram (ERG) are 
generally undetectable in patients with established AIPL-related disease. 
Figure 1.15 shows ERGs from an affected proband with homozygous W88X 
mutation and a heterozygous carrier parent of the patient. No measureable 
responses are seen in the affected patient, and both scotopic and photopic 
responses were equally extinguished (Figure 1.15A).  Although most 
heterozygous carriers of AIPL1 mutations are clinically normal, some ERG 
abnormalities have been reported in the form of reduction of rod b-wave 
amplitudes below the lower limit of normal (Figure 1.15B) [103]. No 
abnormalities have been reported in flicker and photopic ERGs in 
heterozygote carriers.  
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The large number of genes associated with retinal dystrophies makes 
genotyping a time-consuming task. However, genotyping is an essential step 
before any therapeutic approach can be established. One way of facilitating 
this is the establishment of phenotype-genotype correlations in order to direct 
molecular studies to the underlying gene in a new patient. With further 
studies and the use of more detailed imaging, it may be possible to 
distinguish different types of mutation within the same gene from the 
phenotype of patients, such as between missense mutation and null 
mutations which are likely to be phenotypically more severe. To date, no 
such correlation study has been performed. Although LCA phenotypes are 
variable and change with age, certain distinctive phenotypical features can 
be identified to suggest the underlying gene, and similarly, it may be possible 
to identify LCA patients who potentially have AIPL1 mutations from their 
clinical presentation. However, a genetic diagnosis will always be required to 
confirm the gene defect. 
 
Overall LCA patients with AIPL1 mutations appear to have a more severe 
disease with a progressive course compared to patients with other LCA gene 
mutations. The main challenge is to be able to identify patients with AIPL1 
mutations at a young age since characteristic features of the disease such as 
retinal drusen deposits, peripheral bone-spicule pigmentation, chorioretinal 
and macular atrophy and keratoconus mainly appear at later ages, while the 
appearance of the fundus is relatively normal early in life.  In these young 
patients, it is thus important is to establish an effective screening strategy 
that enables the identification of AIPL1 mutations. This may require a 
combination of clinical and molecular strategies. Part of this study is directed 
at addressing these issues in addition to providing further phenotype-
genotype data and the aetiology of AIPL1-related disease.  
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1.3.2 Photoreceptor cell death in inherited retinal 
dystrophies. 
 
It has been shown that photoreceptor cell death in inherited retinal 
degenerations occurs by apoptosis [380]. However, there is little known 
about the mechanisms that link the genetic defects in inherited retinal 
dystrophies and the subsequent death of retinal cells by apoptosis. 
Understanding the disease mechanism by which genetic mutations lead to 
apoptotic cell death in inherited retinal dystrophies such as RP and LCA may 
provide an insight into ways to intervene to prevent or delay photoreceptor 
loss.  
 
Apoptosis is one of the physiological processes required to control cell 
numbers in multicellular organisms and constitutes a controlled programme 
of cell death mediated by a signalling cascade involving the activation of 
caspase enzymes by proteolytic cleavage. The initial stimulus for the 
activation of this cascade can be intrinsic in response to damage within the 
cell such as in genetic retinal diseases, or extrinsic secondary to external 
insults or signalling from other cells (Figure 1.16). The homeostasis of 
intracellular Ca2+ levels in photoreceptor cells appear to be of central 
importance in the initiation of apoptosis in retinal dystrophies. In CNS 
diseases due to excitotoxic damage such as epilepsy and ischaemia, 
excessive synaptic release of glutamate leads to neuronal damage and cell 
death through Ca2+ disregulation and excessive influx of Ca2+  from 
overactivation of post synaptic receptors [27,515]. Forms of RP and inherited 
retinal dystrophies caused by mutations that ablate photoreceptor function 
completely are likely to cause cell death via calcium overload. These 
mutations create a metabolic state that can be equated to exposure to 
continuous darkness and hence the ‘equivalent dark’ hypothesis. An 
example in which elevated intracellular Ca2+ levels may lead to apoptosis in 
an inherited retinal dystrophy is the retinal degeneration (rd) mouse, a model 
of rapid retinal degeneration due to a null mutation in the Pde6b gene 
encoding β-subunit of phosphodiesterase (PDE). Loss of PDE activity results 
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in elevated levels of cGMP in the mutant retina and a continuous influx of 
calcium ions through the cGMP-and voltage-gated Ca2+ channels. This 
calcium overload eventually leads to apoptotic cell death in photoreceptor 
cells [123]. Mutations such as AIPL1[282], PDE6B [377] and PDE6A[414] 
which result in loss or disruption of PDE activity and GUCY1A[356] where 
enhanced guanylyl cyclase sensitivity leads to increased cGMP-gated 
channel activity, are also thought to cause photoreceptor degeneration due 
to high Ca2+ levels triggering the apoptotic process. 
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Another hypothesis to explain cell death in retinal dystrophies is the 
‘equivalent light hypothesis’ which postulates that certain mutations causing 
retinal dystrophies may cause constitutive overstimulation of the 
phototransduction cascade, resulting in signals being sent to the inner retina 
that are ‘equivalent’ to those sent in response to the detection of incident 
light [122,278]. The cell death in these circumstances could be similar to that 
seen in light damage models of RP, in which retinas exposed to either short 
intense intervals of light or prolonged low intensity light suffer loss of 
photoreceptors. Evidence has emerged from various models of RP that the 
equivalent light hypothesis may be the the main contributing factor to the 
degeneration seen in these forms of retinal dystrophies. One of the most 
convincing evidence to support the equivalent light hypothesis comes from 
the transgenic mouse model of LCA, the   Rpe65-/- mouse. The rod 
photoreceptors in Rpe65-/- mice behave as if they are in the presence of a 
continuous background light with reduced circulating current in response to 
light stimulation, reduced light sensitivity and accelerated turn-off of 
photoresponse [500]. The lack of RPE65 protein causes photoreceptor death 
through accumulation of opsin that is not bound to 11-cis retinal in outer 
segments which causes the constitutive activation of the phototransduction 
cascade and this effectively acts like an equivalent light background. Further 
support for the equivalent-light hypothesis comes from studies involving the 
arrestin knockout (Sag-/-) mouse and rhodopsin kinase knockout (Rhok-/-) 
mouse; the photoreceptors in these animals rapidly degenerated when the 
animals were placed in constant light too dim to produce degeneration in 
normal animals, but the degeneration was spared if the animals were kept in 
darkness [81,82,504]. The introduction of a second mutation that blocked the 
transduction cascade, through the mating of these animals (Rpe65-/-, Sag-/- or 
Rhok-/- mice) with another strain of mice that lacked the gene encoding the 
rod transducin α subunit, resulted in a protective effect where the double 
knockout animals were no longer sensitive to damage by moderate constant 
illumination [175,500], thus providing photoreceptor apoptosis was mediated 
by constitutive activation of the phototransduction cascade. Evidence from 
other models of retinal dystrophies also support the equivalent light 
hypothesis. Some mutant forms of rhodopsin are known to constitutively 
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activate transducin independent of light excitation [397,526]. Recessive 
mutations in the gene encoding the rod α subunit of the cGMP-gated channel 
[111] and retinal guanylyl cyclase (RetGC-1)[229,428] have been described, 
that  would be expected to lead to a lack of functional cGMP-gated calcium 
gated channels and calcium not being transported into the cell. This should 
lead to a permanent state of hyperpolarisation in the photoreceptor inner 
segments and consequently a signal equivalent to light being sent to bipolar 
cells. 
 
It has been hypothesized that constant hyperpolarisation may lead to 
cytotoxicity by two different mechanisms: an intrinsic mechanism that is a 
cell-autonomous intracellular pathway to cell death, and the other an 
extrinsic mechanism that involves other cell types. Intracellular responses 
from within cells that harbour mutations leading to an equivalent light signal 
could trigger apoptosis due to disturbances in intracellular calcium levels and 
oxidative stress. In the first, overstimulation of the phototransduction cascade 
by aberrant expression of genes result in calcium being no longer 
transported into the cell to maintain a depolarised ‘ground state’. As a result, 
there is a permanent state of hyperpolarization in the photoreceptor inner 
segment and glutamate is never released from the photoreceptors. The 
exact mechanism by which low Ca2+ concentration lead to apoptosis is not 
fully understood. Evidence shows that neurons appear to tolerate a Ca2+ 
concentration only within a restricted range [277], and the same situation has 
been proposed for photoreceptors. Cultured neurons deprived of growth 
factors can be rescued in a medium containing high K+ which has its effects 
by depolarizing the cells and opening voltage-gated Ca2+ channels, 
producing an increase in the intracellular free Ca2+ [144,145,338].  The 
suggestion that prolonged decrease in Ca2+ levels may trigger apoptosis is 
supported by the existence of  numerous mechanisms that photoreceptors 
have evolved for regulating the rate of phototransduction and maintaining 
Ca2+ concentration within certain limits; this includes the modulation of cGMP 
channels by calmodulin[192,193], regulation of Ca2+ concentration by the 
Na+/Ca2+K+ exchanger [424] and light-dependent translocation of transducin 
and arrestin to decrease activation in bright light [445,520]. It has been 
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proposed that mutations that cause equivalent light signals and those that 
disrupt photoreceptor function, may also lead to cell death through an 
increase in oxidative stress [469]. Due to the high density of mitochondria in 
the inner segments, photoreceptors are particularly sensitive to mutations 
that alter their metabolic requirements. Mutations that cause a reduction in 
metabolic activity lead to an increase in mitochondrial free radical production 
in the form of reactive oxygen species. This is because, whist other tissues 
are able to modulate their blood supply by vasoconstriction, the 
choriocapillaris that serves the retina is largely unable to constrict, meaning 
the same level of oxygen is supplied to photoreceptors despite their altered 
metabolic state. These reactive oxygen species induce oxidative damage to 
the mitochondria, resulting in cytochrome–c release and subsequent 
activation of caspase proteins, leading to apoptosis [165,214]. The second 
mechanism in which cells may die in response to an equivalent light signal 
involves secondary messengers being released by cells in the inner retina. 
Bipolar cells, Mϋller cells and ganglion cells secrete neurotrophic factors that 
promote the survival of photoreceptors under normal circumstances and 
following retinal injury [219,491]. In retina which has been exposed to light for 
long periods of time, it has been observed that activated microglia invade the 
degenerating photoreceptor layer and alter the expression of neurotrophic 
factors such as nerve growth factor (NGF), ciliary neurotrophic factor 
(CNTF), and glial cell line-derived neurotrophic factor (GDNF)[176]. 
Furthermore, microglia-derived factors influence the production of secondary 
trophic factors in Mϋller cell, suggesting that microglia-Mϋller glia cell 
interactions play a critical role during photoreceptor degeneration[176]. It has 
been hypothesized that these microglia may either exert a cytotoxic function 
by releasing reactive oxygen species, nitric oxide, or inflammatory cytokines 
that trigger an extrinsic apoptotic pathway in the 
photoreceptors[201,245,346], or modulate the secretion factors that normally 
promote photoreceptor survival [176]. 
 
 It has been observed that the microenvironment of the degenerating retina 
can exert a negative effect on surrounding cells, where healthy 
photoreceptors are known to die in the presence of mutant cells. This ‘by-
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stander effect’ suggests a non-cell autonomous mechanism for cell death, 
possibly involving secondary cells and their secreted factors [226]. Evidence 
for this by-stander effect comes from chimeric mice generated from albino 
Prph2Rd2/Rd2 mice and pigmented mice that were wild-type. Photoreceptors 
were found to degenerate not only in the regions overlying non-pigmented 
RPE, but also in regions overlying pigmented RPE, indicating that the 
photoreceptors that are genetically normal die in the presence of 
photoreceptors carrying RP-causing mutations [417]. A different example of 
non-cell autonomous cause of photoreceptor death is seen where the loss of 
rods is responsible for the cone cell death. The rod-derived cone viability 
factor which is normally secreted by rods, was found to enhance the survival 
of cone-rich retinal explants from rd1 mice in culture and in vivo when 
delivered subretinally into rd1 mice [266,331]. Thus by understanding the 
different mechanisms and pathways leading to apoptotic photoreceptor cell 
death, therapeutic intervention to prevent the loss of cells may be made 
easier. 
 
Following photoreceptor cell death in inherited retinal degeneration, it was 
previously thought that the neural network and cell population pattern in the 
inner retina was spared. It has become apparent that deafferentation of the 
neural retina invokes a series of changes known as remodelling, that these 
events commence even before there is any cell death and that neuronal 
remodelling is the common fate for all conditions with photoreceptor 
degeneration regardless of the initiating event or gene defect. Indications of 
altered circuitry in retinal degeneration have been documented as early as 
1974[241] but the concept of retinal remodelling did not take hold until later, 
when different studies described sprouting from various retinal cell 
populations including photoreceptors, bipolar and horizontal cells in a 
haphazard manner during photoreceptor degeneration [128,322,375,450-
452] and aberrant formation of new synapses in the degenerating retina with 
neuronal translocation, glial transformation and ectopic neurite complexes 
which were believed to be attempts by remaining neurons to find synaptic 
excitation [217,218,299]. Despite evidence of plasticity, this new circuitry was 
corruptive of retinal signal processing. The implications of retinal modelling 
Muller cell 
Rewiring of rod and 
cones, bipolar and 
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Muller cell 
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for therapeutic intervention would be significant as most current approaches 
such as cell transplantation and electronic implants are late-stage schemes 
and depend on the existence of an intact retinal architecture. This negative 
plasticity emphasizes the importance of early diagnosis and intervention to 
retard or prevent remodelling, and provides a compelling argument as to why 
gene therapy may be a more appropriate treatment for genetic retinal 
diseases.   
 
More pertinent to this study are the effects of remodelling in models of fast 
retinal degeneration and the implications of this on therapeutic strategies to 
treat rapid retinal degeneration. The rd1 mouse contains a nonsense 
mutation in ß subunit of phosphodiesterase (PDE) and exhibits rapid retinal 
degeneration, similar to that seen in Aipl1 -/- mice. Parallels can be drawn 
between the rd1 mouse and the Aipl1 -/- mouse in that both conditions result 
in loss of PDE function, elevated cGMP which is ultimately lethal to rods. The 
remodelling process has been examined in the rd1 mice and despite rapid 
rod degeneration, retinal modelling is slower than expected and is severely 
advanced at postnatal day 610 [218]. It is thought that the delay of late stage 
of remodelling is associated with persistence of residual cone photoreceptors 
[212] that provide a source of input to the neural retina and prevent complete 
early global remodelling. Since AIPL1 is expressed in both rods and cones, 
photoreceptor degeneration in the Aipl1 -/- mouse is much more rapid 
compared to the rd1 mouse. In rapid degenerations, gliosis and aberrant 
sprouting occur at a slower pace compared with the loss of photoreceptors. 
Hence, gene therapy may be effective if the treatment is administered before 
there is significant loss of photoreceptor cells in rapid degenerations. In slow 
degenerations, there is more time for reactive changes to occur in response 
to the gradual loss of photoreceptor function such that by the time the 
condition is detected, significant remodelling has taken place. Taking these 
factors into consideration, it would be reasonable to expect that the Aipl1 -/- 
mouse may respond well to gene therapy. Furthermore, cone death due the 
the absence of AIPL1 is inherently slow; this is seen in a novel transgenic 
mouse model tg hAipl1;Aipl1 -/- , in which rod photoreceptors were 
exclusively rescued by the expression of human AIPL1 and AIPL1-deficient 
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cones in this novel model degenerate at a much slower rate in comparison to 
the complete AIPL1 knockout model [232]. It was hypothesized that the 
reduced rate of cone photoreceptor degeneration in tg hAipl1;Aipl1 -/- mice 
was due to the expression of rod-derived cone viability factor from preserved 
rod photoreceptors and the maintainance of surrounding cell density  which 
supported  cone viability. In humans, the cone-rich fovea would be 
analogous to the slow-degenerating cones observed in the tg hAipl1;Aipl1 -/- 
mouse model since this area would be immune to the influence of rod cell 
death on cone survival in the absence of AIPL1. This is supported by results 
from an adult LCA patient with a mutation in AIPL1 who showed severe 
retinal degeneration and all survival cells appeared cone-like in 
morphology[478]. These observations suggest that the therapeutic window 
for gene therapy may be further extended in LCA patients, since the cone 
cells in the fovea may survive for a longer period of time. 
 
1.3.4      Animal models of inherited retinal dystrophies 
 
Much of the advances in ocular gene transfer and gene therapy would not 
have been possible without the availability of animal models. Animal models 
have been instrumental in advancing our understanding of genetic diseases 
processes. To develop a gene-based strategy and test the efficacy of the 
treatment requires an animal model with a mutation in the gene of interest. 
There are many naturally occurring and engineered animal models of RP 
and hereditary retinal dystrophies, most of which are rodents. However, 
some large animal models of retinal disease exist in the form of dogs, cats 
and pigs. Several considerations need to be taken into account when testing 
therapeutic strategies in animal models. The timescale of the degeneration 
needs to be factored in, degeneration which progresses too rapidly limits the  
window of opportunity for gene therapy to work while too slow a rate make 
assessments of efficacy difficult. The animal model chosen to investigate 
therapeutic strategies should reflect the human disease as closely as 
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possible and finally, the strategy to treat the disease should be cogniscent of 
the underlying disease mechanism. 
 
Although all vertebrate eyes are similar in structure and function, there are 
some differences depending on the life style and survival needs of various 
species. Whilst animal models are valuable model systems, they should only 
be seen as an approximation to the morphological, physiological and 
pathophysiological conditions of humans. Mice and rats have been used 
most extensively for various reasons including their short gestation time, the 
existence of several readily available retinal degeneration mutants, and the 
possibility to create transgenic animals by genetic modification. Although 
rodents are frequently the animals of choice in most experiments, the 
differences between rodent and human eyes can make interpretation of 
results obtained from the animal difficult. Rodents have only 2 types of cones 
which detect medium and short wave-length light, and are thus unable to see 
long-wave light. Each neural cell in the rodent retina is connected to a larger 
number of photoreceptors than those of the human retina, which increases 
sensitivity at the expense of acuity. Humans on the other hand, have 3 types 
of cones and higher cone density; in humans, 5 % of the photoreceptors are 
cones compared to only 1-2 % in rats and mice.  Another major difference is 
the lack of an anatomical macula or cone-rich region in rodents, while the 
macula is of utmost importance and subserves high acuity vision in humans 
and primates. Thus mutations leading to macular degeneration may be 
harder to study in rodents. As many animal models of disease differ in some 
aspects from their human counterparts, the study of therapeutic strategies 
need to account for these differences before conclusions from animal studies 
can be applied to clinical disease. Findings based on rodent models may 
need to be further validated in larger animal models with eyes that more 
closely resemble human eyes.  
 
Larger animal models of inherited retinal dystrophies exist and are 
particularly useful in establishing efficacy and safety parameters prior to 
human trials. Large animals such as pigs and dogs have the advantages of 
being anatomically more similar to the human eye. Even though the pig 
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retina lacks a foveal-macular region, the retina has a greater proportion of 
cones than the rodent retina. Given the strong similarities in phenotype to 
that of RP patients, the transgenic pigs provide a large animal model for 
studying retinal degeneration (especially cone degeneration) found in RP 
[271,371]. The canine retina has a similar composition and distribution of 
cones, and contains a cone-rich area called the visual streak, which shares 
some of the characteristics of the macula in humans[339]. The large size of 
the dog eye allows intraocular surgical procedures to be carried out more 
easily than in rodents and it also permits fundal examination of different 
retinal regions of the same eye.  Because the canine eye bears greater 
resemblance to human eye with respect to size and retinal morphology, 
retinal defects in dogs can provide useful animal model of disease for pre-
clinical studies of gene therapy. Primate eyes are the most similar to those of 
humans in many ways and possess a macula that is rich in cones. It has 
been shown that diurnal species, such as the rhesus monkey, have a fovea 
that consists of all three types of cones (red, green and blue). Macular 
changes that are similar to that in age-related macular degeneration in 
humans have been reported in the rhesus monkey[369]. Because of the 
similarity to humans, monkeys would be the animal model of choice to 
investigate such disorders. However, due the long lifespan of monkeys, 
retinal degenerations occur over a longer period of time compared to mice 
and rats, making experiments long lasting. Moreover, no primate models of 
inherited retinal dystrophies have yet been identified and characterized.  
 
The most widely studied naturally-occuring rodent models of RP are the rd1 
mouse and the retinal degeneration slow (rds) mouse.  The rd1 mouse was 
the first mammalian retinal degeneration model to be described [379]. Pittler 
et al identified the genetic defect causing photoreceptor degeneration in the 
rd mouse, a nonsense mutation in the phosphodiesterase beta-subunit gene 
(Pde6b) gene. This gene encodes the β-subunit of the rod cGMP 
phosphodiesterase (β-PDE). The phenotype in the rd1 mouse is extremely 
rapid degeneration with complete loss of rod photoreceptors by postnatal 
week 4, although cones survive slightly longer. Mutations in the human 
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homolog of Pde6b, mostly affecting the catalytic domain, have been found in 
patients with autosomal recessive retinitis pigmentosa, which bears 
phenotypic resemblance to that in the mouse apart from one feature [312]; 
the disease in humans presents later in life and has a slower time course. A 
further discrepancy is the fact that the mutations found in humans are mostly 
missense substitutions affecting the catalytic domain and result in reduced 
protein activity as opposed to the loss of protein function from the null 
mutation in the mouse model [312,377]. A model that is both genetically and 
phenotypically more similar to Pde6b mutations in humans is the rd10 
mouse,a hypomorphic Pde6b mutant which harbours missense mutation in 
exon 13 [359]. The mutation causes a partial loss of PDE acitivity and a 
milder phenotype than the rd1 mouse, and the rate of photoreceptor cell loss 
in the rd10 mouse is more comparable to that seen in human disease. 
  
The rds or Prph2 Rd2/Rd2 mouse is a naturally occurring mouse model that 
carries an insertional mutation in the peripherin/rds gene [288] which 
encodes peripherin-2, a photoreceptor-specific structural protein found in the 
outer segments of rods and cones. Peripherin is major structural component 
of the membranous discs within the outer segments. The lack of peripherin 
leads to the failure of disc morphogenesis and absence of outer segments 
from birth. As a result, phototransduction is greatly reduced and 
photoreceptors die although the mechanisms leading to this is not completely 
clear. Homozygotes show early onset retinal degeneration and an 
intermediate rate of photoreceptor cell loss, slower than the rd1 mouse but 
faster than many other models. The outer nuclear layer in homozygotes is 
reduced by 50% by 2 months of age and there is complete pan-retinal loss 
by 12 months of age[210]. The absence of peripherin/rds leads to rods 
without outer segments that eventually undergo apoptosis[129,415,416] and 
therefore have negligible rod function[404], but retain functioning cones 
although these have atypical outer segments [130]. The heterozygous 
animals exhibit haploinsufficiency and a much milder phenotype; they have 
disorganized outer segment whorls, the mice retain normal ERG amplitude 
levels until adulthood and have a later onset of phenotype with a much 
slower progression of degeneration with 50% of outer nuclear layer lost by 
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18 months[182]. Peripherin/RDS mutations in humans are associated with a 
variety of retinal dystrophies depending on the causative mutation, and do 
not show a straightforward dependence on the position of the mutation in the 
primary protein sequence or the type of mutation. Moreover, a single 
mutation may cause a spectrum of phenotypes ranging from different 
macular dystrophies and cone-rod dystrophies to autosomal dominant 
RP[56,319,372,376,490]. This phenotypic heterogeneity along with the 
anatomical differences make the interpretation of animal models of the 
human disease more complex. Despite this, animal models have still proven 
valuable, particularly given the high degree of identity of peripherin/RDS 
sequence between human and murine orthologs (the murine peripherin/rds 
gene is 91% identical to the human orthologue) [92,470]. Studies from 
animal models suggest that both haploinsufficiency and dominant negative 
mechanisms both play a role in human retinal dystrophies caused by 
peripherin/RDS mutations; phenotypes dominated by rod photoreceptor loss 
may be caused by a haploinsufficiency and/or dominant negative effect, 
while phenotypes with predominantly cone dysfunction appear to be due to a 
dose-dependent dominant negative effect[129]. The rds mouse represents a 
model for peripherin/RDS mutations in humans that lead to 
haploinsufficiency or loss of function phenotype. 
 
As well as several naturally occurring mouse models, there are several large 
animal models of inherited retinal dystrophies. In dogs, mutations have been 
identified in a number of genes including RPGR, PDE6B and CNGB3 
[368],[369] BEST1[170]). The RPE65-deficient dog, also known as the Briard 
dog has a homozygous 4-bp deletion within the Rpe65 gene and is a canine 
model of LCA type 2[4]. Affected dogs have congenital night blindness and 
various degrees of visual impairment under photopic illumination.  Along with 
the visual impairment, affected dogs have an abnormal ERG trace in keeping 
with severely depressed rod and cone-mediated responses. Morphologically, 
pathologic abnormalities were mainly confined to the RPE layer; electron 
microscopy studies of the retina demonstrated large, cytoplasmic lipid 
inclusions in the RPE, while photoreceptor outer segments appeared largely 
normal. No evidence of photoreceptor degeneration or cell death were seen 
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as indicated by the preservation of the outer nuclear layer thickness [4]. 
Difference however, exist between RPE65 mutations in humans and in the 
dog model; although the severe visual deficit early in life is similar in human 
and dog, the lack of ophthalmological signs of advanced retinal degeneration 
in the adult dog is unlike the human condition, and the course of the disease 
is stationary in the dog model while in humans, the disease progresses to 
severe visual impairment and blindess. These issues need to be taken into 
consideration when evaluating therapies in the experimental treatment of the 
disease. Apart from canines, other large animal models of RP and retinal 
dystrophies exist such as the feline models of LCA caused by mutations in 
CEP290[316] and CRX[317]. 
 
Genetic engineering has made possible the development of transgenic 
animals which are created using constructs that either disrupt, imitate or 
over-express the candidate gene in order to mirror the human form of the 
disease. To date, rodents and pigs have been bioengineered to create 
“knockout” models representing recessive diseases or “knock-in” models that 
provide models of dominant forms of retinal dystrophies. Knock-out models 
are created by causing a specific targeted disruption of an endogenous gene 
which results in the loss of the protein function. Knock-out mouse models 
have been generated to recapitulate human LCA or RP. Table 1.5 sumarizes 
the available natural and man-made mouse models of LCA to date. All 
human LCA genes have orthologues in mouse. Four mouse LCA genes 
(Cep290, Crb1, Rd3, Rpe65) have been found to contain naturally occurring 
mutations, while the others have been generated mostly by targeted 
disruption. Most of the knock out models of LCA genes exhibit severe retinal 
degeneration which parallel that seen in humans, with the exception of Crb1, 
Gucy2D and Rdh12. Different levels of gene disruption in the Aipl1 gene 
resulted in varying rates of photoreceptor cell loss. Two Aipl1 knockout 
(Aipl1-/-) mouse models have been created, both models are fully deficient in 
AIPL1 activity and exhibit very rapid photoreceptor degeneration [119,391].  
A relatively mild mutation was introduced in the Aipl1 gene by the insertion of 
a neomycin cassette in intron 2 of the gene to create a “knock-down” model, 
the hypomorphic (Aipl1h/h) mouse. This model which has reduced levels of 
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Aipl1 exhibits a much slower retinal degeneration and may represent milder 
forms of the disease [282]. The studies presented in this thesis focus on the 
two models of Aipl1-related retinal degeneration that, by virtue of their 
different kinetics of photoreceptor loss and are valuable tools in assessing 
the efficacy of treatment strategies. Further details of these models will be 
discussed in the following section. Knockout models have also been 
generated that mimic mutations found in RP and other types of retinal 
dystrophies. Rhodopsin knock-out (rhodopsin-/-) mice exhibit a 
morphological absence of rod outer segments and a fast degeneration. Rod 
photoreceptor cell loss occurs first, followed by cone degeneration which 
begins at about postnatal week 6. By 3 months of age, there is almost a 
complete loss of photorecetors with only single row of nuclei left in the outer 
nuclear layer which are thought to be residual cones[194]. Heterozygous 
rhodopsin knockout mice carrying one functional allele on the other hand, 
retain majority of their photoreceptors, although the inner and outer 
segments of photoreceptors were shorter and the level of rhodopsin in 
individual rod photoreceptor cell is reduced }[194][264]. Tulp1 knock-out  
(Tulp-/-) mice are another model of recessive RP, and exhibit mislocalisation 
of rod- and cone-opsins, accumulation of vesicles in the inter-photoreceptor 
matrix, and a relatively fast photorecetor degeneration that reaches end-
stage by 5 months of age [171].  Knockout mice lacking RPGR and RPGRIP, 
which encode proteins found in the photoreceptor connecting cilia, serve as 
models of X-linked and LCA respectively [189,524]. It has been subsequently 
shown that RPGR is a client protein of RPGRIP, which functions to anchor 
RPGR in the connecting cilium [190,524]. Consistent with the notion that 
RPGRIP subserves the function of RPGR in regulating protein trafficking 
across the connecting cilia, Rpgrip-/- mice exhibit a more severe disease 
than Rpgr-/- mice. This difference in phenotype in the mouse models 
analogous to clinical findings, where RPGR mutations in patients manifest as 
X-linked RP while the loss of RPGRIP leads to LCA in patients. 
 
Many transgenic models have been made that incorporate mutations in 
peripherin/rds and rhodopsin genes that are associated with dominant RP. 
Peripherin/rds (Prph2) transgenic mice have been generated which carry the 
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amino acid substitution P216L. The mutant P216L mutant protein does not 
preclude peripherin-2 tetramer formation but these tetramers are 
dysfunctional, probably due to hyperglycosylation of the protein [283,501]. 
Consequently, the phenotype caused by the P216L mutation is due to a 
dominant negative effect on rod outer segment structure.These animals 
exhibit a slow retinal degeneration and a phenotype similar to that of 
dominant RP caused by P216L mutation in patients [227]. Other transgenic 
mouse models with mutations in peripherin/rds include models that carry the 
C214S and R172W substitutions which cause late-onset autosomal 
dominant RP[412] and cone or cone-rod dystrophy in humans 
respectively[91,105]. Another transgenic mouse model carrying the L185P 
mutation in peripherin/rds exhibits haploinsufficientcy and is a model for 
digenic RP. In these mice, no photoreceptor degeneration is seen in 
Rom1(+/-)/peripherin/Rds(+/+) mice, but Rom1(-/-)/peripherin/Rds(+/+) mice 
show a mild photoreceptor degeneration[112]}[89,228]. Rhodopsin is both a 
key component of phototransduction and a structural protein for the outer 
segments. The underlying pathogenic process thus varies with the type of 
mutation. Most of the mutations produce a protein that is defective in folding 
or trafficking and has an inability to maintain outer segments[458]. The 
expression levels of wild-type rhodopsin need to be taken into consideration 
in rhodopsin disease models as overexpression of normal rhodopsin can 
also lead to photoreceptor degeneration. Numerous rhodopsin mutant 
animals have been described, most were generated as transgenic mice 
which carry one mutant rhodopsin allele in addition to two wild type alleles.  
Examples of rhodopsin transgenic models include the Q344Ter mouse in 
that the rhodopsin gene has a stop codon leading to a truncated protein. The 
result is mislocalised rhodopsin and a slow retinal degeneration, similar to 
that seen in patients [457]. Two rhodopsin transgenic rats are extensively 
studied; the S334Ter rat that has a rapid degeneration over the course of 
weeks [279] and the P23H rat that has a much slower degeneration which 
takes place over months [357]. Rats heterozygous for the P23H opsin allele 
lose around 50% of their photoreceptors at three months of age [357]. More 
recently, rhodopsin mutants which carry one mutant allele and one wild-type 
allele have been produced by crossing rhodopsin-transgenic with rhodopsin-
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knockout mice or by targeted insertion of a mutant allele into a specific locus 
(knock-in models). These animals have gene dosage and mutant to wild type 
ratios approximating those of human patients and are better representation 
of the human disease. 
 
A good animal model requires that it is representative of human disease in 
terms of the mutation that causes the disease and in the pathology and 
phenotypical features that follows. Many of the LCA mouse models such as 
Aipl1-/-, Cep290 (rd16), Rd3, Rpgrip1-/-, Rpe65 (rd12) and Rpe65-/-    
appear to mimic human LCA phenotype and demonstrate retinal 
degeneration at various rates (Table 1.3). Large animal models which bear 
greater resemblance to the human eye are excellent models for study; the 
Rpe65-deficient dog is an example which has been vital in providing proof-of-
principle of gene replacement therapy. Successful restoration of vision using 
AAV-mediated gene therapy has been reported in these dogs [2] and 
provided the drive for moving into clinical trials which are ongoing 
[34,181,293]. Undoubtedly, a large part of this is due to the fact the disease 
in the dog model resembles the human version in terms of anatomy and 
phenotype, and it is anticipated that similar benefits from treatment should 
follow. For treatment efficacy studies, a model that has an intermediate rate 
of degeneration is ideal, so that there is a window of opportunity for 
intervention and yet not so slow that evaluating the efficacy of the therapy 
becomes difficult.  Experiments in rodents have indicated that the fastest 
retinal dystrophies are the most difficult to treat successfully. Despite 
numerous attempts to treat the Pde6b-deficient rd1 mouse using gene 
replacement therapy mediated by a variety of viral vectors [50,216,247], 
effective rescue of this model has proved elusive. More convincing rescue 
has been reported in the rd10 mouse which has partial PDE6b deficiency 
and slower degeneration [359].  This difference in success may be in part 
due to the slower degeneration affording better timing for intervention. Since 
the rate of photoreceptor cell loss is in this model is more comparable to the 
human disease, these results indicate that patients with PDE6B mutations 
may also respond favourably. The Crb1, Rdh12 and Gucy2D knock-out mice 
demonstrate subtle degeneration and progress at a relatively slower rate 
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than in humans lacking these genes. The Rpgr -/- mice also demonstrate 
very slow degeneration of photoreceptor cells compared with that in 
human[189]. The Abca4-/- mouse model of Stargardt exhibits some features 
of the disease such as accumulation of lipofuscin in the RPE but does not 
have photoreceptor degeneration that is characteristic of the human 
form[494]. The milder pathology in these mice thus make it difficult to assess 
the effects of therapeutic intervention and also to extrapolate findings to 
humans. In the absence of larger animal models generated by genetic 
bioengineering, future clinical trials may have to proceed based on efficacy 
data in small animal models such as rodents. Comparison of the efficacy of 
treatment in mice, dog and humans from previous studies may help 
determine the suitability of mice as models of human retinal disease, while 
thorough characterization and careful selection of a model will facilitate 
translation of animal studies into clinical trials. 
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Table 1.3  Overview of all natural and man-made mouse models for LCA. 
Gene Mutated 
exons 
Method Degeneration of 
photoreceptors 
(age) 
Similarity to 
human LCA 
References 
Aipl1 1-2 KO +++, 7 weeks yes [119] 
 2-5 KO +++, 3 weeks yes [391] 
 Intron 2 KD +, 8 months no [282] 
Cep290 Del35-39 Natural 
(rd16) 
+++, 4 weeks yes [78] 
Crb1 3841delC Natural (rd8) + no [314] 
 1 KO +, 3-9 months no [473] 
 3(C249W) KI +, 24 months no [474] 
Crx 2-4 KO(-/-) +++, 2 weeks yes [150] 
  KO(+/-) ERG reduced, 2 
months 
no [337,375] 
Gucy2D 5 KO +, cone 
degeneration only 
no [509] 
Impdh1 9 KO unknown unknown [168] 
Lrat 1 KO ++, 6-8 weeks yes [41] 
Rdh12 1-3 KO +/-, 1 year No [290] 
 1-3 KO +/-, 7 months No [248] 
Rd3 3(R107X) Natural (rd3) ++, 15 weeks yes [146,276] 
Rpe65 1-3 KO ++, 15 weeks No [400] 
  Natural 
(rd12) 
++, 15 weeks Yes [360] 
Rpgrip1 Intron 14 
insertion 
KO +++, 2-3 months Yes [524] 
Tulp1 8-9 KO +++, 4 weeks Yes [195] 
 
KO, knock-out; KD, knock-down; KI, knock-in; - absent; +/- subtle; + moderate; ++ severe; 
+++ full degeneration.  
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1.3.4.1 The Aipl1-/- mouse model of retinal degeneration 
 
Two study groups have created mice with targeed disruption of the Aipl1 
gene[119,391]. Dyer et al. generated Aipl1-/- mice by targeted disruption of 
exon 1 and 2 using a 1.6kb DNA fragment containing neomycin 
cassette[119].  The Aipl1-deficiency in these mice led to early severe retinal 
degeneration, beginning at postnatal day 12 (P12) in a distinct central-
peripheral gradient: degeneration of the central retina was faster than 
degeneration in the peripheral retina. At this early stage, severe shortening 
of rod photoreceptor outer segments and disorganisation of the membranous 
discs were seen, cone photoreceptors were also morphologically abnormal 
and thinning of the outer nuclear layer was already noticeble compared with 
age-matched wild type mice. Synoptogenesis in the inner plexiform layer 
remained relatively intact, but the outer plexiform layer showed signs of 
disruption of synapse formation at this stage. Down-regulation of several rod-
specific markers such as Nrl and Nr2e3, and genes encoding PDEβ and γ 
subunits, and cGMP channel protein was detected at P15. In addition, there 
was also decreased expression of genes from the Wnt-frizzled signalling 
pathway that is involved in the regulation of retinal proliferation and cell fate 
determination. The central to peripheral pattern of photoreceptor 
degeneration progressed rapidly until there was almost total loss of 
photoreceptors by the time the Aipl1 -/- mice were 8 weeks old. Total 
photoreceptor cell count in Aipl1 -/- mice at this age was 13% of wild type 
counts, the contribution of cell loss was not solely from the loss of rods. The 
severe cell loss in the Aipl1-deficient mice corresponded to complete loss of 
photoreceptor function, indicated by absent a- and b-waves on ERG 
recorded from Aipl1 -/- mice (Figure 1.17C). Immunostaining of Aipl1 -/- mice 
retina at this age indicated a reduction of cones in addition to loss of rods 
and a potential expansion of bipolar cells. Although GFAP immunostaining 
showed a marked increase in Mϋller cell reactive gliosis, markers for other 
neuronal cell types showed no change in horizontal cells, amacrine or 
gangion cells. Despite the early onset of degeneration, the authors did not 
find evidence of abnormal cell death exceeding that of normal retinal 
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development nor defects in the generation of different cell types or 
differences in cell type proportion during early stages of retinal development. 
RT-PCR for markers of retinal cell proliferation and cell fate at P2 and P8 
demonstrated normal expression of markers of commitment to cell fate and 
retinal progenitor cell genes. The abscence of gross abnormalities in early 
stage retinas of the Aipl1 -/- mouse suggests that normal retinal development 
occurs in the background of Aipl1-deficiency, and that Aipl1 is not required 
for retinal proliferation or the commitment to photoreceptor cell fate despite 
its reported interaction with NUB1, a cell cycle regulatory protein[7,8]. A 
possible explanation could be the presence of protein redundancy in which 
there may be other proteins in the pathway that are performing 
compensatory roles in retinal proliferation[119]. Mice that were heterozygous 
for Aipl1 deficiency (Aipl1 +/- mice) were found to demonstrate some 
phenotype abnormalities; ERG recordings from Aipl1 +/- mice showed 
increased implicit time, indicating a delayed rod response on ERG (Figure 
1.17B).  
 
 
A                                              B                                          C 
 
Figure 1.17  Flash ERG of normal wild-type mouse (A), heterozygous Aipl1+/- (B) and 
homozygous Aipl1-deficient mouse (C)[119]. 
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This was similar to the observation that some patient carriers of AIPL1 
mutations demonstrate rod function abnormalities. Additionally, 8 week old 
Aipl1+/- mice had photoreceptor cell counts that were 80% of wild type 
indicating some degree of cell loss had occurred.Ramamurthy et al 
engineered  an Aipl1-/- mouse model by replacing exon 2 to 5 of Aipl1 gene 
with a neomycin-resistance gene vector [391]. In these Aipl1 null mutants, 
the retina was also observed to develop normally; no morphological 
developmental abnormalities were seen at birth and the formation of rods 
and cones were seen in the developing photoreceptor layer. At P8, when 
outer segments are being formed, electromicrograph studies of retinal 
ultrastructure of Aipl1-deficient mice did not show any difference from wild-
type retina, indicating that retinal development indeed occurs normally. The 
earliest sign of cell death was the presence of apoptotic nuclei in the outer 
nuclear layer seen at P9. By P11, outer segments of Aipl1-/- mice appear 
shorter, disorganised and fragmented. Light microscopy evidence of retinal 
degeneration was first seen at P12, with loss of photoreceptor cell layer 
which progresses rapidly. By P14, only half of the photoreceptor layer was 
left and the degeneration was completed by 3 weeks with total loss of the 
outer nuclear layer in these mice. The degeneration appeared specific to the 
photoreceptor layer, affected both rods and cones equally and was more 
severe in the central retina compared to the periphery. Up-regulation of 
GFAP was seen in the outer nuclear and plexiform layer, while the other 
retinal layers, inner nuclear layer and ganglion cell layer appeared unaffected 
at 3 weeks of age. 
 
To establish the relationship between AIPL1 and PDE, the authors quantified 
levels of PDE at P8 before any significant degeneration had occurred. Levels 
of all three subunits of PDE (α,β,γ) were reduced but the mRNA levels of all 
three PDE subunits were normal. Assay of PDE acitivity revealed no 
significant PDE activity in the Aipl1-/- mouse despite the presence of low 
amounts of PDE present. Additionally, levels of cGMP were elevated, a 
feature that precedes the retinal degeneration. The temporal and spatial 
course of the retinopathy in these Aipl1-/- mice closely resembles that of the 
rd1 mouse. However distinct differences exist:  in the rd1 mouse, the loss of 
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the PDE-β subunit gene causes reduced levels of PDE-β mRNA and 
complete loss of the PDE-β subunit affecting rod photoreceptors[373], in the 
Aipl1-/- mouse, PDE mRNA are normal but all three PDE subunits are 
destabilized by AIPL1 deficiency resulting in loss of PDE activity which leads 
to photoreceptor degeneration. While the Aipl1-/- mouse have no detectable 
ERG response from birth, the rd1 mouse produces no rod responses but has 
reduced responses generated by existing cones during early stages of retinal 
development.  
 
To date, the most common AIPL1 mutations in patients are premature 
termination mutations which are likely to be functionally null[7,103,222,440] 
and lead to LCA these severest phenotype. Both Aipl1 knockout mouse 
models phenocopy LCA patients with AIPL1 mutations, in whom there is lack 
of visual function very early in life and retinal degeneration occurs and 
progresses quickly. Similarly, whilst the heterozygous patient carriers of 
AIPL1 mutations have some rod function abnormalities, the heterozygous 
Aipl1+/- mouse also has an increased implicit time indicating a delayed rod 
response on ERG.The rapid degeneration of photoreceptor cells in the AIPL1 
null murine model poses logistical difficulties for a feasible gene therapy 
strategy. Compounded by the time lag required for AAV-mediated transgene 
expression, it was felt that there may not be an adequate window for 
effective therapeutic intervention in this model.  An alternative model that 
may better facilitate the assessment of gene replacement therapy is the Aipl1 
hypomorphic mouse (Aipl1h/h), which has a later onset and slower rate of 
photoreceptor degeneration, thus affording a larger time window of 
opportunity. 
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1.3.4.2 The Aipl1 h/h hypomorphic mouse model. 
 
Liu et al. generated an Aipl1  hypomorphic mouse (Aipl1h/h) in which AIPL1 
function was diminished but not extinguished in an attempt to study the 
function of AIPL1 in the retina in more detail[282].  The AIPL1 targeting 
vector was generated by cloning a neomycin-resistance gene marker flanked 
by genomic fragments of exon 1,2 and 3 into a targeting plasmid. This 
construct was used to insert the neomycin resistance cassette into intron 2 of  
the Aipl1 gene in the same orientation as the gene. The resultant mutant was 
a strong hypomorph in which the level of AIPL1 was decreased to 20-25% of 
that in wild-type mice. Levels of rod cGMP phosphodiesterase was reduced 
in parallel to 20% that of wild-type levels and all the three subunits (α,ß, and 
γ) of cGMP phosphodiesterase were similarly decreased. 
 
Photoreceptors in the hypomorphic mutant develop normally but degenerate  
at a later age due to AIPL1 deficiency. Morphological evidence of 
degeneration is not seen until 12 weeks of age. However under electron 
microscopy, an increase in pyknotic nuclei and some outer segment 
disorganization can be observed in the week before this. From 3 months 
onwards, there is steady degeneration with a reduction in photoreceptor 
layer thickness and outer nuclear layer. By 8 months, more than half of the 
photoreceptors are lost as seen by marked thinning of the outer segments 
and outer nuclear layers. Cone degeneration was not detected up to 11 
months of age. Full field flash ERG showed some changes in young mice (5-
6 weeks old) in the form of increased latency and mean gain of 
phototransduction compared to wild-type mice. The a and b-wave amplitudes 
were normal at early ages of the Aipl1 h/h mice but progressively decreased 
due to the outer segment shortening and loss of photoreceptors with time.  
The single rod responses to flash stimuli showed similar characteristics to 
the ERG findings of the mass photoreceptor response; maximal amplitude of 
single rod responses to flash stimuli in young mice achieved the same levels 
as wild type rods, but showed delayed onset and slower initial rise of the 
single photon response. However, the single photon response in mutant rods 
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continued to rise for a longer period, taking a longer time to peak and 
achieved larger final amplitude compared with that in wild type rods. Mutant 
rods also had increased flash sensitivity and slower recovery following 
phototransduction. The ERG changes were thought to reflect the 
physiological consequences in the in PDE reduction subsequent to the 
AIPL1 deficiency. In darkness, cGMP hydrolysis by PDE is balanced by its 
synthesis by guanylate cyclases[124]. The basal activity of PDE is decreased 
along with a fall in PDE concentration secondary AIPL1 deficiency. 
Decreased PDE activity leads to a reduction in cGMP hydrolysis and 
accumulation of free cGMP in photoreceptors, causing more cGMP channels 
to open and thereby increasing intracellular Ca2+ levels. This would then 
feedback to cause a decrease in guanylate cyclase activity and bring cGMP 
and Ca2+ to an elevated steady-state. The increase in latency representing 
the delayed initiation of the photoresponse was consistent with the delayed 
diffusional encounter of activated transducin with PDE due to the lower 
concentration of available PDE[254]. The reduction in the gain of 
phototransduction and slower rise in single photon response suggested that 
PDE was activated at a lower rate in mutant rods.  The slower recovery 
phase in dim flash responses and a higher sensitivity to light in mutant rods 
were also thought to reflect a reduction in basal PDE activity[351]. An 
understanding of the photoreceptor electrical response to light stimulation 
would provide a basis in interpretreting the ERG changes following gene 
replacement therapy in these animals (see later Chapter 3). 
Recenly, a study described a patient with later-onset retinitis pigmentosa with 
caused by compound heterozygous mutation consisiting of a null mutation 
and a missense mutation. The clinical features and visual loss in this patient 
was less severe and the progression of the disease was protracted with 
preservation of some vision into adulthood[204]. It is thought that the Aipl1 
h/h hypomorphic mouse is remisniscent of this subset of patients who have a 
milder disease due to AIPL1 mutations. 
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1.4    Gene Therapy   
 
1.4.1   The eye as a target for gene therapy 
 
The eye has a combination of unique properties that makes it particularly 
suitable as a model system for gene therapy. The level of understanding of 
the molecular pathology of the eye is advanced compared to that of many 
other organ systems and a large number of inherited ocular diseases have 
been described at the molecular level. Furthermore, a wide range of animal 
models are available for the development of experimental therapies. The 
highly compartmentalized anatomy of the eye facilitates accurate delivery of 
vector suspensions to specific tissues, while the transparent nature of the 
cornea and lens allow direct visualization to facilitate surgery and permit non-
invasive techniques to monitor and measure the effects of treatment such as 
using fundus photography, slit lamp biomicroscopy, electrophysiology and 
psychophysical tests [10,408]. 
 
It is thus possible to achieve precise targeting of vector to desired sites within 
the globe while minimising systemic dissemination. The globe is also easily 
accessible, meaning that therapeutic agents can be administered via 
intravitreal or subretinal injections without much disruption to other vital 
systems. Intraocular tissues comprise of small but stable populations of cells 
and may be transduced efficiently and by small volumes of vector 
suspension. The blood-retinal and blood-aqueous barriers maintain a degree 
of protection from immune responses directed against vector antigens that 
might otherwise invoke inflammation and limit transgene expression. 
Additionally, the eye has the ability to induce an immune-deviant response 
when exposed to new antigens and to suppress delayed-type 
hypersensitivity [22,49]. Finally, visual function as an outcome measure of 
any intervention is readily quantifiable using psychophysical and 
electrophysiological parameters common in standard clinical practice. As 
paired organs, the fellow eye can serve as a valuable internal control for 
experimental interventions. 
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1.4.2  Vectors for gene transfer to the retina 
 
A variety of viral and non-viral vectors have been tested for their ability to 
transduce various cells in the retina, in particular the photoreceptor cells and 
RPE which are the cell types most commonly affected in retinal 
degeneration. The choice of vector to be used in a particular gene therapy 
strategy is crucial to the success of the treatment and requires several 
factors to be taken into consideration. Longevity of transgene expression is 
an important factor in the choice of gene therapy vector for retinal dystrophy 
because the disease requires lifelong correction. The ideal vector should 
have low immunogenicity as strong host immune responses result in short-
term transgene expression [36,80](for a review, see also [436]. Since most 
cell types in the eye are non-dividing, integration of the vector DNA into the 
host genome is not essential for prolonged transgene expression. Moreover, 
integration could lead to adverse events as a result of insertional 
mutagenesis. Other desirable features of an gene transfer vector include 
cell-specificity where only targeted cells are transduced, have a large or 
unlimited cloning capacity, no toxicity and easy to production at high titres 
and purity.  
 
1.4.2.1  Non-viral methods 
 
Gene delivery to target tissues in the eye can be achieved without the use of 
a viral vector, by either injecting or electroporating cells with naked plasmid 
DNA (for review see [384]). The main advantages of this are safety and 
biocompatibility, with little risk of inducing host immune response and the 
possibility of delivering large size DNA or multiple constructs to target 
tissues. Using direct injection of plasmid DNA into corneal stroma, localised 
reporter gene expression has been observed although this lasted less than 2 
weeks [358]. Transfection efficiency has been shown to improve substantially 
with adjunctive electroporation in several tissues [446]. Electroporation after 
intravitreal plasmid DNA injection resulted in efficient introduction of DNA into 
retinal ganglion cells (RGC) in vivo [102]. However, the value of this method 
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of gene delivery was limited by the transient gene expression which lasted 
only 21 days. Transfer of DNA into photoreceptor cells in vivo by 
electroporation is more readily achieved in immature retina. Subretinal 
injection of a GFP expression vector followed by electroporation into 
newborn mouse and rat retina resulted in highly efficient transfection of rod 
photoreceptors. The reporter gene expression was observed in 50% and 
80% of mouse and rat retinae respectively and seen up to postnatal 50 
days[305]. The gene transfer efficiency of this method of in vivo 
electroporation was sufficiently high to prove useful in functional analyses 
using DNA-based RNA interference (RNAi) vectors and reporter constructs 
carrying retinal cell-specific promoters or genes of interest. However, similar 
methods applied to adult mouse retina resulted in significantly fewer GFP-
positive cells and immunostaining revealed these cells to be mostly Mϋller 
glial cells[305]. It has been shown that it is possible to determine the cell 
types that are transduced by the route of administration of plasmid DNA prior 
to electroporation and that the transgene expression can be further specified 
by using plasmids containing tissue-specific promoters [220]. These 
techniques may be of use for in vivo analysis of gene regulation or promoter 
analysis but are inefficient for clinical applications due to their transient 
effect.  
 
Aside from electroporation, DNA can be delivered to cells in liposomes. 
Lipofectin or cationic liposome has been mainly used for gene transfer in 
vitro, but its ability to deliver DNA in vivo has been tested in tissues such as 
muscle [497]. Cationic lipids condense DNA and thereby protect it from 
degradation and facilitate endocytosis. In the eye, lipofection can lead to 
reporter gene expression in vivo; liposomal-mediated transfection has been 
reported in the cornea, trabecular meshwork and retina by various means of 
administration but the transfection efficiency remains inadequate compared 
to that of viral vectors and the effects are transient [31]. Novel transfection 
agents that incorporate ligands for specific cell-surface receptors have been 
developed, which allows receptor-mediated endocytosis of cationic liposome-
DNA complexes to increase transfection efficiency and specificity of cell 
types transduced [159].  
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In summary, non-viral methods offer potential for gene transfer without the 
complications that accompany viral vectors such as immunological response, 
toxicity and lower the risk of insertional oncogenesis. The main disadvantage 
of non-viral gene transfer approaches, however, is the poor efficacy and 
longevity to date in vivo.  For this reason, non-viral methods of DNA delivery 
may not be suitable for therapeutic uses, such as gene therapy of inherited 
retinal diseases. 
 
1.4.2.2 Adenovirus 
 
Adenoviruses are extensively exploited as gene therapy vectors because of 
their ability to efficiently tranduce a wide variety of cell types independent of 
cell cycle and to direct high-level transgene expression. In the eye, 
adenoviral vectors are capable of transducing a variety of cell types 
depending on the route of administration. Following subretinal delivery, 
adenoviral vectors are efficient at transducing the RPE and Muller cells 
[24,51,270], while intravitreal injection results in transduction of anterior 
segment tissues such as the iris, cornea endothelium and trabecular 
meshwork, and some limited transduction of retinal ganglion 
cells[187,215,302,334]. The transduction of photoreceptor cells by adenoviral 
vectors is poor. Higher levels of transduction are seen if the photoreceptors 
are in the process of development, such as in neonatal mice; or in the 
process of degeneration as in adult rds mice[270]. It is possible that the long 
densely packed outer segments and interphotoreceptor matrix in normal 
adult mouse retina may serve as a physical barrier virus-mediated gene 
transfer. As the photoreceptor outer segments in both the developing and 
pre-degenerate retina have shorter or absent outer segments, they may 
more accessible to the virus in these scenarios [270].	  The former finding is of 
limited clinical importance though, because photoreceptor cells in humans 
are fully developed at birth. The transduction profile of adenoviral vectors 
appears to be better suited for the treatment of RPE defects. Vollrath et al. 
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were able to show a restoration of phagocytosis and consequently an 
improvement in photoreceptor function and numbers in areas which had 
subretinal injection of rAd expressing MERTK gene in the RCS rat at 1 
month after treatment [482]. However, the survival of photoreceptors was not 
followed up for longer period, therefore it is unclear how long the 
improvements lasted. Adenoviral vectors may be particularly suited to deliver 
anti-angiogenic agents for the treatment of proliferative retinopathies 
because they preferentially transduced proliferative tissue following 
intravitreal delivery in animal models of proliferative retinopathy[334]. 
Additionally, adenoviral-mediated transgene expression was higher in the 
disease models than in wild type mice[334]. Adenoviral vectors have also 
been used in a Phase I clinical trial for choroidal neovascularisation 
associated with age-related macular degeneration (AMD) [67]. The gene 
transfer vector was an E1-, E3-, E4- deleted replication deficient adenovirus 
serotype 5 carrying the cDNA for human pigment epithelium-derived factor 
(PEDF), a potent anti-angiogenic protein. The trial was an open-label, dose-
escalation study, using low vector titres of between 1X106 and 10X109 to 
treat patients with severe neovascular AMD [398]. No adverse effects were 
reported and the treatment was well tolerated overall. The authors claimed 
that the treatment was effective in ameliorating vision in a number of patients 
[67], but the efficacy data were difficult to interpret since the number of 
patients in the study was small and the natural history of AMD patients’ 
visual acuity is such that some month-on-month improvement in outcome 
measure can be expected without intervention. 
 
While adenoviral vectors have certain advantages over other vector systems 
such as the ability to carry large inserts up to 48 kb, many limitations have 
also become apparent with their use, particularly in humans [68]. The main 
difficulty with adenoviral vectors is the issue of safety and lack of longevity of 
expression, due to the expression of viral genes from the vector backbone in 
the transduced cells. This induces an immune response againset transduced 
cells resulting in transient transgene expression and long term toxicity 
[221,353]. This problem renders these vectors unsuitable for many gene 
therapy applications in which long term transgene expression is desired. 
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Much work has been carried out to develop safer and more efficient 
adenoviral vector, by incorporating fewer viral genes in the recombinant 
virion [480]. The first generation vectors are deleted in the E1 region making 
them replication defective, and in the E3 regions which enable these vectors 
to carry DNA inserts of up to 7.5kb [164,382]. Newer ‘second-generation’ 
adenovirus have been engineered with additional deletions or mutations in 
the viral E2 and E4 regions, preventing transcriptional control of viral gene 
expression and viral genome replication respectively [20,486]. Despite this, 
the utility of first- and second-generation adenoviral vectors for ocular gene 
transfer remained limited due to the aggressive immune response triggered 
by these vectors in the eye. Following administration to the retina, T-cell 
mediated responses led to the loss of transgene expression just 3 weeks 
after treatment. Abrogation of immune response in nude mice which lack T-
cells population resulted in prolongation of transgene expression up to 3 
months after treatment [402]. Immune suppression by co-injection of a 
adenovirus encoding CTLA4-Ig, an immunomodulatory molecule that blocks 
stimulatory signals for T-cell stimulation, with an adenovirus carrying a 
reporter gene also led to longer reporter gene expression up to 18 weeks 
following treatment [11]. 
 
Further improvement in the safety and efficacy of adenoviral vectors came 
with the development of helper-dependent adenoviral vectors (HDAds, also 
referred to as gutless, gutted, mini, fully-deleted, high capacity, pseudo) 
which are deleted of all viral coding sequences. They contain only the viral 
inverted terminal repeats (ITR) and packaging sequences [233,354]. They 
retain the advantages of first generation adenoviral vectors in terms of high-
efficiency in vivo transduction and transgene expression, these HDAds are 
able to mediate high-level, longer term transgene expression in the absence 
of chronic toxicity [115,352,493]. Following subretinal delivery of 
encapsidated Ad mini-chromosomes carrying β-PDE, the transgene product 
has been found to persist in the form of mRNA for 18 weeks post-treatment 
and protein for up to 5 months in treated rd1 mice  [247]. Howver, there were 
problems associated with these techniques, such as contaminating helper 
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virus, vector instability and the emergence of replication-competent 
adenovirus [233,354,447].  
 
1.4.2.3  Lentiviral vectors 
 
Lentiviral vectors are being developed in ocular gene therapy because of 
their ability to infect non-dividing cells [481]. Lentiviruses are a subgroup of 
retroviruses which are RNA-based viruses that possess a reverse 
transcriptase, through which they are able to integrate their reverse-
transribed proviral DNA into host cell chromosomes. Retroviruses have 3 
transcription units - gag, pol and env and cis-acting RNA elements 
recognised by viral proteins that package the RNA into infectious particles. 
To generate recombinant retroviruses, the gag, pol and env are removed to 
give a carrying capacity of approximately 8kb; the gene of interest is cloned 
into a plasmid containing 3’- and 5’ long terminal repeat (LTR) sequences 
and the 350 bp ψ sequence required to package this recombinant genome, 
while the gag, pol and env genes are provided in trans in helper plasmids 
that are ψ-negative. The general advantage of retroviruses as vectors is the 
ability of these viruses to integrate efficiently into host cell genome, thus 
confering stable longterm transgene expression. However, retroviruses are 
only able to infect dividing cells as they gain access to the host cell 
chromosomes when the nuclear membrane dissolves during cell division. 
This limits the target tissues for which retroviral vectors can be used, making 
them unsuitable for use in the eye. 
 
While lentiviruses are similar to retroviruses in that they are both use RNA as 
their genomic nucleic acid, there are many distinguishing features that confer 
special advantages to lentiviral-based vectors. Lentiviral genomes encode 
additional genes such as rev, tat, vif, and vip that code for accessory proteins 
involved in the regulation of proviral gene expression.  They mediate 
transgene expression in quiescent or terminally differentiated cells as well as 
dividing cell types because their pre-integration complex containing the 
reversed transcribed cDNA is able to cross the host cell nuclear membrane 
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by active transport via nuclear pores during interphase [64]. Vectors from 
various members of the lentivirus family have been developed for gene 
transfer, including the human immunodeficiency virus type I and II (HIV1, 
HIV-2), equine infectious anaemia virus (EIAV), feline immunodeficiency 
virus (FIV), simian immunodeficiency virus (SIV) and bovine 
immunodeficiency virus (BIV) [83,197,284,328,462][196]. The most 
commonly used lentiviral vectors are based on the HIV1 which has a natural 
tropism for CD4+ T-lymphocytes.	   Tissue specificity or cellular tropism is 
determined by the surface glycoproteins on lentiviral envelopes. 
Pseudotyping results in lentiviruses expressing envelope proteins from other 
viruses on their surface, thus altering the expression of glycoproteins in the 
viral envelope and subsequently, lentiviral vectors can be modified to infect a 
broad range of cell types.  For gene therapy applications, HIV1 is most 
commonly pseudotyped with vesicular stomatitis virus surface protein (VSV-
G protein) because of the broad cell tropism; VSV-G envelope protein 
recognises a ubiquitous phospholipid in the cell membrane that enables the 
virus to infect different cell types. In the eye, subretinal delivery of HIV vector 
pseudotyped with VSV-G and driven by a ubiquitous cytomegalovirus (CMV) 
or spleen focus forming virus (SFFV) promoter results in reporter gene 
expression limited to the RPE [35].  Photoreceptor cell transduction has been 
reported when VSV-G pseudotyped vector is injected into neonatal mice, 
possibly because of better access of vector to photoreceptors whilst the 
retina is still developing [30,330]. However, the transduction efficiency in 
photoreceptors is poor compared with that achieved by AAV vectors (see 
section 1.4.2.4). Subretinal delivery of VSV-G pseudotyped SIV, FIV, and 
BIV vectors results in a similar pattern of transduction[84,117,462]. However, 
subretinal delivery of VSV-G pseudotyped EIAV results in some transduction 
of photoreceptor cells as well as efficient transduction of RPE cells [37]. 
 
The main safety concern when using HIV-based vectors in particular, is the 
possibility of generating wild-type viruses through recombination. The 
likelihood of this type of recombination depends on residual cis-acting 
sequences in the packaging plasmid, allowing some level of encapsidation, 
and on the extent of sequence homology between packaging and vector 
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constructs. This risk is minimized in newer generations of lentiviruses which 
have most of the viral genome deleted and the viral accessory proteins and 
envelope excluded from the production phase[118,528]. Third generation 
HIV-1 vectors are packaged by three non-overlapping expression constructs 
– two expressing HIV proteins and the other expressing the envelope of a 
different virus [225,307]. The development of self-inactivating viruses is 
another conceptual breakthough in which the transcriptional enhancer and 
promoter regions in the 3’U3 long terminal repeat (LTR) are deleted which 
prevents them from activating inappropriate transcription of genes 
downstream of the integration site. Following reverse transcription of the 
vector RNA, this modification is copied over into the 5’ LTR, thus causing 
inactivation of both LTRs in the integrated proviruses [329,423,527]. The 
resulting vector cannot be converted into a full length vector RNA in 
transduced cells, thereby reducing the risk of vector genome mobilization 
and also reducing the likelihood of enhancement or aberrant expression of 
surrounding cellular genes.	   
 
Although integration into the host genome has the advantage of being able to 
mediate long term gene expression, it increases the risk of insertional 
mutagenesis. This has lead to the development of non-integrating vectors 
that have comparable transduction efficiencies and persist as episomal 
double-stranded DNA circles that are capable of transducing non-dividing 
cells [287,411,479].	   These vectors are rendered integrase-deficient by the 
introduction of a point mutation in the integrase gene. Efficient and sustained 
transgene expression has been demonstrated using non-integrating lentiviral 
vectors in vivo in post-mitotic tissues such as the RPE, and at levels 
equivalent to that of their integration-proficient couterparts [507].  
 
Thus the newest lentiviral vectors incorporate additional safety features that 
may facilitate their clinical application given the improved safety profiles; the 
generation of self-inactivating, pseudotyped and integrase-deficient lentiviral 
vectors have been found to be effective in animal gene transfer studies. 
Lentivirus-mediated Mertk expression was shown to restore RPE 
phagocytosis, improve rod function on ERG and maintain outer nuclear layer 
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thickness in the Royal College Surgeon rat, a model of retinal degeneration 
[471]. However so far, the use of lentiviral vectors for gene therapy in the eye 
appears to be limited to gene correction in the RPE as that is the only cell 
type transduced with high enough efficiency for therapeutic purposes.  
Lentiviral vectors may be of use for the treatment of photoreceptor defects by 
mediating the delivery of secreted factors, such as neurotrophic or anti-
apoptotic factors to the RPE. 
 
1.4.2.4 Adeno-associated viral vectors 
 
Among all the vectors that have been used in the eye for gene transfer to the 
retina, vectors based on adeno-associated virus (rAAV) have emerged as 
the most promising in terms of efficiency and stability of gene transfer. 
Several main features of AAV that render them ideally suited for retinal gene 
therapy include the lack of pathogenicity, minimal immunogenicity, their 
ability to transduce non-dividing cells and their capacity to mediate long and 
sustained levels of therapeutic gene expression. They have been used to 
treat animal models of a wide range of retinal disorders from LCA and RP to 
autoimmune uveitis and neovascular 
disorder[14,29,32,34,62,250,251,280,301,311,335,363,390,403,464,525]. 
They have also recently been used in clinical trials for the treatment of LCA 
[34,181,293] (see later).   
  
Adeno-associated viruses are one of the smallest viruses with a non-
enveloped icosahedral capsid of approximately 22 nm. As they require a co-
infecting helper virus for replication to occur, adeno-associated viruses are 
categorised as dependoviruses that is naturally replication-deficient and non-
pathogenic. Wild-type AAV has a linear single-stranded DNA genome of 
about 4.8 kb which is composed of two open reading frames (ORFs) 
encoding capsid structural proteins (cap) and replication proteins (rep), 
flanked by two 145 bp inverted terminal repeats (ITRS). These ITRs are the 
minimal cis-acting elements necessary for viral genome integration, 
replication and packaging into the capsid shell. The virus does not encode a 
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polymerase and instead relies on cellular polymerase activities to replicate its 
DNA. The first ORF (rep) encodes four Rep proteins that are involved in 
replication of the viral genome, whereas the second ORF (cap) encodes 
three structural viral proteins (VP1, 2 and 3) which together assemble into 
near-spherical shell of 60 subunits with icosahedral symmetry. The genome 
of wild-type AAV is known to integrate into host chromosome DNA in a site-
specific manner; this integration occurs at a locus on human chromosome 19 
and is mediated by the AAV gene rep [244]. This property is lost in the 
recombinant vectors used in gene therapy due to the absence of the rep 
gene.  The recombinant virus, however, retains ability to integrate with low 
efficiency into heterogenous sites around host genome [38,345]. The 
recombinant AAV genome persists mostly as high molecular weight 
concatemers and stable long term transgene expression with rAAV is 
thought to be primarily due to these extra-chromosomal vector 
genomes[136,318]. Most of the time AAV vector genomes persist within cells 
as episomes, with only fraction of the genomes integrating into host 
genome[345]. Vector integration events are non random and tend to favour 
transcriptionally active regions of chromosomes[342-344], and have been 
observed in various experimental studies to occur either at non-homologous 
sites where DNA damage may have occurred[199,323] or by homologous 
recombination (for a review, see [438]). Concerns were raised when a study 
by Donsante et al. suggested that insertional mutagenesis resulting from the 
integration of AAV vectors was associated with tumorigenesis[107]. In this 
study, newborn normal mice and mice with the lysosomal storage disease 
mucopolysaccharidoses VII that received high-dose intravenous AAV vector 
expressing the human β-glucuonidase gene driven by a β-actin promoter and 
CMV enhancer, had increased incidence of hepatocellular 
carcinoma.[106,107]. These findings, however, need to be considered in light 
of the many studies using AAV vectors which have been done in rodents, 
dogs and primates where no increased in the incidence of tumours have 
been reported. Experimental factors which were unique to the study such as 
the treatment of very young mice, the particular strain of mice, the route of 
delivery, possible effects of the transgene and promoter-related effects may 
have contributed to the phenomenon. Large scale studies involving adult 
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mice or p53-deficient mice found no evidence for AAV-induced 
malignancies[44,45] and thus far, the bulk of experimental evidence suggest 
that tumours are not routinely observed following AAV vector administration. 
Furthermore, the favourable safety profile, minimal risk of germline 
transmission[425] and long-lasting transgene expression obtained in organs 
of animal models of human disease have lead to the initiation of several 
Phase 1 and 2 clinical trials with rAAV vectors[72,93,166]. Various diseases 
are being targeted including Parkinson’s disease, Alzheimer’s, muscular 
dystrophy, rheumatoid arthiris, cystic fibrosis, melanoma, α1-antitrypsin 
deficiency, haemophilia B (factor IX deficiency) [140,224,297], Factor XIII 
deficiency and RPE65-associated LCA[34,181,293] (for a review see [71] 
and [121]). In the context of ocular gene therapy, the issue of tumorigenesis 
is even less likely to be a concern, given the low dose of vector that is 
normally being delivered, the lack of systemic dissemination (see later), and 
so far, there has been no reports of ocular tumours or tumours elsewhere 
following intraocular AAV vector delivery. 
 
Recombinant AAV (rAAV) particles are generated by transfecting producer 
cells with a plasmid bearing a cloned rAAV genome flanked by the ITRs and 
a plasmid expressing rep and cap genes in trans (Figure 1.17). The ITRs 
contain all the cis-acting elements involved in genome rescue, replication 
and packaging. AAV is an inherently defective virus, its replication requires 
functions supplied by co-infection with helper viruses, such as adenovirus 
and herpesvirus[94,306]. In the absence of helper viruses or helper 
functions, the viral DNA can become integrated into host chromosomal 
genome to establish a latent infection[244]. AAV is capable of infecting both 
dividing and non-dividing cells, and has wide tropism allowing it to infect 
many cell types depending on the particular serotype[460,502]. To date, over 
100 AAV serotypes from different animal species have been 
isolated[152,153,336,422]. The different serotypes differ from each other in 
the sequence of their capsid protein. Recombinant AAV (rAAV) vectors used 
for gene therapy are mainly based on the serotype 2 (AAV2); this was the 
first human serotype described and the best characterised AAV serotype. 
Since the capsid protein of AAV is responsible for its tropism and hence 
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efficacy, a pseudotyping strategy was developed where ‘pseudotyped’ or 
hybrid AAV vectors encode rep from one serotype, usually AAV2, and the 
cap gene of a different serotype. Such hybrid virions produced in this 
instance contain genomes usually based on AAV2 and the capsid of a 
different serotype such as AAV5; in this instance, the chimeric AAV vector is 
designated AAV2/5 where the first number indicates the ITR of origin and the 
second denotes the capsid. The hybrid vectors generated in this way have 
expanded the available repertoire and cell tropism of AAV vectors, and 
additionally have the combined advantage of safety and long term 
expression of AAV2 and the improved in vivo efficacy and tropism of the 
novel serotypes. Cell-targeting strategies determine not only the cell types 
with which the vector interacts with but also the efficiency of the gene 
transfer process since processes related to virus uptake by cells and 
intracellular vision trafficking depend directly or indirectly on capsid 
conformation[133,135,180,466]. Apart from pseudotyping, other strategies 
for engineering custom-made capsids have been employed to further 
broaden the utility of AAV vectors to either transduce tissues that are 
refractory to naturally occurring AAV serotypes or to limit transduction to 
specific tissues. These include generating mosaic capsids (composed of a 
mixture of capsids subunits from different serotypes), chimeric capsids 
(containing capsid proteins that have been modified by domain or amino acid 
swapping between serotypes), targeting ligand insertion into the capsid, and 
recently, library selection and directed evolution have emerged as promising 
approaches to modulate AAV tropism[58,156,179,294,340,341,364,386] (for 
reviews, see [320,502,516]). In the context of ocular gene therapy, 
pseudotyping of vectors remains the most important strategy for targeting 
gene delivery to specific cell types. 
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In the eye, AAV 1 through 9 and two additional AAV capsids isolated from 
rhesus monkey, AAVrh8 and AAVrh10  have been evaluated in the retinas of 
rodents and primates[12,13,18,30,158,262,348,387,508]. Each cell type in 
the retina can be targeted by choosing the appropriate combination of AAV 
serotype, promoter and intraocular delivery route. In general, subretinal 
injections of AAV vectors lead to transduction of photoreceptors and RPE, 
while intravitreal injections transduce retinal ganglion cells. Table 1.4 
displays the transduction characteristics of pseudotyped rAAV in various cell 
types in the eye. The first AAV serotype to be tested in the retina was AAV 
2/2[13] and its transduction profile has been well established. Subretinal 
administration of AAV2/2 leads to transduction of photoreceptors and RPE 
cells, with an onset of transgene expression after 2-4 weeks and peaks at 4-
6 weeks after vector administration[12,13,30,47,139,262,389,409,418,459]. 
Intravitreal administration of AAV2/2 leads to transduction of ganglion cells, 
trabecular meshwork, cells of the inner nuclear layer including Müller cells 
[12,30,57,116,169,273,274,300].  Amongst the other AAV serotypes tested 
so far in the retina, AAV 2/1, AAV 2/6 and AAV2/4 are considered ideal for 
RPE gene transfer[30,461,489,508]. AAV2/5, AAV2/7, AAV2/8 and AAV2/9 
have been shown to be particularly promising for the delivery of transgene to 
photoreceptor cells, noteably the expression levels in photoreceptors 
mediated by AAV2/7 and AAV2/8 are six- to eightfold higher than AAV2/5, 
previously the favoured vector for photoreceptor gene 
transfer[18,286,348,508]. AAV2/9 additionally transduces Mϋller cells 
following subretinal delivery [18]. Following intravitreal injection, only AAV2/2 
and AAV2/8 have been observed to transduce retinal ganglion cells, with 
some transduction of Mϋller cells[19,262,460]. Anterior segment structures 
such as the trabecular meshwork, iris, corneal stroma and lens epithelium 
are more readily transduced by AAV2/7, AAV2/8 and AAV2/9 following 
intravitreal delivery[262]. Previous studies have suggested that the inability of 
many AAV vectors to effectively transducer the inner retina from an 
intravitreal injection is due to the barrier created by the inner limiting 
membrane. However, recent studies showed that AAVrh8 and AAVrh10, 
novel capsids isolated from rhesus monkey, are able to transduce amacrine 
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cells, horizontal cells and bipolar cells effectively following intravitreal 
delivery[158]. 
 
As well as tropism towards given cell types, the kinetics of transgene 
expression are also determined to some extent by the serotype. The time of 
onset of transgene expression differs for the various serotypes: subretinal 
injection of AAV-2/1, 2/7 and 2/8 results in early onset of transgene in mice 
within 5 days, AAV-2/5 around 1 week and AAV2/9 at 11 days, all of which 
are much faster in onset compared to AAV2/2[30,262,408,418]. The 
transduction efficiency and intensity of expression also vary amongst the 
different capsids, with newer AAV serotypes such as 2/7, 2/8 and 2/9 being 
more efficient and mediating higher levels of transgene expression compared 
to AAV2/2 or AAV2/5[18,262,348]. The pseudotyping approach may also be 
beneficial in evading neutralizing antibodies to capsid components in 
individuals seropositive for AAV2 or in those patients needing vector 
readministration.  
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Table 1.4   Different cellular tropism and expression kinetics based on serotype and 
delivery method in the mouse retina. 
	  
Delivery method rAAV 
serotype 
Onset period Cell types transduced 
Subretinal AAV2/1 Rapid, 3-4 days RPE 
Subretinal AAV2/2 Delayed, 2-4 wks PR, RPE, some RGCs 
Subretinal AAV2/4 2 weeks RPE 
Subretinal AAV2/5 Rapid 3-5 days PR, RPE 
Subretinal AAV5/5 Rapid, 3-5days PR, RPE 
Subretinal AAV2/6 Rapid, 3-5 days RPE 
Subretinal  AAV2/7 5 days PR, RPE 
Subretinal AAV2/8 Rapid, 1-5 days PR, RPE, Mϋller cells, RGC. 
Subretinal  AAV2/9 10-11 days PR, RPE, Mϋller cells. 
Intravitreal AAV2/2  Inner retina, RGC, some Mϋller cells, 
optic nerve fibers trabecular 
meshwork, small amount of ciliary 
body,  
Intravitreal AAV2/7  Anterior segment (TM, corneal 
stroma, iris, lens epithelium), small 
amount of ciliary body. 
Intravitreal AAV2/8  Inner retina, RGC, some Mϋller cells 
, anterior segment (TM, corneal 
stroma, iris, lens epithelium), small 
amount of ciliary body. 
Intravitreal  AAV2/9  Mϋller cells, anterior segment (TM, 
corneal stroma, iris, lens epithelium). 
Intravitreal AAVrh8  RGC, amacrine cells , horizontal 
cells, Mϋller cells 
Intavitreal AAVrh10  RGC, amacrine cells, horizontal cells, 
Mϋller cells, bipolar cells. 
Compiled from various publications.[12,18,30,158,262,348,408,460,508].  
PR – photoreceptor cells; RPE – retinal pigment epithelium; RGC-retinal ganglion cells. 
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One of the limitations of recombinant AAV is its small packaging capacity of 
4.7 kb which precludes many therapeutically important coding sequences. 
Emerging technologies in AAV vector design employing a split gene principle 
(trans-splicing AAV vector system) have allowed to assembly of large cDNAs 
in target cells by splitting the gene and cloning the fragments in 
independently into the rAAV genome. The AAV encoding the 5’ end of the 
gene is designed to possess a splice donor while the vector encoding the 3’ 
end possesses a splice acceptor. Following co-transduction of target cells by 
both vectors, head-to tail heterodimerization via intermolecular recombination 
between the two vector DNA molecules restores the full-length expression 
unit and results in the desired protein synthesis [505,506][253]. Its utility for 
therapeutic application has thus far been limited by its lack of efficiency. The 
efficiency of the process depends on the number of AAV genome copies 
entering the nucleus, and is increased in tissue systems where transduction 
occur through an enclosed space, such as the muscle or subretinal space, 
as this favours the entry of both vectors in the same cell[401]. The use of 
efficient AAV serotypes which mediate high levels of transduction further 
increases the efficiency of transplicing since there are more genome copies 
of the dual vectors per cell[508]. A recent study suggests that the limited 
capacity of AAV2 can be exceeded by AAV5[17]. Packaging of genes up to 
8.9 kb was shown to be possible using AAV2/5, and following intraocular 
delivery, the expression of the appropriate protein obtained and resulted in 
morphological and functional improvement in an animal model of retinal 
dystrophy[17]. Another new development in vector design is self-
complementary AAV vectors (scAAV), which uses the ability of AAV to 
package replicons half the size of wild-type DNA in the form of single-
stranded dimeric genomes with an inverted repeat configuration [308]. In the 
target cell, these self-complementary molecules fold back into double-
stranded forms without the need for de novo DNA synthesis or the annealing 
of complementary genome that occurs in conventional rAAV replication. Self-
complementary AAV has been shown to have faster initiation of gene 
expression in eyes that received subretinal injection of scAAV than titre- and 
serotype- matched single-stranded AAV [348]. Many also mediate higher 
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levels of expression although an expression cassette of only 2.4 kb can be 
used.  
 
The tissue-specific expression patterns, non-pathogenicity, together with the 
replication-deficient nature of AAV make this vector a safer and attractive 
alternative to other available vectors. Studies evaluating biosafety of rAAV 
have shown minimal systemic dissemination following intraocular 
administration and to date, there has been no reports of tumorigenesis or 
toxicity in the long term[45,333]. Biodistribution of rAAV in distant organs 
following intraocular delivery has never been reported[408]. Biodistribution 
studies of different rAAV serotypes delivered to the subretinal space or 
intravitreally in rats and dogs failed to detect vector sequences in liver or 
gonad samples, indicating that the risk of germ-line transmission of vector 
DNA is very low [383]. Following intravitreal injection, rAAV sequences were 
detected in the optic nerve and along the visual pathway in the brain, 
indicating that anterograde and transynaptic transport of rAAV is possible. 
High levels of green fluorescent protein (GFP) were found in the optic nerves 
and brains of mice and dogs following intravitreal administration and 
persisted for up to 6 months[116]. However, this risk appears to be reduced 
with subretinal injection - in another study, vector DNA was consistently 
detected along the visual pathway in the brains of rats and dogs following 
intravitreal injection of rAAV2/2, while subretinal injection resulted in 
detection of vector DNA in the optic nerve only [383]. There is also evidence 
that the potential for transynaptic transfer is higher with AAV8; subretinal 
delivery of an AAV2/8 vector carrying gfp gene in rats and dogs resulted in 
the transduction of not only the RPE and photoreceptor cells, but also of the 
inner nuclear layer, ganglion cells and in brain tissue along the visual 
pathway including the lateral geniculate nucleus and beyond that in dogs. 
[448].  Vector sequences were also found in various parts of the brain of the 
contralateral hemisphere after subretinal injection of AAV8 in dogs.  These 
findings highlight the importance of restricting expression of the transgene to 
the targeted tissues by using vector design which incorporate tissue-specific 
promoters and pseudotyping of rAAV vectors.  
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Compared to other viral vectors such as adenoviral vectors, rAAV is less 
immunogenic. However, more recent studies have shown that AAV is 
capable of stimulating an immune response that can inhibit the efficacy of 
repeated vector administration[298,488], although the route of administration 
and vector dose appear to be key elements in determining the degree of anti 
AAV immunity that is generated. A degree of humoral response to rAAV 
capsid proteins has been reported particularly following intravitreal delivery 
which was sufficient ot block vector expression upon readministration into the 
partner eye [269]. Subretinal delivery of rAAV is better tolerated, although 
there is a dose dependent effect [39]; low doses of rAAV2 did not lead to the 
development of neutralising antibodies in mice and transgene expression 
after readministration of the vector was achievable, whereas higher doses of 
vector lead to the induction of humoral responses which reduced the efficacy 
of repeated vector administration [21][39]. Immune responses to rAAV may 
be species-dependent; greater immune responses have been observed in 
large animal models such as dogs than in mice which have received the 
equivalent vector dose [45,46]. However attenuation of the immune 
responses can be achieved using transient immunosuppression, thereby 
permitting long-term transgene expression [33,48,286]. 
 
The potential of AAV vectors for the treatment of retinal disorders for ocular 
disorders has been extensively evaluated in a variety of animal models of 
dominant and recessive retinopathies (see section 1.4.3). The majority of 
retinal dustrophies are due to mutations in genes specifically expressed in 
photoreceptor cells. Since other vectors do not transduce photoreceptors 
effectively, AAV appears to be the most suitable vector for gene delivery to 
photoreceptors. AAV-mediated gene transfer has been evaluated a number 
of large animal models including dogs and primates, which better reflect the 
human eye in terms of anatomy, proportions and immunological responses 
and similar efficiency and stability of transduction have been observed 
[33,48,260,383]. Proof-of principle using AAV-mediated gene replacement 
for the treatment of LCA has been demonstrated in several animal models, 
including non-human primates [53,60,203,363,455,464]. Longer term studies 
in non-human primates and dogs have found no adverse effects on retinal 
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function or morphology and stable transgene expression in ocular tissues for 
up to 36 months following subretinaI injection of rAAV [261].The pre-clinical 
success, long lasting transgene expression mediated by AAV vectors and 
their favourable safety profile has made it the vector of choice in clinical trials 
for LCA [34,181,293] and so far, it has shown great promise in several of the 
concluded phase I clinical studies (see following section below). 	  
	  
	  
1.4.3  Gene therapy for inherited retinal dystrophies 
  
Due to the tremendous genetic heterogeneity associated with inherited 
retinal degeneration, different gene-mediated therapy strategies have been 
developed for treatment of inherited retinal degenerations. These causal 
mutations lead to disease through the loss of function of a mutated gene for 
example in autosomal recessive or X-linked recessive retinal degeneration, 
or through a toxic gain of function such as in autosomal dominant retinal 
degenerations. There are two broad strategies employed to rescue retinal 
cells from degeneration. The first is a specific gene targeted treatment in 
which the aim is the correction of the underlying gene defect. “Gene 
correction” may be achieved by augmenting the defective gene with a 
functional copy in the case of monogenic recessive diseases and 
haploinsufficiency, or by ablating the expression of the ‘toxic’ message from 
a dominant mutation. The second strategy involves a more generic approach 
and does not depend on the underlying defect. This entails the delivery of 
genes that express neurotrophic factors that help prolong photoreceptor 
survival [63,289]. The advantage of this approach is that it is not specific to 
the disease and can therefore be applied to many conditions, including 
disorders with a multifactorial aetiology. The disadvantage is that this 
approach has not been very effective to date and may have a better role as a 
supplementary treatment to gene replacement therapy in monogenic 
disorders. 
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1.4.3.1   Gene therapy for treatment of dominant diseases 
 
Autosomal dominant retinitis pigmentosa (AdRP) due to gain-of-function 
mutations in rhodopsin (RHO) is one of the common forms of RP and 
accounts for 30-40% of cases of adRP. Rhodopsin-based autosomal 
dominant RP (RHO-adRP) has considerable mutation heterogeneity, a 
situation that is mirrored in many dominantly inherited diseases. Hence, 
RHO-adRP has been frequently used as a model disorder for developing 
treatment for dominant diseases. In RHO-adRP, causal mutations can lead 
to the expression of mutant alleles that interfere with native wild-type alleles, 
hence producing a toxic gain of function[315]; studies in transgenic mice 
have shown that lower levels of mutant rhodopsin are associated with less 
severe disease [357]. The treatment of disorders that are associated with 
toxicity of a mutant allele require that the mutant gene must be repaired or 
silenced. Two strategies have been proposed for mRNA silencing. The first 
includes the use of allele-specific inhibitors that promote the degradation of 
only the defective mRNA and allow the expression of the normal allele that 
might be sufficient to maintain the function of the photoreceptor cells [275]. 
The second strategy is a mutation-independent approach where transcripts 
from both wild-type and mutant alleles are suppressed, and replaced by a 
non-silenced normal version [131]. Both approaches can be mediated by a 
variety of antisense inhibitors such as ribozymes, antisense oligonucleotides 
and small inhibiting RNA (siRNA). Ribozymes are catalytic RNA molecules 
that bind to specific mRNA sequences and catalyse the cleavage of that 
messages associated with the disease [108][374]. It has been established 
that ribozymes can limit gene expression by cleavage of targeted mRNA in 
vivo in the retina.  The P23H transgenic rat is a model for adRP and carries 
the most frequently found mutation in rhodopsin [113]. AAV delivery of 
ribozymes specific for the P23H transgene mRNA selectively knocked down 
the mutant mRNA in P23H transgenic rats and led to preservation of the 
photoreceptors for up to 8 months [109,267][258]. However, an optimal 
ribozyme cleavage site had been engineered into the transgene, enhancing 
the efficacy of the therapy. 
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The considerable heterogeneity of mutations in dominant disorders renders 
mutation-specific gene therapies neither economically nor technically 
feasible because this would require the development of a large number of 
mutation-specific inhibitors in order to be widely applicable. The use of allele-
independent RNA inhibitors is more realistic since a single reagent can be 
used against different mutations in the same gene. For optimal therapy, this 
should be accompanied by simultaneous provision of a replacement gene 
that encodes the wild-type protein but is resistant to suppression by utilising 
the degeneracy of the genetic code [355]. In vitro data have demonstrated 
that ribozymes directed against the 5’ untranslated region of rhodopsin 
mRNA could cleave all rhodopsin transcripts, mutant or wild-type, and that a 
rhodopsin gene designed not to be cleaved by these ribozymes could 
replace the ablated gene product [324]. In vivo efficacy was demonstrated 
when AAV2/5-mediated delivery of an allele-independent mouse-specific 
ribozyme targeting wild-type and mutant rhodopsin lead to partial rescue of 
photoreceptor function and structural preservation in P23H transgenic rats 
[162]. In vivo mouse rhodopsin mRNA levels were reduced by 46% following 
treatment. Since the P23H mutant transgene in the rat model was derived 
from a mouse genomic clone, a reduction in the mutant P23H trangene was 
obtained while the rhodopsin mRNA level (which was resistant to the 
ribozyme) was unchanged [162]. 
 
Despite these claims of success in the application of ribozymes in vivo, many 
researchers consider RNAi a more potent and durable approach. RNA 
interference (RNAi) involves the use of small interfering double-stranded 
RNA molecules (siRNA) which are able to mediate site-specific cleavage of a 
target mRNA molecule [120,268] by recruiting Dicer proteins to a multi-
protein complex known as RNA-induced silencing complex (RISC)[429]. A 
common way of using RNAi is to generate short-hairpin RNA (shRNA) 
molecules through transcription of DNA templates. Using a viral vector, the 
DNA template can be delivered to the target tissue; the shRNA is then 
transcribed and processed to siRNA [503]. Short-hairpin RNA have been 
shown to be effective in silencing more than 90% of mutant (P23H) 
rhodopsin transcript in vitro and in retinal explants [74,231]. In vivo, it has 
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been shown that rhodopsin can be effectively down-regulated with resultant 
decrease in retinal function and outer nuclear layer thickness by AAV2/5-
delivered rhodopsin-specific siRNA to the retina in wild type and 
heterozygous rhodopsin knockout mice [163] 
 
Both in vitro and in vivo validation of suppression and replacement strategy 
for RHO-adRP was demonstrated by O’Reilly et al. Using AAV2/5-mediated 
delivery of shRNA, approximately 90% in vivo suppression of RHO was 
obtained in mice which expressed a human transgene on Rho-/- background 
[313][355].. Using AAV2/5 vectors that express shRNA targeting RHO 
together with a codon-modified RHO replacement gene in vivo into the eyes 
of P23H+/- Rho+/- mice (expressing a mutant human RHO allele), therapeutic 
benefit was seen in the form of a 33% difference in outer nuclear layer 
thickness between treated and untreated eyes[355]. In another transgenic 
mouse model of adRP, the P347S mouse, AAV-mediated shRNA expression 
targeting RHO in the presence of expression of an endogenous mouse Rho 
gene that is refractory to suppression (due to divergence between mouse 
and human rhodopsin) resulted in improved retinal histology and function as 
assayed by ERG [76]. These studies thus demonstrate that RNAi-based 
suppression in conjunction with codon-modified gene replacement can lead 
to photoreceptor rescue as evidenced by structural and functional benefit 
following treatment in animal models of adRP.  
 
 
1.4.3.2 Gene replacement therapy for treatment of  
recessive diseases 
 
Early attempts at gene replacement therapy were not successful in rescuing 
phoptoreceptors in the rd1 mouse, a well characterised model of autosomal 
recessive retinitis pigmentosa and has a homozygous nonsense mutation in 
the gene encoding the β-subunit of rod cGMP phosphodiesterase, Pde6b. 
These experiments were performed using a variety of viral vectors including 
adenovirus [50], AAVs [216], gutted adenovirus [247], and lentivirus [463]. 
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The lack of rescue was largely due to the failure of adenovirus[51] and HIV-
1[463] to efficiently transduce photoreceptors. In a study using an AAV2 
vector, only faint β-PDE immunostaining and a slight shift in in vitro 
electrophysiological response was seen in the rd1 mouse following treatment 
[216]. It has been very difficult to rescue the rd1 mouse even with better AAV 
vectors such as AAV5 and AAV8.  However, gene replacement therapy has 
been more effective in rd10 mice, a hypomorphic Pde6b mutant with a 
missense mutation in exon 13.  The mutation causes partial loss of PDE 
activity and a milder phenotype than the mutation in rd1 mice. Loss of 
photoreceptor cells begins at P16 and is complete by P60. Dark rearing 
slows the degeneration by a further 4 weeks and allows the formation of 
outer segments that are not normally formed in either rd10 or rd1 mice. Pang 
et al. showed it was possible to preserve photoreceptors and retinal function 
following gene replacement therapy using an AAV2/5 vector. However, this 
was made easier by dark rearing the animals until vector administration at 
P14, and also for a further two weeks after treatment.  They were then 
exposed to light for one week before the effect of treatment was assessed 
[359].  
 
More convincing rescue was achieved in the rds mouse, another model of 
autosomal recessive RP, which is homozygous for a null mutation in the 
peripherin2 gene encoding a membrane glycoprotein essential for the 
formation of photoreceptor outer segment discs. Subretinal injection of AAV-
2 carrying a peripherin2 transgene driven by a bovine rhodopsin promoter 
resulted in the formation of discs and restoration of photoreceptor structural 
integrity [14] with some long term persistence of the structures which were 
detectable 42 weeks post-treatment. The structural rescue was accompanied 
by functional improvement seen on ERG responses [420] and improved 
central visual function seen on recordings from visually responsive neurons 
in the superior colliculus [421]. These studies provided the first indication of 
the potential for gene replacement therapy in the treatment of photoreceptor 
defects. Longer term studies however, found that the functional 
improvements were not maintained over time; the electrophysiological 
improvements appeared to peak six weeks after treatment and then 
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assumed a downward trend following that, although treated eyes retained 
statistically significant improvement in b-wave amplitude over uninjected 
eyes [419]. Longer term improvements in function were not sustained in this 
model, probably due to inapropriate levels of peripherin2 expression and the 
failure of the intervention to delay apoptotic photoreceptor loss.  
 
Gene replacement therapy for inherited retinal degenerations caused by 
RPE defects has generally been more successful. There are several 
postulated reasons as to why RPE defects are more amenable to gene 
therapy. The photoreceptors in RPE defects are inherently healthy and 
structurally intact and therefore, restoring function to the underlying RPE 
allows these photoreceptors to resume normal function. It is also possible to 
influence a wider area of photoreceptors by transducing the RPE as each 
RPE cell communicates with numerous photoreceptors. Extensive work has 
been carried out on models for Lebers Congenital Amaurosis (LCA), a 
severe early-onset form of inherited retinal dystrophy (see Chapter 1.3). In 
particular, success has been reported animal models of LCA caused by 
defects in an RPE-specific gene, RPE65. The RPE65 gene encodes a 
protein expressed in the RPE that is essential for the synthesis of 11-cis-
retinal in the retinoid cycle. Consequently, there is an inability to generate 
adequate visual pigment for initiation of phototransduction. These animal 
models with RPE65 defects have severely depressed dark and light ERG 
responses with poor vision from early life and are phenotypically similar to 
LCA caused by RPE65 mutation in humans. Mice with targeted disruption of 
RPE65 have a relatively slow photoreceptor degeneration, losing about 50% 
of photoreceptors at 4 months of age, reduced amount of opsin in 
photoreceptor outer segments and undetectable scotopic ERG from birth 
[400]. Treatment of RPE65-/- mice using AAV2/2 vector resulted in transient 
functional recovery of photoreceptors on but this was not accompanied by 
any delay in the photoreceptor degeneration[249]. Following improvements 
in the vector design, a different study demonstrated more substantial 
improvement in ERG following subretinal injection of AAV2/2 carrying chick 
β-actin driven human RPE65 cDNA although the follow up period was only 3 
125 
 
months and there was no assessments on the effect of treatment on the rate 
of photoreceptor degeneration[53]. 
 
Another mouse model with a naturally occurring homozygous null mutation in 
the murine Rpe65 gene is the rd12 mouse [360]. The retinal degeneration in 
this mouse model is similar to the genetically engineered model, 
approximately one-third of the outer nuclear layer is lost by 7 months of age. 
Subretinal delivery of AAV2/5 vector carrying the RPE65 transgene resulted 
in the normalisation of retinyl ester levels in the RPE, restoration of retinal 
morphology and significant delay of the photoreceptor degeneration. The 
improvement in morphology also correlated with dark- and light-adapted 
ERG responses being restored to wild-type levels and was accompanied by 
improvement in vision-dependent behaviour [361]. The first demonstration of 
long term success with the restoration of visual function was reported in a 
naturally-occurring canine model of Leber Congenital Amaurosis (LCA), due 
to RPE65 mutations[2,4]. Treatment of the Briard dogs with AAV-2 carrying 
normal RPE65 gene driven by chicken βactin promoter led to the restoration 
of visual function in treated eyes; a 16% improvement in scotopic and cone 
flicker ERGs was obtained in treated compared to uninjected eyes, and 
higher order visual function such as pupillometry and visual evoked cortical 
potentials demonstrated significant improvement in function in treated 
eyes[2].  Evaluation of the treatment up to 3 years post-injection showed long 
term preservation of the treatment[1]. Another study also studied the efficacy 
of AAV2 containing canine RPE65 driven by a CMV promoter delivered 
subretinally into the dog model [347]. Similar success in photoreceptor 
rescue was reported. To target transgene expression specifically to the RPE, 
a different study evaluated subretinal injections of AAV2/4 vector carrying a 
human RPE65 cDNA driven by a human RPE65 promoter in RPE65-/- Briard 
dogs and showed early restoration of rod and cone photoreceptor function 
which remained stable in the long term. Whereas all dogs that were treated 
at 8-11 months of age showed improvement, dogs that were treated at a 
later age of 30 months did not recover retinal function or vision, suggesting 
that there might be a therapeutic window for gene therapy to be successful in 
this model[260]. 
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Another form of RPE-based severe early-onset retinal dystrophy is caused 
by mutations in the MERTK gene. The RCS rat, is a well characterised 
recessive model of RP and has a null mutation in the receptor tyrosine 
kinase gene, Mertk which is exclusively expressed in the RPE [96].The 
defect results in the inability to phagocytose shed photoreceptor outer 
segments and the accumulation of the debris which subsequently leads to 
photoreceptor cell degeneration. Subretinal delivery of Mertk initially using 
recombinant adenovirus demonstrated functional recovery of phagocytosis 
and a temporary delay in photoreceptor degeneration [482]. Following both 
AAV-mediated [437] and lentivirus-mediated [471] Mertk gene delivery, 
treated eyes showed significantly higher numbers of photoreceptors and an 
increased ERG b-wave amplitude when compared to contralateral uninjected 
eyes. However the improvement in retinal function following treatment as 
assessed by ERG was transient; AAV-2 mediated Mertk delivery  resulted in 
significant improvement in ERG b-wave for only 9 weeks post injection [437], 
while lentiviral-mediated gene replacement improved ERG function for up to 
four months [471]. A more rapid initiation of transgene expression and better 
RPE targeting specificity of lentiviral vector were thought to account for the 
more superior therapeutic effect when using this vector. 
 
Together, all of these studies suggest that gene replacement therapy 
directed to the RPE represents a promising therapeutic strategy. The reports 
of efficacy, particularly in the Briard dog, showed proof-of-concept of the 
efficacy of gene replacement in RPE65 gene defects and provided the 
impetus for the start of the first human ocular gene therapy clinical trials, 
assessing gene replacement therapy in LCA patients with RPE65 mutations. 
This condition was chosen not only because of the impressive results from 
pre-clinical studies, but also because its characteristics enable rapid 
assessment of efficacy. Since photoreceptors in this condition are presumed 
to be healthy, gene replacement would be expected to improve vision owing 
to the restoration of absent photoreceptor function, whereas for many other 
retinal dystrophies, the aim would be to preserve vision by preventing 
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photoreceptor loss. In these trials, which are phase I studies, recombinant 
AAV 2/2 vector expressing human RPE65 cDNA driven by either a tissue-
specific [34] or constitutive promoter [181,293], was used to target retinal 
pigment epithelial cells in aldult patient subjects with relatively advanced 
disease. Differences that existed between the studies were in the type 
promoters used to drive transgene expression, vector titres, surgical 
protocols and functional assessments. Preliminary results from the trials 
demonstrated favorable safety profile of vector administration and lack of 
adverse reactions and toxicity [34,87,181,293]. Although there was no 
improvement detected in retinal function on electroretinography (ERG), two 
groups found improvements in subjective measures of vision such as visual 
acuity and navigational vision in dim illumination [34,293]. All three studies 
however detected improvements in retinal sensitivity using microperimetry, 
dark-adapted perimetry and pupillometry. The demonstration of improved 
retinal sensitivity but not by ERG suggests that the effects of treatment were 
relatively modest, which may be explained by the advanced stage of disease 
in the adult subjects[86,87][292]. Longer term evaluation showed that the 
functional amelioration seen in patients was stable and minimal evoked 
immunological responses was observed in the form of a transient rise in 
neutralising antibodes to the AAV capsid, which did not cause any significant 
loss of the treatment effect [434]. 
 
Although some forms of retinal dystrophies are caused by RPE defects, the 
majority of inherited retinal dystrophies originate from photoreceptor-based 
mutations. Gene replacement therapies have until more recently been more 
challenging for photoreceptor-specific defects due to the relative inefficiency 
of photoreceptor transduction and the fact that the defect is in the 
photoreceptor cell itself. Furthermore, for the treatment to be effective, highly 
efficient transduction over a wide area is needed as each photoreceptor cell 
needs to be transduced to prevent the death of photoreceptor cells.   Despite 
this, there have been few reports of therapeutic benefit following gene 
replacement therapy. Recently, gene replacement studies carried out in a 
mouse model of LCA due to mutations in RPGRIP reported improvement in 
the phenotype following treatment [363]. The RPGRIP gene encodes a 
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protein which localizes to the connecting cilium linking the inner to the outer 
segment and has a role in tethering RPGR to the cilium and also in outer 
segment disc morphogenesis. RPGR is required in the regulation of protein 
trafficking across the cilium. The RPGRIP mouse model has a rapid retinal 
degeneration which starts at postnatal day 15 and is almost complete by 3 
months of age. Subretinal injections of an AAV2/2 vector carrying an 
RPGRIP expression cassette that is driven by a photoreceptor-specific 
murine opsin promoter resulted in a restoration of RPGR and opsin protein 
localisation to the outer segments of photoreceptors. A significant slowing of 
photoreceptor loss in treated eyes was accompanied by electrophysiological 
improvements in scotopic ERG b-wave amplitudes at 5 months post injection 
[363]. Two animal models carrying null mutations in the Gucy2d gene have 
been used to evaluate gene replacement therapy, the naturally occurring 
GUCY1B chicken and the guanylate cyclase-1 (GC1) knockout 
mouse[172,496]. This gene is expressed in both rods and cones 
photoreceptors and encodes guanylate cyclase, an enzyme in the recovery 
phase of phototransduction whose role is to replenish cGMP stores after light 
exposure. Prehatch lentiviral-mediated transfer of bovine Gucy2d cDNA to 
the retina of these chicks restored visual function to these animal as 
evidenced by behavioural testing and ERG analysis, but did not preserve 
retinal structure in the long term[496]. The GC1 knockout mouse exhibits 
cone photoreceptor degeneration; the loss of cone function in this model 
precedes cone degeneration but the rod photoreceptors do not degenerate 
and continue to give rise to ERG responses to light due to the presense of 
GC2, a close relative of GC1 in the rod cells[90,509]. AAV2/2-mediated 
transfer of the Gucy2d to the post natal retinal of GC1 knockout mice 
restored light-driven translocation of cone arrestin but failed to restore cone 
ERG responses or prevent cone degeneration[172]. It was thought that the 
heterologous nature of the gene transfer using a bovine Gucy2d cDNA may 
be the reason for the incomplete success. A later study using AAV2/5 vector 
to mediate targeted delivery a murine version of Gucy2d to rod and cone 
photoreceptors of the postnatal GC1 knockout mouse demonstrated 
restoration of visual function and visually evoked behaviour[60]. Although the 
follow up period was short (3 months), evidence of restoration of cone-
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mediated function was seen following treatment in the form of improved ERG 
amplitudes, visual acuity and contrast sensitivity, while preservation of cone 
photoreceptors was seen with the restoration of normal cone arrestin 
distribution and increased cone cell density in treated areas[60]. 
 
Mutations in ABCA4 gene cause Stargardt disease, a form of autosomal 
recessive juvenile macular degeneration. The ABCA4 protein belongs to the 
ABC transporter family of proteins involved in the ATP-dependent transport 
of substrates across cellular membranes; the ABCA4 protein is responsible 
for the translocation of N-retinylidene-PE, an intermediate in the visual cycle, 
from the lumen of the disc to photoreceptor cytoplasm.  Although the ABCA4 
is expressed in the disc rims of photoreceptors outer segments, the disease 
phenotype originates from the loss of RPE due to the accumulation of 
lipofuscin in these cells [234]. Until recently, the ABCA4 cDNA was 
considered too large to be packaged into AAV vectors, which are the only 
vectors capable of efficiently transducing photoreceptors. However, recently 
it was found that vectors based on AAV5 can package large recombinant 
genomes up to 9 kb. This enabled gene replacement studies in an Abca4-/- 
mouse model of Stargardt disease; subretinal injection of an AAV2/5 vector 
carrying Abca4 lead to reduced lipofuscin content and improvement in retinal 
morphology and function for up to 5 months [17]. 
 
So far, most gene therapy strategies developed in rodent studies have 
focussed on conditions primarily affecting rod photoreceptors. This is likely 
due to the rod-rich nature of the rodent retina. However, recent advances in 
rodent ERG, a better understanding of the molecular processes in cone 
dystrophies and increasing use of large animal models have facilitated the 
study of gene therapy for inherited cone dystrophies. One such condition that 
is most likely to be amenable to gene therapy is achromatopsia, which is 
caused by mutations in any of the four causative genes known to date, 
GNAT2 which encodes the alpha subunit of cone transducin[238][15,410], 
PDE6C which encodes the catalytic alpha subunit of cone 
phosphodiesterase[77,465],  CNGA3 [239][499] and CNGB3 
[237][456,498][325]  which encodes the alpha and beta subunits of the cone 
130 
 
cyclic nucleotide-gated (CNG)channel located in the plasma membrane of 
the cone outer segment. AAV-mediated gene replacement has been shown 
to restore cone-mediated ERG responses to a mouse model of 
achromatopsia, the Gnat2cpfl2 mouse, which is homozygous for a nonsense 
mutation in Gnat2 [9]. Improvement in visual acuity was also observed using 
an optokinetic behavioural assay. More recently, cone-directed gene therapy 
using AAV2/5 vector was evaluated in two independent canine models of 
achromatopsia[242,243]. These naturally occurring dog models of 
achromatopsia result from either a missense mutation in exon 6 of CNGB3 or 
a genomic deletion of the entire CNGB3 gene[430].  Single subretinal 
injection of AAV2/5 containing the human CNGB3 driven by different 
versions of human red opsin promoter led to restoration of cone function in 
both CNGB2-mutant dog models as measured by flicker ERGs and recovery 
of day vision in treated animals[243]. The robustness and stability of the 
treatment effect was promoter and age dependent however, sustained 
rescue of cone function was only obtained using vectors that contained the 
long version of the red cone opsin promoter and in younger animals[243]. 
This study provided evidence that cone-specific disorders could be 
ameliorated using targeted AAV-mediated gene replacement and may hold 
promise for future therapy in humans. One step closer toward this direction 
has made in the form of AAV-mediated gene therapy to restore trichromacy 
in colour-blind primates [296]. Subretinal injection of AAV2/5 vector 
containing the human L-opsin gene under the control of the L/M opsin 
enhancer and promoter elements was delivered to adult primates with red-
green colour vision deficiency, thus co-expressing the L-opsin transgene 
within a subset of endogenous M-cones. At about 20 weeks following 
subretinal injection, treated primates showed a shift in spectral sensitivity 
measured on colour multifocal ERG towards long wavelength light which was 
accompanied by evidence of trichromatic colour vision behaviour. The 
improvement in colour vision appeared stable for over 2 years of follow up, 
and demonstrates the restoration of colour vision may be possible even in 
adulthood as the acquisition of new colour vision capacity did not appear to 
require a developmental process unlike that in monocular deprivation [296] 
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The experiments described above demonstrate that in many models of 
diseases caused by loss-of-function mutations, gene therapy is able to delay 
apoptotic cell loss. The best results in treating hereditary retinopahies to date 
are obtained using gene replacement strategies.  In other conditions where 
gene replacement may not be not possible or where there is no other 
available alternative, neuroprotection therapy may be used but the effects of 
this is often partial and transient.  
 
 
1.4.3.3 Neuroprotection and anti-apoptotic therapy for   
treatment of retinal dystrophies 
 
Although gene replacement and gene silencing strategies offer good 
prospects for the treatement of specific inherited retinal dystrophies, many 
other disorder, particularly inherited dystrophies that is advanced at birth, 
acquired and multifactorial conditions such as age-related macular 
degeneration (AMD) are less amenable to these corrective approaches. With 
the vast genetic heterogeneity of these conditions, the prospect of 
developing individualized corrective gene therapy strategies for patients with 
disorders due to rare mutations would be technically and economically 
unfeasible. Generic strategies do not correct the gene defect and hence do 
not cure the disease, but are aimed at secondary targets such as those 
involved in apoptosis or in modulating the microenvironment of 
photoreceptors in a manner that promotes cell survival in order to ameliorate 
condtion. Such approaches include the localized, targeted delivery of 
neurotrophic factors and antiapoptotic proteins with the aim of enhancing 
photoreceptor cell survival. 
 
Irrespective of the gene defect, the death of photoreceptors in inherited 
retinal dystrophies occurs through apoptosis. Since apoptosis is a final 
common pathway in all genetic diseases, this form of generic therapy would 
be applicable across the spectrum of retinal degenerations and does not 
require gene-specific treatments. Gene transfer of bcl-2, an antiapoptotic 
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gene has been shown to delay retinal degeneration in the rd mouse, an 
animal model of retinitis pigmentosa [52].  However,the rescue was only 
detectable histologically and lasted only 6 weeks after birth, indicating that 
the limited benefit conferred by the treatment was not sufficient to prevent 
further loss of photoreceptor cells. The X-linked inhibitor of apoptosis protein 
(XIAP) is a potent inhibitor of apoptosis and acts by inhibiting caspase 3, 7 
and 9 [265]. AAV-mediated delivery of XIAP to P23H and S334X rhodopsin 
transgenic rat models of retinitis pigmentosa was shown to inhibit caspase 
activity and delay photoreceptor cell loss. Six months post injection, the outer 
nuclear layer in treated eyes was almost twice the thickness of untreated 
eyes in both models. However, ERG functional improvements were observed 
in the P23H rat treated eyes but not in the S334X rats, indicating that 
increased survival of photoreceptor cells  which were non-functional in the 
latter did not lead to restoration of function. Although anti-apoptotic gene 
therapy approach would theoretically provide a more comprehensive 
treatment applicable to a wide range genetic of inherited retinal dystrophies, 
this study shows that not all forms of retinal dystrophies would respond to 
this form of treatment. Further evaluation is needed as to which disorders are 
better suited and whether there are other external factors that need to be 
taken into account that could determine the success of the treatment. 
 
Neurotrophic factors such as fibroblast-growth factor (FGF), glial-derived 
neurotrophic factor (GDNF) and ciliary neurotrophic factor (CNTF) have been 
found to retard photoreceptor degeneration in several animal models of 
retinal degeneration [125,126,259,472].  To achieve longer term effect 
without the need for readministration, AAV-mediated expression of genes 
encoding neurotrophic factors has been widely studied. AAV2-delivered 
bovine FGF-2 has been found to increase photoreceptor survival for up to 4 
months post injection in the S334X transgenic rat model of dominant RP 
which expresses a mutant Rhodopsin allele. Thicker outer nuclear layer seen 
in treated eyes although this was not reflected in improved retinal function as 
assayed by ERG [256]. ERG amplitudes in treated eyes were better than 
non-injected eyes but showed no significant difference from eyes injected 
with a reporter gene. It has been suggested that some degree of 
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photoreceptor rescue could be injection-related in keeping with the theory 
that retinal injury also induces the release of survival factors [126]. Subretinal 
delivery of GDNF using AAV2 vector in the same animal model resulted in 
increased  photoreceptor survival with corresponding in ERG improvement in 
treated eyes [154]. It has been further shown that AAV-mediate expression 
of the gene encoding GDNF can enhance photoreceptor survival in two 
rodent models of retinitis pigmentosa, the Prph2rd2/rd2 mouse and the RCS 
rat, and affords additive improvement of retinal function when combined with 
gene replacement [63]. In this study, animals treated with the combination of 
gene replacement and GDNF had up to 50% higher ERG amplitudes than 
those give gene replacement alone. More importantly, no deleterious effect 
on retinal function was seen on ERG, unlike the paradoxical effects that have 
been reported with AAV-mediated expression of CNTF. 
 
Ciliary neurotrophic factor or CNTF has been shown to be a therapeutic 
neurotrophic agent, particularly as the delivery of the recombinant protein 
results in transient improvement of photoreceptor survival in rodent models 
of retinal degeneration [257,259]. AAV-mediated CNTF expression also 
resulted in slowing of photoreceptor cell death for up to 4 months in rodent 
models of RP such as Prph2rd2/rd2 mouse, P23H and S33ter rhodopsin 
transgenic rats [272]. However, despite the morphological protection seen 
following treatment, significant dose-dependent deleterious effects on retinal 
function were seen on ERG and behavioural tests [63] [309]. When 
administered in combination with AAV-mediated gene replacement therapy 
in Prph2rd2/rd2  mice, AAV2.CNTF delivery negated any improvement of retinal 
function by gene replacement therapy and furthermore, a marked decrease 
of 50% in ERG b-wave amplitude was seen following intraocular injection of 
AAV expressing CNTF into wild-type mice[420]. These data regarding 
vector-mediated CNTF delivery suggests that although CNTF exerts a potent 
effect on the survival of photoreceptors in retinal degeneration, there is a 
certain harmful effect exerted by this neurotrophic molecule that reduces 
overall retinal function. It has been suggested that the negative functional 
effects may be due to molecular changes and downregulation of 
photopigment expression as a consequence of long term activation of 
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signalling molecules downstream of CNTF [492]. Despite this, a recent 
phase I clinical trial of patients with end-stage retinitis pigmentosa 
demonstrated that a device that is implanted intraocularly and using 
encapsulated cell technology to deliver CNTF to the retina, is well tolerated 
for several months (the implants were removed after 6 months) [431]. This  
small scale clinical study showed that short-term CNTF delivery at low doses 
were well tolerated without any reports of negative effects on visual function. 
However, assessments of the impact on visual function were difficult to 
interpret due to the small number of patients involved and the study was not 
designed to test the efficacy of CNTF in preserving vision. As a result of the 
study, phase II/III trials have recently been initiated to investigate whether 
CNTF has any effects in prolonging visual function or improving 
photoreceptor function. 
 
Pigment epithelium-derived factor (PEDF) is a growth factor that has been 
shown to have neuroprotective properties using the recombinant protein in 
models of retinal degeneration [75] although such studies are relatively few. 
To circumvent the transient effects of PDEF due to its short half-live, viral-
mediated delivery of the protein has been used to study treatment effects. 
Benefit was observed when a lentivirus-mediated delivery of PEDF (using 
SIV.PEDF) into eyes of RCS rats showed significant preservation of 
photoreceptors  lasting up to 24 weeks post injection [328]. Histological 
analysis showed twice as many photoreceptor cells in the treated areas of 
the retina compared with untreated areas at 4 weeks post injection, while 
ERG assessment demonstrated a modest improvement with higher b-wave 
amplitudes in SIV.PEDF-treated eyes compared with SIV.lacZ-treated control 
eyes [328].  
 
Despite the encouraging aspects of these results in animal models, the 
clinical use of neurotrophic factors is thus far limited because the rescue 
effects appear to be partial and transient, and the mechanisms underlying 
the benefits afforded by these molecules are not yet fully understood. 
Ultimately, for long lasting improvement of a phenotype, it is necessary to 
prevent the death of the cells involved. Hence, using neuroprotection in 
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conjunction with gene replacement therapy could have a synergistic effect, 
as already shown in some studies above. Co-delivery of therapeutic genes 
and neurotrophic factors may result in a more effective treatment for retinal 
dystrophies in which gene replacement corrects the underlying pathological 
defect while neuroprotective agents protect against photoreceptor cell death. 
However, further studies using GDNF, PEDF, BDNF, CTNF and other 
neurotrophic factors are required before they can considered for clinical use 
alongside gene replacement in retinal dystrophies. 
 
 
1.5  Summary 
 
There has been major progress in the development of gene replacement 
therapy for inherited retinal dystrophies, made possible by technical 
advances in vector technology and better understanding of the underlying 
disease mechanisms and knowledge of potential difficulties surrounding 
gene transfer to specific retinal cells. This has led to successful rescue of 
retinal degeneration in various animal models, particularly of the forms of 
retinal dystrophies caused by RPE-specific defects. The recent positive 
preliminary results from the ongoing clinical trials of gene replacement 
therapy for RPE65 defects will undoubtedly pave the way and call for more 
gene therapy strategies for other retinal dystrophies to be developed and 
translated to clinical trials. As majority of inherited retinal dystrophies are 
caused by defects in photoreceptor-specific genes, it would be logical and 
crucial to focus the development of new gene therapy strategies for these 
disorders. These disorders have generally been more difficult to treat and 
have a variety of kinetics of photoreceptor degeneration. In such disorders, 
improved and very efficient viral vectors would be required and are most 
likely to be based on AAV vectors, which are the only vectors shown to 
transduce photoreceptor cells well. In line with these points, this study 
focuses on developing gene replacement strategy and assessing its efficacy 
to treat a form LCA and retinal dystrophies caused by mutations in a 
photoreceptor-specific gene AIPL1. Bearing in mind the difficulty in treating 
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photoreceptor defects, we will investigate the efficacy using mouse models 
which have either reduced or no Aipl1 expression and thus different rates of 
degeneration. In order to treat the different rates of degeneration, different 
serotypes of AAV vectors will be required. The experiments described in this 
study will form a comprehensive preclinical assessment of gene replacement 
therapy for AIPL1-associated retinal dystrophies and may also provide proof-
of-principle for clinical trials to treat these disorders. 
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2 Materials and methods 
 
2.1 Amplification of plasmid DNA in bacteria 
 
2.1.1 Transformation of competent cells 
 
For transformation DH5α™ competent cells  (Invitrogen Ltd., Paisley, UK) 
were thawed on ice. A 100 µl aliquot was incubated with the plasmid DNA 
(30minutes on ice) before heat shock at 42oC in a pre-warmed water bath for 
90 seconds followed by 120 seconds on ice. LB (Luria-Bertani) medium 
750µl was added at room temperature to the mix and incubated for 1 hour at 
37oC before spreading onto an LB agar plate containing 100 µg/ml ampicillin 
or kanamycin. Plates were incubated overnight at 37oC to allow growth of 
antibiotic-resistant colonies. LB agar plates were prepared using 14 g of 
Bacteriological agar (Oxoid Ltd.) per litre of water, 5 g/L yeast extract, 10 g/L 
tryptone (Oxoid Ltd), 10 g/L sodium chloride, and 100 µg/ml ampicillin or 
kanamycin.  
 
2.1.2 Amplification and recovery of recombinant plasmid 
DNA 
 
Bacterial colonies from agar plates were inoculated into 2.0 ml of LB medium 
containing 100 µg/ml ampicillin (1000X; Sigma Aldrich Company Ltd.) the 
following day and incubated at 37oC with gentle shaking at 1200 rpm 
overnight to allow growth. For small scale preparations, plasmids were 
recovered using QIAprep® Spin Miniprep Kit (Qiagen Ltd., Sussex, UK). For 
large scale preparations 200 µl of the 2 ml culture was used to inoculate a 
further 1000 ml LB medium and was incubated as described above. Plasmid 
DNA was recovered using QIAGEN® Plasmid Mega Kit (QIAGEN Ltd.). 
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2.1.3 Quantification of nucleic acid 
 
Nucleic acids produced with the QIAGEN Mega Kits were quantified using a 
Unicam UV 500 Spectrometer and the Nanodrop™ spectrophotometer. An 
absorption of 1 at OD260nm equals a concentration of 50 µg/ml double 
stranded DNA. Nucleic acids produced with QIAGEN Mini Kits were 
quantified on a 1% agarose gel. 
 
2.2 DNA analysis 
 
2.2.1 Restriction enzyme digestion 
 
Digestion of DNA was carried out in accordance to the manufacturer’s 
specifications (New England Biolabs Ltd., Herts, UK), in a 1X buffer with an 
excess of enzyme (5-10 U/µg DNA). 
 
2.2.2.  DNA electrophoresis 
 
DNA fragments were separated on a 1-1.5% (w/v) agarose gel using 1 X 
TBE buffer. Ethidium bromide 1 µl of 10 mg/ml concentration per 50 ml of 
gel) was added to enable visualization of DNA bands. A 1 kb DNA ladder 
(Bioline Ltd., UK) was simultaneously run to provide size markers. Samples 
were loaded using gel-loading dye (6 X; 0.25% (w/v) bromophenol blue and 
30% (v/v) glycerol in water). Gels were run using the voltage and duration 
required for the separation of the required DNA bands. Gels were 
photographed on an ultraviolet transilluminator. 
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2.3 Cloning and plasmid construction 
 
To create a recombinant virus for the purpose of gene transfer, most of the 
viral genome must be replaced with a recombinant genome carrying the 
therapeutic gene under the control of an appropriate promoter, which drives 
its expression in the right cell type and at an efficient level. The genes which 
encode viral capsid and are required for in-vivo replication need to be 
deleted to ensure that the recombinant virus does not invoke the an immune 
response which would lead to removal of transduced cells and short-lived 
transgene expression. Recombinant viruses are produced in-vitro and hence 
consideration needs to be given towards safety and purification issues. Risks 
of toxicity are minimized by ensuring through purification of the viral particles. 
Efficiency of gene transfer is optimized by ensuring that the recombinant 
viruses that is administered is of sufficiently high titres. 
 
2.3.1 Isolation of murine-AIPL1 cDNA 
 
The murine AIPL1 cDNA  (see appendix for cDNA sequence) was PCR 
amplified from murine cDNA. Primers used for PCR were : 
 
Maipl5 (5–GCCTGAACAAACCTCTCCCCTA)  
Maipl3 (5’-CCACCCAACCTAACCCAGTCTAAC) 
 
The PCR fragment obtained of 1016 bp in size was checked using restriction 
enzyme digests and sequenced after cloning into pGem-T easy (Promega, 
Madison, WI). 
 
2.3.2 Creating appropriate DNA fragments 
 
DNA fragments that were required for cloning were made using the 
appropriate restriction enzyme digests as indicated by respective plasmid 
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maps. Where possible, non-complemetary ends were created to enhance the 
efficiency and ensure the correct orientation of the transgene insertion. 
Where necessary, the vector molecule was pre-treated with calf intestinal 
alkaline phosphatase (New England Biolabs (UK) Ltd.) to remove 5’-
phosphate groups to prevent intra-molecular ligation. One microlitre of 
alkaline phosphatase was added after the restriction enzyme digest  and the 
mixture incubated at 37oC for 1 hour. Where a blunt ligation was necessary, 
the 5’ overhang was filled with 1µl Klenow fragment DNA-polymerase I (New 
England Biolabs (UK) Ltd.) in the presence of excess (0.5 mM) 
deoxynucletide triphosphates (dNTPs- Promega UK, Southampton, UK), 
both added after the restriction enzyme digest and incubated at room 
temperature for 15 minutes. These reactions were terminated by the adding 
of gel loading dye or where required, heating  for 20 minutes at 65oC. 
Samples were run on agarose gel and the required bands excised with a 
scapel under ultraviolet light. 
 
2.3.3 Isolation of DNA fragments from agarose gels 
 
DNA fragments excised from agarose gels were extracted from agarose 
using QIAquick™ Gel Extraction Kits (QIAGEN Ltd.) according to 
manufacturer’s specifications. DNA was eluted from the column using 50 µl 
of TE buffer (supplied by manufacturer). The concentration of the eluted 
sample was determined using the Nanodrop spectrophotometer. 
 
2.3.4 DNA ligation 
 
The ligation of gel purified DNA fragments was carried out at 16oC for 12-16 
hours, using T4 DNA ligase (New England Biolabs (UK) Ltd.) with supplied 
buffer at recommended concentrations and at insert to vector backbone 
molar ratio of 3 to 5. Where PCR fragments were ligated into pGEM®-T Easy 
141 
 
plasmids (Promega UK) ligations were performed according to 
manufacturer’s instructions. 
 
2.3.5 Checking cloned plasmids 
 
A 20 µl sample of the ligation mixture was transformed into and amplified in 
bacteria. Successful ligation was determined by obtaining the appropriate 
DNA bands following restriction enzyme digestion of the purified plasmid 
DNA. 
 
2.3.6 PCR and sequencing 
	  
To ensure that the isolated fragments have the correct sequence they were 
amplified using appropriate primers and cycling conditions. PCR reactions 
were performed in a total volume of 20 µl. 0.2 mM dNTPs (Promega UK), 25 
pM of each primer and 1 U of Taq polymerase (Promega UK), and 8 µl of 
buffer were mixed and DNA was added to a final DNA concentration of less 
than 10 ng/µl. The amplified fragments were then sequenced (MWG-
Biotech). 
 
2.4 Polymerase chain reaction (PCR) 
 
PCR reactions were performed in a volume of 30 µl using 0.33 mM dNTP 
(Promega UK), 0.5 µM of each primer and 1 U of Taq DNA polymerase 
(Promega UK), 0.5 mM Mgl2 and 8 µl of buffer supplied by the manufacturer. 
DNA was added to a final concentration of less than10 ng/µl. In each PCR 
run, an additional control reaction was made, to which no template DNA had 
been added. Reactions were cycled using a Techne Touchgene Thermal 
Cycler. The optimal annealing temperature for each primer set was 
calculated using the program PrimerSelect™ (DNASTAR Inc.) 
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Cycling conditions were based around the following: 
 Initial denaturation   5 minutes at 95oC 
 Denaturation   1 minute at 94 oC  
 Annealing   30 seconds at Ta  X  35 cycles 
 Extension    120 seconds at 72 oC  
 Final extension  10 minutes at 72 oC  
 
During the extension step, 1 minute was allowed for every kb of amplicon 
(minimum extension time 1 minute).  Five microlitres of each PCR reaction 
was analysed on an agarose gel. 
 
2.5 Tissue culture 
 
2.5.1 Cell lines and culture of cell lines 
 
The baby hamster kidney (BHK) cell line was obtained from European 
Collection of Animal Cell Cultures (ECACC, Porton Down, UK). BHK cells 
were grown in BHK-21 medium (Invitrogen Ltd) supplemented with 10% heat 
inactivated fetal calf serum (FCS), 5% tryptose phosphate broth (Invitrogen 
Ltd.), 5ml of 0.1 mg/ml streptomycin and 100 U/ml penicillin (Invitrogen Ltd.), 
5ml of 200 mM L-glutamine (Invitrogen Ltd.) and 4ml of 50 mg/ml geneticin 
G418 (Invitrogen Ltd.) were added to 500 ml of medium. 293T cells were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 
5 ml/500 ml of 0.1 mg/ml streptomycin and 100 U/ml penicillin and 10% FCS.  
Cells were grown in a Sanyo CO2 incubator at 37oC with 5% CO2. 
 
2.5.2 Passaging of cell cultures 
 
To ensure that cells were kept at an optimal density and to avoid overgrowth 
of cells, they were split every 2-3 days. Prior to splitting, the old medium was 
removed and plates were washed twice with sterile PBS (10 X phosphate 
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buffered saline tablets (Oxio Ltd.) dissolved in 1L sterile ddH 2O). Trypsin-
EDTA (Invitrogen Ltd.) approximately 1.0 ml for each 15 cm dish was added 
until all the cells were thinly covered. The plates were incubated at 37oC for 
15 minutes. The trypsinisation was stopped with the addition of FCS-
containing growth medium and the cells were split in the ratio of one in four.  
 
2.5.3 Long term storage of cell line 
 
Following trypsinization, the cells were pelleted by centrifugation and 5X106 
cells/ml  were resuspended in 1 ml growth media with 20% FCS and 10% 
dimethylsulfoxide (DMSO, Invitrogen Ltd.) and aliquoted to storage tubes. 
The tubes were cooled slowly to -70oC overnight in a box containing pre-
cooled isopropranolol. The next day, the cells were transferred to liquid 
nitrogen for long term storage. Frozen cells can be re-cultured by thawing the 
cryovials in a water bath at 37oC. Cells were then pelleted by centrifugation 
and the DMSO containing medium was removed. The process was repeated 
washing the cells with 1X PBS before resuspending them in the appropriate 
medium. 
 
2.6 Adeno-associated viral vectors 
 
2.6.1 Constructs 
 
The murine Aipl1 cDNA was PCR amplified from murine retinal cDNA using 
primers which have been designed to encompass the whole of the coding 
region. The PCR fragment obtained (1016 bases) was sequenced after 
cloning into pGem-T (Promega, Madison, WI) . The mAIPL1 cDNA was 
cloned between the CMV promoter and the SV40 polyadenylation site of the 
construct AAV-CMV-gfp [523] to form the construct AAV-CMV-Aipl1 (total 
length 5733 bases). The construct was then checked using a series of 
restriction enzyme digests StuI, KpnI  AccI, PstI and StuI and sequencing. 
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Refer to section 3.2 for details of cloning strategy and plasmid map.  
Recombinant AAV2 vector was generated from the murine construct , AAV2-
CMV-Aipl1.[523]. The human AIPL1 cDNA was also PCR amplified from 
human retinal DNA using primers which covered the whole coding region 
and included part of the untranslated regions at the 5’ and 3’ ends. The PCR 
fragment of 1215 bases was cloned into pGem-T (Promega Madison, WI) 
and checked by sequencing and restriction digests.  The AIPL1 cDNA was 
inserted into the parental plasmid AAV-CMV-gfp, replacing the gfp gene to 
generate the human construct AAV-CMV-AIPL1. For details of the cloning 
and plasmid map, please refer to section 3.8. The plasmid  containing human 
AIPL1 cDNA was packaged into AAV2 and AAV8 to generated two 
pseudotyped AAV viral vectors, AAV2-CMV-AIPL1 and AAV8-CMV-AIPL1, 
as described below. Recombinant AAV2 and AAV8 vectors were also made 
from the parental plasmid AAV-CMV-gfp for control experiments. 
 
2.6.2 Production of rAAV2  
 
Production of recombinant rAAV2/2 (AAV2/2) was carried out by co-
transfection of two plasmids in the presence of a helper virus in BHK cells as 
previously described [523]. Prior to the day of transfection, BHK cells were 
split and plated at concentration of 106 cells/150 mm dish and incubated 
overnight so that there was approximately 70% confluency on the day of 
transfection. Fourty dishes were used for large-scale preparation of rAAV 
particles. Recombinant AAV particles were produced using ITR-bearing 
plasmid containing AIPL1 transgene (described in section 2.6.1), the helper 
plasmid containing the rep and cap genes, pHAV 7.3, and the PS1 HSV 
helper virus. The construct plasmid containing AIPL1 and pHAV 7.3 helper 
plasmid were used to co-transfect BHK cells in a 1:1 ratio. Each 150 mm 
plate contained 30 µg of construct plasmid and 30 µg of pHAV7.3 (60 µg 
total/plate) in 10 ml Opti-MEM/plate. In a separate tube, 240 µg of a β-
integrin-targeting peptide use to improve the binding of DNA 
[(K16)GACRRETAWACG)], was mixed with 45 µl of Lipofectin reagent 
(Invitrogen Ltd., UK). The two tubes were mixed and incubated at room 
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temperature for 1 hour in order for the DNA to bind the Lipofectin-peptide 
complex. Old medium was removed from the plates and the plates were 
washed twice with Opti-MEM prior to the addition of the transfection solution. 
Then 12.5 ml of the transfection mix was added to each plate and the cells 
were incubated at 37oC for 4 hours. After that, the transfection solution was 
removed and replaced by normal growth medium containing PS1 HSV helper 
virus at MOI (multiplicity of infection= the ratio between the number of virus 
particles and the number of cells infected) of 10-20 infectious units. Cells 
were incubated at 37oC for 24 to 36 hours. At the completion of a lytic cycle, 
cells were collected and pelleted by centrifugation at 3000 g for 10 minutes. 
 
2.6.3 Purification of rAAV2  
 
Cells were harvested in batches of 10 plates, pelleted and resuspended in 5 
ml of DMEM. They were lysed by three cycles of freeze thawing between -
70oC and 37oC. Genomic DNA was removed by digestion with 50 U of 
endonuclease benzonase per millilitre of lysate at 37C for 30 min. The lysate 
was clarified by centrifugation at 3000 g for 15 min. The supernatant which 
contained the virus was retained and treated with 0.5% deoxycholic acid for 
30 min at 37oC and filtered through 5.0 and 0.8 µm syringe filters (Millipore, 
USA; SLSV R25 LS and SLAA 025 LS). After filtration, the supernatant was 
transferred onto a heparin-agarose column (Sigma, USA) which was first 
prewashed  with PBS-MK (1 X PBS, 2.5 mM KCL, 1 mM MgCl2). After the 
virus solution had run through, the column was washed  with 10 ml PBS-MK 
+ 0.1 M NaCl. Viral particles were eluted with 6 ml of PBS-MK + 0.4 M NaCl. 
The first 2 ml were discarded and the remaining suspension containing the 
purified virus was collected. The eluate was concentrated using Centricon 
100 columns (Millipore, USA) by centrifugation at 5000 xg for 25 minutes 
followed by a wash with PBS-MK. The Centricon columns were then turned 
upside down and the concentrated rAAV was spun into a collection tube. The 
average yield of the rAAV2/2 production protocol is approximately 100 µl of 
concentrated virus (1012 viral particles/ml) per 10 plates fo transfected BHK 
cells. The virus was then aliquoted and frozen at -80°C. 
146 
 
2.6.4 Production of rAAV8 
 
Production of recombinant AAV2/8 (rAAV2/8) was carried out by co-
transfection of three plasmids in 293T cells. In addition ot the pD10-based 
plasmids, pAAV (that carries rep and cap genes) and pHGTI (that carries 
helper accessory genes) plasmids were used in a CaCl2-based transfection. 
293T cells were seeded into 150 mm plates at a concentration of 106 
cells/plate. The plates were incubated overnight so that they reached 70% 
confluency the following day. The transfection medium was prepared using 
the following amounts: 
For 10 plates: 
pAAV8  -  100 µg 
pHGTI  -  30 µg 
pD10-RNAi  -  100 µg 
CaCl2 2.5M  -  1.25 ml 
dH2O  -  up to 12.5 ml 
The same amount in volume (i.e. 12.5 ml) of 2x HBS buffer was added 
dropwise to the plasmid solution followed by 25 ml of full DMEM medium. 
Five ml of the transfection solution was then added to the 293T plates 
without removing the old medium and the cells were incubated for 36 hours 
before scraping and harvesting in TD buffer.  
 
2.6.5 Purification of rAAV8  
 
The freeze-thaw cycles, benzonase and deoxycholic acid treatments were 
carried out in the same way as performed in the rAAV2/2 production. The 
lysate was then filtered through a 0.45 µm syringe filter before proceeding 
with the exchange chromatography purification using an ÄKTA™ prime 
FPLC apparatus (Amersham, UK) to bind the rAAB2/8 particles on an 
anionic sephacryl S300 and a POROS 50HQ column. The FPLC purification 
was carried out in Dr Amit Nathwani’s laboratory (UCL) with the assistance of 
Dr Jenny McIntosh. FPLC purification is carried out by binding the viral lysate 
first to the anionic column followed by the POROS 50HQ column and eluted 
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using an increasing salt gradient (Buffer A and B; see Buffers and solutions). 
Approximately 15 ml of eluate are produced by 100 plates which are 
subsequently concentrated in Centricon 100 columns to a final volume of 
approximately 200 µl. The virus was then aliquoted and frozen at -80°C. 
 
2.7 Titration of AAV particles 
 
2.7.1 Isolation of viral DNA from AAV particles 
 
Two aliquots of 1 µl and 5 µl were taken from the concentrated virus 
suspension produced in section 2.6. These samples were digested with 10 
µg (1 µl) of proteinase K (Promega UK) in 100 µl of 2 X Protein K buffer (100 
mM Tris (pH7.4), 50 mM EDTA and 0.5% SDS) and 99 µl or 95 µl ddH20 
respectively. The proteinase K digest was incubated at 56oC for 30 minutes.  
The DNA was subsequently precipitated by adding the following reagents in 
the order specified :  20 µg (1 µl of 20 mg/ml) glycogen (Sigma Aldrich 
Company Ltd), 1/10 volume (20 µl) of 3 M sodium acetate and 260 µl of pure 
ethanol. The mixture was incubated for 30 minutes at -20oC. DNA was 
pelleted by centrifugation at maximal speed 14000 rpm for  10 minutes. The 
supernatant was removed and the pellet was washed with 200 µl 70% 
ethanol and spun at maximal speed for 2 minutes and dissolved in  200 µl of 
0.4 M sodium hydroxide and 10 mM EDTA solution. 
 
2.7.2 Preparation of dot-blot 
 
A standard curve was prepared by making a dilution series of a plasmid 
containing the section of DNA that was to be used as a probe. Seven 
samples were usually prepared which ranged from 106 molecules to 1012 
molecules of plasmid in 10- fold serial dilutions. The samples were prepared 
with 0.4 M NaOH and 10 mM EDTA to a total volume of 200 µl. The samples 
from the dilution series and those from section 2.7.1 containing recombinant 
viral genomes were denatured at 95oC for 2 minutes and then immediately 
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cooled for 2 minutes on ice to prevent re-annealing. Dot-blots were prepared 
on pre-wetted 0.45 µm Hybond™- N+ membrane (Amersham Pharmacia 
Biotech, UK, Bucks,UK) – positively charged nucleic acid binding membrane 
-  in a dot blot manigold (Bio-Rad Laboratories Ltd., Herts, UK). Each well of 
the manifold was pre-washed with 200µl of ddH20 and vacuum dried. The 
denatured DNA samples were loaded and the vacuum reapplied until wells 
were empty. Then 200 µl of 0.4 M NaOH and 10 mM EDTA was added to 
each well. Excess solution was removed by applying vacuum and the 
membrane was dried between sheets of Whatman paper at 80oC for 120 
minutes. 
 
2.7.3 Preparation of probe 
 
The section of DNA to be used as the probe was excised from the plasmid 
with a restriction enzyme digest , separated on a gel and extracted from a gel 
fragment and resuspended in 50 µl of water. 35 µl of the resuspended DNA 
fragment was placed in a fresh eppendorf tube and denatured at 95oC for 2 
minutes. Immediately after, this was placed on ice for 2 minutes, 
subsequently spun down to collect the evaporated fluid from the lid.  A 
Neoblot biotinylated probe kit (Biolab) was used to label the probe according 
to manufacturer’s instructions. According to this, the components were 
added to the denatured DNA fragment in the following order: 10 µl of 5 X 
labelling mix supplied in the kit (contains random octamers), 5 µl dNTP mix 
(containing biotin-dATP), and 1 µl Klenow.i The mixture was incubated at 
37oC for 1 hour to overnight. The biotynylation reaction was terminated by 
adding 5 µl 0.2 EDTA pH8. The probe was subsequently precipitated by 
adding 5 µl 3 M NaOAc, 150 µl 100% ethanol and incubated at -20oC for 20 
minutes. After centrifuging at 14000 rpm for 10 minutes, this was washed 
with 70% ethanol, spun down and finally resuspended in approximately 20 µl 
of water or TE. Five microlitres of the probe was used for each dotblot and 
the remainder of the probe was stored at -20oC. 
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2.7.4 Hybridization of the probe to membrane 
 
The hybridization oven and hybridization bottles were preheated to 65oC for 
30 minutes before use. The membrane was wetted with ddH2O by allowing it 
to float on the surface of the ddH20  before submerging. The wetted 
membrane was placed in the pre-warmed hybridization bottle folded between 
hybridization mesh. The Church mix (pre-warmed to 65oC, 0.5 M sodium 
phosphate buffer, 7% w/v SDS, 0.01 M EDTA) was added to the 
hybridization bottle and the membrane pre-hybridised for 30 minutes in the 
hybridization oven. The biotinylated probe (section 2.7.3) was added to the 
Church mix and left to hybridise overnight at 65oC.  The membrane was then 
washed thrice with 50 ml of 33 mM NaPi buffer at 65oC. The third wash was 
left for 5 minutes at 65oC.  The membrane was placed in a plastic container 
filled with 20-30 ml of block solution (5% SDS, 125 mM NaCl, 25 mM NaPo4 
pH7.2) and incubated at room temperature on a shaking platform for 5-10 
minutes.  The membrane was subsequently processed using the CDP Star 
kit (Biolab), according to the instruction of the manufacturer as follows. The 
block solution was replaced with 20-30 ml of streptavidin diluted 1:1000 in 
block solution and incubated again at room temperature on a shaking 
platform.  Two 5 minute washes were then performed, each with wash 
solution I (which is 1 in 10 dilution of block solution) at room temperature on 
a shaking platform. The membrane was incubated with biotin-conjugated 
alkaline phosphatase that was available in a kit, Phototope-Star detection kit 
for nucleic acid (Biolab). The biotin-conjugated alkaline phosphatase was 
diluted 1:1000 in block solution and 15-20 ml of this dilution was used for the 
incubation for 5 minutes at room temperature with shaking. The membrane 
was washed once with block solution for 5 minutes at room temperature with 
shaking. Two further washes were performed with 20 ml of wash solution II 
(10mM Tris-HCL, 10mM NaCl, 1mM MgCl2 pH 9.5), each for 5 minutes at 
room temperature on a shaking platform. During the second and final wash, 
CDP-Star reagent (available in the Photope-Star Detection Kit for nucleic 
acids) was diluted 1:100 in 1 X assay buffer (comes in 25 X concentration) to 
make up a total of 2.5 ml. After the final wash, the membrane was placed 
facing upwards on a clear plastic sheet. The diluted CDP-Star reagent was 
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placed over the membrane, ensuring that all areas with dots were well 
covered. The blot was read on a chemi-luminescence reader at settings of 
470 nm, temperature  -25oC  and approximately 1-5 minute exposure time. 
 
2.8 Quantification of expression 
 
2.8.1 Total RNA isolation 
 
Whole retinas dissected from eye cups (quick frozen in liguid N2) were 
resuspended in 500 ml TRI-BD® reagent (Sigma, UK). Vigorous 
resuspension with a pipette (or a homogeniser) is essential to ensure 
breaking down of the cell wall. When the solution was homogenous, 200 µl 
chloroform was added and the samples were mixed by inversion. Straight 
after, the samples were centrifuged at 5000 xg for 15 minutes at 4°C. The 
clear top phase (containts RNA) was removed to another tube and the 
organic phases were kept for protein isolation (see 2.8.3). Equal amount of 
isopropanol was added to the clear phase and the samples were frozen for a 
minimum of 2 hours at -80°C. Overnight incubation at -20°C is favourable, 
however, because it increases the amount of RNA precipitation. Then, the 
samples were spun at 5000 xg for 10 minutes at 4°C. The supernatant was 
carefully decanted without disturbing the pellet. One ml of ethanol was added 
and the RNA pellets were spun at 5000 xg for 5 minutes at 4°C. The ethanol 
was removed and the samples were left to air dry for 5 minutes at room 
temperature. Each pellet was resuspended in 20 µl dH2O. Alternatively, the 
RNeasy Mini Kit (QIAGEN Ltd., UK) was used for RNA extraction of cell 
pellets according to manufacturer’s instructions. The RNA concentration was 
measured using a NanoDrop® ND-1000 spectrophotometer (LabTech Int., 
UK). Total RNA was stored at -80°C. 
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2.8.2 Generation of cDNA and relative quantification  
 
For cDNA generation the QuantiTect® Reverse Transcription Kit (QIAGEN 
Ltd., UK) was used according to manufacturer’s instructions. Briefly, the RNA 
samples were thawed on ice and up to 12 µl (or up to 1 µg) were added to 2 
µl of gDNA Wipeout Buffer. The reaction was made upto 14 µl with water and 
incubated at 42°C for 2 minutes. In a separate tube, 1 µl of Quantiscript 
Reverse Transcriptase, Ct4 µl of Quantiscript RT buffer and 1 µl of RT primer 
mix (containing random octamers and dT nucleotide mix) were mixed before 
adding them to the template RNA. The reaction tube (20µl final volume) was 
incubated at 42°C for 1 hour to enable reverse transcription, followed by a 3 
minute incubation at 95°C to inactivate the Quantiscript Reverse 
Transcriptase. The efficiency of the reaction provides a 1:1 conversion ratio 
of RNA:cDNA, hence up to 1 µg of cDNA was made per sample. Total cDNA 
was stored in -20°C. 
 
Fifty ng (or approximately 1 µl) of total cDNA from each sample was loaded 
onto a 96-well plate with 2X FastStart TaqMan® Probe Mastermix (ROX) 
(Roche, UK), forward and reverse primers for amplification of gene of interest 
(final concentration of 900 nM each), appropriate hydrolysis probe that binds 
the amplified area (final concentration of 250 nM; Roche, UK), ROX 
reference dye (final concentration of 400 nM; Roche, UK) and dH2O to make 
the final reaction volume up to 50 µl. The amount of cDNA template used in 
each reaction ranged from 5-500 ng with 50 ng being the usual loading 
amount. Quantitative real-time PCR was run on an ABI Prism 7900HT Fast 
Real-time Sequence Detection System (Applied Biosystems, UK) and the 
manufacturer’s software (SDS 2.2.2) was used to obtain Ct values for the 
reactions. The relative expression between comparable samples in relation 
to the expression of the gene of interest was calculated through the formula: 
2-∆∆Ct 
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2.8.3 Protein isolation and evaluation of sample protein 
content  
	  
Retinal tissue was dissected from whole eye cups and lysed using a 
commercial buffer (RIPA, Sigma Aldrich, Gillinghan, UK) with added 
protease inhibitor cocktail (Sigma Aldrich, Gillingham, UK). Cell membranes 
were disrupted using a sonicator with a micro-tip (Soniprep 150, MSE 
London UK). Lysates were stored at -80°C.  The concentration of protein in 
each sample was measured using a Lowry-based calorimetric protein assay 
done in triplicate (DC protein assay kit, Bio-Rad, Hemel Hempstead UK) 
compared to a bovine serum albumin standard curve. Samples were diluted 
in assay buffer to bring concentration to within linear portion of the standard 
curve (0.2-0.9 mg/ml). Measurement of optical density was performed using 
an ELISA reader (Emax, Molecular Devices Ltd, Berkshire UK) reading the 
absorbance at 650 nm. Equal amounts of protein were loaded in subsequent 
assays. 
 
2.8.4 Western Blot 
 
Polyacrylamide gels were made as two discontinuous gells, a 12% 
separating and a 4% stacking gel. Eight µg of each sample was made up to 
15 µl with 1X Laemni bugger and bromophenol blue was added to 0.05% 
concentration. The samples were boiled for 5 minutes and loaded on the gel 
together with a prestained molecular weight marker (Bio-rad,UK). The gel 
was run in Running buffer until bromophenol blue run out of the gel (200V for 
50 min). The glass plates were separated and the stacking gel removed. The 
separating gel was marked (cut at corner) and equilibrated in Transfer buffer 
for 20 minutes. Immobilon P membrane (Amersham, UK) was cut at the size 
of the gel and put in methanol for 15 sec. Then it was rinsed in water for 2 
min, and equilibrated in Transfer buffer for 5 minutes. The transfer formation 
was set up on the appropriate apparatus in the order: anode-Immobilon P- 
Gel-Cathode with 4 pieces of Whatman 3 MM paper in between. It was run 
for 30 minutes at 10 V. Immediately after transfer, the membrane was 
washed with PBS and immersed in methanol for 10 seconds. Then it was 
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dried on filter paper and blocked with Blocking solution for 2 hours at 4°C. 
The membrane was washed 3 times with PBS-T, and the 1° 
antibody/antibodies (rabbit anti-Aipl1 antibody, rabbit β-PDE antibody and 
mouse mononclonal anti β-actin antibody [Sigma] for loading controls) were 
incubated in Hybridisation solution at appropriate concentration overnight at 
4°C (see section 2.10.4 and 2.10 .5 for concentrations). The following day, 
the membrane was washed 3 times with PBS-T, then the horseradish 
peroxidise (HRP)- conjugated 2° antibodies (goat anti-rabbit IgG and goat 
anti-mouse IgG) were incubated in Hybridisation solution for 50 minutes at 
room temperature. The membrane was washed 3 final times with PBS-T and 
put on a plate. ECL reagents (ECL Plus Western Blotting Detection System, 
GE Healthcare) were mixed and added onto the membrane for 1 minute. The 
western blot was imaged using a UVIchemi Chemiluminometer (UVItec Ltd., 
UK). 
 
2.9 In vivo experiments 
 
2.9.1 Animals 
 
Aipl1 h/h knockdown mice that expressed lower than normal levels of AIPL1 
and Aipl1 -/- mice that were deficient in AIPL1 were used for this study. For 
control experiments, wild type C57B/6 mice were used. Treatment was 
performed only in one eye in each animal while the other eye served as an 
internal control in all experiments. This was to account for inter-animal 
variability in the rate of degeneration so that data were comparable. Each 
eye received two subretinal injections of viral suspensions or PBS, one in the 
superior hemisphere and one in the inferior hemisphere, as described in 
section 2.9.3. Subretinal injections were performed in 4-5 weeks old mice. 
Animals were sacrificed by exposure to carbon dioxide or cervical 
dislocation. All animals were cared for in accordance with the Animal 
Scientific Procedures Act 1986 and procedures were in accordance with the 
ARVO statement for the Use of Animals in Ophthalmic and Vision Research. 
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2.9.2 Animal anaesthesia 
 
For Intraocular procedures, animals were anaesthetised by intraperitoneal 
injections of Dormitor (1 mg/ml, Pfizer Pharmaceuticals, UK) and ketamine 
(100 mg/ml, Fort Dodge Animal Health, UK) mixed with sterile water in the 
ratio 5:3:42. Young mice weighing 200 g received 0.2 ml of the anaesthetic 
solution. After treatment, 1 % Chloramphenicol (FDC International Ltd., UK) 
was applied topically to the cornea. To reverse the anaesthesia, 0.2 ml of 
Antisedan (0.10 mg/ml), Pfizer Pharmaceuticals, UK) was injected 
intraperitoneally and the mice were placed into an oxygenated chamber on a 
heat mat until they regained consciousness. All animal anaesthesia and 
recovery were performed by the author. 
 
 
2.9.3 Subretinal injections  
 
In the Aipl1 h/h mice, subretinal injections were performed at postnatal age 
of 4 weeks, when animals were older and their eyes less susceptible to 
surgical trauma and significant photoreceptor cell loss has not yet occurred 
at this age. In the  Aipl1 -/- mice, subretinal injections were performed at 
postnatal day 12 due to the early onset of photoreceptor degeneration; at this 
age, the mouse retina is fully developed and the mice have opened their 
eyes thus facilitating subretinal injections and photoreceptor degeneration is 
not yet established at this stage. Animals were anaesthetised as described in 
in section 2.8.2 and pupils dilated with tropicamide 1% and phenylephrine 
2.5%. Subretinal injections were performed under the guidance of an 
operating microscope. The fundus was visualized by means of a contact lens 
system consisting of a drop of coupling medium solution    (Viscotears, 
Novartis Pharmaceuticals, UK) on the cornea and a glass coverslip placed 
against the cornea. A 10 mm, 34 gauge needle, mounted on a 5 µl Hamiton 
syringe (Hamilton, Bonaduz, Switzerland) was used to inject the vector 
suspensions intraocularly. The tip of the needle was guided underneath the 
coverslip, tangentially through the sclera at the equator of the globe to create 
a self-sealing tunnel into the subretinal space. Using direct visualization via 
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the microscope, it was possible to ascertain that the needle tip was in the 
correct space by bringing the needle tip into focus between the retina and the 
RPE. A volume of 1.5 µl of virus suspension containing around 108-109 
particles of rAAV was injected to produce a transient bullous retinal 
detachment which involved about 30% of the fundus in the superior 
hemisphere. A second injection was performed subsequently to produce a 
similar detachment in the inferior hemisphere. All animal subretinal injections 
were performed by James Bainbridge with the assistance of the author. 
 
2.9.4 Electroretinography method and analysis 
 
Electroretinography (ERG) from mice was recorded in a standardised fashion 
at various pre-determined time points. All animal ERGs were performed by 
the author. All animals were dark-adapted overnight (16 hours) prior to ERG 
recording. Animals were anaesthetized for ERG and pupils were dilated 
using tropicamide 1% (Chauvin Pharmaceuticals Ltd.)applied topically prior 
to recording. A water-based coupling medium (Viscotears, Novartis 
Pharmaceuticals Ltd., UK) was used to improve electrical contact with the 
electrode and keep the eyes moist during the recording procedure. All 
manipulations before ERG were performed under dim red light illumination. 
ERGs were obtained using commercially available systems, Toennies 
Multiliner Vision, (Jaeger/Tonnies, Wurzburg, Germany) and Espion ERG 
Diagnosys system (Diagnosys LLC, Cambridge UK). 
 
Ganzfeld ERGs were obtained from both eyes simultaneously using contact 
platinum corneal electrodes on each eye and one reference electrode placed 
sublingually. Midline reference and ground electrodes were placed 
subdermally in the center of the forehead and caudally. Electrode 
impedances were kept symmetrical and low between 5 and 10 kOhm. 
Scotopic flash intensity series was performed. Recordings were filtered from 
0-1 kHz with a sampling frequency of 5 kHz.   In all measurements, 400 ms 
of response was recorded. The first 10 ms of each recording was 
automatically used to zero the trace.  
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For scotopic flash recordings using the Tonnies Mulitliner Vision, single flash 
intensities were obtained at light intensities increasing from 0.1 mcds/m2 to 
3000 mcds/m2. Ten responses per intensity level were averaged with an 
inter-stimulus interval of 5 s (0.1, 1, 10, 100 mcds/m2) or 5 responses per 
intensity with 17 second interval (1000 and 3000 mcds/m2). Readings 
obtained were analysed with software provided from Tonnies Multiliner 
Vision.  For scotopic flash examination using Espion ERG Diagnosys 
system, a multiple flash intensity series was performed, with light intensity 
increasing from 0.001 cd.s/m2  to 5 cd.s/m2 (-3 to 0.5 log cd.s/m2). Ten 
(intensities < 1 cd.s/m2) or 5 (intensities ≥ 1 cd.s/m2) responses per intensity 
were collected and averaged for use in subsequent analysis.  
 
 
2.10 Histological methods 
 
For histological and immunohistochemistry analysis, mice were sacrificed at 
various pre-determined time points to examine for evidence of a therapeutic 
effect, which took into account the transduction kinetics of the vector being 
used, timing  of the subretinal injections and the rate of retinal degeneration 
in the animals. More specific details regarding exact time points used in the 
different experiments are described in Chapters 3 and 4. 
 
 
2.10.1 Paraffin wax sectioning 
 
Animals were sacrificed by exposure to CO2. Eyes were immersion-fixed in 
4% (w/v) paraformaldehyde overnight. Eyes were dehydrated overnight in a 
Leica Histokinette Processing machine and embedded in paraffin wax. 
Sections 7µm were cut using a microtome and stored at room temperature. 
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2.10.2 Cryosections 
 
Animals were sacrificed by exposure to CO2. Eyes that were designated for 
AIPL1 immunostaining were embedded directly in Optimal Cutting 
Temperature (O.C.T) medium (RA Lamb, E. Sussex, UK) and frozen in 
isopentane that had been pre-cooled in liquid nitrogen. Eyes which were 
designated for beta-PDE immunostaining were immersion-fixed in 4% (w/v) 
paraformaldehyde for 2 hours at room temperature. They were then 
cryoprotected by immersion in 20% (w/v) sucrose solution at 4C 
overnight..The eyes were then embedded in O.C.T. medium and frozen in 
isopentane which had been pre-cooled in liquid nitrogen. Specimens were 
stored at -80C and cut using a cryostat (Bright, UK) at thickness of 10-12µm. 
Sections were kept frozen at -20C until use. 
 
 
2.10.3 Staining of sections by haemoatoxylin and eosin 
 
Paraffin wax-embedded and cryosection specimens embedded in O.C.T 
were washed in xylene and alcohols to water. Sections were stained using 
haematoxylin for 5 minutes and washed in distilled water. Sections were then 
stained using eosin for 5 minutes and washed in distilled water. Slides  were 
then passed through increasing concentrations of alcohols to xylene and 
mounted in DPX. 
 
 
2.10.4 Immunohistochemistry of AIPL1  
 
Unfixed cryosection slides were air dried for 10 minutes. Slides were post-
fixed for 1-2 minutes with 2% (w/v) paraformaldehyde and then washed with 
PBS.  The slides were then incubated for 1 hour in blocking buffer (5% (v/v) 
normal goat serum (Dako Ltd) in 1%BSA/TBS (w/v) and 0.1% Triton-X100 at 
room temperature. Following this,the slides were incubated overnight with 
the primary antibody (anti-rabbit AIPL1 – gift from Tiansen Li) at a dilution of 
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1:2000 in blocking buffer at 4C. After 3 washes (10 minutes with TBS), the 
slides were then incubated with the secondary antibody, goat anti-rabbit 
Alexa-471 or Alexa-546 at a dilution of 1:500 in blocking buffer and left at 
room temperature for 2 hours. The slides were washed again three time (10 
minutes with TBS). Counterstaining of the nuclei was performed using Hoerst 
dye at dilution of 1:1000. Excess solution was removed and slides were 
mounted in fluorescent mounting medium (Fluormount, Dako), Sections were 
examined by fluorescent microscopy and images captured on Leica 500 
(Zeiss, Germany) digital camera and viewed on Adobe Photoshop software. 
Sections were also analysed by confocal microscopy. 
 
 
2.10.5 Immunohistochemistry of β-PDE in rod inner    
segments 
 
Cryosections which were designated for beta-PDE immunochemistry 
(section 2.9.1) were air dried for 10 minutes. The slides were then rehydrated 
for 5 minutes with water and incubated with blocking buffer consisting of 4% 
(v/v) normal goat serum and 1% BSA (w/v) for 1 hour at room temperature. 
The primary anti-rabbit β-PDE antibody (Affinity BioReagents, Neshanic 
Station, NJ), was applied at a dilution of 1:500 in blocking buffer and left to 
incubate overnight at 4C. On the next day, following 3 washes using the 
blocking buffer (3x 10 minutes), the slides were incubated with the secondary 
goat anti-rabbit antibody Alexa 594-conjugated streptavidin (Molecular 
Probes Europe, Leiden, The Netherlands) at a dilution of 1:500 in TBS for  2 
hours. The slides were then washed twice with TBS (2X 10 minutes) and 
Hoerst dye 1:1000 dilution in blocking buffer was applied. Following a final 
wash with PBS, slides were mounted with fluorescent mounting medium 
(Fluormount, Dako) and examined using fluorescent microscopy and images 
were captured on Leica 500 (Zeiss, Germany) digital camera and viewed 
using Adobe Photoshop software. Sections were also analysed by confocal 
microscopy 
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2.10.6 Confocal Imaging 
	  
Cryosections were analysed using the 3-laser ZEISS LSM 510UV Confocal 
Imager and its software was used to capture images at X40 and X60 
objective, at various thickness layers (Z-stack) of the section. The images of 
the Z-stack were either used individually or as projected composite of each 
other. 
 
 
2.10.7 Fixation of eyes for semithin and ultrathin 
sections 
 
At various time points mice were sacrificed and their eyes were immediately 
removed and orientated with a nasal stitch. Then eyes were immersion fixed 
in 3 % glutaraldehyde and 1 % paraformaldehyde buffered to pH 7.4 with 
0.07 M sodium cacodylate-HCl buffer (Karnovsky’s; 0.2 M 
(CH3)2AsO2Na.3H2O with 0.2 N HCl). After 12 hr the anterior part of the eye 
was removed by microdissection. The posterior segments were then 
osmicated for 2.5 hr in a 1% aqueous solution of osmium tetroxide, followed 
by a dehydration series through ascending alcohols (50 – 100%, 10 min per 
step). After 3 changes of 100% ethanol, specimens were passed through 
propylene oxide (3x 10 min) and left overnight in a 50:50 mixture of 
propylene oxide and araldite. Following a single change to fresh araldite (5 hr 
with rotation) the specimens were embedded in resin and cured for 48 hr at 
60ºC. 
 
 
2.10.8 Semithin sections 
 
Semithin sections were cut and stained by Dr. Emma West. Semithin 
sections (0.7 µm) were cut using a Leica ultracut S microtome fitted with a 
diamond knife (Diatome histoknife). Sections were stained with toluidine blue 
stain (25 ml 2 % hydrated sodium borate, 25 ml 100 % ethanol, 0.5 g 
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toluidine blue, SPI-ChemTM) and slides were mounted with DPX after the 
sections had dried. Sections were analysed using a Leitz Diaplan 
microscope for observation and imaged with a Leica DC 500 digital camera. 
 
 
2.10.9 Ultrathin sections 
 
The ultrathin sections were cut, stained and prepared for electron 
microscopy by Dr Peter Munro.  Ultrathin sections (50 nm) were cut using a 
Leica ultracut S fitted with a diamond knife for ultrathin sections (Diatome 
histoknife for ultrathin sections). Sections were taken of treated areas of 
retinae and collected onto grids. Sections were stained with uranyl acetate 
for 10 min and lead citrate for 7 min and then washed with dH2O. After the 
sections had dried they were analysed by electron microscopy (JEOL 1010 
TEM). 
 
 
2.11 Statistical Analysis 
	  
The choice of an appropriate statistical method is important to draw 
conclusions from data that are subject to experimental error. Generally, 
statistics yield the probability value for a particular result. In science, a 
probability (p) of 0.05 or less is usually accepted as convincing evidence that 
a particular outcome is significant and not due to chance.  
 
A “Student's t-test” can be performed knowing only the mean and standard 
deviation of two data sets. The Student's t-test determines a probability that 
two populations are the same with respect to the variable tested. The 
populations are assumed to follow a normal distribution (Gauss distribiution). 
For independent samples, as it was the case for most of the histological data 
presented in this thesis, an unpaired Student’s t-test was used (unless stated 
differently). This test compares two small, independent sets of data that do 
not have to have the same number of data points in each group and are 
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collected randomly. In order to evaluate the significance of the difference in 
number of surviving photoreceptor cells and retinal layer thickness between 
either non-dystrohic or dystrophic, treated or untreated animals, cell counts 
and thickness meassurements were carried out and on 10 sections per eye, 
in the middle of the superior injection site. Since the number of animals for 
each condition varied, the sets of data should to be regarded as randomly 
collected and independent.  Therefore an unpaired Student’s t-test was 
applied. 
 
For functional ERG results presented in this thesis, a paired Student’s t-test 
was performed. A paired t-test can only be applied if the numbers of points in 
each data set are the same, and if they are organised in pairs. Generally, it is 
used when measurements are taken from the same subject before and after 
manipulation, in this case the viral mediated expression of a transgene. 
Since ERG records electrical responses of both eyes simultanously, and 
recordings can be obtained at different time points over a period of time from 
the same animal, a paired Student’s t-test was used. For each animal, the 
height of b-wave amplitude of the ERG recording obtained at a flash intensity 
of 100 mcds/m2 was used for statistical analysis. The b-wave values (a-wave 
through to b-wave peak) of the treated (right) eye were paired with the 
untreated contralateral (left) eye to provide an internal control. A paired 
Student’s t-test was used to evaluate significance (p<0.05). This method 
controls for interanimal variance and test-retest variance present in rodent 
ERGs. 
 
2.12   Patient Screen 
	  
2.12.1  Patients and controls 
	  
The patient panel consisted of 309 probands with simplex and autosomal 
recessive retinal dystrophy who were ascertained from the medical retinal 
clinics at Moorfields Eye Hospital. The study was conducted in accordance 
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with the tenets of the Declaration of Helsinki and was approved by Moorfields 
Hospital Ethics Committee. All patients gave written informed consent to be 
included in the study and provided a blood sample for subsequent DNA 
extraction and DNA analysis.  
 
The control panel consisted of 96 control DNA samples originating from a 
normal population of randomly selected, non-related UK Caucasian blood 
donors. The panel (Human Random Control-1 DNA panel) was obtained 
from European Collection of Cell Cultures (ECACC). 
 
 
2.12.2 DNA isolation 
 
Blood samples were collected in EDTA tubes. DNA was extracted using a 
Nucleon Genomic DNA Extraction Kit (BACC2, Tepnel Life Sciences plc) 
following manufacturer’s instructions. Solution A provided by thew supplier 
was added to each sample and samples were shaken for 5 min. After 
centrifugation for 7 min at 5000xg the supernatant was carefully removed. 
Each pellet was then resuspended in 2 ml solution B, samples were 
transferred to a new tub and mixed with 450 µl of sodium perchlorate. Tubes 
were inverted several times in order to mix the samples and 1.5 ml 
chloroform was added. After mixing thoroughly 300 µl of Nucleon resin was 
added and samples were centrifuged for 5 min at 4000xg. The aqueous 
phase containing the DNA was transferred into a new tube and mixed with 6 
ml 100 % ethanol. After a 5 min spin the supernatant was removed and DNA 
pellets were washed with 500 µl 70 % ethanol. Samples were centrifuged 
again at 4000xg for 5 min, the ethanol was removed and pellets were air 
dried. The DNA was resuspended in 400 µl dH2O, rotated over night at 4°C 
to dissolve DNA, and stored at -20°C. 
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2.12.3 PCR 
	  
Primers were designed corresponding to intronic sequences for PCR 
amplification of all 6 exons of AIPL1. Sequences of primers used are listed 
below. All PCR reactions were performed in a total volume of 30 µl using 200 
µM dNTPs (Promega UK), 0.5 µM of each primer, 2 µM DNA, magnesium 
containing Optimase reaction buffer (Transgenomic UK) and 2.5 U TaqGold 
(Transgenomic UK). Reactions were cycled using a Techne Touchgene 
Thermal Cycler. The optimal annealing temperature for each primer set was 
calculated by using the program PrimerSelectTM (DNASTAR Inc.).  
 
Cycling conditions were as followed: 
Initial denaturation  5 min at 95°C 
Denaturation   1 min at 95°C 
Annealing   15 sec at Ta 
Extension   1 min at 72°C 
Final extension  10 min at 72° 
 
Table 1.1  Amplification of the human AIPL1 gene. Primer pairs were designed to cover 
the entire coding sequence and important intronic sequences of the human AIPL1 gene (see 
also Appendix). Primer sequences and annealing temparatures for PCR are summarised in 
the table. 
 
  
AIPL1 Forward primer 5’-3’ Reverse primer 5’-3’ Ta [°C] 
Exon 1 ACTGGAAGCAAAGGTGGATG GCCCATGCTAAAGTTGAATCT 54 
Exon 2 TGAACTGAGTGAGCTGACCC GAATAAGTTTGCAGGACTGGCTTTG 58 
Exon 3 CATAGTGAGGGAGCAGGATTC CATGGCTTATGAACCCTCTCG 56 
Exon 4 CTTGTCTGTATGCACTTGACCAG CAGGGAGAAGGTCAGCCATG 60 
Exon 5 GAAGTGGCGCTGACTCTGG CGGCTGGGTGGAGACAAG 56 
Exon 6 TTGAGGAAACCGAGGGATGG CAATCGAACCAGAAGTGACCAGG 60 
35 cycles 
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2.12.4 Gel electrophoresis 
 
Fragment size and purity of PCR reactions were controlled by gel 
electrophoresis. Samles were loaded onto a 2 % agarose gel made with 1% 
TBE buffer and 8 µl ethidiumbromide/200 µl total volume. The fragments 
were characterised under UV-light. 
 
2.12.5 ExoSapIT treatment 
 
Samples were processed for direct sequencing for characterisation. For each 
sample two reaction – one for the forward primer and one for the reverse 
primer – were set up. DNA fragments were purified by ExoSAP-IT® (Usb 
Corporation) treatment in a total volume of 18 µl using 2 µl (approximately 10 
ng) of the amplified DNA fragment and 0.5 µl ExoSAP-IT enzyme with sterile 
dH2O. The purification mix was incubated for 15 min at 37°C and then the 
enzyme was inactivated for 15 min at 80°C.  
 
2.12.6 Big Dye 
 
Samples were sequenced using a BigDye® Terminator v1.1 Cycle 
Sequencing Kit	   (Applied Biosystems). The Big Dye was diluted in 2.5 x Big 
Dye Buffer containing 200 mM Tris pH 8, 5 mM MgCl2 with sterile dH2O. To 
each ExoSAP IT treated sample 1 µl Big Dye v1.1 and either 1 µl (0.8 µM) 
forward or 1 µl reverse primer were added.  
Cycling conditions were as followed:  
30 cycles: 95°C for 30 sec 
  50°C for 30 sec 
  60°C for 4 min 
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2.12.7  Purification and sequencing 
 
Samples were then purified using Millipore MontageTM Cleanup Kit (Millipore 
Corporation). The total volume of samples was transferred to a Millipore 96 
plate and a vacuum (15 to 20 psi) was applied for 10 min. Each well was 
washed twice with 25 µl injection solution supplied by manufacturer. Between 
and after the washing steps a vacuum was applied. Another 25 µl of injection 
solution was added to each well, the plate was sealed and shaken for 5 min 
to recover the purified PCR samples. Samples were then transferred onto an 
ABI® 96 plate (Perkin Elmer, Warrington, UK) for sequencing. Samples were 
run over night on an ABI Applied Biosystems 373A DNA Sequencer. 
Sequences were analysed using the DNASTAR software package 
(DNASTAR Inc.). 
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2.13 Buffers and solutions 
 
Ampicillin (1000 x): 50 mg/ml ampicillin (Sigma-Aldrich Company Ltd.) in 
dH2O, sterile filtered, stored at -20°C 
 
Blocking solution (for Western Blot): 1X PBS, 3% BSA or non-fat dried milk 
solution,  0.5% Tween 
 
Big Dye Buffer (2.5 x): 200 mM Tris pH 8, 5 mM MgCl2 with sterile dH2O 
 
Buffer A (for AAV2/8 purification): 5.65 g Bis-Tris propane, 2.42 g Tris up to 1 
l with dH2O, pH 9;  filtered through 0.2 µm. 
 
Buffer B (for AAV2/8 purification): Buffer A + 175.32 g NaCl; filtered through 
0.2 µm. 
 
Church Buffer: 21 g of NaH2PO4, 48.55 g Na2HPO4, 70 g of SDS, 0.5 M 
EDTA and dH2O to 1 litre. 
 
DNA loading buffer (6 x): 0.25 % (w/v) bromophenol blue and 30 % (v/v) 
glycerol in water 
 
HBS (2x): 16 g NaCl, 0.74 g KCl, 0.2 g NaH2PO4H2O, 2 g Dextrose, 10 g 
HEPES, up to 1 l with dH2O, pH 7; filtered through 0.2 µm 
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LB growth medium: 14 g Bacteriological agar (oxoid Ltd.) per litre of water, 5 
g/l yeast extract, 10 g/l tryptone (Oxoid Ltd.), 10 g/l sodium chloride, and 50 
µg/ml ampicillin 
 
PBS (1 x): 85 g NaCl, 4.3 g KH2PO4, dH2O to 10 litres, pH 7.2 
 
PBS (tissue culture): 10 phosphate buffered saline tablets (Oxio Ltd.) 
dissolved in 1 l sterile ddH2O 
 
PBS-MK: 1 x PBS, 2.5 mM KCl, 1 mM MgCl2 
 
PBS-T: PBS 1x with 0.05 % (v/v) Tween-20. 
 
Periodate lysine paraformaldehyde: 2% paraformaldehyde and 0.05% 
glutaraldehyde 
 
Proteinase K buffer: 100 mM Tris (ph 7.4), 50 mM EDTA and 0.5 % SDS 
 
Sodium cacodylate buffer (0.07 M): 0.2 M (CH3)2AsO2Na.3H2O with 0.2 N 
HCl 
 
Sodium phosphate buffer: 97.1 g Na2HPO4, 43.6 g NaH2PO4, pH 7.2 
 
TBE (50x):  242 g Tris, 57.1 ml Boric acid, 18.6 g EDTA, up to 1 l with H2O 
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Toluidine blue stain: 25 ml 2 % hydrated sodium borate, 25 ml 100 % 
ethanol, 0.5 g toluidine blue (SPI-ChemTM) 
 
Western blot sample buffer: 50%(v/v) 0.5 M Tris-Cl, pH6.8, 50% (v/v) 
glycerol, 10% (w/v) SDS, 0.5 M dithiothereitol, 40 mM bromophenol blue. 
 
Western blot gel buffers: Stacking gel- 0.5 M Tris-Cl, pH 6.8, 0.4% (w/v) 
SDS;  Running gel- 1.5 M Tris-Cl, pH 8.8, 0.4% (w/v) SDS). 
 
Western blot running buffer:  25 mM Tris base, 0.2 glycine,  0.1% SDS. 
 
Western blot transfer buffer:  192 mM glycine, 25 mM Tris base, 20% (v/v) 
Methanol, 0.2% (w/v) SDS. 
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3  AAV2/2 - mediated gene replacement 
therapy in the AIPL1 hypomorphic mouse 
 
 
3.1  Introduction 
  
The aim of the work described in this chapter was to determine the potential 
value of AAV2 vectors in alleviating a primarily photoreceptor-based retinal 
degeneration caused by defects in the AIPL1 gene. Inherited retinal diseases 
such as retinitis pigmentosa and LCA are characterised by progressive visual 
impairment due to photoreceptor cell loss. Most forms of inherited retinal 
dystrophies are caused by mutations in genes expressed in rod and cone 
photoreceptors or in the retinal pigment epithelium (RPE).[95][407] There is 
currently no cure for inherited retinal dystrophies. With the advances in gene 
transfer systems, gene therapy holds great potential for the treatment of 
inherited retinal diseases[2,9,12,326,363,455,464,471,496].The goal of a 
gene-based strategy to treat a genetic disease such as retinal dystrophy is to 
achieve efficient, long-term expression of the transgene using only a single 
administration of vector.  Many vectors based on different viruses such as 
adenovirus, herpes simplex virus and human immunodeficiency virus have 
been shown to mediate efficient gene transfer to the RPE [99].  However so 
far, the adeno-associated viral vectors has been particularly effective for 
retinal gene transfer  and are the only viral vector to efficiently transduce 
both RPE and photoreceptor cells. [13][418].[13,388,408]   
  
In this study, the goal is to treat a severe photoreceptor-specific 
degeneration and the efficient transduction of photoreceptor cells is of 
particular importance. Various serotypes of AAV have been isolated from 
non-human primate and human tissues and have different ability to 
transduce different retinal cell types in vivo.[30] [387][508]. Among these, 
AAV2/2 is the serotype most commonly used for the development of ocular 
gene therapy in the eye. Following subretinal administration, rAAV2/2 
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mediate gene expression in both photoreceptor and RPE cells while 
intravitreal delivery results in transduction of retinal ganglion cells. [178][300]  
Photoreceptor transduction by AAV2/2 is aided by the presence of heparan 
sulphate proteoglycan  and other coreceptors such as human fibroblast 
growth receptor 1 (FGFR1) and integrins αvß5 on the cell membrane. 
[385][454]  While there are some serotypes that transduce only the RPE, 
those that tranduce photoreceptor cells also tranduce the RPE.  
 
Despite this the availability of relatively efficient vector systems, rescue of 
retinal degeneration has achieved mixed success. Better outcomes have 
been generally seen in models of retinal degeneration in which there is an 
RPE defect caused for example by mutations in RPE65 and 
MERTK[1,437,471]. This is partly because even with currently available 
vectors, gene delivery to RPE cells is more efficient and widespread than to 
photoreceptors.  In addition, the photoreceptor cells in these conditions are 
inherently healthy despite the metabolic defect in the RPE and may respond 
very well to partial correction of RPE function.  Gene transfer approaches for 
photoreceptor-specific retinal degenerations have previously been more 
difficult, although there are now increasing number of studies reporting 
successful restoration of photoreceptor function and prolongation of 
photoreceptor survival [518][326] [363][9,243]. Another factor that might 
affect how amenable a mouse model may be to gene therapy is the speed of 
disease progression. The window of opportunity in a disease model is 
created by the balance between time for vector-mediated expression and 
rate of photoreceptor degeneration. This is particularly relevant to when sing  
AAV2/2 vectors. Transgene expression is detectable only at  2-3 weeks after 
subretinal injection, peaking after 6-8 weeks. [418] In slower retinal 
degenerations such as the Mertk and RPE65 mutations, there is a longer 
time window for the onset of transgene expression before a critical mass of 
photoreceptors have been lost. As a result, these diseases are generally 
easier to treat using AAV2/2 vectors.  In models of rapid degeneration, the 
onset and speed of disease precludes effective rescue by AAV2/2. An 
example is the rd1 mouse which is characterized by rod photoreceptor 
degeneration from P8 onwards and total loss of rod photoreceptors by 4 
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weeks of age, By the time maximal transgene expression is achieved in the 
target tissue at 6 weeks, most photoreceptor cells would have already been 
lost.  On the other hand, it may be difficult to detect any improvement and 
demonstrate effective rescue in retinal degenerations that are too slow. 
Following treatment with a therapeutic vector, any benefit would only become 
apparent once substantial cell loss has occurred in control eyes in 
comparison with treated eyes. An example is the RPGR murine model in 
which noticeable retinal degeneration is seen at 6 months of age and 
progresses slowly after[189]. As a result, any therapeutic effect would only 
be detected after more than 6 months following treatment. 
 
As described in previous chapters, there are currently 2 mouse models of 
AIPL1-related retinal degeneration, the Aipl1 knockout mouse model (Aipl1 -
/-) and the hypomorphic AIPL1 mouse model (Aipl1 h/h) in which there is 
reduced expression of AIPL1. Both models exhibit normal retinal histology 
and photoreceptor morphology at birth, and is followed by photoreceptor 
degeneration thereafter which occurs at different rates in each case. In the 
Aipl1 -/- mouse, photoreceptor degeneration is very rapid and completed by 
4-6 weeks (depending on the background strain) [391][119]. As a result, the 
treatment of this mutant may not straightforward due to the rapid nature of 
the retinal degeneration which is similar to the rd mouse in time course. 
Retinal degeneration in the Aipl1h/h mouse occurs over months rather than 
weeks and approximately half of photoreceptor cell loss is seen at 6-8 
months. The Aipl1 h/h mouse is a strong hypomorph in which the level of 
AIPL1 is decreased to 25% of wild-type and the level of cGMP PDE, a 
purported client protein is similarly reduced[282]. In this slower model, 
normal retinal development is also noted toprior to the onset of photoreceptor 
degeneration. Thus there is a rationale that replacing AIPL1 would prevent 
the catastrophic events that commit normal photoreceptors to the fate of cell 
death.  With a slower rate of degeneration, the hypomorphic Aipl1 mouse 
model might provide a better model to assess gene-based strategies since 
there is a much greater window of opportunity for therapeutic intervention 
exists. Thus, the hypomorphic model was chosen as the initial animal model 
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in which to assess the efficacy of gene replacement therapy for AIPL1 
deficiency. 
 
 
3.2    Cloning of AIPL1 construct 
 
To produce an rAAV2 vector expressing Aipl1 transgene, a construct was 
created by cloning the mouse Aipl1cDNA between the ITRs of the AAV2 
genome. The normal copy of murine Aipl1 cDNA was amplified from murine 
cDNA using primers which have been designed to encompass the whole of 
the coding region. A PCR fragment of 1016 bp which was consistent with the 
size of murine Aipl1 cDNA was isolated on gel electrophoresis. The Aipl1 
cDNA was cloned into the pGemT.Easy vector which contained the ampicillin 
resistance gene as a selection marker. The plasmid also contains a 
polylinker sequence that facilitates cloning since the PCR product is then 
flanked by a variety of different restriction enzyme sites. Following 
amplification of pGemT-Aipl1, the sequence of Aipl1 was checked using 
digestion with a series of restriction enzymes and sequenced to ensure that 
no mutations had occurred during amplification and isolation of the fragment. 
 
The rAAV backbone containing by the CMV promoter was obtained from 
another construct AAV-CMV-gfp. The restriction enzymes SacII and NotI 
were used to excise the gfp gene. The AAV backbone containing CMV 
promoter was extracted from gel as a 4642 bp fragment (Figure 3.1A). 
Similarly, the murine Aipl1 cDNA was excised from the plasmid PGemT-Aipl1 
using the same enzymes SacII and Not I and following separation by gel 
electrophoresis, a fragment of 1091 bp was obtained (Figure 3.1B). The 
murine Aipl1 fragment was then ligated into pD10 backbone between the 
CMV promoter and SV40 polyadenylation site to form a construct of 5733 bp 
termed AAV-CMV-Aipl1 (Figure 3.2). The ligation mix was transformed into 
DH5α cells and DNA was prepared from the colonies.  A total of 7 colonies 
were obtained and prepared to give 7 miniprep DNA samples. These DNA 
samples were checked using restriction digests with StuI and KpnI. Correct 
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fragments were found in 3 samples. These samples were checked with 
further restriction digests with AccI, StuI, PstI and StuI and correct fragments 
were obtained in all of them.  Finally, a DNA megaprep prepared from 
sample no.2. This was rechecked using restriction digests with AccI, StuI, 
KpnI and PstI (Figure 3.3) and also sequencedS. This construct would later 
be used to generate the recombinant AAV vector expressing Aipl1 for 
therapeutic assessment. 
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Figure 3.1.  Restriction enzyme digest. 
A) The ~ 4.6 kb AAV vector backbone  was isolated from the parental plasmid AAV-
CMV-Egfp. 
B) The ~1.0 kb murine  Aipl1 cDNA was isolated from PgemT-Aipl1 plasmid and 
cloned into the AAV backbone  to form the therapeutic construct AAV-CMV-Aipl1. 
Both restriction digests are flanked by1 kb DNA ladder (Bioline Ltd., UK) 
B 
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pdmAIPL
5733 bp
SV40
CMV ITR
ITR
mAIPL1
ClaI (4849)
HindIII (4631)
NcoI (4369) AflII  (257)
AvrII  (264)
BfrBI (3960)
BmgBI (5200)
BmtI (4604)
BsaBI (37)
BsiWI (3973)
BsrFI (1806)
BstXI (4943)
Bsu36I  (5325)
EagI (19)
EcoRV (400 0)
HpaI (138)
Nhe I (4600)
NotI (19)
NsiI (3962)
PfoI (852)
Ppu10I (3958)
PsiI (158)
Sac II  (4661)
Sal I (4648)
Sbf I (3996)
Sna BI (4349)
Sph I (5681)
Sse 8647I (5108)
Ssp I (1086)
XcmI (5558)
XmnI (1291)
Figure 3.2.  Map of the construct AAV-CMV-Aipl1.   
The transgene AIPL1 was cloned downstream of the CMV promoter fragment , followed by 
SV40 polyA signal and is flanked by viral ITRs . The total size of the construct was 5733 bp. 
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Recombinant AAV serotype 2(rAAV2) carrying the Aipl1 transgene was 
produced using a triple transfection method. Briefly, the method which is 
described in detail in section 2.6.2 uses four main components for the 
production of the rAAV vector. These are the rAAV plasmid, a replicating 
amplicon pHAV7.3 that contains the rep and cap genes and the PS1 HSV 
helper virus, and a packaging cell line. The rAAV constructs and pHAV7.3 
were used to co-transfect BHK cells in a 1:1 ratio. The cells were then 
incubated for 24 to36 hours with PS1 HSV helper virus at 37oC. Before the 
completion of the lytic cycle, the infected BHK cells were harvested and 
centrifuged to isolate the cell pellet.  Following resuspension of the cell pellet, 
the suspension underwent repeated freeze-thawing and enzymatic treatment 
to release the virus from cells. The lysate was purified using a heparin 
column to isolate rAAV2 particles. The molecular titre was determined using 
dot-blot analysis.  Concentration of the virus suspension was estimated by 
comparing to a dilution series, typical titres in this study were about  5 x 1011. 
(Figure 3.4) Two constructs were used to generate rAAV2 for this 
Figure 3.3. Restriction digest with 
AccI, StuI, PstI, KpnI of DNA 
megaprep from the colony 2 of 
ampicillin-resistant colonies of 
pD10-CMV-AIPL1. Correct fragments 
expected with AccI restriction digest 
were 341 bp and 5392 bp and  
expected fragments with StuI digest 
were 497 bp and 5236 bp. With PstI 
digest, fragments expected were 424 
bp,639 bp and 4604 bp while with KpnI 
digest, expected fragments were 580 
AccI StuI PstI KpnI 
 1000 bp 
 500 bp 
 5000 bp 
177 
 
experiment, AAV-CMV-Aipl1 and AAV-CMV-egfp. The AAV-CMV-egfp 
construct was a “parental” plasmid which had been previously generated. It 
was used in this study to serve as a negative control virus to verify treatment 
effects and to determine ether there was any toxicity or inflammation 
resulting from administration of the recombinant virus into the eye. 
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Figure 3.4. A chemiluminescence capture image of a dot blot for AAV2-CMV-
Aipl1  virus suspension.  
The serial dilution of a DNA probe of known concentration serves as a standard 
ladder. 1 µl and 5 µl of the virus suspension were loaded and the concentration 
estimated by comparing the chemilumincence intensity of the sample to the dilution 
series. In this case it was estimated that the virus suspension had a concentration of 
1 x 1011  particles /ml 
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3.3 Aipl1 transgene expression 
 
3.3.1   In vitro assessment of gene expression from AAV-
CMV-Aipl1 and AAV-CMV-eGFP 
 
In order to verify that the viral vectors AAV-CMV-Aipl1 and AAV-CMV-eGFP 
were expressing the genes of interest, both plasmid constructs and viral 
vectors were used to transfect and transduce 293T cells.  In a 24-well plate, 
50 000 293T cells were seeded per well. 1µg of each plasmid construct was 
used to transfect each well along with Lipofectin and peptide 6 in the ratio 
described in methods section. The transfection mix containing the plasmid of 
interest, lipofectin and peptide 6 in Optimem was incubated at 37oC for 4 
hours. After this, the transfection mix was replaced with cell culture medium 
and incubated overnight at 37oC. For infection, 1 µl of each viral suspension 
(1011 vp/ml) was added to each well of 293T cells. Replicates of twelve were 
made for plasmid transfection and virus transduction respectively. The next 
day, the cells were assessed for evidence of GFP expression.  Bright green 
fluorescence was seen in wells where 293T cells were transfected with the 
plasmid AAV-CMV-eGFP and cells infected with the virus suspension of the 
same vector (Figure 3.5). No fluorescence was observed in the negative 
control wells or wells which were transfected with AAV-CMV-Aipl1 plasmid 
construct. Since the AAV-CMV-Aipl1 construct does not contain the GFP 
transgene, expression of the transgene could not be verified by fluorescence 
microscopy.  Instead, the cells which had been transfected with AAV-CMV-
Aipl1 were collected 24 hours later and cells transduced with the vector 
suspension were harvested at 48 hours. These cells were lysed and 
sonicated, and the cell lysates were pooled together in their respective 
groups. A standard Western Blot analysis using an anti-Aipl1 antibody was 
performed on the cell lysates. This included negative control samples 
consisting of 293T cells that had not been treated.  A specific band of 
approximately 38 kDA corresponding to the size of murine AIPL1 was 
detected in transfection and infection cell lysates confirming the presence of 
A 
D C 
B 
B 
180 
 
the protein.  This observation validated the functionality of the plasmid 
construct and transgene expression from the viral vector (Figure 3.6). 
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Figure 3.5. In vitro study of gfp 
expression in 293T cells.  
A) Transfection of 293T cells 
with AAV-CMV-eGFP plasmid 
construct show green 
fluorescence 24 hours later. 
B) 293T cells show green 
fluorescence following 
infection with AAV-CMV-
eGFP virus suspension 
indicating transduction and 
expression  in cells. 
C) No green fluorescence was 
seen in the negative control 
well which was not 
transfected. 
D) 293T cells which were 
transfected with AAV-CMV-
Aipl1 plasmid construct did 
not show any green 
fluorescence. 
Figure 3.6. Western blot 
analysis of AAV2/2-CMV-
Aipl1 expression.   
 Lysates of 293T cells which 
were transfected with the 
plasmid construct AAV2/2-
CMV-Aipl1 and transduced 
with  AAV2/2-CMV-Aipl1 were 
subjected to western blot 
analysis. Band corresponding 
to the size of murine AIPL1 
protein (≈38kD) is seen in 
both transfected and 
transduced cell lysates. 
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3.3.2   Expression and subcellular localization of AIPL1 
in the retina following injection with AAV2-CMV-Aipl1 
 
The viral vectors were injected subretinally as described in the methods 
section into 4- week old Aipl1 h/h mice. Each injected eye received 2 
subretinal injections of virus suspension, one in the superior hemisphere of 
the retina and another in the inferior hemisphere. The volume of virus 
suspension per injection was 1.5 µl of virus suspension at a concentration of 
1 x 1012 vp/µl.  Each Aipl1 h/h mouse was received injections in one eye 
only, leaving the contralateral eye as an internal control. A total of 3 mice 
received subretinal injections for this purpose.  Twenty-eight weeks after 
injections, these mice were culled and the eyes were taken and analysed for 
evidence of Aipl1 expression.  
 
At 28 weeks after subretinal injection of AAV2-CMV-Aipl1, the treated and 
untreated eyes of Aipl1 h/h mice taken for immunohistochemistry. The eyes 
were embedded unfixed in optimal cutting temperature (OCT) medium and 
frozen, and then cryosectioned. Immunofluorescence analysis using an anti-
AIPL1 antibody was performed on cryosections of matched injected and 
uninjected Aipl1 h/h retinas and wild type retinas (Figure 3.7). To ensure that 
comparisons were made at the same levels in each of these eyes, the optic 
nerve was used as a reference point and sections which passed through the 
optic nerve were used for analysis. Analysis of retinas of Aipl1 h/h mice 
following injection of the therapeutic vector revealed an increased 
immunofluorescence with AIPL1 antibody in the layer located at the distal 
border of the outer nuclear layer corresponding to photoreceptor inner 
segments. This was consistent with the description of AIPL1 immunostaining 
in the retina from a previous study[282], and is similar to that seen in the wild 
type retinas albeit at a lower level. In contrast, uninjected control Aipl1 h/h 
retinas showed marked thinning of outer and inner nuclear layer  and weak 
immunofluorescence for AIPL1. These data showed that subretinal injection 
of  the AAV2-CMV-Aipl1 vector resulted in efficient gene transfer and correct 
expression and localization of AIPL1 in the retina. AIPL1 
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immunofluorescence was also seen in the RPE layer of Aipl1 h/h retinas 
injected with the therapeutic vector, while this was absent in untreated Aipl1 
h/h and wild type retinas. This ectopic expression in the RPE layer is further 
verification of vector-driven Aipl1 expression in the retina.  Under the control 
of a ubiquitous promoter such as CMV, subretinal delivery of AAV2 results in 
transduction of both photoreceptor cells and the RPE. 
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Figure 3.7. Expression and subcellular localization of AIPL1 in Aipl1 h/h retina 
following injection with AAV2-CMV-Aipl1 
 
Treated Aipl1 h/h retina shows strong AIPL1 immunofluorescence (green) localized mainly to 
the inner segments (IS) in keeping with AIPL1 expression in vivo. The pattern of staining is 
similar to that seen in wild type retina. In contrast, uninjected AIPL1 h/h retina showed not 
only lower levels of AIPL1 immunofluorescence, but also reduced outer nuclear layer 
thickness.. Sections are counterstained with Hoechst nuclear dye in blue. 
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3.3.3  Quantification of Aipl1 transgene expression in vivo 
 
The levels of Aipl1 transgene expression following subretinal injection of 
AAV-CMV-Aipl1 into Aipl1 h/h mouse retina was assessed by comparing 
levels of transcript between vector-treated eyes and untreated eyes using 
quantitative PCR. 
 
At 28 weeks post injection, eyes were taken from Aipl1 h/h mice that 
received unilateral subretinal injections of vector and from wild type mice. 
The neuroretina was dissected out from each of these eyes. Total RNA was 
isolated from the three pairs of treated and untreated Aipl1 h/h neuroretinas 
and from wild type neuroretinas, and reversed transcribed to obtain cDNA. 
Quantitative PCR was performed on the cDNA from these samples as 
described in the methods section. Since the Aipl1 h/h mouse model is a 
knockdown model in which the level of Aipl1 expression in the retina is 
reduced rather than extinguished, untreated eyes would not be expected to 
show an absence of Aipl1 expression.  Hence, in order to verify the 
functionality of the therapeutic vector, it was necessary to quantify the levels 
of Aipl1 expression in eyes that received subretinal delivery of the vector and 
compare these relative to the levels in untreated eyes.  
 
Levels of Aipl1 expression in treated Aipl1 h/h eyes were found to be 
consistently higher compared with paired untreated eyes(Figure 3.8a). The 
mean relative levels of Aipl1 expression in treated Aipl1 h/h eyes were more 
than 9 times of the mean relative levels in untreated eyes (Figure 3.8b). 
Compared with wild type eyes, the mean relative levels of expression in 
treated eyes were approximately 50% of wild type levels at 28 weeks 
following subretinal injection of AAV-CMV-Aipl1 vector (Figure 3.8b), while in 
untreated eyes the level of Aipl1 expression was 5% of wild type. Treatment 
with the viral vector therefore resulted in an increase in Aipl1 expression of 
about 45% of wild type levels. The double subretinal injections of vector 
performed in each eye would expose approximately 60% of total area of the 
retina to the vector. Taking into consideration that the transduction efficiency 
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of  AAV2/2 vector is known to be about 40-50%,  it would seem that the 
levels of expression of Aipl1 might be close to wild type levels in 
photoreceptor cells that were transduced successfully following subretinal 
injection of rAAV2/2 vector.  
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A 
Figure 3.8. Quantitative PCR for Aipl1 in treated and untreated retinal samples at 
28 weeks following subretinal injection with AAV2/2-CMV-Aipl1. 
A) The relative levels of Aipl1 expression in treated and untreated retinas from 3 
procedured aminals are shown. Error bars indicate standard deviation. 
B) Mean relative expression of Aipl1 in treated retinas were approximately 50% of 
wild type levels while in untreated retina this was approximately 5% of wild type. 
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3.4  Effect of AIPL1 expression on rod 
phosphodiesterase (PDE), a client protein. 
 
3.4.1  Immunohistochemical analysis of AIPL1 and β-
PDE in wild type mouse retina. 
  
In the Aipl1 h/h mouse, there is a decline in phosphodiesterase (PDE) level 
proportional to the reduced level of AIPL1[282]. This effect is highly specific 
for PDE, as analysis of a large number of photoreceptor proteins found no 
change in their expression levels in the hypomorphic mutant [282]. Hence, it 
has been hypothesized that AIPL1 is a specialized chaperone evolved to 
assist in photoreceptor PDE biosynthesis at a post-translational level. 
Phosphodiesterase is a key phototransduction enzyme in the retina and any 
effective therapy should aim to restore PDE biosynthesis, through 
reconstituting AIPL1 function, to a level sufficient to sustain photoreceptor 
function and survival. In view of this, we wanted to investigate the effect of 
rAAV-mediated AIPL1 trangene expression on PDE expression and 
localization in transduced photoreceptors. In order to determine changes in 
PDE levels following subretinal injection of the vector, we evaluated the 
levels of β-PDE and AIPL1 using confocal microscopy. As shown in section 
3.3.3, AIPL1 is  normally localized mainly to in the inner segments of the rod 
photoreceptors, although some weak immunostaining for AIPL1 can be seen 
in the photoreceptor cell body and spherules [475].  In healthy 
photoreceptors, PDE is localized to the photoreceptor outer segments.  
 
Immunostaining of β-PDE was first optimized in wild type mice retina so that 
a standard protocol could be established and a baseline pattern of double 
immunofluorescence for AIPL1 and PDE can be obtained. Since the protocol 
for AIPL1 immunostaining required that retinal sections were fixed as lightly 
as possible, the β-PDE immunostaining was optimized using unfixed retinal 
cryosections so that co-staining for the two proteins could be undertaken 
later. Eyes from wild-type mouse were extracted and immediately frozen in 
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OCT and then cryosectioned. The slides were divided into 3 groups: Group A 
– wild type retina immunostained with anti-AIPL1 antibody followed by a 
green secondary antibody, no second primary antibody followed by a red 
secondary antibody; Group B- wild type retina in which anti-AIPL1 antibody 
was not applied, then followed by a green secondary antibody, then anti β-
PDE antibody followed by a red secondary antibody; Group C 
immunostained with anti-AIPL1 antibody, followed by green secondary 
antibody and then with anti β-PDE antibody followed by a red secondary 
antibody (protocols are described in section 2.9).  
 
In group A, following immunostaining of wild type retina with anti- AIPL1 
antibody, green immunofluorescence is seen mostly at the inner segments of 
photoreceptors with some staining detected in the cell bodies and the 
synaptic spherules in the outer plexiform layer (Figure 3.9 A). There was no 
red immunofluorescence detected as the anti β-PDE antibody was not 
applied in these samples.  In group B, immunostaining with β-PDE antibody 
was present in the outer segments of photoreceptors as indicated by red 
immuofluorescence (Figure 3.9 B). Concurrent immunostaining for AIPL1 
and  β-PDE displays the correct localization of each protein with respect to 
each other (Figure 3.9 C), where there is a distinct layer of green and red 
immunofluorescence next to the outer nuclear layer representing the 
presence of AIPL1 and β-PDE respectively . The yellow fluorescence seen 
between the outer and inner segments is a result of an small degree of 
overlap of the AIPL1 green immunofluorescence and PDE red 
immunofluorescence. More importantly, this also showed that there was no 
non-specific binding of the red secondary antibody to the anti-AIPL1 antibody 
and vice versa since both of the primary antibodies were raised in rabbit. 
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Figure 3.9. Anti-AIPL1 and anti-PDE 
immunofluorescence in wild-type retina.  
 
Confocal microscopy of wild type mouse 
cryosections immunostained with  anti-
AIPL1 antibody only (Group A),; anti-βPDE 
only (Group B), and sequentially with anti-
AIPL1 antibody and anti-PDE antibody 
(Group C). 
 
A) Wild type retina immunostained with 
rabbit anti- AIPL1 antibody and 
Alexa- 488 goat anti-rabbit 
secondary (green); then TBS 
followed by Alexa-546 goat anti-
rabbit secondary antibody (red). 
 
B) Wild type retina immunostained with  
initially with TBS followed by Alexa-
488 goat anti-rabbit secondary 
antibody (green); then with anti- 
βPDE antibody followed by Alexa-
546 goat anti-rabbit secondary (red) 
 
C) Wild type retina immunostained 
sequentially with anti- AIPL1 
antibody followed by Alexa-488 goat 
anti-rabbit secondary antibody 
(green); then with anti- βPDE 
antibody and Alexa-546 goat anti-
rabbit secondary antibody (red). 
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3.4.2  Immunohistochemical analysis of AIPL1 and β-
PDE in Aipl1 h/h following gene transfer. 
 
Retinas of Aipl1 h/h mice received subretinal injection of AAV2-CMV-Aipl1  
were co-immunostained for AIPL1 and β-PDE at 28 weeks to assess if there 
were any differences in the levels and localization of these proteins.  
Representative paired retinal sections of treated and untreated eyes 
following treatment were co-immunostained for AIPL1 and β-PDE (Figure. 
3.10).  
 
Without treatment, retinas of Aipl1 h/h mice showed only weak green 
immunofluorescence for AIPL1 in the inner segments. Red 
immunofluorescence for β-PDE was reduced and mislocalized to the inner 
segment in untreated eyes resulting in overlapping of red and green 
immunofluorescence (Figure 3.10). Following treatment with AAV2-CMV-
Aipl1, substantially increased AIPL1 immunofluorescence (green) was seen 
and accompanied by  increased immunofluorescence for ß-PDE (red). More 
interestingly, a shift in the subcellular localization of β-PDE was seen in 
treated retinas:  it appeared to be restored to the outer segments of 
photoreceptors (Fig. 3.10 B). The relative amount and localization of AIPL1 
and β-PDE in treated eyes appeared similar to that seen in wild type sections 
(Fig. 3.10 C). These results indicate that not only the amount of β-PDE but 
also its subcellular localization is dependent on AIPL1. This association 
between the correct localization of β-PDE and AIPL1 has not been reported 
before. It is thus likely that the stability of PDE is dependent on AIPL1 and it 
suggests that AIPL1 functions in the final maturation step of PDE 
biosynthesis, as a molecular chaperone for the folding and/or cellular 
translocation of cGMP PDE. 
 
 
 
A 
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Figure 3.10.  Confocal images of double immunofluorescence microscopy for AIPL1 
and β-PDE in AAV2-CMV-Aipl1 treated and untreated retinas of Aipl1 h/h mice at 28 
weeks post injection.  
Representative paired treated and untreated retinal cryosections from Aipl1 h/h mice were 
co-immunostained for AIPL1 and β-PDE, and imaged using confocal microscopy.
Comparison of untreated and treated eyes of Aipl1 h/h mice showed restoration of the 
normal localization of ß-PDE in the outer segments.  
(A) In untreated retina, ß-PDE immunofluorescence (red) colocalizes with AIPL1 
immunofluorescence (green) in the photoreceptor inner segments (IS). 
(B) Following subretinal injection of AAV2-CMV-Aipl1, ß-PDE immunofluorescence is 
translocated to the outer segments (OS) in the treated retina. Hence in treated 
retina, AIPL1 immunofluorescence in the inner segment is separate from ß-PDE 
immunofluorescence in the OS, which is similar to that found in wild type retina. 
(C) Co-immunostaining of AIPL1 and β-PDE in wild type retina shown for comparison. 
 
Cell nuclei were counterstained with Hoechst dye 33342 (blue).  
INL- inner nuclar layer; ONL – outer nuclear layer; IS –inner segments; OS –outer segments.  
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3.5   Effects of AAV-mediated Aipl1 transgene 
expression on retinal morphology 
 
3.5.1   Analysis of retinal histology in Aipl1 h/h retina 
following treatment with AAV2-CMV-Aipl1 and in untreated 
retina 
 
Following the verification of the vector and that the Aipl1 transgene was 
expressed in treated murine retina, the next step was to evaluate the effect 
of the treatment on retinal morphology and whether retinal degeneration was 
being prevented or delayed. Sixteen Aipl1 h/h mice received subretinal 
injections of AAV2-CMV-Aipl1 viral vector. To achieve the maximal total area 
of treatment, the virus suspension was injected into the superior and also in 
the inferior hemisphere of the retina, using an injection volume of 1.5 µl viral 
suspension to create an area of bullous retinal detachment. Each injection 
created temporary bullae which covered 30-40% of the fundus. By injecting 
in 2 hemispheres, approximately 70% of the retina is exposed to the virus. In 
each animal, only the right eyes received subretinal injections and the left 
eye was left untreated to serve as an internal control, to eliminate external 
confounding factors which could influence the rate of photoreceptor cell loss 
and the considerable variation in the rate of retinal degeneration that exist 
even between animals from the same litter due to an inherent biological 
variability. The mice were injected at 4 weeks of age and this time point was 
selected based on the observation that the Aipl1 h/h mouse has a relatively 
slow degeneration in comparison to the null mutant and injecting very young 
mice would cause relatively more damage to the retina. Since the first signs 
of degeneration are only seen at 12 weeks and AAV2/2 vectors are known to 
give rise to transgene expression approximately 3-4 weeks following 
injection, we assumed that the delivery of the viral vector at 4 weeks of age 
should allow enough time for transgene expression to occur before there was 
significant photoreceptor degeneration; in this case we  would expect  to see 
Aipl1 expression by 8-9 weeks of age. Maximal expression would be 
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expected to occur at about 3 months after injection, when the mice are 16 
weeks old. 
 
Two of the procedured animals were sacrificed at 8, 16 and 28 weeks 
respectively following subretinal injection.  The eyes of these mice were 
orientated and fixed in paraffin before being sectioned and stained with 
haematoxylin and eosin. Adult wild type mice were sacrificed and eyes 
similarly processed for histological comparison. Using light microscopy, we 
examined these eyes for evidence of retinal degeneration at the various time 
points (Figure 3.11). At the age of 12 weeks (8 weeks following subretinal 
injection), no differences were seen in treated and untreated eyes and there 
was no evidence of any disorganization of the retinal architecture. At 20 
weeks of age (16 weeks following subretinal injection), untreated eyes had 
noticeable thinning of the ONL and disruption of layered structure of the 
retina. Treated eyes at 20 weeks of age had relatively well preserved ONL 
and INL thickness, although there were some early signs of disorganization 
of the retinal architecture. At 32 weeks of age (28 weeks following subretinal 
injection), clear retinal degeneration was observed in untreated eyes, as 
indicated by the collapse of the retinal layers and substantial loss of ONL. 
Treated eyes at this time point had relatively well preserved retinal 
architecture and although some thinning of the ONL was seen, ONL loss in 
treated eyes was noticeably less compared with untreated eyes.   
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Figure 3.11. H&E comparison of representative matched pairs of treated and untreated 
Aipl1h/h eyes at 8,16 and 28 weeks following subretinal injection of AAV2/2-CMV-AIPL1. 
Treated and untreated Aipl1 h/h retina at 12 weeks of age (8 weeks post injection) had no obvious 
signs of retinal degeneration. At 20 weeks of age (16 weeks post injection), the signs of 
degeneration become more evident in the untreated eye with progressive thinning of the outer and 
inner nuclear layers. By 32 weeks of age (28 weeks post injection),  a substantial difference is seen 
between the treated and untreated eye in terms of disorganization of the retinal architecture and 
thinning of the ONL and INL that is more marked in the untreated retina. For comparison a wild-
type retina at 9 weeks of age is shown. The retina in AIPL1 h/h animals appears to develop 
normally. 
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3.5.2   Morphometric analysis of the rate of retinal 
degeneration following gene transfer. 
 
To quantify the extent of photoreceptor cell rescue in treated eyes compared 
with untreated eyes, morphometric analysis was performed on retinal 
sections by counting the number of photoreceptor cell nuclei in the ONL 
(Figure 3.12). Retinas were taken at 28 weeks post-injection for sectioning. 
Cryosections were taken at various depths and each eye had been 
orientated during embedding in such a way that when cryosectioned, each 
section spanned over the superior and inferior retina which were the sites of 
injection. The cryosections were immunostained for photoreceptor nuclei with 
propidium iodide (PI) and imaged using the confocal microscope. To 
standardise measurements and eliminate any bias, only sagitally orientated 
central retina sections that passed through the optic nerve head were 
selected for this analysis.  
 
Eyes from a total of seven animals were analysed. For each eye, three3 
central retinal sections were selected that appeared to pass through the optic 
nerve head. In each retinal section, images were captured from each side of 
the optic nerve head so that a total of two images were obtained from each 
section. Hence, a total of six confocal images of the retina were obtained for 
each eye. Standardized confocal images of photoreceptor nuclei under the 
same magnification were captured in the area between the ora serrata and 
optic nerve head approximating to the middle of the injection site.  The nuclei 
in the outer nuclear layer in this area were counted by a single masked 
observer. Figure 3.12 illustrates the method of assessment and 
representative retinal sections from treated and untreated eyes. 
Photoreceptor nuclei which appeared less than 25% complete were not 
counted. The photoreceptor cell count for each eye was determined by 
averaging the cell counts from each confocal image of the particular eye. 
Mean number of photoreceptor nuclei was obtained for each of the 6 treated 
eyes and 6 matched untreated eyes. To control for inter-animal variation in 
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the rate of degeneration, a paired t-test was performed between the 
photoreceptor cell counts in the treated and untreated eyes of each animal.  
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Figure 3.12. Method for assessing number of photoreceptors in outer nucler layer (ONL) in 
treated and untreated retina. 
Sagittally orientated central sections that passed through the optic nerve head (ONH) were used. At 
about midway between the ONH and ora serrata, high power images of the ONL were captured on 
each side of the ONH using the same magnification (X40). The photoreceptor nuclei in these images 
were counted by a single observer. 
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Confocal images of representative retinal sections of treated and untreated 
eyes are shown in Figure 3.13. Treated retinas had substantially thicker ONL 
compared with untreated retinas. Statistical analysis showed that the mean 
number of photoreceptor cell nuclei in treated eyes of Aipl1 h/h mice (n=7) 
was found to be 41 % higher than in the untreated eyes (mean photoreceptor 
cell count in treated eyes = 479.3 ± 16.6 versus untreated eyes = 339.3 ± 8.2 
; p=0.0003) (Figure 3.14A). Preservation of photoreceptors in treated eyes 
was observed in all of the seven animals that were assessed as each animal 
had significantly greater number of photoreceptors in treated compared with 
untreated contralateral control eyes (p≤0.05) (Figure 3.14B). However, the 
ONL cell count following treatment with the therapeutic vector was lower 
compared with age-matched wild type eyes (p=0.02), indicating that although 
retinal degeneration was slowed, it was not halted and there was still 
ongoing photoreceptor cell loss (Figure 3.14B). 
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Figure 3.13. Confocal images of paired retinal sections of treated and untreated eyes 
from 3 representative animals that were assessed for morphometric analysis.  
The number of nuclei in the outer nuclear layer were counted in each of these images by a 
masked observer. The paired statistical analysis of the mean number of outer nuclear layer 
nuclei showed significant differences between treated and untreated retinas. 
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Figure 3.14 Graphs of mean ONL cell counts . 
(A)  Graph comparing mean ONL cell counts of 7 animals. Treated eyes have significantly higher 
mean ONL cell counts compared with untreated eyes indicating preservation of photoreceptor cells 
following subretinal injection of AAV2-CMV-Aipl1. However, treated eyes have lower ONL count 
compared with age-matched wild type eyes. 
(B)  ONL cell counts at 32 weeks of age (28 weeks post injection) for the right and left eyes of each 
individual animal is shown. There is a consistently higher cell count seen in the right treated eyes of 
each animal which is statistically significant (p<0.005). 
B 
Mean ONL cell count in individual animals at 28 weeks 
post injection 
Individual Aipl1h/h mouse that received AAV2-CMV-Aipl1 
A Mean ONL cell count at 28 weeks post injection  
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3.6  Effects of AAV2-mediated Aipl1 expression 
on retinal function in Aipl1 h/h retina. 
 
Histological analysis and quantification of the outer nuclear layer suggested 
that photoreceptor cell loss was significantly delayed following treatment with 
AAV2-CMV-Aipl1. AAV2-mediated Aipl1 expression led to the correction of 
β-PDE mislocalization in Aipl1 h/h retina. Consequently, the cellular biology 
of individual photoreceptor cells was restored, and the survival of 
photoreceptor cells was prolonged. It was thus important to ascertain 
whether this preservation of photoreceptor cells following treatment would 
have an effect on retinal function which could translate into visual 
stabilization or improvement.  
 
Current established literature has defined a role for AIPL1 in rod and cone 
photoreceptor cells and therefore the retinal disease due to AIPL1 gene 
mutations is attributed to an insufficiency of rod and cone PDE 
biosynthesis[282][232][240]. An effective therapy for this condition should 
aim to restore rod and cone PDE biosynthesis by reconstituting AIPL1 
function. Since rods represent the majority of the population of 
photoreceptors in the murine retina[211][514], we looked for improvement in 
retinal function following AAV-mediated gene delivery by assessing rod 
photoreceptor function. Measurements that usually are recorded for a 
selected ERG signal are the amplitude and implicit time. In this study, the 
responses from rod photoreceptors were evaluated by analyzing the 
amplitudes of a and b-waves of dark-adapted ERGs that have been recorded 
from Aipl1 h/h mice. The a and b-wave amplitudes were chosen as the 
outcome measure of retinal function. The a-wave is generated by 
photoreceptors and thus is a direct reflection of photoreceptor response. 
However,  it is very much smaller in size and is more difficult to record 
accurately especially with a machine with limited sensitivity. The b-wave is 
much larger in amplitude and easier to record and measure. Although the b-
wave is generated by the inner retina, the amplitude of the response relies 
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on the extent of the a-wave response and provides an indirect reflection of 
photoreceptor cell activity. 
 
3.6.1  ERG intensity series following treatment with 
AAV2-CMV-Aipl1   
 
To evaluate the effect of AAV-mediated Aipl1 expression on retinal function, 
dark-adapted, scotopic ERG recordings were obtained from 16 Aipl1 h/h 
mice that received unilateral subretinal injection of AAV2-CMV-Aipl1 (titre of 
1 x 1011 viral particles /ml) at 4 weeks of age. Only right eyes were injected, 
leaving the left eye as an internal control. The internal control is provides a 
means for paired analysis that would eliminate any bias caused by inter-
animal variation that may occur within an ERG recording session. Scotopic 
ERG responses were recorded using a series of flash intensities consisting 
of 0.1, 1, 10, 100, 1000 and 3000 mcds/m2 flashes via a stimulating Ganzfeld 
bowl.  Control injections with PBS were carried out in 5 Aipl1 h/h mice, and 
similarly subretinal injections of a control virus AAV2-CMV-gfp were 
performed on 6 Aipl1 h/h mice under the same circumstances.  
 
Simultaneous bilateral recordings were performed to optimize comparison of 
treated and untreated eyes, and ERG recordings were performed after a 
period of dark adaptation at regular intervals of 4 weeks, 8 weeks, 12 weeks, 
16 weeks, 20 weeks, 24 weeks and 28 weeks post injection.  Statistical 
analysis was performed on data obtained at flash intensities of 100 and 1000 
mcds/m2. The responses to flashes of intensities of 100 and 1000 mcds/m2 
from the eyes of treated and control animals were chosen for several 
reasons. At flash intensity of 100 mcds/m2, a purely rod response is 
obtained.  At intensity of 1000 mcds/m2, responses from both rods and cones 
are recorded and provides an indication of the overall retinal function.  
 
Representative ERG recordings from a single Aipl1 h/h mouse at 20 weeks 
post-injection (Figure 3.15A) and ERG waveforms at 28 weeks post-injection 
are shown in Figure 3.15B. Compared with untreated eyes, the ERG 
204 
 
amplitudes in treated eyes were substantially higher. Oscillatory potentials, 
representing post-synaptic neuronal activity in the inner retina, were more 
obvious in the treated eye but reduced in the untreated eye. There was a 
general improvement in the shape of the ERG trace following treatment in 
that the ERG tracing resembled that of a wild type mouse ERG while the 
tracing from the untreated eye was flattened, indicating diminished 
responses. The ERG intensity series recorded from eyes that received 
subretinal injections of the control virus AAV-CMV-gfp or PBS similarly 
showed diminished responses (Figure 3.15C).The improvement in ERG 
recordings hence was a result of AAV-mediated Aipl1 expression since 
injections of GFP control vector or PBS did not alter the size of the ERG 
response or shape of the trace. 
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Figure 3.15. Functional rescue assessed by ERG analysis following subretinal injection 
of AAV2-CMV-Aipl1.  
(A) ERG intensity series of the treated and untreated eye of a 24-week old Aipl1 h/h 
mouse at 20 weeks following treatment. ERG traces shown in each chart were 
recorded at intensities of 0.1, 1, 10, 100, 1000, and 3000 mcds/m2. The treated eye 
maintains substantially larger amplitudes and oscillatory potentials, while in the 
untreated eye, there is loss of amplitude even at higher flash intensities. The ERG 
intensity series from a wild type animal is shown for comparison. 
(B) Representative ERG waveforms at 28 weeks post-injection from the treated and 
untreated eyes of an Aipl1 h/h mouse. A wild type waveform is shown for comparison. 
The treated eye shows a discernible a-wave and a higher b-wave compared to the 
untreated eye. 
(C) Injection of PBS and control vector AAV2-CMV-gfp did not lead to any improvement 
in the ERG recordings suggesting that the improvement in treated eyes was due to 
the AAV-mediated expression of the Aipl1.  
	  
A Aipl1 h/h untreated Aipl1 h/h treated 
B 
Wild type 
206 
 
3.6.2  ERG timecourse and statistical analysis ERG 
amplitudes.  
 
 A series of ERG recordings were obtained from the treated and untreated 
eyes of an Aipl1 h/h animal at various follow up time points following 
subretinal injection of AAV2-CMV-Aipl1 (Figure 3.16). This flash intensity 
was chosen because the electrical response of both rods and cones are 
obtained and this allows the analysis of the overall rescue of photoreceptor 
cells.	  Over the 28 week period, the untreated eye showed a steady decline in 
a-wave and b-wave amplitude, whereas the treated eye showed stabilization 
of amplitude and waveform. Differences in improvement between the treated 
and untreated eyes are more apparent from 12 weeks post injection onwards 
(Figure 3.16). The treated eye consistently maintained higher amplitudes 
throughout the follow-up period. At the final time point of 28 weeks post 
injection when the animal was 32 weeks of age, the ERG response from the 
untreated eye was markedly reduced or almost flat, while the treated eye still 
had good ERG responses, indicating rescue of photoreceptor function by the 
AAV-mediated transgene expression. This suggested that not only there 
were more photoreceptor cells present in the treated eyes compared to 
untreated eyes but that the surviving photoreceptor cells also retained 
normal function. The degeneration of photoreceptors appeared to be slowed 
by the treatment. 
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Figure 3.16  ERG time course.  
Representative ERG traces from a single Aipl1 h/h mouse taken at various ages of 8 weeks (4 
pi),16 weeks (12 weeks pi), 24 weeks (20 weeks pi) and 32 weeks (28 weeks pi) following 
subretinal injection of AAV2-CMV-Aipl1  is shown. Averaged responses at a flash intensity of 
1000 mcds/m2 were recorded simultaneously from both treated and untreated eyes of the same 
Aipl1 h/h mouse following treatment.  From 12 weeks post injection onwards, a noticeable 
difference in the amplitude and shape of the trace between the two eyes is seen. ERG 
amplitudes from the untreated eye diminish with time, whereas ERG responses are maintained 
in the treated eye. 
* pi- post injection 
Aipl1 h/h treated Aipl1 h/h untreated 
* 
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Statistical analysis of the ERG recordings was performed to ascertain 
whether the differences in amplitudes between treated and untreated eyes 
were significant. Average ERG a-wave and b-wave amplitudes of treated and 
untreated eyes were calculated for the various time points at flash intensities 
of 100 mcds/m2 and 1000 mcds/m2.  At each time point assessed, there was 
considerable inter-animal variation in the ERG amplitudes in the untreated 
eyes of individual Aipl1 h/h mice, indicating an element of variability in the 
rate of photoreceptor degeneration in this model. Furthermore, the ERG 
results of the same cohorts of animals varied substantially between recording 
sessions, suggesting inter-session variability. In view of this variation, paired 
t-tests were used to analyse the mean a-wave and b-wave amplitudes 
between treated and untreated eyes at the various time points from 4 to 28 
weeks (Figure 3.17 and Figure 3.18). Analysis of mean a-wave amplitudes 
showed that treated eyes maintained higher amplitudes compared with 
untreated eyes, this difference was statistically significant (p≤0.05) from 20 
weeks post injection onwards up to the final time point of 28 weeks post 
injection (Figure 3.17). At 20 weeks post injection, the mean a-wave 
amplitude in treated eyes (n = 15; mean = 109.6±20.4 µV) was 
approximately 38% higher than that in untreated eyes (n = 15; mean = 
79.2+33.8 µV). Mean b-wave analysis was performed at flash intensities of 
100 mcds/m2 and 1000 mcds/m2 representing rod response and maximal rod 
and cone response respectively (Figure 3.18A and B). At a flash intensity of 
100 mcds/m2, mean b-wave amplitudes in treated eyes were consistently 
higher compared with untreated eyes and this difference was statistically 
significant at 20 weeks post injection and 28 weeks post injection 
(p≤0.05)(Figure 3.18A). At 1000 mcds/m2, b-wave amplitudes were 
significantly higher in the treated compared with the untreated eyes at 20, 24 
and 28 weeks post-injection (p≤0.05) (Figure 3.18B). There was an initial 
increase in ERG amplitudes from birth until adulthood (8 weeks) that 
reflected normal development in mice. Four weeks after vector 
administration, there was a reduction in b-wave amplitudes in treated eyes 
that was probably due to injection-related trauma. However, from 20 weeks 
post injection onwards, b-wave amplitudes were significantly higher in 
treated compared with untreated eyes (p≤0.05), a difference which remained 
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consistent up to the final time point of 28 weeks post injection. The mean b-
wave amplitude at flash intensity of 1000 mcds/m2 in treated eyes (n = 15; 
mean = 295.3±13.6 µV) at 20 weeks post injection was approximately 20% 
higher than in untreated eyes (n = 15, mean = 243.6 ± 15.6 µV).  
	  
In the group of PBS-injected animals, no significant differences were seen in 
the b-wave amplitudes between injected and uninjected eyes at flash 
intensity of 100 mcds/m2 and at 1000 mcds/m2 (Figure 3.19). These results 
suggest that there were no detrimental effects despite the trauma of 
subretinal injections to the eye. In the group of Aipl1 h/h mice that received 
unilateral subretinal injections of the control virus AAV2-CMV-gfp however, 
the injected eye had significantly lower b-wave amplitudes than the 
uninjected eye (Figure 3.20). Previous experience in our laboratory have 
found that that vector-mediated gfp expression did not result in loss of ERG 
amplitude nor any inflammatory or toxic effects due either to the transgene or 
rAAV vector. It is thus likely that this finding may have been caused by 
external confounding factors such as the quality of the virus purification. 
Impurities in the viral prep can result in toxic effects thereby decreasing the 
ERG response in the injected eyes.  Alternative, it may suggest that Aipl1 h/h 
mice are particularly sensitive to gfp expression. More significantly, the 
observations from both PBS-injected and AAV2-CMV-gfp injected eyes 
indicate that the therapeutic effect seen from AAV2-CMV-Aipl1 injected eyes 
is a result of the Aipl1 transgene expression and not due to the effects of the 
surgical procedure or the vector itself. 
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Figure 3.17.  Mean ERG a-wave amplitudes at flash intensity of 1000 
mcds/m2 in Aipl1  h/h mice that received subretinal injections of AAV2-
CMV-Aipl1.   
Treated eyes maintained higher ERG a-wave amplitudes compared with 
untreated eyes. Statistical differences in a-wave amplitudes were seen when the 
mice were 24 weeks old and upwards (at 20 weeks post-injection onwards) 
(p≤0.05). Error bars, ±SEM. 
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Figure 3.18  Mean ERG b-wave amplitudes  in Aipl1  h/h mice  that received subretinal 
injections of AAV2-CMV-Aipl1.  
The mean b-wave amplitudes and standard error of the mean (SEM) of treated and untreated 
eyes are shown at various time points after treatment. Statistical significance of the difference 
between the treated and untreated eyes was determined using a paired t-test. 
(A) At a flash intensity of 100 mcds/m2, treated eyes had consistently higher b wave 
amplitudes compared with untreated eyes. The difference was statistically significant when 
the mice were 24 weeks and 28 weeks old (at 20 weeks and 28 weeks post injection 
respectively) (p<0.05). 
(B) At  flash intensity of 1000 mcds/m2, statistical significance was obtained at more time 
points. B-wave amplitudes of treated eyes were significantly increased from the age of 24 
weeks onwards (at 20 weeks post injection onwards) (p<0.05).  
. 
A 
B 
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Figure 3.19  Mean ERG b-wave amplitudes in Aipl1  h/h mice at various time points 
following subretinal injections of PBS.  
At flash intensities of 100 mcds/m2  and 1000 mcds/m2, no significant differences in b-
wave amplitudes were found comparing injected and uninjected eyes . Error bars, ±SEM. 
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Figure 3.20 Mean ERG b-wave-amplitudes of Aipl1 h/h mice at various time points 
following subretinal injection of control virus AAV2-CMV-gfp.  
 
 At flash intensities of 100 and 1000 mcds/m2, ERG b-wave amplitudes of injected eyes 
were significantly lower than b-wave amplitudes of uninjected eyes. Error bars, ±SEM. 
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An initial transient increase in ERG b-wave amplitude was seen up to 8 
weeks post injection (or 12 weeks in age) in both treated and untreated eyes 
of Aipl1 h/h mice. This observation is most likely to be due to a manifest 
developmental phase that exists in mice, during which the ERG b-wave 
amplitude initially increases, together with a reduction in the implicit time. 
This physiological phenomenon has been previously described in young 
mice [209]. However, to exclude the possibility that this observation might 
have been caused by variation in recording conditions between ERG 
sessions, a control experiment was performed to compare the ERGs over 
time in Aipl1 h/h mice and wild type mice.  Two age groups of Aipl1 h/h mice, 
one group aged 6 weeks (n=3) and another group aged 12 weeks (n=3) were 
selected along with a control group consisting of wild-type C57B/6 mice (n=4) 
aged 5 weeks. ERG recording was performed on the 2 groups of Aipl1 h/h 
mice and the control group of wild type mice at various time points, each 
separated by an interval of 1 or 5 weeks.  At each time point, all three groups 
of animals underwent ERG recording at the same session. The ERG 
recordings was performed under similar conditions as described for the 
previous experiments and by the same operator.  A total of 5 sessions of 
ERG recording was performed and the mean b-wave amplitudes of the right 
and left eyes of each group is shown in Figure 3.21.  A large amount of 
variation in b-wave amplitudes was seen between the animals during a 
single ERG recording session. This is indicated by the standard deviation 
which amounted to a substantial proportion of the mean b-wave amplitude in 
some sets of the data. There was also a degree of variability seen in the 
amplitudes obtained from the same animal during different recording 
sessions; although it is difficult to tell whether the variability between different 
recording sessions is significant, other data from our laboratory has shown 
that this is less substantial at higher flash intensities of 1000mcds/m2 and 
above. The phenomenon of an initial transient improvement in b-wave 
amplitudes was observed in all 3 groups of animals, in both right and left 
eyes (Figure 3.21).  The ERG b-wave amplitudes of the young Aipl1 h/h and 
wild-type mice increased from the age of 4 weeks up to 12-13 weeks, 
whereas the older Aipl1 h/h mice showed a decrease in amplitude during the 
same recording sessions. These observations support the fact that this is a 
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physiological phenomenon seen in young animals rather than caused by 
external factors affecting the different recording sessions. 
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Figure 3.21.  Mean ERG b-wave amplitudes of Aipl1 h/h  mice and wild type mice of 
different ages.  
 Graphs showing the b-wave amplitudes of right and left eyes of 2 groups of AIPL1 h/h mice 
(young and old) and control wild-type C56B/6 mice.  ERG recordings were taken at 5 
different time points, indicated by 5 sets of data in each graph. Each set of data in each 
group of animals were recorded at a single sitting. The x-axis indicated the age of the 
respective animals at each ERG time point.  Error bars- represent standard error of the 
mean. 
A) In the young group of Aipl1 h/h mice, an initial increase in b-wave amplitude with 
age is seen from 6 weeks up to 14 weeks of age. 
B) In the older group of Aipl1 h/h mice, b-wave amplitude is stable from 12 weeks until 
16 weeks of age. From 16 weeks onward, a decrease is observed which is due to 
the onset of retinal degeneration. 
C) In wild type mice, a similar initial increase in b-wave amplitude is seen from 5 weeks 
of age onwards up to 13 weeks of age. 
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 3.7  Effects of overexpression of Aipl1 in the 
retina. 
 
Vector-mediated expression is unlikely result in physiological levels of 
expression in target cells since this is an artificial system that is subjected to 
various external factors, and additionally may cause  expression in other cell 
types that do not normally express the transgene especially if expression is 
driven by a strong ubiquitous promoter. Therefore, there may be 
overexpression or mis-expression of a transgene following gene replacement 
therapy. In our experiments, AAV-mediated Aipl1 expression was driven by a 
CMV promoter and we observed Aipl1 expression in the RPE in addition to 
photoreceptor cells. Since Aipl1 is not known to be naturally expressed in 
RPE cells, we sought to investigate whether the anomalous expression 
would have any deleterious effects, and whether higher than normal levels of 
Aipl1 expression would be detrimental to photoreceptor cells.Six wild type 
adult C57B/6 mice received unilateral subretinal injections of the therapeutic  
AAV2-CMV-Aipl1 vector into the right eyes. These animals were assessed 
using electroretinograms at 4 weekly intervals and were sacrificed 28 weeks 
later. The treated and untreated eyes of these animals were retained and 
processed for immunohistochemistry analysis and also for light microscopy 
to look for any alterations in retinal morphology. 
 
Figure 3.22 shows representative ERG recordings from a treated and 
untreated eye of a wild type animal 24 weeks after treatment. The ERG 
traces in treated and untreated eyes have similar b-wave amplitudes and 
waveform.  Mean b-wave amplitudes of treated and untreated eyes at 
various time points were obtained and analysed statistically (Figure 3.23). At 
both flash intensities of 100 mcds/m2 and 1000 mcds/m2, there were no 
significant differences in the b-wave amplitude between treated and 
untreated eyes of these wild type mice.  These findings indicate that 
overexpression of Aipl1 in photoreceptors and RPE did not affect retinal 
function adversely. 
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Immunostaining with an AIPL1 antibody showed AIPL1 immunofluorescence 
mainly in the inner segments of photoreceptors and some in the outer 
plexiform layer in injected and uninjected wild type eyes (Figure 3.24 A). 
However in the treated eyes, there was additional immunofluorescence in the 
RPE layer although to a lesser degree, suggesting that Aipl1 was also being 
expressed in RPE cells. Light microscopy of H&E sections of treated and 
untreated retina from these wild type mice did not reveal any noticeable 
differences in terms of the overall retinal architecture and the outer nuclear 
layer thickness (Figure 3.24 B), suggesting that additional expression of 
Aipl1 in photoreceptor cells and in the RPE did not have deleterious effects 
on retinal morphology or photoreceptor cell survival. The photoreceptor cell 
nuclei in the outer nuclear layer were counted in 5 animals using the same 
method as described in section 3.5.2. Representative confocal images of the 
retina from an injected and uninjected eye of a single animal showed no 
obvious differences in the quantity of photoreceptor nuclei (Figure 3.24 C). 
Paired t-test did not reveal any significant differences between the mean 
photoreceptor cell count of eyes that received subretinal injection of AAV2-
CMV-Aipl1 and uninjected eyes (Figure 3.24 D). 
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Figure 3.22. ERG intensity series of treated and untreated eyes of a wild type 
mouse receiving unilateral subretinal injection of AAV2-CMV-Aipl1.  
The ERG was recorded at different light intensities at a single time point of 24 weeks.  
The b-wave amplitude and the shape of the trace were normal and there was no 
noticeable difference in amplitudes between the treated  and untreated eye. 
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Figure 3.23  Mean b-wave amplitude for wild type mice which received unilateral 
subretinal injection of AAV2-CMV-Aipl1.  
At flash intensities of 100 mcds/m2 and 1000 mcds/m2 , no significant difference was 
found between treated and untreated eyes (P>0.05) Error bars, ±standard error of the 
mean.  
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Figure 3.24. Morphological assessment and photoreceptor cell count of wild type mice 
receiving unilateral subretinal injection of AAV2-CMV-Aipl1. 
(A) AIPL1 immunofluorescence is seen at the mostly at inner segment of injected and 
uninjected wild type eyes, but there is also AIPL1 imunofluorescence  in the  
RPE layer of injected eyes which is not present in uninjected eyes, due to AAV2-
mediated transduction.  ONL, outer nuclear layer; INL, inner nuclear layer, is, inner 
segment. 
(B) Histological analysis of H&E retinal sections showed no noticeable difference in 
morphology and retinal architecture between injected and uninjected WT eyes. ONL, 
outer nuclear layer; INL, inner nuclear layer; is, inner segment; os, outer segment 
(C)&(D) Quantification of the outer nuclear layer did not reveal any statistical difference in 
mean photoreceptor cell count comparing injected and uninjected eyes. 
is- inner stress; os- outer segment; INL-inner nuclear segment; ONL-outer segment. 
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 3.8  Cloning of the human AIPL1 construct 
 
In the interest of future clinical application, a therapeutic construct that might 
be used in clinical studies was developed by substituting the mouse Aipl1 
cDNA within the expression cassette with a human AIPL1 cDNA.  The 
human AIPL1  transcript is 2970 bp with 6 exons providing a coding region of 
1155 bp. The 384 amino acid human AIPL protein has 3 tetratricopeptide 
(TPR) repeat domains and a polyproline rich region at the C-terminus (Figure 
3.25A). Mouse Aipl1 has a smaller transcript with a size of 1076 bp 
consisting of 6 exons and a shorter coding region of 987 bp (Figure 3.25B). 
Comparing the human AIPL1 protein to the mouse protein, an 86% identity 
was found and 96% level of similarity between the two species, indicating 
that most of the AIPL1 protein is highly conserved across species (Figure 
3.26). The highly conserved region includes the 3 TPR domains that are 
thought to be important in mediating protein-protein interactions. The human 
AIPL1 protein has an additional 56 amino acid proline-rich region at the C-
terminus that is only found in primates, thus absent in the mouse. Its role in 
protein function is not yet understood. 
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Figure 3.25 Comparison of human and mouse AIPL1 transcripts.  
Both human and mouse transcripts contain 6 exons and 3 tetratricopeptide domains encoded by 
exons 3, 4 and 5 which are highly conserved across species. The human AIPL1 transcript is 
larger than the mouse. Additionally, the human transcript contains untranslated regions at the 5’ 
and 3’ ends and a 56-amino acid polyproline sequence encoded by exon 6.  
Human  
AIPL1 
transcript 
Exon 1 Exon 4 Exon 2 Exon 5 Exon 6 Exon 3 
A 
B 
Mouse  
Aipl1 
transcript 
Exon 1 Exon 2 Exon 3 Exon 5 Exon 4 Exon 6 
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Figure 3.26. Comparative analysis of human AIPL1 to mouse Aipl1. 
Protein sequence of the human AIPL1 is compared to mouse AIPL1 which shows 
that the two proteins are 87% identical and share a 96% homology.  
Score =  606 bits (1562),  Expect = 2e-171 
Identities = 286/327 (87%), Positives = 316/327 (96%), Gaps = 0/327 (0%) 
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The human AIPL1 cDNA was cloned from commercially available retinal 
cDNA using primers which amplified the entire coding region of AIPL1.  The 
sequence of the 5’primer was GGTGAGATTATCTCCGCCTGTGCTG and 3’ 
primer was CCTCAGGGGGCTCAGTGC. A PCR product of 1215 bp was 
obtained, which contained the coding region of AIPL1 and included a part of 
the untranslated regions at the 5’ and 3’ ends. The PCR product was gel 
purified and ligated into pGemT-easy vector to produce a construct of 4232 
bp that was named pGemT-huAIPL1. The resulting plasmid was used to 
sequence the human AIPL1 cDNA to ensure that no sequence changes had 
occurred during amplification and isolation of the fragment, and also to 
ascertain the orientation of the gene in the plasmid. After the sequence was 
confirmed, we used restriction enzymes SpeI and NotI to excise AIPL1 from 
pGemT-huAIPL1 in which a fragment of 1238 bps was obtained (Figure 
3.27). We digested the parental plasmid pd10-CMV-egfp with NheI and NotI 
to extract a fragment of 6115 bp containing the AAV backbone (Figure 3.27). 
The AAV backbone was ligated with the human AIPL1 fragment to produce 
the therapeutic construct AAV-CMV-AIPL1 carrying the human cDNA (Figure 
3.28). This construct was checked by restriction digests and direct 
sequencing to ensure that the transgene within it was correct (Figure 3.29). 
Recombinant AAV2 was produced from the therapeutic construct containing 
the human transgene using the same method as described previously and 
the titre of the resultant virus suspension obtained was determined to be 5 x 
10 11 vp/ml.   
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Figure  3.27.  Cloning of human therapeutic construct.  
	  
The pGemT-huAIPL1 plasmid was digested with SpeI and NotI to 
isolate the ~1.2 kb AIPL1 fragment. The parental plasmid pd10-CMV-
egfp was similarly digested with NheI and NotI to excise the ~4.5 kb 
AAV backbone containing the ITRs. The two fragments were 
subsequently ligated together to form the therapeutic construct AAV-
CMV-AIPL1. 
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Figure 3.29. Check restriction digests 
of AAV-CMV-AIPL1.    
 The therapeutic construct AAV-CMV-
AIPL1 was digested with restriction 
enzymes to check that appropriate 
fragment sizes were obtained. In lane 1, 
the construct was digested with XhoI 
and the expected fragments of  ~ 4.9 kb 
and 850 bp were obtained. In lane 2, 
the construct was digested with SmaI 
and the expected fragments of ~ 3.4 kb, 
1.6 kb and 720 bp were obtained. 
 
Figure 3.28. Map of the construct 
AAV-CMV-AIPL1.                                               
The human transgene AIPL1 was 
cloned downstream of the CMV 
promoter fragment, followed by SV40 
polyA signal and is flanked by two viral 
ITRs . The total size of the construct 
was 5819 bp. 
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3.9  Assessment of function following AAV2/2-
mediated expression of human AIPL1 in the Aipl1 h/h 
mouse retina. 
 
To test whether any beneficial effects might be obtained by the expression of 
a human AIPL1 transgene, a group of Aipl1 h/h mice (n=10) received a 
subretinal injection of AAV2-CMV-AIPL1 in one eye, leaving the other eye to 
serve as an internal control using the same injection method as described 
before. All injections were performed by the same individual as for previous 
experiments. The animals were subjected to regular electrophysiological 
assessments in the form of scotopic ERG recording at various time points, 
starting from 4 weeks post injection onwards. The follow up period in these 
animals included long term time points up to a year to see whether any 
beneficial effects were sustained.ERG recordings were obtained 
simultaneously from both eyes using the similar method described 
previously. Analysis of functional outcome was performed on scotopic ERG 
b-wave amplitudes at flash intensities of 100 mcds/m2  and 1000 mcds/m2 .    
 
Figure 3.30 shows the mean scotopic ERG  a-wave and b-wave amplitudes 
of Aipl1h/h mice injected with AAV-CMV-AIPL1. Treated eyes consistently 
maintained higher mean ERG b-wave amplitudes compared with untreated 
eyes throughout the follow up period at flash intensities of 10 mcds/m2 amd 
1000 mcds/m2 (Figure 3.30 A and B). There was statistically significant 
difference between treated and untreated eyes from 16 weeks post injection 
onwards up to 50 weeks (paired Student’s t-test p ≤ 0.05). At the final time 
point of 50 weeks post injection, the mean b-wave amplitude in treated eyes 
(n=10, mean = 194.6 ± 25.2 µV) was 57% higher than the mean b-wave 
amplitude in untreated eyes (n=10, 123.98 ± 20.42 µV) at a flash intensity of 
1000 mcds/m2. AAV-CMV-AIPL1 treated eyes also showed significantly 
higher a-wave amplitudes than in untreated eyes between 16 and 50 weeks 
post injection (p ≤ 0.05) (Figure 3.30 C).  
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Figure 3.30 A & B. Mean ERG b-wave amplitudes for Aipl1 h/h mice following 
subretinal injection of AAV2-CMV-AIPL1. 
At flash intensities of 100 mcds/m2  (A) and 1000 mcds/m2 (B), the mean b-wave 
amplitudes in the treated eye are significantly higher than those of the untreated eye 
from 16 weeks onwards. At 50 weeks post injection, there was still a significant 
difference (p ≤ 0.05) between the treated and untreated eye indicating beneficial long 
term effect of the treatment. Statistical analysis was performed using paired t-test. Error 
bars , ± SEM.	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Figure 3.30 C. Mean ERG a-wave amplitudes for Aipl1 h/h mice following subretinal 
injection of AAV2-CMV-AIPL1.  
AAV-CMV-AIPL1 treated eyes showed significantly higher a-wave amplitudes than 
untreated eyes between 16 and 50 weeks post injection (p ≤ 0.05). Error bars, ±SEM. 
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3.10  Morphological analysis following AAV2/2-
mediated expression of human AIPL1 in the Aipl1 h/h 
mouse retina.  
 
3.10.1  Light and electron microscopy of retinal sections.  
 
To determine the effects of AAV2/2-mediated human AIPL1 gene expression 
in Aipl1 h/h retina, the retinal morphology was assessed by light microscopy 
and electron microscopy. Treated eyes had received double subretinal 
injections of the therapeutic vector in the superior and inferior hemisphere of 
the eye.  Animals (n=2) were sacrificed 52 weeks after treatment, the eyes 
were enucleated and processed for semithin and ultrathin sections (methods 
described in sections 2.9.6). Prior to fixation and embedding, the eyes were 
carefully orientated using a stitch through the conjunctiva on the nasal aspect 
of the eyes. The eyes were fixed in Karnovsky’s fixative, and the cornea and 
lens were removed the next day. Using the nasal suture, the eyes were 
embedded sagittally so that sectioning occurred in the vertical plane and the 
retinal sections contained the superior and inferior retina which were the 
areas of treatment. Semithin sections (0.7 µm thick) were cut from treated 
and  untreated eyes and stained with toluidine blue for light microscopy. 
Ultrathin sections (0.07 µm thick) were cut of the corresponding areas and 
following sequential contrast processing, they were analysed using a 
transmission electron microscope. 
 
For histological analyses, semithin sections of treated and untreated eyes 
were examined with light microscopy (Figure 3.31). The untreated retina 
showed substantial loss of photoreceptor cell nuclei, disorganization and 
shortening of the outer segments (Figure 3.31 A). In contrast, the retina of 
treated eyes had considerably more photoreceptor cell nuclei; since there 
was an evidently thicker outer nuclear layer compared with untreated eyes 
(Figure 3.31 B). The photoreceptor outer segments were longer and more 
densely packed and arranged in a more organized fashion. The outer 
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nuclear layer was uniformly preserved throughout the whole circumference of 
the treated eye.  
 
 Ultrastructurally, substantial differences were seen in the morphology of 
photoreceptor OS. In the untreated retina, the number of photoreceptor OS 
were substantially reduced, markedly shortened and form disorganized 
rounded whorls (Figure 3.32 A). The OS disk membranes contained inside 
these photoreceptor OS were also disorganized, less tightly packed and 
there was a loss of the normal laminar arrangement (Figure 3.32 D). 
Vacuolar inclusions containing debris material was present in the IS region of 
the retina (Figure 3.32 D). The contact between the RPE and photoreceptor 
OS was also abnormal and reduced. Intervening vacuoles could be seen 
between OS tips and RPE cells. In contrast, in treated Aipl1 h/h retina, 
photoreceptor OS were elongated and the membranous OS disks had a 
regular and densely packed laminar arrangement (Figure 3.32 B), that was 
similar to that seen in wild-type mice (Figure 3.32 C). The photoreceptor OS 
in the treated retina maintained close contact with the RPE and showed 
normal interdigitation with the microvilli (MV) of RPE (Figure 3.32 E). The IS 
also appeared more normal and contained numerous mitochondria (Figure 
3.32 E). 
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Figure 3.31. Semithin light micrographs of treated and untreated retina 52 weeks following  
subretinal injection of AAV2-CMV-AIPL1. The samples were taken from a single Aipl1 h/h 
animal. Higher magnification images are shown in the centre. 
 
(A) Semithin light micrographs of representative Aipl1 h/h retina treated 52 weeks after 
subretinal injection of AAV2-CMV- AIPL1 shows preservation of photoreceptors. This is seen 
throughout the superior and inferior sections of the retina which are the treated areas. On 
higher magnification, it is clear that the outer nuclear layer in the treated retina is significantly 
thicker and the photoreceptor outer segments are longer and densely packed, indicating that 
AIPL1 replacement prolongs photoreceptor survival.  
 
(B) Semithin light micrographs of the corresponding untreated Aipl1 h/h retina shows loss of the 
outer nuclear layer thickness throughout the entire retina. Higher magnification image shows 
that loss of photoreceptor nuclei and also outer segment length and density 
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Figure 3.32. Electron microscope (EM) analysis of retinal tissue samples taken from a single 
Aipl1 h/h mouse at 52 weeks after subretinal injection of AAV2-CMV-AIPL1 (light microscopy 
of retina from the same animal is shown in Figure 3.33).  
(A)   In untreated Aipl1 h/h retina, the photoreceptor outer segments (OS) appear 
shortened, rounded and folded over. The membranous disks inside the outer segments 
were disorganized and formed whorls instead of stacks. 
(B)      Treated Aipl1 h/h retina shows relatively well organised and densely packed outer 
segment membranous disks, resembling those of wild-type retina shown in (C).  
(C)      Wild type mouse retina is shown for comparison. The outer segments in wild type 
retina is long containing membranous disks organized in a laminar fashion. 
(D)      Compared to treated retina, the untreated retina has very few outer segments and 
photoreceptor cell nuclei (PR). The inner segments are interrupted by multiple debris-
filled vacuoles (D). 
(E)      Outer segments and photoreceptor cell nuclei in the treated Aipl1 h/h retina are 
numerous and show normal interdigitation with the RPE microvilli (MV), indicating that 
there is normal functional interactions between the outer segments and RPE. The inner 
segments (IS) are also densely packed and contain numerous mitochondria. 
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3.10.2    Quantification of the outer nuclear layer in Aipl1 
h/h mice following subretinal injection of AAV2-CMV-AIPL1 
 
To assess the effect of AAV-mediated human AIPL1 gene replacement in 
Aipl1 h/h retina and also to determine whether there is sustained and long 
term photoreceptor cell survival, quantification of the outer nuclear layer was 
performed. Six of the Aipl1 h/h mice that received unilateral subretinal 
injection of AAV2-CMV-AIPL1 were sacrificed at 50 weeks post injection and 
cryosectioned. Centrally located retinal sections that passed through the 
optic nerve and spanned the treated areas in superior and inferior 
hemispheres of the retina were selected for outer nuclear layer 
quantification. The retinal sections were stained with propidium iodide and 
imaged with confocal microscopy. The method of quantification was the 
same as described in the previous section (section 3.5.2). The photoreceptor 
cell count for each eye was determined by averaging the cell counts from 
each confocal image of the eye. To control for inter-animal variation in the 
rate of degeneration, a paired t-test was performed comparing the mean 
photoreceptor cell count in the treated and untreated eyes.  
 
Representative confocal images of retinal sections from treated and 
untreated eyes of a single animal at 50 weeks post injection are shown in 
Figure 3.33 A. The outer nuclear layer in the treated retina is noticeably 
thicker than the contralateral untreated eye. Paired analysis of the mean 
photoreceptor cell count of all the treated and untreated eyes in the group of 
animals (n=6) showed that treated eyes had 73% more photoreceptor cells 
than untreated eyes at 50 weeks post injection (p=00006). Mean 
photoreceptor cell count in treated eyes was 463.5 ± 19.8, while in untreated 
eyes the mean photoreceptor cell count was 267.4 ±13.9 (p = 0.00006) 
(Figure 3.33 B). It has been reported that approximately half of the 
photoreceptor cells are lost by 8-9 months in the Aipl1 h/h mouse. This is 
evident in untreated Aipl1 h/h eyes where the outer nuclear layer cell count is 
approximately half of that in wild type. The mean photoreceptor cell count in 
treated eyes were also less than in age-matched wild type eyes (Figure 3.33 
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B),  indicating that there was still ongoing degeneration in the treated eyes.  
However, this difference did not achieve a level of significance (p=0.05). 
Treated eyes at 50 weeks post injection had 13% fewer photoreceptor cells 
than wild type eyes, while untreated eyes had lost about 50% of 
photoreceptor cells compared with wild type. Hence, despite evidence of 
ongoing degeneration, AAV2-mediated expression of the human AIPL1  
have slowed down the rate of degeneration in the treated eyes. This was a 
consistent result in all of the animals that were assessed, as the 
photoreceptor cell count in the treated eye of every animal was significantly 
higher than in the untreated eye (Figure 3.33 C).  
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Figure 3.33. Quantification of the outer nuclear layer (ONL) in Aipl1 h/h mice following 
subretinal injection of AAV2-CMV-AIPL1. 
 
(A)Representative confocal images of retinal sections taken from treated and untreated eyes 
from a single animal at 50 weeks following injection with AAV2-CMV-AIPL1. The treated retina 
has a substantially thicker ONL compared with the untreated retina 
(B)Quantification of the photoreceptor nuclei in the ONL showed that the mean photoreceptor 
cell count in treated eyes (n=6) were significantly higher that untreated eyes (p=0.00006). 
However the level of ONL count in treated eyes were lower that those of wild type eyes. 
(C)There was consistency in the preservation of photoreceptor survival across all the animals 
that were assessed. In each mouse, the treated eye has significantly higher ONL count than the 
untreated eye. 
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3.11  Discussion 
 
In this chapter a detailed assessment of the duration and extent of the 
morphological rescue and functional benefit following AAV-mediated gene 
replacement therapy in Aipl1 h/h mouse was presented. The preservation of 
retinal function and morphology was observed up to a year. This is the most 
significant rescue of a retinal degeneration to date. It is also the first study to 
demonstrate effective long term rescue for a photoreceptor-specific defect 
which are generally difficult to treat. The results presented provide further 
evidence to support gene therapy approaches for the treatment of severe 
inherited retinal dystrophies. 
 
There are three goals that gene-based treatments for autosomal recessive 
retinal conditions should aim to achieve; the expression of a normal copy of 
the defective gene leading to the production of the key protein, restoration of 
function to disabled cells and ultimately the prevention of progressive cell 
death or retinal degeneration as a result. To produce an effective long-term 
therapy, degeneration must be prevented. Our therapy addressed the first 
two goals where by subretinal delivery of AAV2-CMV-Aipl1 and AAV2-CMV-
AIPL1 resulted in increased production of AIPL1 in photoreceptor inner 
segments and subsequently the restoration of normal cellular biology and 
function that was substantiated by the translocation of PDE from inner to the 
outer segments. As a result, retinal degeneration was significantly slowed. A 
concomitant stabilization of ERG amplitudes was also seen in treated eyes 
following subretinal injection of the therapeutic vector. ERG b-wave 
amplitudes were significantly higher in eyes treated with AAV2-CMV-Aipl1 or 
AAV2-CMV-AIPL1 compared with untreated, PBS-injected or AAV2-CMV-gfp 
injected eyes. The presence of OPs on ERG traces of treated eyes implies 
appropriate retinal function.  After treatment with the therapeutic vectors, the 
pattern of the ERG response to a series of increasing stimuli resembled that 
of normal animals, with increasing b-wave amplitudes and decreasing b-
wave latencies indicating successful functional rescue at the time point 
assessed. We observed improved photoreceptor cell survival, preservation of 
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outer segment morphology and stabilization of retinal function. Both 
therapeutic constructs, one containing the murine Aipl1 cDNA and the other 
containing the human AIPL1 cDNA were similarly effective. This is not 
surprising since AIPL1 is highly conserved between species; there is 96% 
similarity and 86% identity between the murine and human cDNAs. 
 
AAV-mediated gene replacement therapy resulted in significant preservation 
of photoreceptors and retinal function in Aipl1 h/h mice one year after 
treatment – the latest time point examined. This is the most sustained rescue 
of a photoreceptor-specific gene defect reported to date. Previous gene 
replacement therapy studies targeting photoreceptor cell defects did not 
include such long term time points. [50][463][14][363][496]  The most 
sustained rescue reported previously was following AAV-mediated gene 
replacement therapy in an RPGRIP mouse model [363]. This study 
demonstrated functional and histological improvement for up to 5 months. 
 
Although significantly better than in untreated eyes, AAV-mediated gene 
replacement did not completely prevent loss of photoreceptor cells. The 
mean ERG b-wave amplitude in AAV2-CMV-Aipl1-treated eyes at 7 months 
after treatment was approximately 85% that in wild type mice at that age 
(data not shown). The mean b-wave amplitude in untreated Aipl1 h/h eyes at 
7 months however was about 60% of wild type, indicating that the 
degenerative process was very slow. Morphologically, at 28 weeks following 
injection, treated eyes show a 14% loss of photoreceptor cells from age-
matched wild type eyes, while untreated eyes showed 40% loss from wild 
type eyes. In animals that were treated with the human construct, treated 
eyes at 50 weeks following treatment showed a 13% loss of photoreceptor 
cells from wild type levels while untreated eyes had approximately 50% less 
photoreceptor cells than wild type eyes.  Although retinal degeneration was 
not completely prevented following treatment, photoreceptor loss was 
significantly delayed with the rate of degeneration substantially reduced in 
treated eyes to the magnitude of 3-4 fold. Furthermore, in animal which were 
treated with the human construct, the difference in photoreceptor cell count 
between treated eyes at 50 weeks post injection and wild type did not reach 
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statistical significance (p=0.05). Considering that transduction of the retina is 
usually incomplete following subretinal injections, this suggests that the 
expression of AIPL1 in treated areas has a substantial effect in arresting the 
degeneration. 
 
There may be several reasons why photoreceptor degeneration proceeds 
despite treatment. Firstly, only two-thirds of the retina, at most, is transduced 
following double subretinal injections into an eye and hence the transduction 
efficiency have not have been adequate. Considering that the transduction 
efficiency of AAV2/2 is not 100 %, the final area of the retina that is 
transduced is likely to be about 50-70 % and may have been insufficient to 
ultimately prevent degeneration in treated areas. Secondly, the late onset of 
AAV2/2-mediated expression compromises its efficacy. By the time maximal 
transgene expression is attained, the retinal degeneration in the Aipl1 h/h 
mouse may be already significantly advanced. The animals were injected at 
P28 and AAV2/2-mediated transgene expression would be expected to 
commence 3-4 weeks later.  ERG recordings from 8 week old Aipl1 h/h mice 
are already lower than age-matched wild type mice[282], suggesting that 
damage to photoreceptors has commenced by the time the treatment takes 
effect.  The residual one-third of the retina consisting of degenerating 
photoreceptor cells may further contribute to ongoing loss of photoreceptor 
cells by creating negative impact on photoreceptor survival in treated 
regions. Changes in degenerating photoreceptors are likely to generate a 
microenvironment that has a negative influence on the survival of healthy 
cells. The phenomenon of non cell- autonomous degeneration in which the 
loss of trophic factors normally produced from rods [185][413]  or the release 
of toxic substances from rod cell death[226][405] has been frequently 
described and observed in other retinal dystrophies such as retinitis 
pigmentosa . In these conditions, cone loss is invariably seen even though 
the primary genetic defect and cell death is in rod photoreceptors. Lastly, the 
levels of expression in terms of gene copies per photoreceptor cell that is 
mediated by AAV2 may have been insufficient, despite the use of a 
ubiquitously expressed constitutive promoter that drives strong transgene 
expression. AAV2/2 vectors are known to target RPE and photoreceptor 
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cells, with a higher tropism for RPE cells than photoreceptors. In comparison 
to other AAV pseudotypes such as AAV5 and AAV8, the maximal levels of 
transgene expression from  AAV2 vectors known to be lower as a result of 
fewer copies of the transgene per cell [348]. Hence, on a single cell basis, 
the expression levels mediated by AAV2 may not be adequate to achieve full 
correction of the cellular defect or restore normal cellular function and 
subsequently stem the retinal degeneration process.  
	  
Interestingly, the morphological rescue of Aipl1 h/h retinas was better than 
might have been expected given the relatively modest functional 
improvement in ERG amplitudes between treated and untreated eyes. This 
may be due to the unusual phenotype of the Aipl1 h/h mice. It has been 
previously shown that Aipl1 h/h rods have a higher sensitivity to light 
compared with normal rods photoreceptor cells, and require fewer photons to 
elicit a response[282][295]. They manifest supra-normal ERG when young, 
presumable because of a larger than normal dark current due to higher free 
cGMP levels. The restoration of functional AIPL1 in Aipl1 h/h rods would 
therefore, result in correction of this abnormality so that photoresponses 
become more similar to that of wild type photoreceptors with a reduction in 
the altered sensitivity of Aipl1 h/h rods. Hence, it is likely that the relative 
modest difference in ERGs compared with difference in photoreceptor 
preservation seen after treatment is partly due to a reduction in ERG 
amplitudes as a result of a reduction in photoreceptor hypersensitivity 
following gene transfer. 
 
An initial increase in ERG amplitudes was observed in treated and untreated 
eyes as well as in the wild type control group.  This initial increase occurred 
from 4 weeks post injection up to about 8 weeks post injection. Similar 
observations of ERG amplitude rise was also seen in the control experiment 
which recorded ERGs from unprocedured Aipl1 h/h mice of various ages and 
wild type mice. This confirmed that the phenomenon was unrelated to the 
treatment or the surgical procedure. A physiological increase in ERG 
responses have been described in young mice, normally occurring from birth 
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up to postnatal age of 12 weeks[209].  It is thought to reflect the normal 
development in mice.  In AAV-CMV-gfp treated Aipl1 h/h mice, ERG b-wave 
amplitudes in injected eyes were lower than in uninjected eyes. This may be 
due to a particular batch of viral prep that contained impurities that might 
have attenuated the ERG responses, since the laboratory has extensive 
experience with intraocular administration of AAV vectors and has rarely 
observed toxic effects following injection of vectors expressing gfp. 
 
A number of studies have suggested various roles for AIPL1 in the retina. It 
was originally suggested that AIPL1 may have a role in development as a 
result of its putative interactions with NUB1 [7], but this is unlikely since both 
Aipl1 -/-  and  Aipl1 h/h have normal architecture prior to the onset of 
degeneration [282,391]. Biochemical studies using a yeast two-hybrid screen 
suggested AIPL1 may have a general role in enhancing the protein 
farnesylation in the retina. Among the retinal proteins known to be 
farnesylated are PDE α-subunit, γ-transducin, and rhodopsin kinase. 
However, this hypothesis did not appear to be supported by the findings that 
levels of rhodopsin kinase and transducin were unaffected  in Aipl1 -/- mice 
[391]. Further assessment of candidate retinal proteins in the Aipl1 -/- and 
Aipl1 h/h mouse found that cGMP-PDE was the only protein in which all 
three α,ß and γ subunts were absent or reduced in levels, suggesting that 
cGMP-PDE is a specific client protein of AIPL1[282][391]. This study 
confirms that  that AIPL1 and cGMP-PDE are intricately linked. We found 
that cGMP-PDE, in particular the β-subunit of PDE was mislocalized to 
photoreceptor inner segments in untreated AIPL1 h/h eyes when the animals 
were examined at 28 weeks following subretinal injection in the other eye. In 
the contralateral treated eyes of these animals, the β-PDE signal was 
present in the photoreceptor outer segments suggesting that AIPL1 could 
indeed be a molecular chaperone ensuring PDE translocation to the outer 
segments. The fact that photoreceptor cell loss in the Aipl1 h/h mouse 
proceeds slowly and outer segments are present for most of the 
degeneration makes it possible to compare and localize β-PDE expression in 
the outer segments of treated and untreated eyes. In the Aipl1 -/-  mouse, 
retinal degeneration is too rapid for this analysis since most of the 
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photoreceptor cells and outer segments have been lost in the untreated eye 
by the time vector-mediated expression of AIPL1 commences in the treated 
eye. Hence AIPL1 may protect PDE subunits from proteosomal degradation 
or assist in the assembly or folding of the PDE holoenzyme whereby only 
properly protein is transported to the outer segments. The exact molecular 
mechanism and relationship between AIPL1 and cGMP PDE remains to be 
elucidated. Precise regulation of cGMP synthesis and cGMP PDE 
degradation is critical to the health of photoreceptors and mutations which 
disrupt the balance between the two, result in dysregulation and 
degeneration of these cell [127]. Mutations in the PDE6B gene encoding the 
ß-subunit of cGMP PDE lead to abnormal increases in cGMP and 
subsequent photoreceptor death. Mutations in retGC1 impair synthesis of 
cGMP, leading to a state equivalent to sustained photo-excitation and 
photoreceptor cell death [127][428][366]. Similarly, one of the most important 
consequences of mutation in AIPL1 is likely to be the effect on cGMP PDE 
levels, leading to photoreceptor dysfunction and rapid retinal degeneration. 
This however, may not be the only function of AIPL1 in the retina or the  
only mechanism of cell death due to loss of AIPL1. Further studies are 
required to fully elucidate the exact role or AIPL1 in the retina. 
 
In patients, AIPL1 defects present as a clinical spectrum and present with 
LCA as well as cone-rod dystrophy and juvenile retinitis pigmentosa 
[103][442]. This variability in phenotype may be explained by the nature of 
the mutations. To date, 20 disease-causing mutations in AIPL1 have been 
reported (HGMD; www.hgmd.org). Out of these, five of them are likely to 
lead to complete loss of AIPL1 function; four are nonsense mutations 
resulting in a severely truncated protein and one affects the splice site in 
intron 2 leading to a frame shift. The other mutations comprise of missense 
mutations in the N-terminal or the tetratricopeptide domains and deletions in 
the C-terminal region. In vitro assays have shown that many of these 
mutations did not lead to loss of AIPL1 expression or abolished protein 
function completely [7,393,476]. It is also likely that there are other variants 
that give rise to an altered protein with reduced function. Hence, it is possible 
that AIPL1 mutations results in a partial as well as complete loss of function 
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of the protein. Efficient rescue of the Aipl1 h/h mouse suggests that patients 
with mutations that do not lead to complete loss of AIPL1 function might 
respond particularly well to gene replacement therapy.  
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4.  Gene replacement therapy in rapid 
retinal degenerations due to AIPL1 
deficiency 
 
 
4.1   Treatment of retinal degeneration in Aipl1 
h/h murine model under light acceleration 
 
Following evidence of significant rescue in the Aipl1 h/h mouse using AAV2/2 
vector encoding both the murine and human AIPL1 gene, we proceeded to 
determine whether we can rescue photoreceptor cells in a faster 
degeneration using AAV-mediated gene replacement  and by accelerating 
the photoreceptor cell loss in Aipl1 h/h mice. The rate of retinal degeneration 
in the Aipl1 h/h mice has been observed to increase by 2-3 fold by keeping 
the animals in constant white light illumination (personal communication from 
Tiansen Li, Massachussetts Eye and Ear Infirmary). The mechanism of the 
acceleration of retinal degeneration under light in these mice is not known 
but is thought that this could be related to the light-induced increase in 
mitochondria free radical production and oxidative stress. To ensure that a 
more rapid onset of gene expression from the AAV vector was obtained, we 
produced AAV2/8 pseudotyped vector containing the murine Aipl1 cDNA 
under the control of the ubiquitously active cytomegalovirus (CMV) promoter. 
The therapeutic construct was developed in Chapter 3 (section 3.8) by 
cloning the murine Aipl1 cDNA between the ITRs of the AAV2 vector 
genome, and we packaged this therapeutic construct using AAV8 capsid to 
produce AAV2/8-CMV-Aipl1. The murine cDNA was chosen to give the best 
possible chance of a rescue and to reduce the risks of rejection and protein 
incompatibility. 
 
As is the case with all viral vector systems, the choice of an appropriate 
promoter is important to achieve efficient expression of a transgene. The 
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CMV promoter is a strong viral promoter that is ubiquitously active. AAV2/8-
CMV-Aipl1 was produced using a triple plasmid transfection method in 293T 
cells (described in Chapter 2) and purified using ion exchange 
chromatography. The resulting virus preparation was concentrated with 
Centricon 10 columns (Millipore, Bedford, MA), washed in PBS, and 
concentrated again to a volume of approximately 100-150 µl. Control AAV2/8 
virus was also produced from the AAV-CMV-egfp construct (described in 
Chapter 3) to generate AAV2/8-CMV-egfp vector. This control vector will 
serve to verify AAV2/8 expression in photoreceptor cells and to control that 
any beneficial effect is due to the expression of the transgene rather than the 
administration of an AAV vector. Viral particle titres were determined by 
comparative dot-blot DNA prepared from purified viral stocks and defined 
plasmid controls. Purified vector concentrations used for all experiments 
were of 1-2 X 1012 viral particles/ml (Figure 4.1).   
 
A total of 23 Aipl1 h/h mice received subretinal injections of AAV2/8-CMV-
Aipl1 at postnatal week 4. As in previous experiments, subretinal injections of 
the vector were administered to each treated eye in the superior and inferior 
hemisphere; each subretinal injection amounted to a volume of 1.5 µl. Only 
one eye in each Aipl1 h/h mouse was treated, leaving the contralateral eye to 
serve as an internal control. At 1 week after subretinal injection, the 
procedured mice were moved to a room with constant ambient white lighting. 
Care was taken to ensure all cages received equivalent amounts of light 
exposure, by placing them on racks of equal height and at the same level to 
each other. All cages consisted of transparent perspex plastic material to 
allow maximal light penetration into the cages and any large housing material 
was removed from the cages. Another group of Aipl1 h/h mice (n=9) received 
subretinal injections of the control vector AAV2/8-CMV-egfp while a group of 
C57BL/6 mice (n=10) received subretinal injections of the therapeutic vector. 
These control groups of animals were also subjected to the same conditions 
as the procedured Aipl1 h/h mice and were placed into constant white 
ambient light conditions at 1 week following subretinal injections. All animals 
were examined histologically to investigate the effects of treatment on retinal 
morphology after period of 5 months. To follow the course of degeneration 
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and the effects of gene replacement, retinal function was assessed using 
ERG recording at regular intervals over the same period of time. 
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4.2  Effects of AAV2/8-mediated Aipl1 
expression on retinal function in light accelerated 
Aipl1 h/h retina. 
 
The effects of AAV2/8-mediated gene replacement was evaluated in Aipl1 
h/h mice (n=23) that received subretinal injection of AAV2/8-CMV-Aipl1 in 
one eye at 4 weeks postnatally. These mice were place in continuous white 
light illumination at 1 week following subretinal injection, to accelerate the 
retinal degeneration. Retinal function was assessed through scotopic ERG 
analysis recorded simultaneously from the treated and untreated eyes of 
treated Aipl1 h/h mouse. To determine whether preservation of retinal 
function was achieved as a result of treatment with the therapeutic AAV2/8-
CMV-Aipl1 vector, ERG intensity series were performed on each treated 
Aipl1 h/h mouse at regular intervals of 4-6 weeks following subretinal 
injection until the final time point of 21 weeks. Before recording the ERGs, 
the animals were dark adapted for at least 16 hours.  
 
After 3 months of constant light, ERG amplitudes in untreated eyes 
decreased to half that in wild type mice (Figure 4.2).   Although the retinal 
degeneration progressed at a faster rate, photoreceptor rescue was still 
obtained. When the group of AAV2/8-treated Aipl1 h/h mice that underwent 
light acceleration was compared with the AAV2/2-CMV-AIPL1 treated mice 
Aipl1 h/h mice that did not undergo constant light exposure, larger 
differences between treated and untreated eyes in terms of functional and 
morphological (described in Section 4.4) outcome measures were obtained 
in the light exposed animals. Figure 4.3 shows an ERG intensity series of a 
procedured animal recorded simultaneously from the treated and untreated 
eye at 2 different time points.  At 5 weeks post-injection, differences between 
the ERG amplitudes in treated eyes and untreated eyes were already seen; 
treated eyes had higher amplitudes than untreated eyes. By 21 weeks, the 
ERG responses were lost in the untreated eye, while the treated eye 
maintained substantial ERG amplitudes and showed increasing responses 
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elicited by the increasing light stimuli. Normally shaped waveforms, similar to 
that of wild type mice, were recorded from treated eyes while from untreated 
eyes, the ERG was virtually undetectable. Oscillatory potentials on the 
ascending limb of the ERG b-wave and increasing in size with brighter stimuli 
were seen in treated eyes but not in untreated eyes, indicating an overall 
improvement of retinal activity.  
 
Maximal rod/cone responses were measured at flash intensity of 1000 
mcds/m2 at  4-6 weekly intervals following treatment in the light accelerated 
Aipl1 h/h mice over a period of 5 months. Figure 4.4 shows ERGs at a single 
flash intensity of 1000 mcds/m2 obtained at different time points from a single 
animal treated with AAV2/8-CMV-Aipl1 and subjected to constant light 
exposure. The traces were recorded simultaneously from the injected (right) 
and uninjected (left) eye. Over time, the ERG amplitudes in the untreated 
eye decreased rapidly and disappeared completely by 21 weeks. The ERG 
amplitudes in the treated eye was maintained throughout the follow-up period 
and remained substantially higher than in untreated eye at the final time point 
of 21 weeks after treatment, suggesting that photoreceptor survival was 
prolonged following treatment with AAV2/8-CMV-Aipl1.  
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The average b-wave amplitudes of the ERG recordings were evaluated 
statistically by using a paired Student’s t-test (Figure 4.5).  At 2 weeks post 
injection, ERG b-wave amplitudes in untreated eyes appeared higher than in 
treated eyes, although this difference was not statistically significant. This 
observation may be due to a temporary negative effect from the subretinal 
detachment induced by the procedure and is a well described phenomenon. 
Between 2 weeks and 5 weeks post injection, there was a large decrease in 
ERG amplitudes, indicating an acceleration of the retinal degeneration as a 
consequence of continuous light exposure. The apparent improvement in the 
ERG amplitudes between weeks 5 and 14 was thought to be due to variation 
occurring between recording sessions. 
 
The AAV2/8-CMV-Aipl1 treated eyes showed significantly higher b-wave 
amplitudes than the contralateral untreated eyes at time points up to 21 
weeks after injection (Figure 4.5). Compared with the Aipl1 h/h mice treated 
with AAV2/2 vector in the previous chapter, the difference in mean b-wave 
amplitude between treated and untreated eyes was greater in mice that 
received AAV2/8 therapeutic vector. Statistical significance was also 
observed at much earlier time points (9 weeks onwards) in this group. At 
both flash intensities of 100 mcds/m2 and 1000 mcds/m2, mean b-wave 
amplitudes in treated eyes were significantly higher than in untreated eyes 
from 9 weeks following injection onwards (p<0.05). At 21 weeks post-
injection, mean b-wave amplitude at flash intensity of 1000 mcds/m2 in 
treated eyes (n=20; mean = 87.3 ± 5.4 µV) was 130% higher than in 
untreated eyes, p=0.0006 (n=20, mean = 41.5  ± 4.2 µV). Analysis of the 
mean ERG a-waves showed that treated eyes also had significantly higher a-
wave amplitudes compared with untreated eyes (Figure 4.6). Statistically 
significant differences were seen at earlier time points from 5 weeks post 
injection onwards up to the last time point of 21 weeks post injection. At 21 
weeks post injection, mean ERG a-wave in treated eyes was 16.8 ± 2.3 μV 
(n=20) while in untreated eyes it was 8.9 ± 2.8 μV (n=20). 
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4.3  Effects of AAV2/8-mediated Aipl1 
expression on retinal morphology in light accelerated 
Aipl1 h/h retina. 
 
Morphological analysis was performed to investigate the effects of treatment 
on photoreceptor cell loss over time. Specifically, the effects on retinal 
structure and photoreceptor ultrastructure following treatment was examined 
using light microscopy of semithin sections and electron microscopy 
respectively. Light accelerated Aipl1 h/h mice that received subretinal 
injection of AAV2/8-CMV-Aipl1 were sacrificed at 10 weeks and 21 weeks 
post injection (n=2) and semithin sections were taken throughout the each 
treated and untreated eye. To assess whether the rescue effect was 
localized to areas adjacent to the injection sites, sagitally orientated cross 
sections of the eye were taken to encompass the superior and inferior 
hemispheres of the retina, which were the sites of subretinal injections. Eyes 
were taken, carefully orientated with a stitch through the conjunctiva and 
fixed in Karnovski fixative. Cornea and lens were removed the following day 
and the eyecups were processed for electron microscopy (EM). Semithin 
sections (0.7 µm thick) were taken and stained with toluidine blue. For 
electron microscopy analysis, treated areas were identified by orientating 
eyes so that superior and inferior sections of the retina were examined and 
70 nm thick ultrathin sections were then taken of these areas. Eyes were 
also taken from age-matched wild type mice for semithin and ultrathin 
sections as positive controls.  
 
Comparison of treated and control eyes showed a reduction in the loss of 
photoreceptor cells in treated eyes at different time points (Figure 4.7). At 10 
weeks following treatment with AAV2/8-CMV-Aipl1, a substantial difference 
can already be seen between treated and untreated eyes. Comparing the 
midzone area between the ora serrata and optic nerve ie. approximate 
equivalent areas in treated and untreated eyes, the number of photoreceptor 
cells in treated eyes was substantially greater than in untreated eyes at 10 
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weeks post injection. This difference became more marked with time. At 21 
weeks, untreated eyes showed an absence of the outer nuclear layer, no 
photoreceptor cells or outer segments could be found and the inner nuclear 
layer was seen lying adjacent to the RPE layer (Figure 4.7). In contrast, 
treated eyes showed preservation of the outer nuclear layer; photoreceptor 
cells were found in treated eyes along with numerous outer segments as 
seen on light micrographs (Figure 4.7).  To assess the overall effect of 
treatment on the rate of degeneration, we examined the morphology of the 
whole retina in the vertical meridian from the ciliary body in the superior 
hemisphere to the equivalent in the inferior hemisphere of treated and 
untreated eyes (Figure 4.8). Untreated eyes showed complete loss of the 
ONL by 21 weeks and this finding was uniform throughout the eye (Figure 
4.8). On the other hand, the preservation of ONL in treated eyes appeared to 
be present throughout the whole of the eye as depicted in the sagittally 
orientated cross sections of the eye, indicating that the effect was not a 
localized or patchy phenomenon (Figure 4.8).  
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Ultrastructural features of treated and untreated eyes were examined on 
electron microscopy. AAV2/8-treated eyes in Figure 4.9A showed presence 
of numerous OS, although these were substantially shorter compared with 
those of animals that did not undergo light exposure in Chapter 3 (section 
3.10). The membranous disks in these OS were dense but less well-
organized. The close relationship between OS tips and the RPE was 
maintained and the OS tips were seen invaginating the microvilli (MV) 
(Figure 4.9A).  Photoreceptor cells and IS in treated eyes had normal 
morphology. Numerous mitochondria could be seen in the metabolically 
active IS (Figure 4.9B). In contrast, no photoreceptor cells or OS could be 
seen in untreated eyes (Figure 4.9C and D).  The INL and bipolar cells were 
seen to lie adjacent to the RPE. There was loss of RPE microvilli and many 
intervening debris-containing vacuoles (D) could be seen in the untreated 
retina (Figure 4.9D).  
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4.4  Morphometric analysis of light accelerated 
degeneration in Aipl1 h/h retina following AAV2/8-
mediated gene expression. 
 
To assess the extent of photoreceptor cell survival after AAV2/8-mediated 
Aipl1 gene replacement, quantification of the outer nuclear layer was 
performed. Whole eyes were taken from Aipl1 h/h mice (n=7), that had been 
exposed to constant white light, for 21 weeks following subretinal injection of 
AAV2/8-CMV-Aipl1. This time point corresponds to the final time point of 
ERG analysis that was described in earlier sections.  The method used for 
the preparation for retinal sections for outer nuclear layer quantification has 
been described in section 3.5.2.  Centrally located retinal sections that 
passed through the optic nerve and covered the superior and inferior retina 
were selected for outer nuclear layer quantification. These were stained with 
propidium iodide and images of the photoreceptor layer between the ora 
serrata and optic nerve head was taken using the confocal microscope.  For 
each treated or untreated eye, 3 centrally located retinal sections were 
selected for imaging; 2 confocal images were taken from each side of the 
optic nerve in each retinal section.  The photoreceptor cell count for each eye 
was determined by taking the average of the cell counts from each confocal 
image of that eye.  To control for inter-animal variation in the rate of 
degeneration, a paired t-test was performed when comparing the mean 
photoreceptor cell count in the treated and untreated eyes in this group.  
 
Figure 4.10A shows confocal images of the outer nuclear layer from a single 
light accelerated Aipl1 h/h mouse at 21 weeks after treatment with AAV2/8 
vector. The treated eye has preservation of the outer nuclear layer with many 
more photoreceptor nuclei compared with the contralateral untreated eye in 
which the outer nuclear layer is largely absent or reduced to a single cell 
layer.  Statistical analysis showed a significant difference between the mean 
outer nuclear layer cell count in treated eyes compared with untreated eyes 
(p=0.0007) (Figure 4.10B). The mean number of photoreceptor nuclei in 
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treated eyes was 120% higher than in untreated eyes. The mean 
photoreceptor cell count in treated eyes was 202.1 ± 20.2 (n=7) while in 
photoreceptor count in untreated eyes was 90.64 ± 23.0 (n=7) at 21 weeks 
post injection.  There was consistent protection in all of the animals that were 
assessed: in each individual animal that was examined, significant 
photoreceptor cell preservation (p<0.05) was seen in the treated eye 
compared with the contralateral untreated eye (Figure 4.10C).  We compared 
the outer nuclear layer cell count between untreated eyes in light accelerated 
Aipl1 h/h mice with age-matched untreated eyes of Aipl1 h/h mice that did 
not undergo light exposure and found that the rate of retinal degeneration in 
light-exposed eyes was substantially accelerated by 3-4 times. At 21 weeks 
post injection, the mean outer nuclear layer in untreated light accelerated 
Aipl1 h/h retina was 90.64 ±23.0, while the mean outer nuclear layer cell 
count in  untreated eyes without light exposure at  22-24 weeks was 342.7 ± 
11.3, (n=7). Treatment with AAV2/8 vector resulted in significant prolongation 
of photoreceptor survival, but it did not halt the degenerative process 
altogether.  Compared to age-matched wild type eyes which had also been 
subjected to constant light exposure, the mean photoreceptor cell count in 
treated eyes was significantly lower (p=0.00008).  Treated eyes at 21 weeks 
post injection had 54% less photoreceptor cells than age-matched and light 
exposed wild type eyes. Untreated eyes had lost about 80% of photoreceptor 
cells compared to wild type by this time point.            
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4.5   Effect on AAV2/8-mediated Aipl1 expression 
on the levels of cGMP phosphodiesterase 
 
In view of the link between AIPL1 and cGMP phosphodiesterase (PDE), we 
proceeded to investigate whether AAV2/8-mediated gene expression had 
any effects on the levels of cGMP PDE on treated retina. In animal models of 
Aipl1 deficiency such as the AIpl1 -/- and Aipl1 h/h mouse, cGMP PDE is the 
only known retinal protein that lost or reduced respectively[391][282], 
suggesting that AIPL1 is a specialized chaperone for rod PDE. While mRNA 
levels of PDE6B are not affected in these animal models of Aipl1deficiency, 
the level of PDE protein is absent in the Aipl1 -/- mouse and severely 
reduced in the Aipl1 h/h mouse, indicating that Aipl1 has post-transcriptional 
effects on cGMP PDE. 
 
To investigate the effect of AAV2/8-mediated Aipl1 expression on β-PDE 
levels, eyes were taken from 3 procedured Aipl1 h/h mice that received 
unilateral subretinal injections of AAV2/8-CMV-Aipl1 and reared in constant 
light exposure. The mice were sacrificed at 21 weeks post injection and the 
treated and untreated eyes from each animal was enucleated and eye cup 
dissection was performed. The retina was dissected out from the choroid and 
sclera and manually homogenised and sonicated. A total of 6 retinal 
homogenates consisting of treated and untreated retina from 3 procedured 
Aipl1 h/h mice were obtained. Western blot analysis was performed on these 
retinal homogenates from procedured Aipl1 h/h mice and also on retinal 
homogenates from wild type controls.  
 
Immunoblotting with a β-subunit specific PDE antibody showed that β-PDE 
was present in treated eyes but were severely reduced or absent in 
untreated eyes (Figure 4.11A). Quantification of the immunoblotting results 
showed that β-PDE levels in treated eyes were significantly higher than in 
untreated eyes (p=0.02). At 21 weeks post injection under constant light 
acceleration, the mean levels of β-PDE in treated eyes were 65% of that in 
wild type retina. In untreated retina, β-PDE levels were 10% of that in wild 
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type retina (Figure 4.11B). Since treated eyes at this time point contained 
approximately half the normal number of photoreceptor cells following Aipl1 
gene replacement therapy, the level of β- PDE in each cell might be similar 
to that in wild type photoreceptors if adjustment was made for the number of 
cells. 
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4.6   Effect on subretinal injection of control 
vector AAV2/8-CMV-gfp in Aipl1 h/h mice with light 
acceleration.  
 
There have been studies suggesting that mechanical injury can lead to 
expression of neurotrophic factors [69,70,491]. Consequently, surgical 
manipulation of the retina including subretinal surgery may result in some 
short term negative effects such as trauma, or positive effects such as 
possible trauma-induced neuroprotective effects. To determine whether any 
positive improvements in AAV2/8-CMV-Aipl1 injected eyes were due induced 
by the surgical procedure or the AAV virus itself, rather than by Aipl1 
transgene expression, a further group of 10 Aipl1 h/h mice received 
subretinal injection of a control virus, AAV2/8-CMV-gfp in one eye only. The 
contralateral eyes were not treated to serve as negative controls.  The 
animals were also subjected to constant light exposure from 1 week after the 
subretinal injections and ERG recordings were performed at various time 
points to monitor the effects of the procedure. 
 
Statistical analysis of the mean b-wave amplitudes showed that there was no 
significant difference between treated and untreated eyes at any time point 
(Figure 4.12) The results obtained at flash intensities of 100 mcds/m2  and 
1000 mcds/m2  did not differ substantially. Overall, the b-wave amplitudes for 
both injected and uninjected eyes continued to decrease over time. This was 
due to the ongoing retinal degeneration caused by the underlying genetic 
defect. These findings indicate that delivery of a non-therapeutic vector has 
no influence on photoreceptor survival over the long term.  
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4.7   Effect of AAV2/8-mediate AIPL1 
overexpression. 
 
While most other AAV serotypes preferentially transduce the RPE following 
subretinal delivery, a select few such as AAV serotypes 2,5,7,8 and 9 
transduce both photoreceptor cells and the RPE after subretinal 
administration[28,508][18]. In many gene transfer studies, AAV2/5 was 
considered to be the most efficient vector for photoreceptor gene transfer 
before the discovery of novel serotypes such as AAV 7,8 and 9[18]. These 
novel serotypes are far more superior in terms of transduction efficiency and 
also mediate several fold higher levels of transgene expression. In contrast 
to AAV2/2 and AAV2/5 which have a higher tropism for the RPE, AAV2/8 
demonstrates equal tropism for RPE and photoreceptor cells and results in 
6-8 fold greater transgene expression in photoreceptor cells[18][348]. 
Consequently, AAV2/8 and AAV2/7 (AAV2/9 is less effective than the former 
two serotypes) are thought to be the most suitable vectors for treating 
photoreceptor gene defects[18], which cause the majority of hereditary 
retinal dystrophies. In this study, we elected to use AAV2/8 in combination 
with a CMV promoter, and we rationalized that the levels of AAV2/8 
mediated Aipl1 expression would be expected to exceed endogenous levels. 
 
It would be important to determine whether overexpression of Aipl1 in the 
retina would affect retinal function, and also whether the expression of Aipl1 
in cells such as the RPE that do not normally express Aipl1 has any 
deleterious effects. To do this, 7 wild type C57B/6 mice received subretinal 
injections of AAV2/8-CMV-Aipl1 in one eye only. Functional assessments 
were performed at regular time points using dark adapted scotopic ERG 
recordings obtained simultaneously from injected and uninjected eyes. A 
representative ERG intensity series from a wild type mouse at 24 weeks 
following injection of AAV2/8-CMV-Aipl1 is shown in Figure 4.13A. The 
amplitudes and waveform of the ERG recordings did not differ substantially 
between injected and uninjected eyes. Statistical analysis of the mean b-
wave amplitudes showed no significant difference between injected and 
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uninfected eyes (Figure 4.13B). After ERG recordings, all animals were 
sacrificed and their eyes processed for semithin sections. The retinal 
morphology and histology of eyes which received the vector injection was 
normal and similar to the contralateral eyes which were uninjected (Figure 
4.14). These findings indicated that the high levels of AIPL1 expression in 
the retina and the additional Aipl1 expression in the RPE cells had no 
negative effects. 
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4.9   Effects of AAV2/8-mediated gene 
replacement in the Aipl1 -/- mice  
 
Since an AAV2/8 vector proved effective for mediating gene replacement 
therapy in the light accelerated Aipl1 h/h model, we proceeded to evaluate 
the efficacy of AAV2/8-CMV-Aipl1 mediated gene replacement therapy in 
mice that are completely deficient in AIPL1. The Aipl1 -/- mouse is 
homozygous for a targeted disruption in Aipl1 and has an extremely fast 
degeneration, in which complete loss of photoreceptor cells is seen by 3 
weeks of age (see chapter 1). Because of the early onset of photoreceptor 
degeneration, these animals were treated at an earlier age,at postnatal day 
12 (P12).  A total of 6 Aipl1 -/- mice received subretinal injections of AAV2/8-
CMV-Aipl1. Each animal received double subretinal injection in the superior 
and inferior hemispheres of the retina in one eye only, with the contralateral 
eye left uninjected as an internal control. Following subretinal injections,  
assessments of retinal function in the form of ERG and morphological 
analysis  of histology and immunohistochemistry were performed at earlier 
timepoints, given the rapid nature of the degeneration. To compare the 
efficacy of AAV2/2 and AAV2/8, a further group of Aipl1 -/- mice received 
with subretinal injections of AAV2/2-CMV-Aipl1. 
 
Immunohistochemistry of treated and untreated Aipl1 -/- retina was 
performed at 16 days post injection, when the mice were 28 days old (Figure 
4.15). In untreated Aipl1 -/- mice the ONL is completely absent, but in mice 
that had received AAV2/8-CMV-Aip1, we observed a thick ONL with good 
preservation of retinal layers. Strong immunofluorescence for AIPL1 was 
seen in the inner segments, accompanied by strong immunofluorescence for 
β-PDE in the outer segments of treated retina.  In contrast, AIPL1 and β-PDE 
immunofluorescence were both absent in untreated eyes (Figure 4.15).  
 
Semithin sections of retina were taken from 4 week old mice at 19 days post 
injection (Figure 4.16). These sections showed that treatment with the vector 
resulted in substantial preservation of photoreceptor cells. In untreated eyes, 
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no photoreceptor cells or outer segments could be seen. The inner nuclear 
layer was seen lying adjacent to the RPE in untreated eyes and there was 
marked retinal thinning. In contrast, treated retina exhibited the presence of 
long, densely packed outer segments and showed good preservation of the 
outer nuclear layer of about 6-7 rows of photoreceptor nuclei.  
 
ERG recordings are normally extinguished by P18 in the Aipl1 -/- mouse. 
ERG analysis was performed on the procedured mice at 16 days following 
subretinal injection with AV2/8-CMV-Aipl1 when the animals were postnatal 
28 days. Single flash scotopic and photopic responses were recorded 
simultaneously from treated and untreated eyes of each animal (Figure 
4.17A).  Scotopic and photopic ERG responses from untreated eyes showed 
flat ERG tracings. In contrast, treated     Aipl1 -/- eyes exhibited good 
scotopic and photopic ERG amplitudes approximately 2 weeks after 
treatment (Figure 4.17). The difference in mean scotopic ERG b-wave 
amplitudes between treated and untreated eyes was statistically significant 
(p=0.03; mean b-wave treated = 243.5 ± 67.2 µV, mean b-wave untreated = 
6.25 ± 3.9 µV, n=4). Further ERG analysis was performed at later timepoint 
of 6 weeks post injection when the animals were approximately 8 weeks old. 
At this timepoint, treated eyes continued to maintain significantly higher ERG 
b-wave amplitude compared to untreated eyes (p=0.006; mean b-wave 
treated = 234.7 ± 51.1 µV, mean b-wave untreated = 28.8 ± 5.6 µV, n=6).  At 
3 months post injection when the animals were 14 weeks old, untreated eyes 
had no ERG response (mean b-wave untreated = 0 µV, n=3), while treated 
eyes showed a substantial ERG response (mean b-wave treated = 181.7 ± 
39.4 µV, n=3 ).These findings indicate that early treatment using AAV2/8-
CMV-Aipl1 is able to significantly improve photoreceptor function and delay 
retinal degeneration in the Aipl1 -/- mouse.  ERG analysis of Aipl1 -/-  mice 
injected with AAV2/2-CMV-Aipl1 did not show any evidence of photoreceptor 
rescue (Figure 4.17B). These mice were also injected at the same time point 
of P12 and neither the treated nor untreated eyes showed any ERG 
responses at P28 (16 days post injection). 
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4.10  Discussion 
 
The window of opportunity in a disease model is created by the balance 
between time required for vector-mediated expression and the rate of 
photoreceptor degeneration. In models of rapid degeneration, gene 
replacement therapy using AAV2/2 vectors is unlikely to be successful since 
most of the photoreceptors are lost before sufficient transgene expression 
can take place.  By choosing a more suitable, faster vector to treat a rapid 
degeneration, the window of opportunity for intervention can be increased. 
This study describes the first use of an AAV2/8 vector to treat a murine 
model of retinal degeneration. Compared with AAV2/2 (described in Chapter 
3), AAV2/8 is much more efficient at transducing the retina. We evaluated 
gene replacement therapy using AAV2/2 and AAV2/8 vectors and found that 
the most effective rescue was achieved using AAV2/8 vector.  
 
Under constant light exposure, the Aipl1 h/h mice exhibited a more severe 
and accelerated form of retinal degeneration; a 2-3 fold increase in rate of 
degeneration is seen with loss of 85% of photoreceptor cells by 5 months. 
This suggests the photoreceptor cells in Aipl1 h/h mice could be more 
sensitive to light damage, as wild type mice kept under identical conditions 
showed no increased loss of photoreceptor cells. For effective treatment of 
this animal model, a vector with faster transduction kinetics was required. 
Normally, all photoreceptor cells are lost by the time Aipl1 -/- mice are 3 
weeks old. Following AAV2/8-mediated gene replacement in Aipl1 -/- mice, 
there was significant preservation of photoreceptor cells and retinal function 
for over 3 months. This represents the most effective rescue of a rapid retinal 
degeneration to date.  To ensure adequate transgene expression before a 
critical mass of photoreceptor cells were lost, the Aipl1 -/- mice were treated 
at a much younger age, at postnatal day 12. In doing so, the potential benefit 
of gene transfer had to be weighed against the risks of retinal damage from 
surgical manipulation in younger mice. At P12, mice have a fully developed 
retina and have opened their eyes, thus facilitating subretinal injections. 
AAV2/8-mediated gene expression should occur by P15-P16, at this time 
there would still be surviving photoreceptor cells in Aipl1 -/- mice. Superior 
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results using AAV2/8 may have resulted from its higher transduction 
efficiency and higher levels of maximal transgene expression which have 
been previously described [18,348]. More importantly, the rapid onset of 
gene expression may have been vital in preserving photoreceptor cell 
survival in the Aipl1 -/- mouse. We observed photoreceptor rescue with 
AAV2/8 but not with titre-matched AAV2/2 in the Aipl1 -/- mouse, this is most 
likely because photoreceptor degeneration would have been completed by 
the time maximal transgene expression was achieved with AAV2/2. 
 
In the experiments described in this study, we injected a single eye of each 
animal with a therapeutic vector, leaving the contralateral uninjected eye to 
serve as an internal control during follow up assessments. Similar studies by 
other groups have used control injections (subretinal injections of a control 
vector) into the contralateral eye to detect trauma-induced neuroprotective 
effect. Since the statistical significance in differences between treated and 
untreated eyes were of such large magnitude and seen at long term time 
points, it is unlikely that hypothetical surgically-induced neuroprotection has 
any major contribution to differences observed. Whilst injection of a control 
vector into the contralateral eye will allow assessment of the therapeutic 
transgene in isolation, it is important to leave the contralateral eye as an 
untreated control as the aim of this study is to provide a tangible 
improvement in retinal function and morphology after treatment, which also 
includes the delivery of the treatment. Moreover, injecting the contralateral 
eye may increase the risk of creating false positive results, where injection of 
therapeutic vector results in better function than control injections, and also 
in an undetected worsening because of trauma-related decrease in retinal 
activity. Therefore, we injected one eye only in each animal with the 
therapeutic or control vector. In the control group of animals consisting of 
Aipl1 h/h mice that received unilateral subretinal injection of AAV2/8-CMV-
gfp or AAV2/2-CMV-gfp, there was no significant differences seen in ERG 
amplitudes or cell count when comparing the injected eye with the 
contralateral uninjected eye. Further groups of animals comparing injections 
of PBS with untreated eyes (section 3.6.2), showed that injection-related 
trauma had no significant positive effect on retinal function.  
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Because AIPL1 is required for the biosynthesis/stability of PDE, no PDE 
accumulates in the photoreceptors of Aipl1 -/- mice and the decline in PDE 
levels is proportional to the reduced level of AIPL1 in Aipl1 h/h mice. 
Elevated PDE levels would be ameliorative to the downstream effects of 
disease at the molecular level in this disease model, and therefore would be 
expected to alleviate the disease phenotype. Hence, in preclinical animal 
studies, a useful and quantifiable outcome measure which is predictive of 
successful treatment would be an increase in PDE levels in rod 
photoreceptors of treated animals. Treatment with AAV2/8-CMV-Aipl1 in light 
accelerated Aipl1 h/h mice led to increased production of AIPL1 in 
photoreceptor cells and subsequently increased levels of cGMP-PDE in 
photoreceptor cells as demonstrated on Western blotting (Section 4.6), and 
localised correctly to photoreceptor outer segments.  In contrast, untreated 
eyes had almost undetectable PDE levels. The difference in PDE levels 
between treated and untreated eyes may partly be due to the loss of 
photoreceptor cells in untreated eyes. At 21 weeks post injection, the mean 
level of PDE in treated eyes was 65% of wild type while untreated eyes had 
10% of wild type levels. In order to compare the levels of PDE expression in 
single photoreceptor cells with and without treatment, the data was corrected 
for the average number of cells in the treated and untreated eyes at that time 
point. The PDE expression levels in the samples were normalized to total 
protein content in the eye (β-actin was used as normalization standard) and 
hence, is proportional to the number of photoreceptor cells present. Using a 
photoreceptor-specific protein such as alpha-transducin as normalization 
standard, it would have been possible to directly compare the levels of PDE 
expression in photoreceptor cells. 
 
In the studies presented here and the preceding chapters, ubiquitously active 
CMV promoter was used to drive transgene expression. The advantage of a 
ubiquitous viral promoter such as CMV is its high expression levels, the 
ability to drive expression in both rods and cones and its wide use in animal 
studies. For clinical application, a tissue-specific promoter would be more 
appropriate because patients may have deleterious effects secondary to 
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ectopic expression of the transgene. Particularly in situations where 
photoreceptors are the targets for gene delivery, a non-specific promoter 
would also result in the ectopic expression of the transgene in the RPE. This 
could have unknown long term effects, and is therefore undesirable for 
clinical gene therapy in humans. It has been recently shown that AIPL1 is 
essential for the viability and function of cone photoreceptors as well as rods, 
and that photoreceptor disease due to AIPL1 gene mutations is caused by 
an insufficiency of rod and cone PDEs [232]. Thus an effective therapy for 
this condition should aim to restore rod and cone PDE biosynthesis, through 
reconstituting AIPL1 function to a level sufficient to sustain photoreceptor 
function and survival. The ideal vector design for AIPL1 gene therapy should 
be one with well-defined promoter/enhancer elements with uniform, 
photoreceptor-specific transcriptional activity and target both rods and cones 
in order to fully restore retinal function. AAV vectors have a relatively small 
carrying capacity for foreign DNA that typically does not exceed 4.5 kb. The 
limited carrying capacity of AAV vectors dictates that such promoters ideally 
be short, no more than several kilobases in length, to allow for packaging of 
the transgene. A number of promoters such as the derivatives of rod and 
cone opsin promoters have been validated as efficient and specific for driving 
expression in rods and cones respectively[160,161,263,487]. More recently, 
a human rhodopsin kinase promoter fragment was characterised and shown 
to be relatively small in size [512,513]. Packaged into an AAV2/5 vector, the 
rhodopsin kinase promoter was shown to be specifically active in both rods 
and cones but not in the RPE or the inner retina, driving expression at a 
relatively high level [230]. For human gene therapy purposes, constructs 
incorporating promoters such as these may be more suitable for AAV-
mediated gene delivery. A further issue of importance in the context of 
human gene therapy is the level of expression that is produced from the 
therapeutic vector. Ideally, the level of vector-mediated expression should 
closely match that of endogenous levels. This can be addressed by choosing 
a suitable promoter and one that is human-derived (see Chapter 5 Final 
discussion).  
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Combining the results from this chapter with those in the previous one, we 
demonstrated that mouse models of AIPL1 deficiency with very different 
rates of disease progression respond favourably to AIPL1 gene replacement 
therapy. AAV-mediated transene expression in the Aipl1 murine models 
appears stable and the efficacy of rescue long-lasting. In the hypomorphic 
mutant, AAV2/2 and AAV2/8 mediated gene expression remained in the 
retina at 50 weeks and 21 weeks post injection respectively and the 
photoreceptor cells were well maintained at that age. Similarly, in the Aipl1 -/- 
model, AAV2/8 mediated delivery of the AIPL1 gene appears to be stable for 
at least 3 months, which is the latest time point examined. The results 
together provide further evidence to support gene replacement  therapy for 
the treatment severe inherited retinal dystrophies caused by defects in 
AIPL1.  
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5  Screening of patients with early-
onset severe retinal dystrophy for 
mutations in AIPL1 and characterization of 
the phenotype 
 
5.1   Introduction 
 
Mutations in AIPL1 have been estimated to account for approximately 7% of 
LCA cases [442]. The phenotype of AIPL1 mutations is variable as it has 
also been associated with autosomal dominant cone-rod dystrophy and 
juvenile retinitis pigmentosa [103,440,442]. The development of potential 
targeted therapies for the treatment of degenerative retinal diseases has 
heightened the necessity for accurate molecular diagnoses. There is a need 
for a comprehensive molecular screen not only to establish the causative 
gene for the possibility of treatment in the future and further the 
understanding of the molecular pathways involved in the pathogenesis of the 
retinal disease, but also to distinguish between the types of degenerative 
retinal diseases.   Ultimately, the vector system and gene therapy strategies 
developed in preceding chapters to target photoreceptors and prevent 
photoreceptor degeneration in the animal models of AIPL1–deficiency are 
aimed at treating RP and LCA due to mutations in AIPL1. The results 
presented in chapters 3 and 4 suggest that defects within this gene are 
suitable targets for the development of gene therapy approaches in patients. 
Any therapeutic intervention is more justified in a severe disease where the 
potential benefits far outweigh the risks; patients with AIPL1- related retinal 
degeneration generally have a severe phenotype with peripheral field loss 
and frequently also involvement of central vision causing marked visual loss 
early in life. In order to move AAV-mediated photoreceptor gene transfer 
from bench to bedside, identification of patients and characterization the 
disease caused by mutations in AIPL1 is required.  The identification of the 
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molecular basis of LCA is challenging, given the high genetic heterogeneity 
of LCA and the absence of clinical landmarks in most cases that may help 
distinguish one form of LCA from another.  The molecular diagnosis and 
systematic clinical characterization of patients is instrumental for the 
selection of appropriate patients for gene therapy clinical trials and will 
enable the natural history and phenotype of the disease to be better 
established, especially since this is still not well ascertained. Additionally, this 
will contribute towards determining clinical baselines and assessment targets 
to guide treatment and facilitate genetic counseling of candidate patients. 
 
 
5.1.1    Mutations of AIPL1 
 
To date, there are 22 known disease-causing mutations in AIPL1 but it is 
anticipated that there may be more mutations to be discovered by screening 
a wider population that includes patients with LCA and early onset retinal 
dystrophies. Table 5.1 summarizes the currently known disease-causing 
mutations and polymorphisms in AIPL1 (http://www.retina-
international.com/sci-news/aipl1mut.htm).  
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Table 5.1. AIPL1 mutation database. Current known mutations and benign variants of AIPL1 
updated from March 2009. (extracted from HGMD) 
Phenotype Exon Base change Protein Description Accession 
number 
ADCRD 6 del 1053-1064 Pro350∆12 12 base pair deletion 
within hinge region. 
CD003288 
LCA4   1 c.40A>G Lys14Glu Missense mutation. CM034773 
LCA4 2 c.116C>A Thr39Asn Missense mutation CM034201 
LCA4 2 c.126T>A Cys42X Nonsense mutation. CM042287 
LCA4  2 c.211G>T Val71Phe Missense mutation. CM040669 
LCA4 2 c.236T>C Met79Thr Uncommon missense 
mutation. 
CM003225 
LCA4 2 c.244C>T His82Tyr Misssense mutation. CM034202 
         LCA4 2 c.264G>A Trp88 X Nonsense mutation. CM003226 
LCA4 Intron 
2 
c.277-2A>G IVS2-2A>G Splice site mutation. CS003285 
LCA4 3 c.286G>A Val 96 Ile Uncommon missense 
mutation. 
CM003227 
LCA4 3 c.341C>T Thr114 Ile Missense mutation. CM003228 
LCA4 3 c.401A>T Tyr134Phe Missense mutation. CM042288 
LCA4 4 c.487C>T Gln163 X Nonsense mutation. CM003229 
LCA4 4 c. 589G>C Ala197Pro Missense mutation. CM003230 
LCA4 5 c.715T>C Cys 239 Arg Missense mutation. CM000002 
LCA4 5 c. 784G>A Gly262Ser Missense mutation. CM003231 
LCA4 6 c.809G>A Arg270His Missense mutation CM074007 
LCA4 6 c.834G>A Trp 278 X Nonsense mutation. CM000003 
LCA4 6 c.905G>T Arg 302 Leu Missense mutation. CM003232 
LCA4 6 del1010-1011 Ala336∆2 2 base pair deletion. CD001471 
LCA4 6 ins12bp1122-
1123 
Pro374ins12
bp 
12 base pair insertion CI056866 
LCA4 6 c.1126C>T Pro376Ser Missense mutation. CM003233 
Polymorphism 1 c.111T>C Phe 376Phe   
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Polymorphism 2 c.234C>T Ser 78 Ser   
Polymorphism 2 c.267C>T Cys 89 Cys   
Polymorphism 3 c.300G>A Leu 100 leu   
Polymorphism 4 c.516T>C His 172 His   
Polymorphism 4 c.651G>A Pro 217 Pro   
Polymorphism 4 c.765T>C Asp 255 Asp   
 
 
 
 
To date there have been three large studies of AIPL1 mutation analysis in 
LCA patients. In the first study, AIPL1 mutations were found in 11 families 
following screening of 118 probands [442] In another study, a comprehensive 
mutational analysis of all LCA-associated genes in 179 unrelated LCA 
patients identified AIPL1 mutations in 6 (3.4%) patients [174]. Finally, the 
largest study described 26 probands with AIPL1 mutations from a cohort of 
303 unrelated patients (8.6%)[103]. The majority of the AIPL1 alleles which 
have been identified so far represent null (nonsense, frameshift, or severe 
splice site) mutations.  Most of the current reported disease-causing AIPL1 
mutations appear to lie within the sequences encoding the 3 tetratricopeptide 
repeat (TPR) motifs which are regions of high sequence conservation across 
different species. A nonsense mutation in the TPR III domain (W278X) is the 
most frequently reported mutation in LCA patients. It was originally found in 
consanguineous Pakistani families and may represent a founder 
mutation[97,440,442]. Despite the lesser degree of conservation in the 
proline-rich region, a 4 amino acid deletion in this hinge region P351^12bp 
has been reported in 2 unrelated patients with autosomal dominant cone-rod 
dystrophy and juvenile retinitis pigmentosa [442] suggesting that AIPL1 
mutations may also account for other types of inherited dystrophies.  
  
Patients with AIPL1-related LCA have been described in current literature to 
have a particularly severe phenotype, characterized by marked early visual 
impairment, non-detectable fields and ERGs, optic disc pallor, maculopathy 
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in most patients, peripheral bone-spicule-like pigmentation. There is also a 
significant prevalence of keratoconus and cataracts [103]. Some of the 
mutations lead to a truncation of the reading frame and are not expected to 
produce a functional protein. Other reported mutations such as missense 
mutations may not abolish protein function completely and may produce a 
milder phenotype. A small number of patients with milder disease than LCA 
associated with AIPL1 mutations have been reported.  In a previous study, 
screening of a large cohort of retinal degeneration patients led to the 
observation that three probands from two families had a heterozygous 12 bp 
deletion in AIPL1. They were diagnosed with cone-rod dystrophy and 
juvenile RP but their phenotypic details were not provided[441]. Another 
recent study identified an individual with compound heterozygous mutaton in 
AIPL1 who had a later-onset protracted course of disease and was 
diagnosed with retinitis pigmentosa[204]. Thus further screening of a large 
cohort of patients with RP or cone-rod dystrophy may identify more such 
patients with residual AIPL1 function.  
 
Patients who are homozygous or compound heterozygous for a null mutation 
are reported to have more severe disease than patients who are 
homozygous for missense mutations. In a study of 26 probands with AIPL1 
mutations, 2 patients who were compound heterozygotes for missense 
mutations T114I and P376S retained visions of 20/400 and had moderate 
retinopathy while 9 patients who were homozygous for W278X had vision of 
hand motion or light perception and severe retinopathy[103].  In another 
study which identified 7 AIPL1 patients from a cohort of 110 LCA patients, 
patients with heterozygous missense mutations were found to have better 
visual acuity[151]. Compared to the other LCA genotypes, there is a high 
prevalence of maculopathy in patients with AIPL1 mutations[103]. This may 
not be surprising as AIPL1 is also expressed in cones and is necessary for 
the continued survival of cone photoreceptors[232] .  More interestingly, the 
majority (11 out of 16) of patients noted to have macular atrophy harboured a 
premature stop codon mutation in either homozygous or heterozygous 
states.  The authors of the study noted there was a high incidence of 
keratoconus noted in patients with a homozygous sequence change and 
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suggested that this observation may be significant. The presence of 
significant keratoconus may be associated with severe mutations as most of 
these patients the study also had severe macular involvement and 
pigmentary retinopathy. There have also been individual reports describing 
unusual notable phenotype found in patients with AIPL1 mutations such as 
abnormal retinal vascular morphology [183]. 
 
Aside from the phenotypic variability seen in AIPL1 patients with different 
mutations, variability has been reported even when there is a common 
molecular genetic aetiology in a family.  In a study of 4 consanguineous 
Pakistani families with a severe form of LCA due to a homozygous nonsense 
mutation in AIPL1, W278X, a spectrum of clinical findings were observed 
among the affected family members; vision ranged from hand motions to no 
perception light, variable fundal findings with different severity of retinopathy 
and maculopathy, and variable findings of keratoconus, even amongst 
members of similar ages [97]. The basis of this phenotypic variability within a 
mutation has not been completely understood, but environmental influences 
and possibly other modifier alleles may contribute to these observations. 
 
5.2   Aims 
 
This chapter aims to investigate the prevalence of sequence variants in 
AIPL1 in a large cohort of DNA from patients with LCA or autosomal 
recessive severe childhood-onset retinal dystrophy, and to compare this with 
that seen in the normal population. By screening these patients for mutations 
in AIPL1, we hope to identify more patients, report any novel mutations and 
characterize the clinical features associated with the mutations. This project 
would aims to identify the subset of patients that would be candidates for 
gene therapy. For this purpose, a panel of 309 probands diagnosed with LCA 
or early-onset retinal dystrophy (EORD) was screened for mutations in AIPL1 
using a combination of microarray LCA chip analysis (Asper-Ophthalmics) 
and direct sequencing. Patients with early-onset retinal dystrophy or EORD 
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are defined as those patients with severe visual loss in early childhood 
before the age of 5. Sequencing of the total patient panel and half of the 
control panel was performed by the author. Help was obtained with 
segregation analysis and sequencing of part of the control panel from Dr Jill 
Cowing, Dr H Tran and Dr D MacKay.   
 
5.3  Patient panel and demographics  
 
In order to identify patients and families with mutations in AIPL1, mutation 
screening was performed on patients enrolled in a genetic database at 
Moorfields Eye Hospital. The genetic database used in this study consisted 
of patients who have been diagnosed with LCA or with EORD and were 
identified through the genetic ophthalmology clinics and medical retina clinics 
at Moorfields Eye Hospital. This database included a clinical spectrum of 
patients with classical LCA whose severe visual impairment was present 
from infancy, to patients who presented later in childhood and may have 
overlapping features with retinitis pigmentosa clinically classified as EORD 
(severe retinal dystrophy symptomatic before the age of 5 years old with an 
abnormal electroretinogram at the time of diagnosis). The inclusion criteria 
were: clinical diagnosis of LCA or a severe retinal dystrophy that was 
symptomatic in childhood, severely reduced or absent ERG at diagnosis and 
autosomal recessive inheritance. Patients with other known ophthalmological 
or systemic diseases that share features with LCA or a family history 
suggestive of autosomal dominant or X-linked recessive disease were 
excluded. Research procedures were in accordance with institutional 
guidelines and the Declaration of Helsinki. Ethics committee approval was 
obtained. All patients and parents were provided with information sheets 
before informed consent was obtained from all patients or their legal 
guardians for the provision of clinical information and blood samples for DNA 
extraction and analysis. All patients also underwent detailed phenotyping 
which included clinical ophthalmological examination via slitlamp 
biomicroscopy and indirect ophthalmoscopy, diagnostic electrophysiology, 
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OCT, Goldmann perimetry, fundus imaging, fluorescein angiography and 
autofluorescence and measurements of visual acuity and color vision. 
Optical coherence tomography (OCT) is a non-contact imaging technique 
that produces high resolution cross sectional images of the retinal 
architecture based on the differences in optical reflectivity of the different 
layers. Using time delays in reflected signals, the distance or thickness 
between different layers of ocular tissues can be measured. The 
ophthalmological examinations were conducted by R.Henderson, P. Moradi 
and colleagues at Moorfields Eye Hospital. 
 
The patient panel consisted of 309 probands who have a clinical diagnosis of 
LCA or EORD, including rod-cone dystrophy and retinitis pigmentosa. The 
number of DNA samples that were screened and analysed was 326, this 
consisted of DNA samples from 309 probands and the remaining 17 DNA 
samples were from relatives of probands who agreed to be part of the study. 
Amongst the probands, majority, 70% (217/309) of the DNA samples were 
from Caucasian subjects, of either British or other European backgrounds, 
21% (64/309) were of Asian extraction, mostly Pakistani or Indian, 3% 
(10/309) were of Middle-eastern extraction, 1.6% (5/309) were African, 0.6% 
(2/309) were Chinese and the remainder were of mixed backgrounds (Table 
5.3). The control panel consisted of 96 control DNA samples originating from 
a control population of randomly selected, non-related UK Caucasian blood 
donors (ECACC Human Random Control-1 DNA panel). 
 
Of the 309 probands in the panel, 26% were offsprings of consanguineous 
marriages. One hundred and fourty-nine (149) probands have a diagnosis of 
LCA, 29 had a diagnosis of early onset retinal dystrophy, 67 were diagnosed 
as rod-cone dystrophy, 25 were diagnosed with retinitis pigmentosa and 39 
with cone-rod dystrophy (Table 5.4).  
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Table 5.2 Table showing the demographic breakdown of the patient population. 
Ethnic group number percentage 
Caucasian (British, 
European, Iranian) 
217 70% 
Asian (Pakistani, Indian, 
Bangladeshi) 
64 21% 
Middle-eastern 10 3% 
African 5 1.6% 
Chinese 2 0.6% 
Mixed 
background/unknown 
11 3% 
total 309 100% 
 
 
 
 
Table 5.3  Details of the LCA and EORD patient cohort.  
Summary of the clinical diagnosis and mean age of diagnosis and onset of disease in the 
panel of   patients . 
Diagnosis Patients 
(n) 
Mean age at 
diagnosis 
(y) 
Mean age at onset 
of symptoms 
(y) 
LCA 
EORD 
Rod-cone dystrophy 
Retinitis pigmentosa 
Cone-rod dystrophy 
Total 
149 
 29 
 67 
 25 
 39 
309 
1.0 
3.8 
5.0 
10.7 
5.1 
0.4 
1.8 
2.1 
7.3 
3.5 
 
Abbreviations: LCA-Leber Congenital Amaurosis; EORD-early onset severe retinal 
dystrophy 
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5.4  Patient screen and sequencing strategy 
 
A two-stage screening strategy was used. First pass screening for mutations 
in AIPL1 was performed using the microarray LCA chip analysis (Asper-
Ophthalmics, Tartu, Estonia). Following LCA chip analysis, samples that had 
not returned any sequence variants or samples that returned only one allelic 
change on the chip were further analysed by sequencing. The DNA samples 
were sent to Asper Ophthalmics by R Henderson and P Moradi. The LCA 
disease chip allows the rapid screening of 423 likely disease-associated 
sequence variants in the 10 out of 13 genes known to be associated with 
LCA or early onset retinal dystrophy. These are AIPL1, RPGRIP1, GUCY2D, 
RPE65, CRX, CEP290, RDH12, LRAT, MERTK and TULP. The chip 
currently contains 32 AIPL1 sequence variants, although not all of these 
sequence variants are listed in official mutation databases.  A list of the 
AIPL1 sequence variants that are contained in the LCA disease chip is 
shown in Table 5.4. DNA samples that did not return any mutations in any of 
the LCA genes using the microarray disease chip or samples in which only 
one AIPL1 disease allele was found were subjected to bidirectional 
sequencing of AIPL1, in order to identify any novel mutations or the 
possibility of a second allele in the latter. The entire AIPL1 coding sequence 
was assayed, including the intron/exon junctions. 
 
Direct sequencing of AIPL1 was performed on genomic DNA extracted from 
peripheral blood leukocytes of patients’ blood samples according to methods 
previously described (Chapter 2). The DNA samples were subjected to PCR 
to amplify the coding exons of AIPL1, except for exon 6 in which only the 
coding part of the exon was amplified. The primers used were designed to 
encompass the entire coding sequence and the flanking the splice acceptor 
and donor sites of each coding exon. Since the promoter region for AIPL1 is 
currently unknown, it was not possible screen this region in the sequencing 
of the gene. The primer sequences are listed in Chapter 2 (see section 
2.11.3). PCR conditions for each pair of forward and reverse primer were 
optimized prior to sequencing of patient DNA and this is listed in Section 
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2.11.3 along with the annealing temperatures. Figure 5.1A shows the results 
of the primer optimization for each exon using normal control DNA. The 
fragment of appropriate sizes were obtained for each individual exon and the 
respective annealing temperatures for each exon is shown.  For each patient 
DNA sample, the 6 coding exons of AIPL1 were amplified and the PCR 
products were checked by gel electrophoresis for specificity and quality. 
Figure 5.1B shows an example of the gel electrophoresis of the PCR 
products of exon 2 from patient DNA samples. Only samples which yielded a 
clean, specific PCR band of the predicted size were subsequently subjected 
to direct sequencing. The adenine (A) of the start codon (ATG) of the AIPL1 
cDNA was assigned as nucleotide 1.  
 
Once a sequence variant is identified, it was determined whether it is 
disease-causing or a polymorphism using the following attributes which 
increase the probability that a sequence variation causes a defect in the 
resulting protein: 1) the predicted effect of the base pair change on the 
protein product; changes such as deletions, frameshifts, splice site mutations 
and nonsense mutations were considered definite null mutations and 
therefore may have more detelerious effects, while mutations such as 
missense mutations or in-frame deletions or insertions may still result in 
some residual protein function. For other sequence variants, a web-based 
protein prediction program was used to help distinguish the benign from 
deleterious effects of a new mutation. 2) The relative frequency of the 
sequence variant in LCA patients versus normal controls. A sequence 
variation was considered likely to be pathogenic when it was found 
exclusively in patients and not in 192 chromosomes from 96 control DNA 
samples (although caution has to be taken when considering an infrequent 
allele), whereas >1% frequency in the controls were likely to be 
polymorphisms. 3) The identification of two pathogenic alleles. 4) Appropriate 
co-segregation of the mutant allele in the affected and non-affected members 
of the families. 5) Conservation of the mutant codon or protein residue 
across other species. The reference sequence for sequence analysis was 
taken from the Genbank reference sequence (accession number 
NM_014336.3). NCBI Reference Sequence: NP_055151.3 
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Table 5.4  List of AIPL1 sequence variants contained in the LCA microarray chip by Asper-
Genetics. A total of 32 different sequence variants is screened for by the chip. 
 
Gene 
 
Exon 
 
nucleotide change 
 
amino acid change  
 
AIPL1 1 41A>G K14E 
AIPL1 2 97 ins 8bp (GTGATCTT)  FS 
AIPL1 2 112delC;111C>T  R38fs;F37F 
AIPL1 2 116C>A 739N 
AIPL1 2 126T>A C42X 
AIPL1 2 157C>T R53W 
AIPL1 2 211G>T V71F 
AIPL1 2 236T>C M79T 
AIPL1 2 244C>T H82Y 
AIPL1 2 264G>A W88X 
AIPL1 2 265T>C C89R 
AIPL1 2 268G>C D90H 
AIPL1 IVS2-2 277-2A>G Premature stop/frameshift/deletion 
AIPL1 3 286G>A V96I 
AIPL1 3 341C>T T114I 
AIPL1 3 401A>T Y134F 
AIPL1 3 423G>T/C Q141H 
AIPL1 3 461 T>C L154P 
AIPL1 IVS3+1 IVS3+1 G>A Premature stop/frameshift/deletion 
AIPL1 4 487C>T Q163X 
AIPL1 4 538G>A V180I 
AIPL1 4 589G>C A197P 
AIPL1 4 617T>A I206N 
AIPL1 5 715T>C C239R 
AIPL1 5 733_735 del E245del 
AIPL1 5 769 del 9bp (CTCCGGAC) frameshift 
AIPL1 5 784G>A G262S 
AIPL1           6 IVS5-10_786 del Premature stop/frameshift/deletion 
AIPL1 6 834G>A W278X 
AIPL1 6 905G>T R302L 
AIPL1 6 1008 del 2bp (AG) frameshift 
AIPL1 6 1126C>T P376S 
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1
	  
2
	  
Figure 5.1A. Optimization PCR of primer pairs for each AIPL1 
exon. Single PCR band of expected size were obtained for each 
exon. The respective optimal annealing temperatures for each exon 
is shown 
Figure 5.1B. Gel electrophoresis of PCR samples of patient DNA for 
exon 2. After PCR amplification of PCR samples were analysed by gel 
electrophoresis. An example of PCR samples of exon 2 is shown. Expected 
bands size was approximately 400 bp. Each lane represents PCR sample of 
one patient DNA. M denotes marker. Numbers 1 to 17 indicates respective 
PCR samples. 
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5.5  Results 
 
5.5.1  Comparative analysis of AIPL1 mutations 
 
LCA chip analysis was performed on all of the 326 DNA samples that were  
obtained from the patient panel of 309 probands and 17 relatives. Bi-
directional sequencing was performed on 153 proband DNA samples of all 6 
exons of the AIPL1 gene including splice-site junctions. These samples 
consisted of DNA from patients in whom a molecular cause had not yet been 
identified for their disease. Of the 153 samples that were sequenced, 129 
consisted of samples that have been screened using the LCA chip prior to 
sequencing and did not return any mutations; 9 samples returned one allelic 
change on the LCA chip; and 15 samples had not been screened on the LCA 
chip prior to sequencing. Bi-directional sequencing of AIPL1 was also 
performed on the control panel consisting of 96 control DNA samples.  
 
The LCA chip identified AIPL1 disease-associated variants or mutations in 
17/326 of DNA samples, giving a positive hit rate of 5% for AIPL1. This is 
similar to the hit rates reported by other studies using the LCA chip and the 
mutation frequency in LCA [103][519]. Homozygous mutations were found in 
4 (1.2%) patients and compound heterozygous mutations in 3 (0.9%) 
patients, and a further 10 (3.0%) patients had a single allelic change 
identified (Table 5.5). Of the patients with only one allelic change, a second 
allele was identified in another LCA gene using the same array (RPGRIP, 
RDH12, CRB1) in 5 patients. Direct sequencing identified 21/153 (14%) 
patients with AIPL1 mutations or missense changes (Table 5.5). Of these, 4 
(2.6%) patients had homozygous mutations, 8 (5.2%) were compound 
heterozygotes and 8 (5.2%) had one allelic change.  
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Table 5.5  Comparison of  mutation screening by Asper LCA chip and direct sequencing.  
The number of disease-associated variants and novel non-conservative variants in AIPL1  
detected by Asper LCA chip and by direct sequencing . 
Method Samples 
detected 
(n) 
Homozygous Compound 
heterozygous 
Single mutation 
 
Asper LCA chip 
Direct sequencing 
 
17/326(7%) 
21/153(14%) 
 
4(1.2%) 
4(2.6%) 
 
3(0.9%) 
8(5.2%) 
 
10(3.0%) 
8(5.2%) 
     
 
 
 
A total of 39 sequence variants (reported and unreported) were found on 
sequencing of the patient samples, of which 26 have not been reported 
before (Table 5.6). None of the novel variants were found on sequencing of 
the control DNA. Sequencing of the panel of 96 control DNA samples 
identified 15 sequence variants, of which 10 have not been previously 
reported. A comparison of the number of sequence variants identified in the 
patient panel and the normal control panel is presented in Table 5.6. Overall 
sequencing of the 153 probands revealed AIPL1 variants (reported and 
unreported) in at least one allele in 109 (69%) subjects. Sequencing of 
normal controls identified AIPL1 sequence variants in 36/96 (39%) samples. 
A summary of the predicted effects of the novel variants found on 
sequencing of the patient and normal panel is shown in Table 5.7. Twenty-
five different novel AIPL1 variants were found.  Silent mutations make up the 
majority (13/26), followed by missense mutations (9/26), frameshift (2/26) 
and splice (1/26) mutations. An overview of all the sequence variants 
identified by direct sequencing of AIPL1 in the patient samples is presented 
in Table 5.8.  The sequence variants which were found by sequencing AIPL1 
in a panel of normal DNA are presented in Table 5.9. These results suggest 
that AIPL1 may be polymorphic in the general population, and sequence 
variants appear to be more common in the population of patients with 
childhood retinal dystrophies. The number of synonymous and non-
synonymous single nucleotide polymorphisms observed per patient would 
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indicate that changes in AIPL1 sequence are more common than expected.  
Furthermore, many of these changes have not been investigated at 
biochemical level and the functional effect of these changes is unknown. 
 
 
 
Table 5.6 Summary of findings from sequencing of patient panel of LCA and childhood 
retinal dystrophies and sequencing of normal controls.   
Numbers in parenthesis () indicated number of samples found in the category of sequence 
variant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
 
 
 
Table 5.7 Predicted effects of novel variants found through sequencing of the patient panel 
of LCA and childhood dystrophies and sequencing of normal controls. 
Numbers in parenthesis () indicated number of samples found in the category of sequence 
variant.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
 
 
 
 
 
 
 
DNA panel Total no. 
variants found 
Reported 
mutations 
Polymorphisms  No. of novel 
variants  
 
Patient(153) 
Control  (96) 
 
39(109) 
15(36) 
 
7(19) 
0 
 
6(121) 
5(92) 
 
26(67) 
10(35) 
     
DNA panel No. of novel 
variants 
Missense 
mutations 
Frameshift 
mutations  
Splice 
site 
Silent 
mutation 
 
Patient(153) 
Control  (96) 
 
26(67) 
10(35) 
 
10 
0 
 
2 
 
1 
 
13 
10 
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Table 5.8  AIPL1 sequence variants found on sequencing the patient panel of LCA and 
childhood-onset retinal dystrophies. A detailed analysis of the sequence variants found in 
AIPL1 mutation screening of the DNA from the in LCA genetic database, summarizing all the 
sequence changes found in the study. Novel changes are indicated in black colour, known 
mutations in red and known polymorphisms are in green. 
Exon Base 
change 
Codon Protein Effect No. in patients No in 
controls 
Ex 1 c.51G>A CTG>CTA Leu17Leu Silent mutation 1 het 0 
 c.1-106C >A Intronic  May affect 
promoter  
6 hets; 1 hom 0 
Ex 2 c.268G>C GAC>CAC Asp90His Rare variant 24 hets; 4 hom 24 
 c.111C>T TTC>TTT Phe37Phe Polymorphism 5 hets; 1 hom 4 
 c.264G>A  Trp88X Termination 2 hom 0 
Ex 3 c.439C>T CTG>TTG Leu147Leu Silent mutation 2 hets 0 
 c.390C>A CAC>CAA His130Gln Missense 
mutation 
1 het 0 
 c.277-10A>G IVS2-10A>C  Polymorphism 15 hets; 27 hom 28 
 c.277-30insG IVS2-30insG  Silent mutation 1 het 0 
 c.300A>G CTA>CTG Leu100Leu Polymorphism 21 hets; 34 hom 28 
 c.286G>A GTC>ATC Val96Ile Missense 
mutation 
5 hets 0 
 c.341C>T 
 
ACA>ATA Thr114Ile Missense 
mutation 
1 hom  
Ex 4 c.555A>G GGA>GGG Gly185Gly Silent mutation 1 het 0 
 c.592T>A TCT>ACT Ser198Thr Missense 
mutation 
5 hets 0 
 c.487C>T CAG>TAG Gln163X Termination 1 hom 0 
 c.641A>G AAG>AGG Lys214Arg Missense 
mutation 
1 het 0 
 c.593C>T TCT>TTT Ser198Phe Missense 
mutation 
1 het 0 
 c.466-2A>G IVS3-2A>G  Affect splicing 2 het 0 
 c.642+48G>A IVS4+48G>A  Silent mutation 4 hets; 30 hom 0 
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 c.466-26T>C IVS 3-26T>C  Silent mutation 9 hets; 5 hom 18 
Ex 5 c.784+8G>C IVS5+8G>C  Silent mutation 5 hets 0 
  c.672insC   Frameshift 3 hets 0 
 c.643-33C>T IVS4-33C>T  Silent mutation 22 hets; 10 hom 7 
 c.784+26G>C IVS5+26G>C  Silent mutation 4 hets 0 
 c.651A>G CCA>CCG Pro217Pro Polymorphism 16 hets; 51 hom 53 
 c.784+18G>A IVS5+18G>A  Benign variant 3 hets; 1 hom 0 
Ex 6 c.834G>A TGG>TGA Trp278X termination 2 hets; 2 hom 0 
 c.853G>A/ 
c.854C>A 
GCG>AAG Arg285Gln Missense 
mutation 
1 het 0 
 c.894G>C CAG>CAC Gln298His Missense 
mutation 
1 het 0 
 c.905G>T CGC>CTC Arg302Leu Known 
mutation 
6 hets; 2 hom 0 
 c.971G>T CGG>CTG Arg324Leu Missense 
mutation 
1 het 2 
 c.1003ins G   frameshift 1 hom 0 
 c.1032A>G GCA>GCG Ala344Ala Silent mutation 3 hets 0 
 c.1038A>G TCA>TCG Ser346Ser Silent mutation 3 hets 0 
 c.1076C>T TCT>TTT Ser359Phe Missense 
mutation 
1 het 0 
 c.1091C>G GCA>GGA Ala364Gly Missense 
mutation 
1 het 0 
 c.1097C>G CCC>CGC Pro366Arg Missense 
mutation 
2 hets 0 
 c.1126C>T CCG>TCG Pro376Ser Known 
mutation 
3 hets 0 
 c.1162A>G  non 
coding 
exon 
Silent mutation 1 het 0 
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Table 5.9   Summary of changes found in mutation screening of normal DNA samples. 
 
 
 
 
 
 
 
 
 
 
Exon Base change Protein Effect No. in control 
Ex 1 c.1-45 C>A   Non reported variant  2 hets  
Ex 2 c.97-16C>T   Non reported variant 1 het  
 c.111C>T  phe37phe  Non reported silent mutation  4 hets  
 c.267C>T  cys89cys  Reported polymorphism  4 hets  
 c.268G>C  Asp90His  Reported  polymorphism 24 hets; 5 homo  
Ex 3 c.277-10A>G   Reported  polymorphism    22 hets;6 homo  
 c.300A>G  Leu100Leu  Reported  polymorphism 24 hets ; 4 homo  
Ex 4 c.466-26T>C   Non reported variant  18 hets  
 c.484G>A   Non reported variant  2 hets  
Ex 5 c.651A>G  pro217pro  Reported  polymorphism    15 hets ; 38 homo  
 c.643-33 C>T   Non reported variant  7 hets  
 c.678G>A  Glu226Glu  Non reported variant 3 hets ; 1 homo  
Ex 6 c.1005C>A  Pro335Pro  Non reported  variant 2 hets  
 c.1110A>T  Pro370Pro  Non reported  variant 1 het  
 c.1023G>A  Glu341Glu  Non reported  variant   3 hets ; 1 hom  
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5.5.2  Identification of patients with AIPL1 mutations. 
 
A summary of patients who are homozygous or compound heterozygous for 
pathogenic sequence variants in AIPL1 identified through mutation screening 
are shown in Table 5.10 to Table 5.12. Patients are divided into 3 groups: 
Patients with definite AIPL1-associated disease, patients with likely AIPL1-
associated disease and patients with possible AIPL1-associated disease.  
 
A total of 11 patients were identified with 2 confirmed mutations and 
therefore have definite AIPL1-associated disease (Table 5.10). The 
sequence changes were verified using bi-directional sequencing and 
segregation analysis.  Five of these patients were found to have 
homozygous null mutations, and three patients were homozygous for 
missense mutations. One patient was compound heterozygous mutation for 
a missense mutation and a splice-site variant, one patient had a compound 
heterozygous mutation for a missense mutation and a novel nonsense 
variant, and a further patient was compound heterozygous for different 
missense mutations. 
 
Table 5.11 summarises the patients who are likely to have AIPL1-associated 
disease. These patients were compound heterozygous for missense 
substitutions, some of these were novel sequence variants. Some of these 
patients are awaiting further confirmation on segregation analysis and 
verification of the pathogenicity of the novel variants. 
 
A further 8 patients were found to have one allelic mutation in AIPL1, and 
therefore may possibly have AIPL1-related disease. This group is 
summarized in Table 5.12. Three patients in this group had another mutation 
found in another gene (RDH12, RPGRIP1). 
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Table 5.10. Patients with disease-causing mutations in AIPL1.  
A summary of patients who are homozygous or compound heterozygous for pathogenic sequence 
variants in AIPL1 identified through mutation screening are displayed.  The mutations have been 
confirmed with sequencing and segregation analysis.   
LCA-Lebers Congenital Amaurosis; EORD- early onset retinal dystrophy. 
* - denotes a novel mutation. 
 
 
 
 
 
 
 
 
 
 
DNA	   Mutations	   Segregation	   Diagnosis	   ethnicity	   consa
nguini
ty	  
Asper/se
quenced	  
9728	   W278X	  hom	  	   Mother	  is	  het;	  no	  
father	  DNA	  
LCA	   African	   no	   A	  
07582	   W278X	  hom	   Mutation	  
segregates	  
	  
LCA	   Caucasian	   No	   A,S	  
14777	   Q163X	  hom	   Mutation	  
segregates	  
LCA	   Middle-­‐
east	  
yes	   A,S	  
14001	   W88X	  hom	  	   Affected	  sister	  
	  
LCA	   Pakistani	   Yes	   A	  
15000	   W88X	  hom	  	  
	  
Sister	  to	  14001	   LCA	   Pakistani	   Yes	   A	  
14874	   IVS2	  277-­‐2A>G	  splice	  
G262S	  
Mother	  has	  splice	  
mutation	  only	  
LCA	   British	   no	   A,S	  
13484	   P376S	  hom	   Mother	  is	  het;	  no	  
father	  DNA	  
LCA	   African	   no	   A,S	  
13052	   T114I	  het	  
P376S	  het	  
Mutation	  
segregates.	  
EORD	   African	   no	   A,S	  
13412	   R302L	  hom	   Mutation	  
segregates.	  
Affected	  sis	  is	  hom	  
and	  mother	  is	  het	  
LCA	   Iranian	   Yes	   A,S	  
31895	   V71F	  het	  
W72X*	  
Mother	  has	  V71F;	  
Father	  has	  W72X	  
LCA	   Israeli	   no	   A,S	  
15618	  
	  
R302L	  hom	   Mutation	  
segregates	  
EORD	   Indian	   No	   A,S	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Table 5.11. Patients with likely disease-causing mutations in AIPL1.  
Summary of patients who have 2 or more non-conservative sequence variants in AIPL1 
identified through mutation screening.  The mutations are awaiting confirmation with 
segregation analysis and verification of the pathogenicity of the novel variants. 
LCA-Lebers Congenital Amaurosis; EORD- early onset retinal dystrophy. 
 
	  
	  
 
 
 
 
 
 
 
 
 
 
 
 
DNA	   Mutations	   Segregation	   Diagnosis	   ethnicity	   consa
nguini
ty	  
Asper/se
quenced	  
14651	   T114I	  het	  
T47R	  het*	  
A285Q*	  
A313S	  het*	  
One	  parent	  has	  
T114I	  het	  
LCA	   Asian	   Yes	   A,S	  
13163	   S198T	  het	  *	  
R270L	  het	  *	  
No	  DNA	  from	  
family	  	  
EORD	   Caucasian	   no	   A,S	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Table 5.12. Patients with one mutation found in AIPL1.  
Summary of patients who have been found to have one mutation or non-conservative 
sequence variant in AIPL1 identified through mutation screening.   
LCA-Lebers Congenital Amaurosis; EORD- early onset retinal dystrophy; RP- retinitis 
pigmentosa. 
	  
 
 
 
 
 
 
DNA	   Mutations	   Segregation	   Diagnosis	   ethnicity	   consa
nguini
ty	  
Asper/se
quenced	  
13353	   R302L	  het	   Unaffected	  sister,	  
brother	  and	  parent	  
are	  het	  for	  this	  
LCA	   Iranian	   no	   A,S	  
6604	   P376S	  het	   Mother	  is	  	  P376S	  het	   EORD	  
	  
African	   no	   A,S	  
13232	   W278X	  het	  
RDH12	  
Father	  has	  W278X	  het	  
	  
EORD	   British	   yes	   A,S	  
13278	   Y134F	  het	   Father	  has	  Y134F	  het	   LCA	   Banglades
hi	  
yes	   A,S	  
14351	  
	  
R302L	  het	   Father	  is	  het	  for	  this	   EORD	   Pakistani	   yes	   A,S	  
14341	   R302L	  het	  
RPGRIP	  
homozygous	  
c.1107delA	  
Unaffected	  father	  has	  
R302L	  hom	  	  	  
LCA	   Pakistani	   Yes	   A,S	  
15324	   Y134F	  het	   Mother	  is	  	  Y134F	  het	   LCA	   Caucasian	   No	   A,S	  
	  
10759	   R302L	  het	  
RDH12	  29del3bp	  
het	  
Father	  has	  R302L	  het	   LCA	   Indian	   no	   A,S	  
13026	   P376S	  het	  
RDH12	  IVS2-­‐12T>G	  
No	  DNA	  from	  family	   RP	   Carribean	   no	   A,S	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5.5.3  Determination of significance of novel sequence 
variation. 
 
A sequence variation is likely to be pathogenic when it is found exclusively in 
patients and not in at least 192 chromosomes from 96 control DNA samples. 
We screened control DNA samples by direct sequencing and were able to 
determine the allele frequency of any sequence variant in control subjects.  
 
To determine whether a sequence variant is likely to be disease-causing, it is 
important to establish whether the sequence variants are likely to be harmful 
to protein function or structure.  Functional analysis is not always available to 
investigate the effect of a missense variant on protein activity. To ascertain 
the likelihood whether a missense substitution was likely to be detrimental, a 
prediction of the functional effect of a novel missense variation was made by 
using information from the characteristics of the amino acid substituted, 
comparing interspecies amino acid conservation using ClustralW {Chenna, 
2003 1010 /id} and protein structural information  using  Uniprot.   
 
In-silico prediction of novel and some known missense mutations on AIPL1 
protein function was performed using three protein function prediction 
software packages : Polyphen [394], SIFT [349] and PMut [134] . All three 
prediction software packages have been previously applied to various 
disease-gene models [350]. Table 5.13 shows the results of in-silico analysis 
of known missense mutations and novel variants that were found in patients 
with AIPL1-associated disease. 
 
Figure 5.2A and B shows the amino acid alignment of AIPL1 between 
different species and the protein sequence comparison of AIP, another 
member from the FKBP protein family which shares homology with AIPL1. 
The positions of highly conserved residues are shown. Sequence 
comparison across different species and with AIP shows that there is a high 
degree of conservation of the protein sequence, particularly within the TPR 
domains which are sites of protein interaction. Figure 5.3 shows a schematic 
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structure of AIPL1 and the relative locations of the disease-causing 
mutations found in this study. The results of the in-silico analysis and 
conservation analysis are further discussed in the context of individual 
patients below. 
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Table 5.13. In-silico prediction of known mutations and novel sequence variants.  
*Denotes	  novel	  sequence	  variant	  
SIFT	  -­‐	  http://sift.jcvi.org/)	  –	  cut	  off	  is	  at	  0.05.	  	  <0.05	  predicted	  to	  have	  a	  deleterious	  effect.	  
>0.05,	  the	  change	  is	  predicted	  to	  be	  tolerated.	  	  The	  higher	  the	  value,	  the	  less	  functional	  
impact	  the	  substitution	  is	  likely	  to	  have.	  	  
Change	  	   SIFT	  	   Polyphen	  	   pMUT	  	  
	   Prediction	  	   Tolerance	  
index	  	  
Prediction	  	   PSIC	  
score	  
differe
nce	  	  
NN	  
output	  	  
Reliability	  	   Prediction	  	  
V96I	  	   Tolerant	  	   0.20	  	   Benign	  	   0.067	  	   0.0794	   8	   Neutral	  
T114I	  	   Tolerant	  	   0.19	  	   Benign	  	   0.179	  	   0.7499	   5	   pathological	  
Y134F	  	   Tolerant	  	   0.26	  	   Benign	  	   1.133	  	   0.0715	   8	   Neutral	  
G262S	  	   Tolerant	  	   0.86	  	   Benign	  	   1.166	  	   0.3055	   3	   Neutral	  
R302L	  	   Tolerant	  	   0.16	  	   Benign	  	   1.086	  	   0.8448	   6	   Pathological	  
P376S	  	   Intolerant	  	   0.00	  	   N/D	  	   N/D	  	   0.7874	   4	   Pathological	  
A285Q*	   Tolerant	   0.11	   Benign	   1.153	   0.9286	   8	   Pathological	  
S198T*	   Tolerant	   0.44	   Benign	   0.025	   0.2553	   4	   Neutral	  
A313S*	   Tolerant	   0.11	   Benign	   0.878	   0.2607	   4	   Neutral	  
V71F*	   Intolerant	   0.00	   Damaging	   3.664	   0.6540	   3	   Pathological	  
R270L*	   Intolerant	   0.00	   Damaging	   2.726	   0.8584	   7	   Pathological	  
T47R*	   Intolerant	   0.04	   Damaging	   2.726	   0.7359	   4	   Pathological	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PolyPhen	  algorithm	  http://genetics.bwh.harvard.edu/pph/	  index.html).	  Polyphen	  
evaluates	  the	  location	  of	  the	  substitution	  and	  the	  function	  of	  that	  region	  and	  whether	  the	  
substitution	  is	  likely	  to	  affect	  the	  three-­‐dimensional	  structure	  of	  the	  protein	  (PSIC	  Score).	  
Scores	  greater	  than	  2.0	  indicate	  probably	  damaging	  to	  protein	  function,	  scores	  of	  1.5–2.0	  
as	  possibly	  damaging,	  and	  scores	  of	  lower	  than	  1.5	  as	  benign.	  
pMUT	  .	  NN=	  neural	  network	  values	  from	  0-­‐1.	  	  >0.5	  is	  predicted	  as	  a	  disease	  associated	  
mutation.	  Reliability	  =	  values	  0-­‐9.	  	  >5	  is	  the	  best	  prediction	  
N/D	  	  -­‐	  Polyphen	  was	  unable	  to	  calculated	  for	  this	  position	  as	  it	  lies	  in	  the	  poly	  proline	  
domain	  and	  this	  region	  only	  occurs	  in	  primates	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Figure 5.2 A.  Comparative amino acid alignment of AIPL1 in different species. 
Identical residues are in background white. Residues which are completely conserved are 
highlighted in blue. Residues which at which similar changes are allowed are in turquoise 
background.  Non conserved residues are in highlighted in green. Tetratricopeptide domains 
(TPRs) are indicated in red background. 
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Figure 5.2B  Amino acid alignment between AIPL1 and AIP from the FKBP immunophyllin family.  
Completely conserved residues are highlighted in background green. Conservative amino acid 
changes in background blue. Positions in which there are different residues are in background white 
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5.6  Patients with definite AIPL1-associated 
disease 
 
5.6.1  Molecular analysis 
 
Two patients (DNA no. 9728 and 07582) were found to carry homozygous 
nonsense mutations c.834G>A (Trp278X) in exon 6.  This mutation was also 
present in compound heterozygous form in one proband (DNA no.13225) . 
This sequence variant changes the TGG codon encoding tryptophan into a 
premature stop codon TGA at position 278 of the amino acid chain, and 
effectively deletes the hinge domain on each AIPL1 allele. When expressed, 
this allele is predicted to encode a severely truncated protein. It is the most 
frequent mutation described in AIPL1 patients and has been reported in 
several families from different ethnic backgrounds around the world including 
Pakistani, American, French and Spanish [440].[95,103]. Two patients (No. 
14001 and 15000) were homozygous for nucleotide substitution c.264G>A 
(Trp88X). This mutation was first described in an affected proband from a 
Bangladeshi family [442]. If expressed, these alleles are predicted to encode 
an AIPL1 protein truncated by more than two-thirds and lacking all three 
tetratricopeptide domains which are central to the protein function. Patient 
14777 was found to have a homozygous C to T nucleotide substitution at 
position 487 which changes the codon for glutamine into a termination codon 
at position 163 of the amino acid chain (Gln163X). This is a known mutation 
which was first reported in homozygous form in affected individuals from a 
Palestinian family.[442]. If expressed, these alleles would encode an AIPL1 
protein truncated by more than half, with the resulting protein lacking 
tetratricopeptide domains II and III. All three nonsense mutations resulted in 
null. This matches the phenotype that is seen in these patients and all of 
these patients were clinically diagnosed with LCA.  
 
Patient 14574 is compound heterozygous for 2 known mutations; c.277-
2A>G and c.784>A (G262S). The first mutation affects the canonical splice 
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acceptor site of intron 2 which may result in the loss or reduced specificity of 
the splice site.  The consequences can be catastrophic, ranging from a 
premature stop codon, loss of an exon or insertion of an intron or loss of the 
reading frame and is likely to prevent functional protein biosynthesis. The 
second mutation is a missense substitution of glycine for serine at position 
262 of the amino acid chain, and has been described as an disease-causing 
mutation in compound heterozygous form along with W278X in a patient with 
LCA [442]. This substitution is located in the main backbone of the AIPL1 
protein sequence and at a position which is conserved across different 
species (Figure 5.2A). Both glycine and serine have different side-chain 
groups and this substitution could thus result in a significant change in 
protein function. Co-segregation studies showed that the both mutations 
were on separate alleles; the patient inherited the c.277-2A>G mutation from 
his mother and G262S from his father. Patient 14874 was diagnosed with 
LCA.  The case histories of the patients mentioned are detailed in the 
appendix. 
 
Patient 31895 was found to have a novel null mutation W72X and a 
missense substitution V71F.  The valine at residue 71 is conserved across 
different species and lie in the N-terminal immunophilin domain. Mutations in 
this domain have been linked to LCA. Segregation analysis confirmed that 
the mutations were located on separate alleles, the mother was a carrier for 
V71F and the father was heterozygous for the null mutation W72X. The 
patient was diagnosed with LCA at the age of 2 years (see appendix 1 for 
case history). Patient 13052 was compound heterozygous for 2 mutations, 
c.341C>T (Thr114Ile) and c.1126C>T(Pro376Ser). The compound 
heterozygous amino acid substitution of both Thr114Ile and Pro376Ser has 
been previously described in an affected proband from an African-American 
family who had a clinical diagnosis of LCA.[442]. The amino acid sequence 
alignment of AIPL1 shows, that the threonine at position 114 is located in a 
region that is fully conserved between the human, chimpanzee, mouse, rat, 
and cow proteins (Figure 5.2a). Comparison of the sequence alignment 
between AIPL1 and AIP shows that only a conservative change occurs at 
this position (Figure 5.1b). Furthermore, the amino acids threonine and 
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isoleucine have different chemical properties; threonine is a polar and 
hydrophilic amino acid while isoleucine has an aliphatic side group and is 
hydrophobic and water-insoluble. The T114I is a known mutation and has 
been described to be associated with LCA in previous literature [442][440].  
Protein prediction analysis revealed conflicting results: SIFT and Polyphen 
predicted that the change was  benign, while pMUT revealed the mutation to 
be pathological. It is possible that the T114I constitutes a mild mutation. Our 
patient was diagnosed with less severe disease of rod-cone dystrophy (see 
appendix 1 for case history), and retained some vision in adulthood (see later 
section).  
 
Three patients were found to carry homozygous missense mutations; patient 
13484 was found to homozygous for P376S, and patients 13412 and 15618 
were both found to be homozygous for R302L and were not related to each 
other and were from different famil and ethnic backgrounds(see appendix 1 
for respective case histories). The c.1126C>T(P376S) mutation was first 
described in an African-American child diagnosed with LCA who was 
compound heterozygote for 2 amino acid substitutions, T125I and P376S 
[442]. Our patient 13484 who has a homozygous P376S mutation was also 
diagnosed with LCA. The P376S mutation represents a non-conservative 
substitution from proline, a non-polar hydrophobic amino acid with a rigid 
structure conferred by a secondary amine side group linked to the α-amino 
group, to serine which is a hydrophilic, polar amino acid. Due to the 
differences in the chemical and physical properties of the proline and serine, 
this missense substitution would result in major changes in the properties 
and function of the AIPL1 protein. This was also supported by protein 
prediction analysis, the substitution was found to be intolerant when applied 
to SIFT and pMUT software. These findings indicate that the P376S mutation 
is very likely to be disease-causing. 
 
The c.905G>T (R302L) substitution in patients 13412 and 15618, was first 
described as a disease-causing homozygous mutation in a proband with 
LCA from an Indian family [442]. Similarly in this study, both patients 13412 
and 15618 were diagnosed with LCA. The arginine residue at position 302 is 
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conserved between human, squirrel monkey, chimpanzee and rhesus 
monkey AIPL1 and therefore is thought to be disease-causing. Furthermore, 
it was not found on sequencing the normal control panel. It is interesting 
however  to note that the arginine at this position is not conserved between 
human and rat and mouse AIPL1 (Figure 5.2A). The functional effect of the 
substitution was not unlikely to be harmful according to SIFT and polyphen 
protein prediction software, but is damaging according to pMUT analysis. Co-
segregation study of the mutation with the phenotype in the original family 
described in the published study was not performed. In this study, we found 
a homozygous R302L change in the unaffected father (clinical state to be 
further confirmed) of another proband carrying a heterozygous mutation. 
Hence it may be possible that this sequence could represent a rare benign 
variant. Both missense mutations P376S and R302L are located within the 
hinge region of AIPL1. This C-terminal polyproline-rich region is only present 
in primate AIPL1 and cross-species comparative analysis of the protein 
sequence indicate that there is a high level of sequence conservation within 
the hinge region between primates (chimpanzee, baboon, rhesus monkey 
and humans). There is evidence to suggest that the polyproline-rich region 
performs an essential function in normal primate vision since reported 
mutations have been identified in this region which cause the severe 
phenotype of LCA [442][440]. Furthermore, two deletion mutations located  in 
this region (A336∆2 and P351∆12)  have been associated with cone-rod 
dystrophy and juvenile RP [442].   Further studies in determining protein 
function is will be necessary to establish the role of the hinge region in AIPL1 
and its significance to vision.  
 
Yeast 2-hybrid screens have demonstrated interactions between between 
AIPL1 and NUB1 [7], a protein implicated in regulation of proteolysis, and 
also between AIPL1 and farnesylated proteins[393].  AIPL1 modulates the 
subcellular localization of NUB1, from the nucleus towards the cytoplasm, 
and behaves in a chaperone-like manner to suppress the formation of 
inclusions arising from NUB1 fragments and redistribute these in the 
cytoplasm [476]. This ability requires the C-terminal region of AIPL1 to be 
intact. Based on these observations of interactions, studies have attempted 
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to characterize various sequence changes at a bio-molecular level by 
determining the effects AIPL1 sequence changes on AIPL1 function with 
respect to the NUB1 translocation or farnesylation, and protein solubility. 
Various mutant forms of AIPL1 were tested and these included W278X, 
G262S and R302L relevant to this study. Many of the mutant forms of AIPL1 
were SDS-soluble (non-solubility is an indication of protein non-function) and 
had similar subcellular distribution compared to wild-type AIPL1, with the 
exception of W278X and R302L. W278X formed SDS-insoluble cytoplasmic 
inclusions, suggesting that the mutant protein undergoes misfolding and 
aggregation, and is therefore non-functional. It was also shown that W278X 
completely defective with respect to modulating the nuclear translocation of 
NUB1. R302L was shown to have reduced activity with respect to modulation 
of NUB1 transocation and subcellular distribution. The G262 mutation on the 
other hand, was found to be hyperactive  in the modulation of NUB1 nuclear 
translocation, and it has been suggested that the basis of disease in this 
case may involve the interaction of AIPL1 with an alternative binding partner 
[476].  There is little evidence however, that NUB1 interaction with AIPL1 is 
physiologically relevant to the role of AIPL1 in the retina. It is therefore 
unclear whether the yeast 2-hybrid screen is informative with regards to the 
pathogenesis of LCA. 
 
Another functional study showed that various mutations in AIPL1 lead to 
various degrees of abolishment of AIPL1 interaction with farnesylated 
proteins, with W278X having the most severe effect [393]. Interestingly, 
R302L substitution did not appear to affect the interaction between AIPL1 
with farnsylated proteins [393], despite being less active with respect to its 
modulation of NUB1 translocation. The conflicting findings on biomolecular 
characterization indicate that AIPL1 may have complex functions involving 
multiple binding partners. Furthermore, strong evidence has emerged from 
animal models indicating that AIPL1 is critical for the biosynthesis of rod and 
cone PDE and that retinal degeneration seen in AIPL1 mutations is not due 
to any defect in farnesylation. In vivo expression studies using animal models 
would be able to provide better evidence of whether a sequence variant is 
pathogenic.  
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5.6.2  Genotype-phenotype correlation 
 
The clinical characterisation of disease due to AIPL1 mutations is important 
for assessment of any future therapies. Clinical assessment of the affected 
individuals included fluorescein angiography, electrophysiology, Goldmann 
perimetry, OCT and autofluorescent imaging. This section aims to describe 
the phenotypic features and clinical subtypes associated with AIPL1 
mutations and observe possible differences and similarities in the expression 
of fundus changes and disease severity between different mutations. The 
phenotype of 11 patients of different ethnic origin with confirmed mutations in 
AIPL1 is described. A summary of the phenotypic characteristic of patients 
with AIPL1-associated disease is shown in Table 5.15 
 
Out of the 11 probands with confirmed AIPL1 mutations, 9 had a clinical 
diagnosis of LCA and 2 were diagnosed with a milder disease of early onset 
rod cone dystrophy (EORD). All of the patients apart from one presented with 
poor vision and nystagmus. Amongst those diagnosed with LCA, the age of 
onset of disease, or the age at which visual difficulties were noticed ranged 
from birth to 6 months of age,  all of the probands were noted to have a 
visual problem before the age of 1 year. The onset of visual symptoms were 
considerably later in the two patients diagnosed with EORD, at ages of 2 
years and 6 years. The patients were examined at various ages, depending 
on when they were referred to the clinic.  
 
Visual acuities were found to vary between probands and ranged from 
logMAR 0.5 to light perception. Most patients had severe loss; six patients 
had light perception, two patient had counting fingers vision and one had 
hand motion vision in one eye. Three patients had measurable vision. 
However, comparison of the visual acuities and clinical features between the 
different mutations should take into consideration the fact that the probands 
were examined at different ages; many of them were seen as adults when 
the condition had progressed to advanced stages. Cycloplegic refractions 
performed in 5 out of 11 patients showed moderate myopia in 2 (-1.50D to -
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3.00D), high myopia in one (-8.50D) and two patients had moderate 
hypermetropia (+3.00D to +5.00D). Astigmatism was frequently noted in 
these patients.  Photoattraction (staring at lights) was reported in 3 patients 
and photoaversion in 1. Nyctalopia (night blindness) was reported in 4 
patients, while about half of the patients had some form of strabismus. All 
except for 1 patient had nystagmus and amaurotic pupils, the exception 
being the patient with clinically EORD who had reasonable remaining vision. 
 
Some form of cataract was seen in majority of patients (6 of 11 patients); 
lens changes included both cortical and posterior subcapsular opacities. 
However, cataracts appeared to be a later finding as the patients who had 
cataracts were in their late adolescence or adulthood. The youngest patient 
noted to have cataracts was 17 years old. Contrary to findings reported by 
Dhamaraj et al. [103] who found that cataracts and keratoconus were 
observed only in patients who were homozygous for AIPL1 mutations, we 
found cataracts in patients had homozygous and compound heterozygous 
AIPL1 mutations.  
 
Retinal findings were notable for pigmentary retinopathy and retinal drusen-
like deposits. Eight out of 11 patients with AIPL1-related disease had some 
form of pigmentary retinopathy that ranged from mild midperipheral bone 
spicule pigmentation to severe pigmentary clumping and chorioretinopathy 
(Figure 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 5.13). Most of these patients with 
pigmentary retinopathy were examined in late adolescence and adulthood. 
Three patients did not have any clinically evident retinal pigmentary changes 
; 2 of these patients were examined at the early ages of 2 and 7 years and 
were noted to have essentially normal-looking retinas (Figure 5.10 – fundal 
photo was taken later when patient turned 5 years old, and 5.11), one patient 
was aged 22 when examined and was found to have clinically unremarkable 
retina and macula. White drusen-like deposits at the level of the retina was 
observed in 2 patients around their second decades of life (Figure 5.4 and 
5.8).  
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Some form of maculopathy of variable appearance was noted in 8 out of 11 
(64%) patients. The maculopathy ranged in appearance from mild foveal 
atrophy with variable degrees of macular mottling to aplasia (Figure 5.4 to 
5.12). The severity of maculopathy appeared to increase with age; severe 
macular atrophy was seen mostly in older patients aged 17 years upwards. 
In the young patients aged 5 and 7 years, no clinically evident maculopathy 
(Figure 5.10) was seen in former, while an abnormal foveal reflex which may 
represent an early stage of maculopathy was seen in the latter aged 7 
(Figure 5.11). Exceptions to this were patients 13052 and 13412 who were 
aged 27 and 18 respectively in whom no obvious macular atrophy was seen 
at clinical examination despite their age (Figure 5.9 and 5.12). Patient 13052 
had a clinical diagnosis of EORD, a milder form of disease with later onset 
and slower progression and retained relatively good vision into adulthood. 
Patient 13412 was diagnosed with LCA with onset of visual problems at the 
age of 2 months. However, he may have a slower course of disease 
progression, as he retained slightly better vision in adulthood when 
compared to the other adult patients. The youngest patient with macular 
atrophy in our study was 17 years old (patient 14874, Table 5.14, Figure 
5.7). It is also interesting to note that patients with homozygous null 
mutations appear to have more severe macular atrophy; amongst the adult 
probands, patients who had severe macular atrophy carried homozygous 
nonsense mutations, W278X and W88X. On the other hand, patient 14874 
who had moderate macular atrophy and carried compound heterozygous 
mutations that included a splice site mutation and a missense mutation, and 
patients with missense mutations exhibited milder maculopathy or none at all 
(patients 13052 and 13412). An exception is patient 13484 with homozygous 
P376S who had severe macular atrophy (Figure 5.8). This may be due to 
influences from other environmental factors or genetic modifiers resulting in a 
more severe phenotype.  Varying degrees of optic nerve pallor were noted in 
majority of older patients who were in their second or third decades of life. In 
children, the optic nerve head largely appeared normal. 
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Goldman visual field (GVF) assessments were available on one patient only 
(Table 5.14). Most of the other patients either had visual acuities that were 
too poor for any visual field assessments or were too young to be able to 
cooperate with perimetry assessments. The Goldman visual field of patient 
13052, who has a clinical diagnosis of EORD, showed severe constriction of 
the central visual field to a residual central field of 10 degrees, and temporal 
sparing of the peripheral fields in each eye (Figure 5.14). Electrodiagnostic 
analysis were obtained in 9 out of 11 patients. Majority of the patients 
showed no measurable rod or cone responses indicating severe generalized 
retinal dysfunction, and where recorded the visual evoked potentials (VEP) 
were markedly reduced (Table 5.15). Only three patients, 13484, 13052 and 
15618 had residual ERG responses, although these were significantly 
reduced.  Different ERG responses were observed between the right and left 
eyes of patient 13484 (Figure 5.15). In the right eye, full field ERG and rod 
ERG responses were subnormal with markedly reduced a and b-wave 
amplitudes; cone flicker ERG was markedly delayed and subnormal. In the 
left eye, no detectable ERG responses could be recorded. The findings in the 
right eye were in keeping with a generalized retinal dysfunction affecting the 
rods more than cone systems. The retinal dysfunction in the left eye was so 
severe that no definite electro-retinal activity could be detected. The pattern 
ERG was undetectable in either eye, indicating severe bilateral macular 
involvement. Patient 13052 and 15618 had residual scotopic ERG and full 
flash ERG responses, although the amplitudes of these were markedly 
attenuated. Cone flicker ERGs were subnormal and delayed . There was 
some preservation of macular function in patient 13052, as shown by the 
presence of PERGs, although they were very reduced. These findings were 
in keeping with a rod-cone dystrophy with some residual macular function 
The PERG was undetected in patient 15618. 
 
OCT gives the possibility of in vivo histological examinations and can be 
used to generate topographical maps or cross-sections through specific 
areas of the retina. It is clinically useful for imaging selected retinal 
dystrophies and the retinal response to the genetic lesion. OCT imaging was 
obtained in 4 out of 11 patients. Generalised retinal thinning and decreased 
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foveal thickness was observed in all 4 patients, although in one patient the 
outer nuclear layer was clearly present at the fovea and retinal lamination 
was seen  (patient 31895, Figure 5.16).  
 
Fundus autofluorescence measures lipofuscin accumulation in the RPE and 
allows for the visualization of the accumulation and distribution of lipofuscin 
in the RPE, which is often not yet visible on ophthalmoscopy. It is known that 
loss of autofluorescence occurs in regions with chronic photoreceptor loss, 
due to absent outer segment turnover by the RPE. We performed fundus 
autofluorescence testing to determine which retinal areas had experienced 
severe photoreceptor degeneration. Autofluorescence imaging was 
performed in 4 patients with null and missense mutations (Figure 5.17); three 
of these patients had clinical LCA while one was diagnosed with EORD. 
Fundal autofluorescence imaging in patient 31895 appeared relatively 
normal, corresponding to their unremarkable macular findings on fundal 
examination. All of the other patients showed loss of autofluorescence 
peripherally beyond the vascular arcades, but variable preservation of 
autofluorescence was seen within the central macular area. A degree of loss 
of autofluorescence in the central foveal region was observed in patients 
14874 and 9728. These areas of reduced signal corresponded to areas of 
macular atrophy seen on slit-lamp biomicroscopy (Figure 5.17). Patient 
13052 showed patchy areas devoid of autofluorescence which was 
particularly marked at the fovea and perifoveal area; these areas of signal 
loss were consistent with areas of marked chorioretinal atrophy at the 
macula. There were also with scattered areas reduced signal in a bone 
spicule-like conformation, which were due to masking of autofluorescence by 
the presence of retinal pigmentation. 
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5.7  Patients with likely AIPL1-associated 
disease 
 
A summary of the phenotypic characteristic of patients with who are likely to 
have AIPL1-associated disease is shown in Table 5.17.  These patients have 
been identified to have 2 or more non-conservative sequence variants, some 
of the variants are novel changes and the pathogenicity of these changes is 
therefore uncertain. At the time of writing, segregation analysis was in 
progress for patient 14651; DNA has been obtained from the parents and 
work is in progress to sequence the sample. We were unable to obtain DNA 
from any family members of patient 13163 for segregation analysis.  
 
Patient 14651 is of Asian origin, specifically Indian in descent, and was from 
a consanguineous family. Four different mutations were identified in this 
patient, 3 of which have not been previously described. Segregation studies 
found that her mother carried one of the novel sequence variant T47R, while 
the mutation T114I and novel variants A313S and A285Q were inherited 
from her father. None of the novel variants were found in the control panel. 
The sequence variants T47R and A285Q are both located at highly 
conserved residues across different species (Figure 5.1).  The change from 
threonine amino acid at position 47 of the AIPL1 protein to arginine 
represents in a change from an uncharged, hydrophobic amino acid to a 
charged amino acid with basic properties; the drastic differences in amino 
acid properties would be predicted to have significant effects on the protein 
function as a result. This was also supported by protein prediction analysis 
which found the sequence change to be damaging by three different 
algorithms  (Table 5.13). Similarly, the change from alanine at position 285 to 
glutamine represents a major change in amino acid properties; alanine is 
small, hydrohobic amino acid, while glutamine is hydrophilic and has a large, 
uncharged polar amide side chain. The residue at position 285 is also 
located within the tetratricopeptide domain that is one of the main interacting 
sites. Hence any significant changes in amino acid residues are likely have a 
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major impact on protein function. This sequence change was predicted to be 
benign on SIFT and Polyphen but was found to be pathological in pMUT 
analysis.On the other hand, novel sequence variant A313S is located at a 
position where conservative substitutions are allowed (Figure 5.1). As both 
alanine and serine are similar in size and have uncharged side chains, the 
substitution would represent a conservative substitution. Protein prediction 
analysis (Table 5.14) further supported that the A313S sequence change 
was likely to be benign. Sequencing of parental DNA confirmed that the 
sequence variants which may have detrimental effects (T47R, A285Q and 
T114I) were located on different alleles. It is therefore very likely that patient 
14651 has a defect in AIPL1 function that is responsible for the retinal 
dystrophy.  
 
Patient 13163 was found to have 2 novel sequence variants, S198T and 
R270L. In-silico analysis of the S198T revealed that the substitution was 
unlikely to be damaging and comparison of the AIPL1 protein sequence 
across species  showed that the residue at position 198 was not a conserved 
residue. It was therefore unlikely that this substitution would lead to any 
significant detrimental effect on AIPL1 function. The R270L change on the 
other hand was potentially harmful based on prediction studies, and the 
residue was also located in a highly conserved region within the third 
tetratricopeptide domain. However, as there was no DNA available from 
family members, it was not possible to ascertain whether the sequence 
variants found segregated with the disease. Given that only one of the 
variant could be potentially harmful and was identified in heterozygous form, 
it was therefore unlikely that this would result in a defect in AIPL1 function. 
  
Phenotypically, patients 14651 and 13163 had clinically different diagnosis. 
Patient 14651 was diagnosed with LCA, presenting with severe visual loss at 
an early age. Clinical examination showed relatively normal fundal findings 
with no obvious signs of maculopathy (Figure). Her scotopic ERG and flash 
ERG responses were undetectable while her cone flicker responses showed 
severe delay and reduction in amplitude. Pattern ERG responses although 
present, were also severely reduced. Patient 14651 had a less severe 
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disease,early onset rod-cone dystrophy, and retained some degree of vision 
going into the third decade of his life. He presented to the eye clinics as an 
adult and despite his age, the fundal findings were unremarkable, with no 
intra-retinal pigmentation or macular atrophy. Electrodiagnostic testing 
showed reduction of the rod responses more than cone responses in 
keeping with a rod-cone dystrophy. Pattern ERG responses were normal. 
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5.8  Patients with possible AIPL1-associated 
disease 
 
In 9 unrelated probands, only one disease allele was found (Table 5.18). 
First pass screening of these DNA samples using the LCA chip returned one 
heterozygous mutation in AIPL1 and no other hits in the other LCA genes 
with the exception of patient 14341. Direct sequencing of AIPL1 failed to 
identify a disease-associated mutation on the second allele. There are 
several possible explanations that could account for the disease in these 
patients. Given that all the coding regions of exons were sequenced 
including splice site junctions, it is unlikely that a second exonic or splice site 
mutation in AIPL1 was left undetected. It remains possible that promoter or 
regulatory sequences of the gene contained yet unidentified mutations as the 
intronic regions and 3’-untranslated regions in exon 6 were not screened by 
our method. A large gene rearrangement or hidden mutation the unscreened 
region could also be complicated with these variants. A possible digenism 
could provide an explanation for this; digenic inheritance exists where a 
particular mutation in a gene causes disease only in patients who also carry 
a mutation in a different gene. However, digenic disease is rare and is 
occasionally found in proteins that function as a dimer or have a close 
interacting partner, such as peripherin and ROM1 or RPGRIP and RPGR. 
Since AIPL1 is not known to associate closely with another protein for its 
functions, it is unlikely that digenism is a factor in these cases. Alternatively, 
it is entirely possible that AIPL1 is not responsible for the retinal dystrophies 
in these patients and that there is a different causative gene that is yet 
unidentified.  
 
Another plausible explanation is that these alleles may act as genetic 
modifiers, modulating the phenotypic expression of the disease and leading 
to varied photoreceptor degeneration despite the same genetic background. 
The existence of modifier genes has been suggested by the fact that a 
higher amount of LCA patients carry a third allele than what would be 
expected by chance only [519], and further supported by the observation that 
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even within a single family, members who carry a third allele in a second 
gene presented with a more severe phenotype than members who did not 
carry the third allele [519][432]. Due to constraints on time and resources, it 
has not been possible to carry out sequencing of the other known LCA genes 
on these patients. One patient (patient 14341) was also included in a 
different mutation study and was found to have a homozygous deletion in 
second LCA gene, RPGRIP. It has been observed in many different 
recessive disorders, that only about 70% of the molecular defects can be 
identified [114]. 
 
In this group of patients, a range of clinical diagnosis was seen, ranging from 
LCA, EORD to RP (Table 5.18). Compared to the group of patients who had 
definite AIPL1-associated disease, over half of the patients in this category 
had a less severe disease such as EORD and RP. Six out of 9 patients had 
measureable vision at clinical examination, although it should be noted that 
most of them were seen at earlier ages. Fewer patients (3 out of 9) had a 
pigmentary retinopathy or a maculopathy, while only one patient with EORD 
presented with both retinal pigmentary clumping and macular atrophy. 
Fundal picture of the fundus of patient 13353 who has a heterozygous 
R302L change is showen in Figure 5.14. 
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5.9  Discussion 
 
This study presents a detailed clinical and molecular report of a series of 
patients affected by a severe inherited retinal dystrophy possibly due to 
mutations in the AIPL1 gene and represents a comprehensive analysis of 
AIPL1 in a patient cohort and a control population.  
 
Common to the other studies in existing literature, AIPL1 mutations have 
been mainly associated with LCA with a recessive inheritance pattern, 
although there has been one report linking the gene to juvenile RP and 
dominant cone-rod dystrophy[97,442]. In this study, we screened 309 
unrelated probands using the LCA chip and sequenced 153 DNA samples 
from this panel that had not returned a molecular diagnosis following the first 
pass screening using the LCA chip. The patient panel consisted of patients 
with a range of early onset inherited retinal dystrophies to determine whether 
AIPL1 mutations may cause other forms of retinal degeneration and also to 
determine the relative contribution of AIPL1 mutations to severe inherited 
retinal dystrophies.  In our study, likely disease-causing AIPL1 mutations 
were found in 12/309 probands, giving a prevalence of 4% in patients with 
various early onset retinal dystrophies, including LCA. In previous studies, 
AIPL1 has been estimated to cause approximately 7% of LCA cases 
worldwide[440,442]. 
 
Phenotypic variability has been well established in LCA patients: 
heterogeneity is seen in retinal appearance, refractive errors, nyctalopia, 
manifest and longitudinal changes in visual function, cataracts and 
keratoconus.  The retinal appearance can vary considerably between the 
different LCA genotypes, although there are gene-specific phenotypic 
features that have been observed in LCA (for further information, please 
refer to Chapter 1, section 1.3.2.2).  Previous published phenotype-genotype 
studies of AIPL1 mutations have been based on cohorts of patients with 
LCA. Compared to the other LCA genes, AIPL1-related LCA have been 
described to be particularly with severe visual loss, pronounced macular 
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involvement and optic nerve pallor. Our study found that AIPL1-associated 
retinal disease is clinically variable; patients identified with AIPL1 mutations 
ranged from less severe early onset retinal dystrophy to LCA. This suggests 
that there may be a spectrum of disease associated with AIPL1 mutations 
and it may be possible that screening for AIPL1 mutations in a different 
patient panel of recessive RP may reveal mutations associated with other 
categories of inherited retinal dystrophies. Since our mutation screen was 
performed on a panel of patients with severe early onset retinal dystrophy, it 
is understandable that the phenotype seen in the patients who were 
identified with AIPL1 mutations would be severe in nature.  The patients in 
this study with LCA and AIPL1 mutations have a severe phenotype which is 
in keeping with other series with AIPL1 phenotypic data[174][103][151][310]; 
these patients had unmeasureable vision, significant maculopathy and some 
degree of optic disc pallor in adulthood. In established disease, patients with 
AIPL1 mutations also develop significant pigmentary retinopathy. Features of 
pronounced atrophic maculopathy, optic disc pallor and significant peripheral 
retinal pigmentation appear to be unique to AIPL1 mutations and distinguish 
this from the other genotypes; while patients with GUCY2D and RPGRIP1 
mutations appear similar to the AIPL1 phenotype in terms of markedly 
decreased vision, visual fields and ERGs, phenotypical differences exist in 
terms of macular atrophy, pattern of pigmentary changes, cataract and 
keratoconus which are more frequent in AIPL1	   patients[367][104][110]. 
Macular atrophy has been reported in majority of patients with CRX-related 
LCA, but unlike in AIPL1 mutations, pigmentary retinopathy is not a 
prominent feature in CRX mutations[208][433][443][522]. Patients with 
RPE65-related LCA are also clinically distinguishable from patients with 
AIPL1 mutation; the RPE65 phenotype is associated with measurable visual 
acuities, better visual fields and ERGs than the AIPL1 phenotype.  Peripheral 
retinal changes are subtle in RPE65 mutations, and macular atrophy are not 
a feature[285][468]. Patients with LCA due to RPE65 mutations often 
experience transient visual improvement in childhood followed by 
deterioration later in life, while the visual function in AIPL1 patients have 
been described to progressively decline[285][103].  Since most of the 
patients in this study were examined at later ages, conclusive observations 
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regarding the visual evolution of patients with AIPL1 mutations could not be 
made from this.   
 
In addition to peripheral retinal pigmentation and macula atrophy, other 
significant posterior pole findings included various degree of RPE and 
choriocapillaris atrophic changes and drusen-like intraretinal white dots. 
Three patients (27%) with AIPL1 mutations had drusen-like intraretinal 
deposits in their first and second decades of life. While extensive pigmentary 
changes and peripheral chorioretinal atrophy have been frequently described 
in other studies[440][435], intraretinal drusen-like deposits in association with 
AIPL1 mutations have only been reported in one other study thus far [151]. 
Other genotypes which have been associated with white retinal deposits 
include RPE65, RPGRIP and CRB1. Neither nyctalopia nor photoaversion 
were frequently reported in this series and refractive findings showed 
moderate myopia and hypermetropia being equally common in patients. This 
differed from observations in other series of AIPL1 mutations which 
described photoaversion and moderate hypermetropia as common findings 
in these patients.  Anterior segment signs were significant for cataracts and 
keratoconus, about 55% of patients in this series had a combination of 
cataracts and keratoconus, which is in keeping with most other series with 
AIPL1 phenotype data [174] [103][151][310]. One study has further described 
the association of cataracts and keratoconus with homozygous mutations 
only[103], but this has not been observed in this study in which cataracts 
were also seen in patients with compound heterozygous mutations. Many 
retinal and anterior segment signs were more prevalent with increasing age; 
peripheral retinal pigmentation, chorioretinal atrophy, macular atrophy were 
not seen before the first decade in this series but became increasingly 
prevalent after the second decade. The association of cataracts and 
keratoconus with other retinal dystrophies and LCA have been well 
documented beyond the second decade of life in patients[184][137]. In this 
study, cataracts and keratoconus were noted before the second decade in 
some patients and were more prevalent with age. Unlike other published 
series, assessments of perimetry, autofluorescence and OCT were included 
to further define the phenotype. The findings from these ancillary tests 
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supported the clinical phenotype, with marked peripheral visual field loss and 
retinal thinning due to primary photoreceptor degeneration. However, it 
should be noted that majority of the clinical characteristics described on 
clinical examination and imaging studies relate to changes seen in older 
patients; most fundal findings begin to appear after the first decade of life. 
The identification of young patients with AIPL1 mutations remains a 
challenge as there are minimal clinical signs, particularly within the first year 
of life.  
 
Despite the clinical heterogeneity, we found that the severity of disease and 
certain phenotypic features may be predicted from the underlying mutation. 
Patients with homozygous null mutations were found to have a more severe 
disease, in terms of retinal pigmentation and macular atrophy. Patients with 
missense mutations may have a less severe disease due to residual protein 
function, with better residual vision, slower progression and later onset of 
maculopathy and present clinically as early onset retinal dystrophy. This may 
be due to residual AIPL1 function from missense mutations, and may be 
analogous to the hypomorphic Aipl1h/h mouse. Variation in clinical severity 
has also been observed with other LCA genes; RPGRIP1, CRB1, TULP1 
and RPE65 have been reported to cause either LCA or an acquired, later-
onset rod-cone dystrophy[173][155]. It has been suggested that a more 
severe retinal dystrophy such as LCA may result from an excess of null 
alleles when compared to other less severe dystrophies such as retinitis 
pigmentosa.  
 
A particular problem highlighted in this study which may render the 
identification of AIPL1 patients difficult is the uncertainty surrounding the 
pathogenicity of the mutations and difficulty in ascertaining the true nature of 
sequence variants. This is compounded by the polymorphic nature of the 
gene, as revealed by the sequencing of both patient and control panels. 
Some of the published mutations have been shown not to have any 
deleterious effects on functional studies [476][393][7], and consequently it 
may be possible that some of the reported mutations in genetic databases 
may not be true mutations. This is particularly pertinent to the R302L 
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substitution which was previously described as a pathogenic mutation. Our 
study indicates that this may be questionable as we identified an unaffected 
relative who carried the homozygous mutation. Furthermore, our analysis of 
the predicted functional effects of the missense substitution using protein 
function prediction software showed that it was not deleterious.  This 
substitution was however not found in our screening of the control panel and 
was found in the panel of probands with an allele frequency of 1.6% and 
mostly in individuals of Asian ethnic origins. It is thus possible that R302L 
represents a rare ethnic polymorphism. 
 
It is difficult to be certain that the AIPL1 mutations are disease-causing 
without performing biochemical and functional analysis of the mutant protein. 
Future work is required in this aspect, and in vivo functional assessment of 
the mutations in question is preferable to in vitro studies. This could be 
performed by creating a transgenic mouse by injecting a construct carrying 
the point mutation of interest into fertilized wild-type mouse oocytes and 
breeding the founders into mice lacking Aipl1 (Aipl1 -/- ) to produce mice with 
the transgene against an Aipl1 -/- background. A more elegant method that 
better replicates the condition in human mutations would be to create a 
“knock-in” mouse using a targeting construct that carries the particular point 
mutation as this would result in the altered gene being inserted in the specific 
locus and thus subjected to the normal regulatory mechanisms of 
expression. Histopathogical studies of the retina for signs of photoreceptor 
degeneration and electrophysiological assessment of these genetically 
engineered animals will confirm the disease-causing potential of these 
specific mutations. Alternatively, an easier and more readily available 
analysis would be to inject an AAV vector expressing the mutant AIPL1 gene 
into Aipl1 -/- mice and examining the treated animals for signs of 
photoreceptor rescue. Any improvement in ERG or morphology would 
indicate that the mutations were probably benign. Due to constraints on time 
and resources, it was not possible to pursue this line of investigations in this 
study, and therefore certain assumptions had to be made in order to be able 
to draw some conclusions to the findings. As we have found disease-
associated mutations, segregating among families, with no other change in 
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the gene sequence and are absent from ethnically matched control subjects, 
it was reasonable to consider these as possible disease-causing mutations.  
 
Despite the availability of genotyping microarrays for LCA, the genetic 
heterogeneity of this condition continues to pose a significant challenge to 
clinicians. Identification of genotype-phenotype correlations in LCA and other 
retinal dystrophies would help to suggest the causal gene and refine the 
molecular screening strategy. The molecular characterization of LCA is 
important for genetic counseling and also with the advent of gene therapy 
trials, for identification of suitable candidates for potential therapy. With more 
correlation studies, it may become easier to use objective data such as the 
presence of key physical signs to implicate certain genes over others in the 
pathogenesis. The clinical characterization of disease in this study such as 
visual acuity, signs in the anterior and posterior segments are helpful in 
identifying patients with AIPL1 mutations and are important to allow for the 
interpretation of any future therapies. The identification of patients with milder 
phenotype due to AIPL1 mutations might provide a wider therapeutic window 
for preventative intervention. However, the prevalence of clinical signs varies 
with age and is subjected to environmental influences, genetic background 
and modifier alleles. All of these should be taken into consideration to 
facilitate the accurate assessment of patients. 
 
 
 
 
 
 
 
 
 
 
351 
 
6.   Final Discussion 
 
The last twenty years have seen enormous growth in the understanding of 
the molecular and histopathological basis of inherited retinal degeneration. 
Many of the causative genes have now been identified, providing an impetus 
to develop gene-based treatments to treat retinal degeneration and improve 
photoreceptor survival. Replacement gene therapy mediated by AAV vectors 
appears to be the most promising potential therapy for retinal degenerations, 
especially for those severe forms such as LCA which are unlikely to respond 
to more conservative forms of treatment. Following landmark preclinical 
studies demonstrating long term functional improvement as a result of gene 
replacement of RPE65 in a dog model of LCA, three clinical trials of ocular 
gene therapy have commenced to treat early-onset severe retinal 
degeneration in patients with defects in the RPE65 gene The preliminary 
success reported from these studies will undoubtedly pave the way for more 
clinical trials to treat other forms of retinal dystrophies. Hence, there is an 
urgent need to identify other candidate disorders suitable for translation from 
the laboratory to human clinical trials. These are most likely to be conditions 
where gene therapy has proven to be efficacious in an animal model 
equivalent. 
 
The selection of a genetic disease for gene therapy clinical trials will depend 
on a variety of clinical and experimental criteria. The disease must be caused 
by loss-of-function mutations for gene replacement therapy to be applicable. 
Most the severe inherited retinal diseases such as LCA and early onset 
retinal dystrophies are caused by recessive mutations of retinal genes 
leading to the loss or relative lack of the encoded protein product . 
Replacement of these genes would restore the target protein and correct the 
deficiency in affected cells. Similarly, the retinal degeneration secondary to 
AIPL1 mutations is caused by the loss or reduction in AIPL1 protein. 
Replacement of AIPL1 in photoreceptor cells led to increased AIPL1 protein 
levels and correction of the downstream effects shown by increased PDE 
biosynthesis and the translocation of cGMP PDE to the outer segments.   It 
352 
 
is also important that the rate of progression of the disease enables a rapid 
read out of the outcome of treatment. The severe nature of AIPL1-related 
retinopathies both in human and mouse would provide a clear indication of 
any benefit following therapeutic gene delivery in the form of either an 
improvement in retinal function or vision, or the delay in progression of 
photoreceptor cell loss. However, this could also act as a double-edged 
sword since experimentally, animal models of rapid retinal degeneration 
have previously been difficult to rescue. With advances in vector technology 
and  the availability of faster and more efficient AAV serotypes such as 
AAV2/8, the prospects of treating such rapid retinal dystrophies has 
improved. That AAV2/8-mediated gene replacement was effective in 
rescuing such rapid retinal degeneration in the Aipl1 -/- mouse indicates that 
the rapid retinal degeneration in LCA patients may also respond favourably 
to treatment. Clinically, the prevalence of the disorder is important in 
determining the potential value of a therapeutic strategy. Treatment for 
conditions which have higher prevalence would make patient recruitment 
easier and have greater clinical impact compared to a rare disease. The 
prevalence of LCA caused by AIPL1 mutations is approximately 7%, which is 
a significant portion of cases when compared to the contribution of other 
known LCA genes[442][103][101]. This is similar to the prevalence of LCA 
cases associated with RPE65 mutations which currently being treated in 
clinical trials. The contribution of AIPL1 to retinal diseases is likely to be even 
higher as it has also been described to cause other types of retinal 
dystrophies such as juvenile cone-rod dystrophy and milder forms of early 
onset retinal dystrophies [103,442].  
 
The function of the transgene product may also dictate the efficacy of gene 
replacement therapy. High efficiency of gene transfer may not be essential 
for conditions where the transgene encodes for secreted protein; expression 
in a few target cells might be sufficient for effective treatment while useful 
therapy may also be achieved by transducing cell types that do not normally 
produce the protein. On the other hand, in conditions where the encoded 
protein is essential for the survival and function of photoreceptor cells such 
as a transcription factor or a phototransduction protein, effective therapy 
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would require the transgene to be delivered specifically to each targeted cell 
type and ideally to mediate transgene expression at physiological levels. 
Since AIPL1 is essential for PDE biosynthesis and photoreceptor cell 
survival, the treatment of AIPL1-related retinopathies requires specific and 
efficient delivery of the therapeutic gene to individual photoreceptor cells. 
AAV2/2 and AAV2/8 were chosen as vectors because of their capability to 
transduce photoreceptors following subretinal delivery. While AAV2/2 was 
able to slow photoreceptor degeneration in the Aipl1 h/h mouse, it was 
unsuccessful in rescuing the Aipl1 -/- model. Switching from AAV2/2 to 
AAV2/8 vector that carried the same expression construct resulted in strong 
therapeutic rescue in the null model.  This observation indicates that in a 
severe disease, a faster, more efficient vector with high expression levels is 
needed. 
 
The availability of an animal model that accurately reflects the disease in 
patients is a critical factor in the development of a treatment strategy. 
Success in treating an animal model that mimics the human disease 
provides strong justification in moving a therapeutic strategy to the clinic, as 
exemplified by the RPE65 treatment trials. In humans, genetic defects in 
AIPL1 give rise to a heterogeous set of clinical conditions[103,440,442] that 
is also reflected in the genetically engineered mouse models of AIPL1  
deficiency.  The Aipl1 -/- and the Aipl1 h/h mice mirror the clinical disease 
spectrum, and are reminiscent of LCA and RP respectively, while the light-
accelerated Aipl1 h/h mouse with an intermediate disease severity is similar 
to patients with early-onset retinal dystrophy. However, one of the 
requirements for the ease of translation to clinical trials is that any new 
therapeutical strategy must be shown to be efficacious in an eye similar to 
that of humans. So far, there are only a few naturally occurring large animal 
models of retinal dystrophies. The naturally occuring RPE65-deficient dog 
has been a critical factor in moving gene replacement therapy from 
preclinical studies to current ongoing clinical trials[2] [260]. Mouse models on 
the other hand, are not limited by the availability of naturally occurring 
models and many gene defects can be recreated in mice by targeted gene 
disruption. In the absence of larger animal models, either naturally-occurring 
354 
 
or artificially generated, future clinical trials may have to proceed based on 
efficacy data from murine studies alone.  
 
 A central issue for any human gene therapy intervention is the assessment 
of the risk to benefit ratio. AAV vectors are frequently used in human clinical 
trials, it is therefore vital to evaluate the risks of its use for personnel involved 
in handling the vector either in research or clinical trials as well as for the 
patients and their future offsprings. Thus far, AAV has shown to have an 
excellent safety profile;  preclinical studies have consistently demonstrated 
the lack of toxicity, minimal inflammatory and immune responses to the 
vector and negligible systemic dissemination to distant organs following 
intraocular delivery. In the recent phase I human ocular gene therapy trials, 
three different groups of investigators have reported the lack of any clinically 
significant adverse effects from the surgical procedure and the absence of 
systemic dissemination, suggesting that any extraocular leakage of vector 
from the subretinal space was minimal [34,181,293] There was no significant 
intraocular inflammatory responses to vector injection and no sustained 
reduction in visual function despite the temporary retinal detachment in the 
patients one year after treatment. However, the long term ocular and 
systemic safety of the procedure in humans will only be known after further 
follow up in the later stages of the trials. Apart from the obvious risks 
associated with a viral vector, other hazards that need to be taken into 
consideration include the effects of transgene overexpression. This is less 
likely to cause any toxicity or adverse effects where the biological function of 
the protein does not require its levels to be within a narrow range. In our 
study, we showed that AIPL1 overexpression did not result in deleterious 
effects. The ectopic expression of AIPL1 in the RPE by AAV2/2 vector driven 
by the ubiquitous CMV promoter did not have any negative effects on 
photoreceptor function or survival. As the exact function of AIPL1 is yet 
completely understood, it is difficult to hypothesize on the effects of AIPL1 
overexpression on the retina. AIPL1 is intricately linked to cGMP PDE, a 
multimeric protein composed of subunits α,β and γ and is specifically 
required for the proper assembly of PDE subunits[240].  The lack of toxicity 
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from AIPL1 overexpression may be due the possibility that its function is 
limited by the availability of cGMP PDE. 
 
The translation of a gene-based strategy into clinical trials also depends on 
the availability of a suitable vector.  To be effective, gene therapy to the 
retina initially requires specific and efficient vector that can mediate 
widespread transduction of the target cells. It is then possible to tailor gene 
expression to the appropriate levels and spatial patterns through the use of 
specific promoter elements. It is also vital that the chosen vector for the 
treatment of inherited retinopathies is able to mediate long term expression 
of the transgene without integration into the host genome since the treatment 
of these disorders necessitate lifelong correction. For this purpose, AAV 
vectors which have considerably lower immunogenity appear to be the best 
suited vector for gene delivery. Together with the immunopriviliged properties 
of the eye, AAV vectors have been able to confer long term transgene 
expression lasting many years without integration into the host genome.  In 
our study, transgene expression and therapeutic effect appeared to be long 
lasting and without the need for retreatment. In Aipl1 h/h mice that received 
subretinal injection with therapeutic AAV2/2 and AAV2/8 vectors, sustained 
transgene expression and photoreceptor rescue was noted up to over 1 year 
and 5 months post injection respectively. AAV2/8-mediated delivery of AIPL1 
in the null mutant, Aipl1 -/- mouse, appeared to be stable for at least 3 
months post injection, the latest time point examined. These were the latest 
time point examined in the study following which the animals were culled to 
allow for histological examination. In order to appreciate the full durability of 
the therapeutic effect, further similar experiments to examine the point of 
decline in transgene expression with a longer period of follow up would be 
required. The main drawback of AAV which often limits its use for gene 
transfer is its small packaging capacity of 4.7 kb and its slow onset of 
expression after transduction. For the purpose of AIPL1 gene replacement, 
the restricted carrying capacity of AAV is less of an issue since both the 
murine and human AIPL1 cDNA are less than 3 kb in size. Faster onset and 
efficiency of in vivo gene transfer was obtained with the use of AAV2/8, 
which was subsequently used to treat faster photoreceptor degeneration. 
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The use of various AIPL1 mouse models of different disease severity in this 
study highlights the importance of timing of gene transfer in relation to the 
disease course, the onset and levels of expression in determining the 
success rate of the treatment. As demonstrated in the difference in efficacy 
comparing AAV2/2 and AAV2/8 vector in the rapid models, these factors 
need to be tailored according to the characteristics and rate of progression of 
the particular condition. 
 
Thus, AIPL1-related retinal dystrophy has progressed through many of the 
steps towards a treatment strategy, from gene identification[440][442] 
followed by clinical characterisation of disease[103][151][485][362] and to 
increased understanding of the molecular 
mechanism[477][282][391][240][295][186] and then now to proof-of-concept 
studies in animal models. The success of gene therapy in correcting the 
disease phenotype in Aipl1-deficient and hypomorphic mice described in the 
preceding sections suggests that human AIPL1-related retinopathies may be 
amenable to treatment and supports the further development of this 
preclinical work to clinical trials. This proof-of-concept study was reinforced 
by another recent work which targeted both rods and cones and rescued 
both photoreceptors following AAV-mediated Aipl1 replacement in Aipl1- 
mutant mice[455]. In justifying a clinical trial, a key question that is posed is 
whether the phenotype of human disease is similar enough to that in the 
animal models and hence, if it is realistic to expect comparable treatment 
benefits in humans to that already seen in the animal models.  Despite the 
similarities in phototransduction defect and severe phenotype in both the 
murine models of Aipl1 and PDE6β deficiency, the human equivalents of 
these genetic defects reveal dramatic differences. In contrast to patient with 
AIPL1-related LCA who have severe early visual impairment, patients with 
autosomal recessive RP due to PDE6β mutations maintain good visual 
acuity until later in life. While the rd1 mouse may not completely mirror the 
human disease, the Aipl1mutant models are consistent with the human 
condition; the Aipl1 -/- mouse has an early and severe degeneration which is 
phenotypically similar to patients with AIPL1-related LCA, and the Aipl1 h/h 
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hypomorphic mutant is reminiscent of the subgroup patients with autosomal 
recessive rod-cone dystrophy that have been described in this study and in 
another recently published study[204]. The main difference between human 
and mouse that need to be considered is anatomical distinction between the 
rod-dominated mouse retina and the human retina that has central cone-rich 
foveal region as this may impact on the treatment strategy. Since AIPL1 is 
essential for the maintenance and survival of both rods and cones[282][232], 
much of the severe visual impairment in patients with AIPL1-related disease 
is due to cone dysfunction and loss. Hence, in treating patients, it is even 
more vital that gene delivery vectors should target both rods and cones 
photoreceptors. By using a rhodopsin kinase promoter to drive transgene 
expression in an AAV vector, a recent study targeted and rescued both rods 
and cones in various Aipl1 mutant mice[455]. Extrapolating these findings, it 
would be reasonable to expect that foveal cones in the human retina would 
benefit from such AAV-mediated gene delivery that targeted both types of 
photoreceptor cells. However, further verification of the rhodopsin kinase 
promoter may be indicated as recent studies have suggested that its ability 
to transduce both photoreceptor cell types may differ in between species[46].  
 
The next important question to be answered is whether there is residual 
retinal architecture and viable photoreceptors in AIPL1 patients to afford a 
reasonable chance of success. The current information available on the 
retinal phenotype of AIPL1-related LCA patients is limited; there are a few 
short clinical descriptions that accompanied the reports of molecular 
identification[441][440], clinical evaluations of AIPL1 patients specifically or 
along with other genotypes[151][103][310][362][485][204] and rare reports 
bearing some histopathological descriptions of donor retinal tissue. 
Frequently described clinical findings included severe visual impairment even 
at very young ages, no visual fields, non-detectable electroretinograms, 
pigmentary retinopathy and atrophic maculopathy. The only two histological 
studies currently available described the paucity of photoreceptors and 
predominance of retinal gliosis with sparing of the RPE layer and Bruchs 
membrane in associated with AIPL1related disease[183][478]. However, it 
should be pointed out that these histological studies were performed in the 
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same adult patient with already advanced disease. While most patient 
studies relating to AIPL1 mutations to date have mostly described clinical 
features seen on eye examination, the advent of new non-invasive imaging 
techniques and psychophysical tests provide another dimension in 
phenotype characterisation of patients.  An single description of the OCT 
scan in a 22-year-old LCA patient with AIPL1 mutation showed abnormal 
retinal laminar architecture[362]. A recent study of provided detailed 
descriptions of retinal structure and function using autofluorescence imaging, 
OCT, pupillometry, perimetry and electrophysiology and on AIPL1 patients 
ranging from 16 to 40 years of age[204]. Findings revealed extensive loss of 
foveal cones and extrafoveal photoreceptors that was more severe with age, 
while variable thickening of the inner nuclear layer was seen that was 
suggestive of retinal remodeling[204]. Perimetry and pupillometry confirmed 
retained rod function in patients, some of whom were in the third and fourth 
decades of life. Some patients even had pupillary light reflexes which were 
within the normal range of responses. More significantly, this study also 
described a patient with retinitis pigmentosa associated with AIPL1 
mutations. This patient had a much later-onset protracted course of disease; 
the onset of symptoms was noted from the first decade of life and retained 
macular photoreceptors was seen up the the sixth decade of life. The 
authors from this novel study implied that given the severity of disease and 
loss of the cone-rich foveal ONL in AIPL1 LCA patients, there may be limited 
response to gene replacement therapy. However, it should be pointed out 
that these findings are indicative of adult patients who already have 
established disease. Our study suggests that macular and foveal 
photoreceptors and RPE remain relatively well preserved in early childhood 
ages, this is particularly highlighted in patient 31895 who was examined at 
the age of 7 years; well preserved autofluorescence at the fovea and 
surrounding macular regions were seen and were almost normal in 
appearance, while OCT scanning revealed present retinal lamination and 
foveal and parafoveal ONL. Evidence of detectable ONL in young human 
retina despite early absence of rod and cone photoreceptor function by ERG 
would support the hypothesis that visual loss in early stages is due to rod 
and cone dysfunction, possibly from a phototransduction defect given the 
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connection with cGMP PDE. Uncorrected, this persistent derangement in 
phototransduction and continuing loss of PDE may later on lead to a rapid 
photoreceptor apoptosis and secondary retinal degeneration. Studies of the 
various mouse models of AIPL1 deficiency appear to support this theory, 
given that normal retinal architecture were observed in young mice 
regardless of the rate of degeneration. Hence, while adult LCA patients may 
not fully respond to gene replacement therapy due to advanced disease, our 
findings suggest that young patients might be amenable to treatment and 
that treatment should be administered in very early ages for maximal 
therapeutic benefit.  A further group of patients who would stand to respond 
favourable to gene-base treatment are the patients who have a milder and 
later onset of retinal dystrophy associated with AIPL1-mutations. To date, 
there are only four patients described as having a different diagnoses other 
than LCA that is associated with AIPL1 mutations; three of these had a 
heterozygous 12 bp deletion in AIPL1 and were diagnosed with cone-rod 
dystrophy and juvenile retinitis pigmentosa[442], while one patient was 
recently described with later-onset retinitis pigmentosa and carried 
compound heterozygous null mutation and a missense mutation (W278X and 
G122R)[204]. Our study identified a further two patients with milder disease 
of rod-cone dystrophy associated with AIPL1 mutations, and suggest that 
there may be a further subset of patients with diagnoses other than LCA due 
to AIPL1 mutations.   Screening of a large cohort of patients with the clinical 
diagnoses of RP or rod-cone dystrophy for AIPL1 mutations have yet been 
undertaken and would be a worthwhile endeavor. Similarly, more studies in 
young children with AIPL1 mutations are needed and will be crucial in 
characterising the retinal structure and function in this age group and also in 
providing further indication of the success gene-based treatment in these 
patients. 
  
There are further issues to be considered in setting up a clinical trial to treat 
AIPL1 patients: who would be suitable target patients to be treated first, and 
what would be the best strategy identify candidate patients for treatment? 
Given the difficulty in obtaining ethical approval for carrying out trials in 
young patients, the group of patients with milder AIPL1 disease may serve 
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well as initial candidates in a gene therapy trial. The slower rate of disease 
and preservation of cones and rods well into adulthood may offer good 
potential of a treatment benefit, although it may take a longer period of time 
to demonstrate this. Ultimately, the goal would be to treat young patients with 
LCA who stand to benefit the most if the treatment is successful. The 
potential for therapeutic application in humans depend the identification of 
candidate patients. One of the major foreseeable obstacle is the identification 
of candidate patients in a timely fashion, particularly the patients with LCA. 
The AIPL1-LCA phenotype has several distinctive features such as the 
severity of visual impairment, retinal bone-spicule pigmentation, atrophic 
maculopathy and an association with keratoconus. However, many of these 
features are age-dependent and it can be difficult to distinguish between the 
different genotypes since the retina responds in similar ways to insults. 
Furthermore, the retina is almost always normal in appearance in very young 
patients with various forms of retinal dystrophies including LCA, regardless of 
the underlying gene mutation. While visual acuity and signs in the anterior 
and posterior segments may be helpful in selecting the genes or loci most 
likely to be implicated, molecular screening remains the mainstay of 
establishing definitive diagnosis, which is a pre-requisite to treatment. 
Specific to AIPL1 mutations, molecular diagnosis need to be undertaken as 
early as possible and preferably in early childhood. In the hospital setting, it 
may be necessary to consider screening offsprings of patients with family 
history of LCA or severe inherited retinopathies and young children or infants 
presenting with impaired vision for AIPL1 mutations. For cost effectiveness in 
a large gene therapy program involving the treatment of several different 
gene defects, first pass screening using the LCA chip will indicate the 
underlying gene involved, and should be followed by resequencing to confirm 
the mutations. Where there is high clinical suspicion of AIPL1-related 
disease, patients should be sequenced directly, this is now made easier with 
the availability of resequencing chips which will enable high volume rapid 
sequencing of patient DNA. 
 
There is now robust proof of efficacy from this preclinical study and recently 
others to justify clinical trials to treat patients with AIPL1 mutations.  Human 
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gene replacement therapy offers these patients the best possibility of 
alleviating a disease that is currently incurable and that has invariably dire 
consequences.  For these patients, the benefits of treatment clearly outweigh 
the risks. Following on from this, there are now efforts in progress to develop 
a clinical grade vector and the infrastructure for an AIPL1 clinical trial, which 
could be expected to commence in the next five years. 
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Appendix: 
 
Patient clinical histories and pedigree (where available) 
 
Patient 9728 
Patient 9728, of African origin, was the product of a consanguineous 
marriage between first cousins. Apart from visual problems, he also suffered 
from autism and epilepsy.  He was diagnosed with LCA and was first 
examined at the age of 19 years old. At that time, he was only able to 
perceive light. His fundal appearances showed bilateral bone spicule-like 
peripheral pigmentation, attenuated blood vessels and macular scarring. 
However, due to difficulties with cooperation, electrophysiology studies were 
not performed. Autofluorescence imaging showed generalised reduction of 
autofluorescence at the fovea and peripheral retina with some residual signal 
in the parafoveal region inside the major vascular arcades. 
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Patient 07582 
Patient 07582 was a male Caucasian patient from South Africa who was first 
seen in 2002 at the age of 19 years old. Severe visual loss was noted since 
birth and a non-progressive course was described. He did not suffer from 
any other medical or systemic problems apart from visual symptoms.  There 
was no history of consanguinity and no other family members were affected. 
At the time of examination, he was only able to perceive light in both eyes. 
There was bone-spicule peripheral retinal pigmentation, central foveal 
atrophy and attenuation of the retinal vasculature in both fundi. Both optic 
discs appeared normal. Electrophysiology performed at the time of 
assessment showed severe loss of rod and cone ERG responses. The ERG 
results of patient 07582 are in keeping with the clinical diagnosis of Lebers 
Congenital Amaurosis, with severe macular involvement. The rod-specific 
ERG and pattern ERG (PERG) were not detectable and the bright flash 
"mixed" ERG was severely reduced. Single flash cone ERGs (photopic) and 
30 Hz flicker ERG showed severely reduced and delayed amplitudes.  
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Patient 14777 
Patient 14777 was from a consanguineous middle-eastern family in Dubai 
whose parents were first cousins. He was diagnosed with LCA at the age of 
18 months. At 3 months of age, he was noted to have nystagmus, a 
convergent squint and poor vision, and later night blindess and peripheral 
field loss. He presented to the eye clinics at the age of 2 years old. Clinical 
examination at that time showed relatively normal-looking fundus and optic 
disc bilaterally. Electrophysiology tests revealed no detectable scotopic or 
photopic ERG amplitudes. He was too young to cooperate with Goldman 
perimetry assessment, while OCT and autofluorescence imaging did not 
reveal anything specific changes. 
 
 
 
 
 
 
 
 
 
 
Patient 14000 
Patient 14000 was first seen at the age of 30 years, and presented with a 
history of nystagmus, nyctalopia and strabismus which was noted from birth. 
Her parents were first cousins and she also had an affected sister. Her visual 
acuities at presentation were only perception of light in the right and left 
eyes. Clinical examination showed intra-retinal pigmentation, attenuated 
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blood vessels and macular atrophy. Both optic discs appeared pale 
indicating optic atrophy. There were also signs of posterior subcapsular 
cataract and keratoconus affecting the right eye. She was diagnosed with 
LCA. Electrodiagnostic tests showed no recordable activity for maximum 
flash ERG, pattern ERG, photopic ERG and 30 Hz flicker ERG. Goldman 
perimetry, OCT and autofluorescence imaging were not performed on this 
patient.  
 
 
Patient 15000 
Patient 15000, an affected sister of patient 14000, is 2 years older. She was 
also noted to have poor vision and nystagmus shortly after birth and later on 
was diagnosed with LCA. At the time of examination, she was 36 years old 
and was unable to perceive light. Clinical examination showed findings in 
keeping with end-stage retinal degeneration, with widespread intraretinal 
pigmentation, bilateral pale discs, severely attenuatied vessels and bilateral 
macula coloboma. There was also posterior subcapsular cataract and 
keratoconus in one eye. Electrodiagnostic tests detected no rod or cone 
responses.  
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Patient 14874 
Patient 14874 came from a non-consanguinous white family and diagnosed 
with LCA. He first presented with poor vision and nystagmus at 6 months of 
age. His parents noticed that he was attracted to bright lights as a child and 
later found that he had poor night vision and sluggish pupils. When he was 
seen in the eye clinic at the age of 17, he was only able to perceive light in 
both eyes. He had posterior subcapsular cataracts and moderate myopia. 
Fundal examination showed retinal pigmentary changes and RPE atrophy in 
the periphery. Although his optic discs appeared healthy, there was bilateral 
early macular atrophy and attenuation of retinal vessels. OCT scan showed 
reduction of foveal thickness and thinning of the macular area in both eyes. 
Autofluorescence imaging showed reduced autofluorescence at the fovea. 
Electrodiagnostic studies showed that both scotopic and photopic ERG 
responses were non detectable. 
 
 
Patient 13484 
Patient 13484 was of African-Carribean descent and has an affected sister 
(patient 6604). Both of them were diagnosed with rod-cone dystrophy. There 
was no history of consanguinity. At 2 months of age, patient 13484 was 
noted to have poor vision, nystagmus and nightblindness. As a child, she 
noted to have a habit of eye-rubbing (oculodigital sign), a divergent squint 
and photoaversion (dislike of light). When she presented to the eye clinic at 
19 years of age, she had heavy pigment clumping in the mid-peripheral 
retina with RPE atrophy, attenuation of retinal vessels and macular atrophy. 
Her visual acuity was logMar 1.6 in the right eye and no perception of light in 
the left eye. Scotopic and photopic ERGs was present although severely 
reduced in the right eye, while the left eye had no detectable ERG response. 
There was no detectable pattern ERG.  
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Patient 13052 
Patient 13052 is of black African origin and her family came Sudan. There 
was no history of inter-related marriages in the family. She was diagnosed 
with rod-cone dystrophy, and was noted to have poor vision and night 
blindness since birth. As a child, she was always attracted to light 
(photoattraction). She first presented to the eye clinic at the age of 27 years; 
she was only able to perceive light in her right eye but had a visual acuity of 
logMar 0.9 in the left eye. Her pupillary reaction was normal and she did not 
have any nystagmus.  Clinical examination showed that her fundal 
appearances were similar to that of advanced retinitis pigmentosa with 
peripheral bone spiccule-like pigmentation, pale optic discs, attenuated blood 
vessels and an epiretinal membrane at both macula. Over the follow up 
period of 10 years, she developed posterior subcapsular cataracts, 
progressive RPE atrophy, white retinal dots and macula pigmentation and 
atrophy. Goldman perimetry showed severe constriction of her visual fields to 
only 5 degrees of horizontal and vertical fields in each eye with preservation 
of the temporal islands. Optical coherence imaging (OCT) showed thinning of 
the retina from the nasal aspect to the fovea while fundus autofluorescence 
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imaging  using the scanning laser ophthalmoscope (SLO) showed patchy 
areas of hyper and hypofluorescence throughout the fundus. ERG 
assessment was not available on this patient.  
 
 
 
 
 
 
 
 
Patient 13412 
Patient 13412 is from an Iranian family with a long history of consanguineous 
marriages in the family. He is related to another patient (No. 13353) as first 
cousins, who has a heterozygous Arg302Leu mutation. Patient 13412 was 
diagnosed with LCA when at the age of 2 months, he was noted to have poor 
vision and nystagmus and later developed a divergent squint. There was a 
history of poor vision in the family, he had an affected brother and 2 first 
cousins who were diagnosed with LCA (including patient 13353) and another 
first cousin who was diagnosed with rod-cone dystrophy. At the time of 
examination, he was 18 years old. His visual acuities were counting fingers 
bilaterally and there was a roving nystagmus. Both of his fundi appeared 
unremarkable on ophthalmoscopy and there was some optic disc pallors. 
Electrophysiology testing revealed severe reduction in scotopic and photopic 
responses. OCT imaging revealed thinning of the retina and fovea. 
Autofluorescence and goldman perimetry was not performed in this patient. 
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Patient 31895 
Patient 31895 is from a family from Israel, whose parents are not related to 
each other. He was noted to have poor vision and nystagmus at the age of 6 
months. There was no family history of blindness or other eye conditions. He 
was diagnosed with LCA at the age of 7 years. Initial ERG performed at the 
age of 3 years showed moderate to severely reduced rod and cone 
responses which was suggestive of widespread retinal degeneration. The 
ERG was repeated again at the age of 7 and showed non-detectable 
responses under all stimulus conditions. Clinical examination and details 
were recorded at the age of 7 years. His visual acuities then were hand 
movements in the right and left eye respectively. There were abnormal foveal 
reflexes bilaterally but no evidence of macular atrophy or pigmentation. 
There was no obvious peripheral retinal pigmentation or any cataract or 
keratoconus. Autofluorescence imaging showed relatively normal level of 
autofluorescence at the macula. OCT scanning revealed thinning of the 
retinal layers although foveal outer nuclear layer appear to be present. 
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Patient 15618 
Patient 15618 is of Indian descent from a non-consanguinous family. The 
onset of his visual symptoms were at the age of 6 years where, his parents 
noticed that his eyes were ‘wobbly’ and that he was having difficulties seeing 
objects. He also developed a divergent squint. He was examined at the age 
of 21 years and his visual acuities at examination was logMAR 1.3 OD and 
hand movements OS. Fundal examination showed bone spicule retinal 
pigmentation in the mid to peripheral retina and peripheral RPE atrophy. 
There were signs of RPE mottling and pigmentation at the macula and the 
optic discs appeared pale. Electrodiagnostic testing showed marked 
reduction of scotopic and photopic responses, worse in the left eye which 
was in keeping with EORD. OCT, autofluorescence and perimetry were not 
performed. 
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Patient 14651 
Patient 14651 is from an Asian background and whose parents are first 
cousins. She was noted to have poor vision at the age of 6 months, 
accompanied by nystagmus and a squint. There was no previous family 
history of any eye problems or blindness. She was examined at the age of 3 
and recorded visual acuities of counting fingers in both eyes. Fundal 
examination showed unremarkable findings in the retina and macula. ERG 
showed non-detectable photopic and scotopic responses in keeping with 
LCA. 
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Patient 13163 
Patient 13163 is from a Caucasian background and a non-consanguinous 
family. Poor vision and nystagus was noted at the age of 6 months. She later 
developed a squint. A diagnosis of EORD was made at the age of 3 year. 
Clinical examination was performed at the age of 29 years old. Her vision 
recorded then was logMAR 0.96 in the right and left eye respectively and she 
was moderately myopic with astigmatism but there was no signs of 
keratoconus. Fundal examination revealed bilateral pale discs and 
attenuated blood vessels but there were no obvious retinal pigmentary 
changes. OCT imaging showed normal retinal thickness and layered 
architecture. ERG responses showed absent rod responses and minimal 
cone responses. . 
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Patient 6604 
Patient 6604 is the younger sister of patient 13484. They both share the 
same mother, but have different fathers. Patient 6604 was noted to have 
poor vision, eye-rubbing, nystagmus and dislike of bright lights at the age of 
2 months. She presented for clinical examination at an earlier age of 8 years 
old, during which she was found to have pigment clumping in the peripheral 
retina, RPE atrophy, white dots and macular pigmentation and atrophy. She 
was diagnosed with rod-cone dystrophy. Her visual acuity was better 
compared with her sister’s, achieving logMar 0.7 (oculus dexter, right) and 
logMar 0.8 (oculus sinister, left). Electrophysiology assessment showed 
absent rod and cone ERG responses and significantly delayed 30 Hz flicker 
ERG with low amplitude. 
 
 
 
Patient 14351  
Patient 14351 was diagnosed at the age of 2 years with early onset retinal 
dystrophy. He presented with visual loss, nystagmus, field loss and 
nyctalopia when he was 2 years old, and came from a consanguineous 
family where his parents were first cousins. There were no other affected 
family members. At the time of clinical examination, he was 5 years old; his 
visual acuities were 1.0 OD and OS and ophthalmoscopy showed a relatively 
unremarkable fundus. Unfortunately, electrophysiology testing, OCT and 
visual fields information were unavailable on this patient. 
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Patient 10759  
Patient 10759 was noted to have poor vision and nystagmus  from birth. Her 
parents are from Indian descent and there is no history of consanguinity.  
She has a non-affected older brother. She was diagnosed with LCA at the 
age of 6 months, after electrodiagnostic testing showed non-detectable 
scotopic or photopic responses. She demonstrated a dislike for light and later 
developed a left divergent squint. She was examined at the age of 1 year. 
On examination,her vision was hand movements in the right and left eye 
respectively. There were no pigmentary changes in the retina or any macular 
abnormality found. Her anterior segments were unremarkable and there 
were no signs of cataracts or keratoconus. 
 
375 
 
Patient 13026  
Patient 13026 was from a white Caucasian background and there was no 
family history of consanguinity. Clinically, she was diagnosed with early 
onset retinal dystrophy after she was found to have poor vision and 
nystagmus shortly after birth and showed an aversion to light 
(photoaversion). When she was examined at the age of 9 years, she had 
visual acuities of 3/60 bilaterally with posterior subcapsular cataracts. Her 
fundi had moderate peripheral pigmentation accompanied by pale optic 
discs. There was involvement of the macular. No data was available on 
electrodiagnostic studies or perimetry. 
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List of Abbreviations 
aa       amino acid 
AAV   adeno-associated virus 
ABCR   ATP-binding cassette transporter 
Ad   adenovirus 
AdRP   autosomal dominant retinitis pigmentosa 
AIPL1   aryl hydrocarbon receptor-interacting protein-like 1 
(human) 
Aipl1   aryl hydrocarbon receptor-interacting protein-like 1 
(mouse) 
AMD   age-related macular degeneration 
ArRP   autosomal recessive retinitis pigmentosa 
ATP   adenosine-5’-triphosphate 
BDNF   brain-derived neurotrophic factor 
bFGF   basic fibroblast growth factor 
β-PDE   β subunit of the rod cGMP phosphodiesterase 
BHK   baby hamster kidney cells 
bp   base pair 
BRB   blood retina barrier 
BSA   bovine serum albumin  
cAMP   cyclic AMP 
cc   connecting cilium 
cDNA   coding deoxyribonucleic acid 
CEP290  centrosomal protein 290 
cGMP   cyclic GMP 
CMV   cytomegalovirus promoter 
CNTF   ciliary neurotrophic factor 
CNS   central nervous system 
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CNV   choroidal neovascularisation 
CRB   Crumbs homolog protein 
CRBP   cellular retinol-binding protein 
CRX   cone-rod homeobox 
DMEM  Dulbecco’s Modified Eagle Medium 
DMSO  dimethylsulfoxide 
DNA   deoxyribonucleic acid 
ds   double stranded 
EAM   encapsidated adenoviral mini-chromosome 
EAU   experimental autoimmune uveoretinitis 
EIAV    equine infections anaemia virus 
gDNA   genomic deoxyribonucleic acid 
eGFP   enhanced green fluorescent protein 
ELISA   enzyme-linked immunosorben assay 
ERG   electroretinogram 
FCS   fetal calf serum 
FGF   fibroblast growth factor 
FIV   feline immunodeficiency virus 
GCAP   guanylate cyclase activating protein 
GCL   ganglion cell layer 
GDNF   glial-derived neurotrophic factor 
GDP   guanosine-5’diphosphate 
GFAP   glial fibrillary acidic protein 
GFP   green fluorescent protein 
GMP   guanosine 5’-monophosphate 
GTP   guanosine 5’-triphosphate 
GUCY2D  guanylate cyclase-1 
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HIV   human immunodeficiency virus 
HSV   herpes simplex virus 
IL   interleukin 
ILM   internal limiting memebrane 
IMPDH1  inosine monophosphate dehydrogenase 1 
INL   inner nuclear layer 
IPL   inner plexiform layer 
IPM   inter photoreceptor matrix 
IRBP   interphotoreceptor retinoid-binding protein 
IS   inner segments 
ITR   inverted terminal repeats 
kb   kilobase 
kDA    kilodalton 
l    litre 
LCA   Leber Congenital Amaurosis 
LRAT   lecithin-retinol acyltransferase 
LTR   long tandem repeats 
m    meter 
m-    milli 
µ    micro 
MERTK  mer-receptor tyrosine kinase 
MOI   multiplicity of infection 
mRNA  messenger RNA 
miRNA  microRNA 
MV   microvilli 
NAD+, NADH	   o xidized and reduced nicotinamide–adenine dinucleotide	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NADP+, NADPH	  	  	   oxidized and reduced nicotinamide–adenine dinucleotide 
phosphate 
NFL   nerve fiber layer 
NO   nitric oxide 
NOS   nitric oxide synthase 
OCT   optical coherence tomography 
O.C.T   optimal cutting temperature 
ORF   open reading frame 
ONL   outer nuclear layer 
OP   oscillatory potential 
OPL   outer plexiform layer 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PDGF   platelet derived growth factor 
PDE   phosphodiesterase 
PEDF   pigment epithelium derived factor 
PFA   paraformaldehyde 
PR   photoreceptors 
Prph2   peripherin” 
R*   metarhodopsin 
rAAV   recombinant AAV 
RCS   Royal College of Surgeons 
rd   retinal degeneration 
RDH   retinol dehydrogenase 
rds   retinal degeneration slow 
retGC   retinal guanylate cyclase 
RGC   retinal ganglion cells 
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RHO   rhodopsin 
RISC   RNA induced silencing complex 
RK   rhodopsin kinase 
RNA   ribonucleic acid 
RNAi   RNA intereference 
ROM-1  retinal outer segment membrane protein-1 
ROS   reactive oxygen species 
RP   retinitis pigmentosa 
RPE   retinal pigment epithelium 
RPGR   retinitis pigmentosa GTPase regulator 
RPGRIP  RPGR-interacting protein 
RT   reverse transcriptase 
scAAV  self complementary AAV 
SCID   severe combined immunodeficiency 
shRNA  short hairpin RNA 
siRNA    short interfering RNA 
SIV   simian immunodeficiency virus 
ss     single stranded 
TNF   tumor necrosis factor 
TULP1  tubby-like protein 
UTR   untranslated region 
VEGF   vascular endothelial growth factor 
vp   viral particles 
VSV-G  vesicular stomatitis virus G-protein 
WPRE  Woodchuck hepatitis virus post-transcriptional element 
w/v   weight/volume percent or mass/volume percent 
XIAP   X-linked inhibitor of apoptosis protein 
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